
==== Front
Br J PharmacolBr. J. Pharmacol10.1111/(ISSN)1476-5381BPHBritish Journal of Pharmacology0007-11881476-5381John Wiley and Sons Inc. Hoboken 10.1111/bph.14752BPH1475210.1111/bph.14752The Concise Guide to Pharmacology 2019/20The Concise Guide to Pharmacology 2019/20THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Enzymes THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: EnzymesAlexander Stephen PH https://orcid.org/0000-0003-4417-497X
1
Fabbro Doriano https://orcid.org/0000-0002-9400-4517
2
Kelly Eamonn 
3
Mathie Alistair https://orcid.org/0000-0001-6094-2890
4
Peters John A https://orcid.org/0000-0002-4277-4245
5
Veale Emma L https://orcid.org/0000-0002-6778-9929
4
Armstrong Jane F https://orcid.org/0000-0002-0524-0260
6
Faccenda Elena https://orcid.org/0000-0001-9855-7103
6
Harding Simon D https://orcid.org/0000-0002-9262-8318
6
Pawson Adam J https://orcid.org/0000-0003-2280-845X
6
Sharman Joanna L https://orcid.org/0000-0002-5275-6446
6
Southan Christopher https://orcid.org/0000-0001-9580-0446
6
Davies Jamie A https://orcid.org/0000-0001-6660-4032
6
CGTP Collaborators Beuve Annie 
7
Boison Detlev 
8
Brouckaert Peter 
9
Burnett John C 
10
Burns Kathryn https://orcid.org/0000-0003-4951-3539
11
Dessauer Carmen https://orcid.org/0000-0003-1210-4280
12
Friebe Andreas 
13
Garthwaite John 
14
Gertsch Jürg 
15
Helsby Nuala https://orcid.org/0000-0001-6570-5368
11
Izzo Angelo A https://orcid.org/0000-0002-8557-2133
16
Koesling Doris 
17
Kuhn Michaela 
13
Ostrom Rennolds https://orcid.org/0000-0002-7204-0357
18
Papapetropoulos Andreas 
19
Potter Lincoln R 
20
Pyne Nigel J 
21
Pyne Susan 
21
Russwurm Michael 
17
Schmidt Harald HHW 
22
Seifert Roland 
23
Stasch Johannes‐Peter 
24
Szabo Csaba 
25
van der Stelt Mario 
26
van der Vliet Albert https://orcid.org/0000-0003-0923-0016
27
Watts Val https://orcid.org/0000-0003-1581-2936
28

1 
School Sciences
Nottingham Medical School
Nottingham
NG7 2UH
UK

2 
PIQUR Therapeutics
Basel
4057
Switzerland

3 
School of Physiology, Pharmacology and Neuroscience
University of Bristol
Bristol
BS8 1TD
UK

4 
Medway School of Pharmacy
The Universities of Greenwich and Kent at Medway
Anson Building, Central Avenue, Chatham Maritime
Chatham
Kent
ME4 4TB
UK

5 
Neuroscience Division
Medical Education Institute, Ninewells Hospital and Medical School, University of Dundee
Dundee
DD1 9SY
UK

6 
Centre for Discovery Brain Sciences
University of Edinburgh
Edinburgh
EH8 9XD
UK

7 
New Jersey
USA

8 
Portland
USA

9 
Ghent
Belgium

10 
Rochester
USA

11 
Auckland
New Zealand

12 
Houston
USA

13 
Wurzburg
Germany

14 
London
UK

15 
Bern
Switzerland

16 
Naples
Italy

17 
Bochum
Germany

18 
Irvine
USA

19 
Athens
Greece

20 
Minneapolis
USA

21 
Glasgow
UK

22 
Maastricht
Netherlands

23 
Hannover
Germany

24 
Rome
Italy

25 
Galveston
USA

26 
Leiden
The Netherlands

27 
Burlington
USA

28 
West Lafayette
USA
11 11 2019 12 2019 11 11 2019 176 Suppl 1 10.1111/bph.v176.S1S297 S396 © 2019 The Authors. British Journal of Pharmacology published by John Wiley & Sons Ltd on behalf of The British Pharmacological Society.This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.The Concise Guide to PHARMACOLOGY 2019/20 is the fourth in this series of biennial publications. The Concise Guide provides concise overviews of the key properties of nearly 1800 human drug targets with an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands (http://www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. Although the Concise Guide represents approximately 400 pages, the material presented is substantially reduced compared to information and links presented on the website. It provides a permanent, citable, point‐in‐time record that will survive database updates. The full contents of this section can be found at http://onlinelibrary.wiley.com/doi/10.1111/bph.14752. Enzymes are one of the six major pharmacological targets into which the Guide is divided, with the others being: G protein‐coupled receptors, ion channels, nuclear hormone receptors, catalytic receptors and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for further reading. The landscape format of the Concise Guide is designed to facilitate comparison of related targets from material contemporary to mid‐2019, and supersedes data presented in the 2017/18, 2015/16 and 2013/14 Concise Guides and previous Guides to Receptors and Channels. It is produced in close conjunction with the International Union of Basic and Clinical Pharmacology Committee on Receptor Nomenclature and Drug Classification (NC‐IUPHAR), therefore, providing official IUPHAR classification and nomenclature for human drug targets, where appropriate.

 source-schema-version-number2.0cover-dateDecember 2019details-of-publishers-convertorConverter:WILEY_ML3GV2_TO_JATSPMC version:5.7.1 mode:remove_FC converted:11.11.2019


Stephen PH 
Alexander 
, 
Doriano 
Fabbro 
, 
Eamonn 
Kelly 
, 
Alistair 
Mathie 
, 
John A 
Peters 
, 
Emma L 
Veale 
, 
Jane F 
Armstrong 
, 
Elena 
Faccenda 
, 
Simon D 
Harding 
, 
Adam J 
Pawson 
, 
Joanna L 
Sharman 
, 
Christopher 
Southan 
, 
Jamie A 
Davies 
 and CGTP Collaborators 
(2019 ) THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Enzymes . British Journal of Pharmacology , 176 : S297 –S396 . doi: 10.1111/bph.14752 .
==== Body
1 Conflict of interest
The authors state that there are no conflicts of interest to disclose.

Overview
Enzymes are protein catalysts facilitating the conversion of substrates into products. The Nomenclature Committee of the International Union of Biochemistry and Molecular Biology (NC‐IUBMB) classifies enzymes into families, using a four number code, on the basis of the reactions they catalyse. There are six main families:

EC 1.‐.‐.‐ Oxidoreductases;

EC 2.‐.‐.‐ Transferases;

EC 3.‐.‐.‐ Hydrolases;

EC 4.‐.‐.‐ Lyases;

EC 5.‐.‐.‐ Isomerases;

EC 6.‐.‐.‐ Ligases.

Although there are many more enzymes than receptors in biology, and many drugs that target prokaryotic enzymes are effective medicines, overall the number of enzyme drug targets is relatively small [http://www.ncbi.nlm.nih.gov/pubmed/17139284?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/24016212?dopt=AbstractPlus], which is not to say that they are of modest importance.

The majority of drugs which act on enzymes act as inhibitors; one exception is metformin, which appears to stimulate activity of AMP‐activated protein kinase, albeit through an imprecisely‐defined mechanism. Kinetic assays allow discrimination of competitive, non‐competitive, and un‐competitive inhibitors. The majority of inhibitors are competitive (acting at the enzyme's ligand recognition site), non‐competitive (acting at a distinct site; potentially interfering with co‐factor or co‐enzyme binding) or of mixed type. One rare example of an uncompetitive inhibitor is lithium ions, which are effective inhibitors at inositol monophosphatase only in the presence of high substrate concentrations. Some inhibitors are irreversible, including a group known as suicide substrates, which bind to the ligand recognition site and then couple covalently to the enzyme. It is beyond the scope of the Guide to give mechanistic information about the inhibitors described, although generally this information is available from the indicated literature.

Many enzymes require additional entities for functional activity. Some of these are used in the catalytic steps, while others promote a particular conformational change. Co‐factors are tightly bound to the enzyme and include metal ions and heme groups. Co‐enzymes are typically small molecules which accept or donate functional groups to assist in the enzymatic reaction. Examples include ATP, NAD, NADP and S‐adenosylmethionine, as well as a number of vitamins, such as riboflavin (vitamin B1) and thiamine (vitamin B2). Where co‐factors/co‐enzymes have been identified, the Guide indicates their involvement.

Family structure
– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=933



S301 Acetylcholine turnover



S302 Adenosine turnover



S303 Amino acid hydroxylases



S304 L‐Arginine turnover



S304 2.1.1.‐ Protein arginine N‐methyltransferases



S305 Arginase



S305 Arginine:glycine amidinotransferase



S305 Dimethylarginine dimethylaminohydrolases



S306 Nitric oxide synthases



S307 Carbonic anhydrases



S308 Carboxylases and decarboxylases



S308 Carboxylases



S309 Decarboxylases



S311 Catecholamine turnover



S313 Ceramide turnover



S313 Serine palmitoyltransferase


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=791



S314 Ceramide synthase



S314 Sphingolipid ∆4‐desaturase



S315 Sphingomyelin synthase



S315 Sphingomyelin phosphodiesterase



S316 Neutral sphingomyelinase coupling factors



S316 Ceramide glucosyltransferase



S316 Acid ceramidase



S317 Neutral ceramidases



S317 Alkaline ceramidases



S318 Ceramide kinase


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=981



S319 Chromatin modifying enzymes


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=869



S319 2.1.1.‐ Protein arginine N‐methyltransferases


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=871


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=872



S320 3.5.1.‐ Histone deacetylases (HDACs)


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=873


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=884


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=558


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=626


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=631



S321 Cyclic nucleotide turnover/signalling



S321 Adenylyl cyclases (ACs)



S323 Exchange protein activated by cyclic AMP (EPACs)



S323 Phosphodiesterases, 3’,5’‐cyclic nucleotide (PDEs)



S327 Cytochrome P450



S327 CYP1 family



S328 CYP2 family



S329 CYP3 family



S330 CYP4 family



S331 CYP5, CYP7 and CYP8 families



S332 CYP11, CYP17, CYP19, CYP20 and CYP21 families



S333 CYP24, CYP26 and CYP27 families



S333 CYP39, CYP46 and CYP51 families


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=1020



S334 DNA topoisomerases



S335 Endocannabinoid turnover



S336 N‐Acylethanolamine turnover



S337 2‐Acylglycerol ester turnover



S338 Eicosanoid turnover



S338 Cyclooxygenase



S339 Prostaglandin synthases



S341 Lipoxygenases



S342 Leukotriene and lipoxin metabolism



S343 GABA turnover



S344 Glycerophospholipid turnover



S344 Phosphoinositide‐specific phospholipase C



S346 Phospholipase A2




S348 Phosphatidylcholine‐specific phospholipase D



S349 Lipid phosphate phosphatases



S349 Phosphatidylinositol kinases



S350 1‐phosphatidylinositol 4‐kinase family



S351 Phosphatidylinositol‐4‐phosphate 3‐kinase family



S351 Phosphatidylinositol 3‐kinase family



S351 Phosphatidylinositol‐4,5‐bisphosphate 3‐kinase family



S352 1‐phosphatidylinositol‐3‐phosphate 5‐kinase family



S353 Type I PIP kinases (1‐phosphatidylinositol‐4‐phosphate 5‐kinase family)



S353 Type II PIP kinases (1‐phosphatidylinositol‐5‐phosphate 4‐kinase family)



S354 Sphingosine kinase



S356 Phosphatidylinositol phosphate kinases



S356 Haem oxygenase



S358 Hydrogen sulphide synthesis



S358 Hydrolases



S360 Inositol phosphate turnover



S360 Inositol 1,4,5‐trisphosphate 3‐kinases



S360 Inositol polyphosphate phosphatases



S361 Inositol monophosphatase


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=1004



S361 Kinases (EC 2.7.x.x)


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=677


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=454


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=500


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=573



S362 Rho kinase


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=283


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=507


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=508


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=937


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=583


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=587


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=604


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=284


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=285



S362 Protein kinase C (PKC) family



S363 Alpha subfamily



S363 Delta subfamily



S364 Eta subfamily


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=535


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=287


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=601


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=466


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=539


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=540


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=541


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=705


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=614


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=616


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=644


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=678


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=448


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=468


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=469


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=450


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=471


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=472


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=556


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=874


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=558


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=576


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=463



S264 FRAP subfamily


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=528


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=530


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=531


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=598


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=465


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=536


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=537


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=538


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=596


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=608


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=626


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=631


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=679


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=561


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=562


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=452


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=474


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=475


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=476


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=477


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=478


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=479


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=480


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=700


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=481


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=482


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=483


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=484


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=563


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=566


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=571


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=572


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=459


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=512


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=513


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=585


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=599


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=600


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=605


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=607


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=609


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=630


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=635


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=636


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=680


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=564


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=627


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=640


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=681


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=568



S365 Cyclin‐dependent kinase (CDK) family


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=485


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=492



S365 CDK4 subfamily


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=495


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=496


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=497


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=489


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=494


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=490


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=498


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=491


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=570


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=455


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=503


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=504


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=505


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=506


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=457



S366 GSK subfamily


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=288


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=514


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=515


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=518


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=519


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=520


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=612


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=620


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=682


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=683


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=451


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=473


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=557


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=559


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=560


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=565


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=567


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=577


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=578


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=580


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=584


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=586


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=588


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=589


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=590


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=591


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=592


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=593


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=594


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=595



S367 Polo‐like kinase (PLK) family


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=462


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=526


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=527


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=597


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=617


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=618


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=628


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=633


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=634


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=637


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=639


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=641


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=642


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=643


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=684


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=449


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=470


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=615


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=890


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=685



S367 STE7 family


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=621


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=467


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=542


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=543


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=544


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=544


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=546


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=547


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=548


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=549


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=622


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=550


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=551


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=552


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=624


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=686


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=936



S368 Abl family



S368 Ack family


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=569


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=574


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=575



S369 Janus kinase (JakA) family



S369 Src family


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=625



S370 Tec family


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=687


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=579


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=582


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=458


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=510


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=511


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=461


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=521


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=522


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=523


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=524


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=525



S371 RAF family


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=613


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=632



S372 Lanosterol biosynthesis pathway


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=928


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=993



S374 Nucleoside synthesis and metabolism



S376 Paraoxonase (PON) family



S377 Peptidases and proteinases


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=707



S377 A1: Pepsin


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=708



S377 A22: Presenilin


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=709


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=728


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=731


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=729


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=730


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=732


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=931


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=711


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=733



S378 C14: Caspase


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=711


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=735


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=712


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=736


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=713



S378 M1: Aminopeptidase N



S379 M2: Angiotensin‐converting (ACE and ACE2)



S379 M10: Matrix metallopeptidase



S380 M12: Astacin/Adamalysin


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=740


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=742


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=714


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=743


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=715


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=744


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=716


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=745


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=717


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=746


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=718


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=747


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=860



S380 M28: Aminopeptidase Y


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=719



S381 M19: Membrane dipeptidase


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=720


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=750


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=721



S381 S1: Chymotrypsin


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=722


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=878



S382 T1: Proteasome


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=753


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=723


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=754


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=724



S382 S8: Subtilisin


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=725



S383 S9: Prolyl oligopeptidase


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=756


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=757


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=917


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=947


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=980


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=948



S383 Poly ADP‐ribose polymerases



S384 Prolyl hydroxylases



S384 Sphingosine 1‐phosphate turnover



S385 Sphingosine kinase



S386 Sphingosine 1‐phosphate phosphatase



S387 Sphingosine 1‐phosphate lyase



S387 Thyroid hormone turnover


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=988


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=840


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=922


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=912


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=899



S388 1.14.13.9 Kynurenine 3‐monooxygenase


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=877


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=843


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=846


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=844


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=978


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=1003


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=979


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=908



S389 2.5.1.58 Protein farnesyltransferase


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=926


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=994


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=880


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=850


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=841


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=909



S390 3.5.1.‐ Histone deacetylases (HDACs)


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=925



S391 3.5.3.15 Peptidyl arginine deiminases (PADI)



S391 3.6.5.2 Small monomeric GTPases



S391 RAS subfamily



S392 RAB subfamily


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=849


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=845


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=847



http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=765

Overview
Acetylcholine is familiar as a neurotransmitter in the central nervous system and in the periphery. In the somatic nervous system, it activates http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=76 at the skeletal neuromuscular junction. It is also employed in the autonomic nervous system, in both parasympathetic and sympathetic branches; in the former, at the smooth muscle neuromuscular junction, activating http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=2. In the latter, acetylcholine is involved as a neurotransmitter at the ganglion, activating nicotinic acetylcholine receptors. Acetylcholine is synthesised in neurones through the action of choline O‐acetyltransferase and metabolised after release through the extracellular action of acetylcholinesterase and cholinesterase. Choline is accumulated from the extracellular medium by selective transporters (see http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=143#show_object_914 and the http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=233 family). Acetylcholine is accumulated in synaptic vesicles through the action of the vesicular acetylcholine transporter http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=193.


Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2480
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2465
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2471
	
Common abbreviation	ChAT	AChE	BChE	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1912, http://www.uniprot.org/uniprot/P28329
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:108, http://www.uniprot.org/uniprot/P22303
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:983, http://www.uniprot.org/uniprot/P06276
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:2.3.1.6: http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3038 + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4551 = http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=294 + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3044
	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.1.7: http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=294 + H2O = http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1058 + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4551 + H+
	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.1.7: http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=294 + H2O = http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1058 + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4551 + H+
	
Inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8807 (pIC50 6.5) [http://www.ncbi.nlm.nih.gov/pubmed/3351860?dopt=AbstractPlus] – Mouse	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6687 (pK
i 7.5) [http://www.ncbi.nlm.nih.gov/pubmed/18479118?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6693 (pIC50 6.3) [http://www.ncbi.nlm.nih.gov/pubmed/12182861?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6602 (pIC50 5.4) [http://www.ncbi.nlm.nih.gov/pubmed/16570913?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6602 (pIC50 7.4) [http://www.ncbi.nlm.nih.gov/pubmed/16570913?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6687 (pK
i 7.2) [http://www.ncbi.nlm.nih.gov/pubmed/18479118?dopt=AbstractPlus]	
Sub/family‐selective inhibitors	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6598 (pIC50 7.6–7.8) [http://www.ncbi.nlm.nih.gov/pubmed/16570913?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6598 (pIC50 7.6–7.8) [http://www.ncbi.nlm.nih.gov/pubmed/16570913?dopt=AbstractPlus]	
Selective inhibitors	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6599 (pIC50 7.7–8.3) [http://www.ncbi.nlm.nih.gov/pubmed/1738151?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8039548?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/16570913?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6600 (pIC50 7.7) [http://www.ncbi.nlm.nih.gov/pubmed/12675140?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6601 (pIC50 8.5) [http://www.ncbi.nlm.nih.gov/pubmed/12675140?dopt=AbstractPlus]	
Comments	Splice variants of choline O‐acetyltransferase are suggested to be differentially distributed in the periphery and CNS (see [http://www.ncbi.nlm.nih.gov/pubmed/21382474?dopt=AbstractPlus]).	–	–	



Comments
A number of organophosphorus compounds inhibit acetylcholinesterase and cholinesterase irreversibly, including pesticides such as chlorpyrifos‐oxon, and nerve agents such as tabun, soman and sarin. AChE is unusual in its exceptionally high turnover rate which has been calculated at 740 000/min/molecule [http://www.ncbi.nlm.nih.gov/pubmed/13785664?dopt=AbstractPlus].

Further reading on Acetylcholine turnover
Li Q et al. (2017) Recent progress in the identification of selective butyrylcholinesterase inhibitors for Alzheimer's disease. Eur J Med Chem
132: 294–309 https://www.ncbi.nlm.nih.gov/pubmed/28371641?dopt=AbstractPlus


Lockridge O. (2015) Review of human butyrylcholinesterase structure, function, genetic variants, history of use in the clinic, and potential therapeutic uses. Pharmacol Ther
148: 34–46 https://www.ncbi.nlm.nih.gov/pubmed/25448037?dopt=AbstractPlus


Masson P et al. (2016) Slow‐binding inhibition of cholinesterases, pharmacological and toxicological relevance. Arch Biochem Biophys
593: 60–8 https://www.ncbi.nlm.nih.gov/pubmed/26874196?dopt=AbstractPlus


Rotundo RL. (2017) Biogenesis, assembly and trafficking of acetylcholinesterase. J Neurochem
142 Suppl 2: 52–58 https://www.ncbi.nlm.nih.gov/pubmed/28326552?dopt=AbstractPlus


Silman I et al. (2017) Recent developments in structural studies on acetylcholinesterase. J Neurochem
142 Suppl 2: 19–25 https://www.ncbi.nlm.nih.gov/pubmed/28503857?dopt=AbstractPlus



http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=248

Overview
A multifunctional, ubiquitous molecule, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2844 acts at cell‐surface G protein‐coupled receptors, as well as numerous enzymes, including protein kinases and adenylyl cyclase. Ex‐tracellular adenosine is thought to be produced either by export or by metabolism, predominantly through ecto‐5’‐nucleotidase activity (also producing inorganic phosphate). It is inactivated either by extracellular metabolism via adenosine deaminase (also producing ammonia) or, following uptake by nucleoside transporters, via adenosine deaminase or adenosine kinase (requiring http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713 as co‐substrate). Intracellular adenosine may be produced by cytosolic 5’‐nucleotidases or through S‐adenosylhomocysteine hydrolase (also producing http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5198).


Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1230
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1231
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1232
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1233
	
Systematic nomenclature	–	–	CD73	–	
Common abbreviation	ADA	ADK	NT5E	SAHH	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:186, http://www.uniprot.org/uniprot/P00813
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:257, http://www.uniprot.org/uniprot/P55263
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8021, http://www.uniprot.org/uniprot/P21589
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:343, http://www.uniprot.org/uniprot/P23526
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.5.4.4: http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2844 + H2O = http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4554 + NH3
	
http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.20
	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.3.5
	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.3.1.1
	
Rank order of affinity	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5109
>
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2844
	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2844
	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2455, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5123, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5124, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5125
>
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5120, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5122
	–	
Endogenous substrates	–	–	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5265
	
Products	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5110, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4554
	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2455
	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4566, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4554, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4556, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2844
	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2844
	
Inhibitors	–	–	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8392 (pK
i 12.3) [http://www.ncbi.nlm.nih.gov/pubmed/3457563?dopt=AbstractPlus] – Hamster	
Selective inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4805 (pIC50 10.8) [http://www.ncbi.nlm.nih.gov/pubmed/849330?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5179 (pK
i 8.8) [http://www.ncbi.nlm.nih.gov/pubmed/849330?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5130 (pIC50 10.2) [http://www.ncbi.nlm.nih.gov/pubmed/11160637?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5131 (pIC50 8.8) [http://www.ncbi.nlm.nih.gov/pubmed/11082453?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5092 (pIC50 8.7) [http://www.ncbi.nlm.nih.gov/pubmed/1169962?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5115 (pIC50 8.5) [http://www.ncbi.nlm.nih.gov/pubmed/7470463?dopt=AbstractPlus]	
Comments	–	The enzyme exists in two isoforms derived from alternative splicing of a single gene product: a short isoform, ADK‐S, located in the cytoplasm is responsible for the regulation of intra‐ and extracellular levels of adenosine and hence adenosine receptor activation; a long isoform, ADK‐L, located in the nucleus contributes to the regulation of DNA methylation [http://www.ncbi.nlm.nih.gov/pubmed/23592612?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/23863710?dopt=AbstractPlus].	Pharmacological inhibition of CD73 is being investigated as a novel cancer immunotherapy strategy [http://www.ncbi.nlm.nih.gov/pubmed/21537079?dopt=AbstractPlus].	–	



Comments
An extracellular adenosine deaminase activity, termed ADA2 or adenosine deaminase growth factor (ADGF, https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1839, http://www.uniprot.org/uniprot/Q9NZK5) has been identified [http://www.ncbi.nlm.nih.gov/pubmed/24933472?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/16245011?dopt=AbstractPlus], which is insensitive to http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5179 [http://www.ncbi.nlm.nih.gov/pubmed/20147294?dopt=AbstractPlus]. Other forms of adenosine deaminase act on ribonucleic acids and may be divided into two families: https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:228 (http://www.uniprot.org/uniprot/Q9BUB4) deaminates transfer RNA; https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:225 (http://www.genome.jp/dbget‐bin/www_bget?ec:3.5.4.37, also known as 136 kDa double‐stranded RNA‐binding protein, P136, K88DSRBP, Interferon‐inducible protein 4); https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:226 (EC 3.5.‐.‐, , also known as dsRNA adenosine deaminase) andhttps://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:227 (EC 3.5.‐.‐, also known as dsRNA adenosine deaminase B2, RNA‐dependent adenosine deaminase 3) act on double‐stranded RNA. Particular polymorphisms of the ADA gene result in loss‐of‐function and severe combined immunodeficiency syndrome. Adenosine deaminase is able to complex with dipeptidyl peptidase IV (http://www.genome.jp/dbget‐bin/www_bget?ec:3.4.14.5, https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3009, also known as T‐cell activation antigen CD26, TP103, adenosine deaminase complexing protein 2) to form a cell‐surface activity [http://www.ncbi.nlm.nih.gov/pubmed/8101391?dopt=AbstractPlus].

Further reading on Adenosine turnover
Boison D. (2016) Adenosinergic signaling in epilepsy. Neuropharmacology
104: 131–9 https://www.ncbi.nlm.nih.gov/pubmed/26341819?dopt=AbstractPlus


Cortés A et al. (2015) Moonlighting adenosine deaminase: a target protein for drug development. Med Res Rev
35: 85–125 https://www.ncbi.nlm.nih.gov/pubmed/24933472?dopt=AbstractPlus


Nishikura K. (2016) A‐to‐I editing of coding and non‐coding RNAs by ADARs. Nat Rev Mol Cell Biol
17: 83–96 https://www.ncbi.nlm.nih.gov/pubmed/26648264?dopt=AbstractPlus


Sawynok J. (2016) Adenosine receptor targets for pain. Neuroscience
338: 1–18 https://www.ncbi.nlm.nih.gov/pubmed/26500181?dopt=AbstractPlus


Xiao Y et al. (2015) Role of S‐adenosylhomocysteine in cardiovascular disease and its potential epi‐genetic mechanism. Int. J. Biochem. Cell Biol. 67: 158–66 https://www.ncbi.nlm.nih.gov/pubmed/26117455?dopt=AbstractPlus



http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=249

Overview
The amino acid hydroxylases (monooxygenases), EC.1.14.16.‐, are iron‐containing enzymes which utilise molecular oxygen and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5276 as co‐substrate and co‐factor, respectively. In humans, as well as in other mammals, there are two distinct L‐Tryptophan hydroxylase 2 genes. In humans, these genes are located on chromosomes 11 and 12 and encode two different homologous enzymes, TPH1 and TPH2.


Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1240
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1243
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1241
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1242
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8582, http://www.uniprot.org/uniprot/P00439
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11782, http://www.uniprot.org/uniprot/P07101
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:12008, http://www.uniprot.org/uniprot/P17752
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:20692, http://www.uniprot.org/uniprot/Q8IWU9
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.16.1: http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3313 + O2 ‐> http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4791
	
http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.16.2: http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4791 + O2 ‐> http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3639
	
http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.16.4
	
http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.16.4
	
Endogenous substrates	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3313
	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4791
	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=717
	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=717
	
Products	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4791
	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3639
	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4671
	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4671
	
Cofactors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5276
	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5276, Fe2+
	–	–	
Endogenous activators	Protein kinase A‐mediated phosphorylation (Rat) [http://www.ncbi.nlm.nih.gov/pubmed/182695?dopt=AbstractPlus]	Protein kinase A‐mediated phosphorylation [http://www.ncbi.nlm.nih.gov/pubmed/33381?dopt=AbstractPlus]	Protein kinase A‐mediated phosphorylation [http://www.ncbi.nlm.nih.gov/pubmed/8592157?dopt=AbstractPlus]	Protein kinase A‐mediated phosphorylation [http://www.ncbi.nlm.nih.gov/pubmed/8592157?dopt=AbstractPlus]	
Inhibitors	–	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9490 [http://www.ncbi.nlm.nih.gov/pubmed/26206858?dopt=AbstractPlus]	–	
Selective inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5093 [http://www.ncbi.nlm.nih.gov/pubmed/944951?dopt=AbstractPlus] – Rat, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5240
	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5095, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5114, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5117, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6956
	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5095, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5126 [http://www.ncbi.nlm.nih.gov/pubmed/6457252?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5240, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4613
	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5095, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5126 [http://www.ncbi.nlm.nih.gov/pubmed/6457252?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5240, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4613
	
Comments	PAH is an iron bound homodimer or ‐tetramer from the same structural family as tyrosine 3‐monooxygenase and the tryptophan hydroxylases. Deficiency or loss‐of‐function of PAH is associated with http://omim.org/entry/612349
	TH is a homotetramer, which is inhibited by dopamine and other catecholamines in a physiological negative feedback pathway [http://www.ncbi.nlm.nih.gov/pubmed/21176768?dopt=AbstractPlus].	–	–	



Further reading on Amino acid hydroxylases
Bauer IE et al. (2015) Serotonergic gene variation in substance use pharmacotherapy: a systematic review. Pharmacogenomics
16: 1307–14 https://www.ncbi.nlm.nih.gov/pubmed/26265436?dopt=AbstractPlus


Daubner SC et al. (2011) Tyrosine hydroxylase and regulation of dopamine synthesis. Arch Biochem Biophys
508: 1–12 https://www.ncbi.nlm.nih.gov/pubmed/21176768?dopt=AbstractPlus


Flydal MI et al. (2013) Phenylalanine hydroxylase: function, structure, and regulation. IUBMB Life
65: 341–9 https://www.ncbi.nlm.nih.gov/pubmed/23457044?dopt=AbstractPlus


Roberts KM et al. (2013) Mechanisms of tryptophan and tyrosine hydroxylase. IUBMB Life
65: 350–7 https://www.ncbi.nlm.nih.gov/pubmed/23441081?dopt=AbstractPlus


Tekin I et al. (2014) Complex molecular regulation of tyrosine hydroxylase. J Neural Transm
121: 1451–81 https://www.ncbi.nlm.nih.gov/pubmed/24866693?dopt=AbstractPlus


Walen K et al. (2017) Tyrosine and tryptophan hydroxylases as therapeutic targets in human disease. Expert Opin Ther Targets
21: 167–180 https://www.ncbi.nlm.nih.gov/pubmed/27973928?dopt=AbstractPlus



http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=239

Overview

http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=721 is a basic amino acid with a guanidino sidechain. As an amino acid, metabolism of L‐arginine to form http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=725, catalysed by arginase, forms the last step of the urea production cycle. L‐Ornithine may be utilised as a precursor of polyamines (see http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=240) or recycled via http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5324 to L‐arginine. L‐Arginine http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=240#Decarboxylases to form http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4127, although the prominence of this pathway in human tissues is uncertain. L‐Arginine may be used as a precursor for http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5325 formation in the http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4496 synthesis pathway under the influence of arginine:glycine amidinotransferase with L‐ornithine as a byproduct. Nitric oxide synthase uses L‐arginine to generate nitric oxide, with http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=722 also as a byproduct. L‐Arginine in proteins may be subject to post‐translational modification through methylation, catalysed by protein arginine methyltransferases. Subsequent proteolysis can liberate asymmetric http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5229 (ADMA), which is an endogenous inhibitor of nitric oxide synthase activities. ADMA is hydrolysed by dimethylarginine dimethylhydrolase activities to generate http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=722 and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5177.


http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=254

Overview
Protein arginine N‐methyltransferases (PRMT, EC 2.1.1.‐) encompass histone arginine N‐methyltransferases (PRMT4, PRMT7, http://www.genome.jp/kegg‐bin/search_brite?option=‐a&search_string=2.1.1.125) and myelin basic protein N‐methyltransferases (PRMT7, http://www.genome.jp/kegg‐bin/search_brite?option=‐a&search_string=2.1.1.126). They are dimeric or tetrameric enzymes which use http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4786 as a methyl donor, generating http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5265 as a by‐product. They generate both mono‐methylated and di‐methylated products; these may be symmetric (http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5271) or asymmetric (http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5229) versions, where both guanidine nitrogens are monomethylated or one of the two is dimethylated, respectively.

Information on members of this family may be found in the http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=254.


http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=250

Overview
Arginase (http://www.genome.jp/kegg‐bin/search_brite?option=‐a&search_string=3.5.3.1) are manganese‐containing isoforms, which appear to show differential distribution, where the ARG1 isoform predominates in the liver and erythrocytes, while ARG2 is associated more with the kidney.

Information on members of this family may be found in the http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=250.

Comments

http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5227, an intermediate in NOS metabolism of L‐arginine acts as a weak inhibitor and may function as a physiological regulator of arginase activity. Although isoform‐selective inhibitors of arginase are not available, examples of inhibitors selective for arginase compared to NOS are http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5091 [http://www.ncbi.nlm.nih.gov/pubmed/10637120?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5264 [http://www.ncbi.nlm.nih.gov/pubmed/11478904?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/11258879?dopt=AbstractPlus] and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5107 [http://www.ncbi.nlm.nih.gov/pubmed/10454520?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/11478904?dopt=AbstractPlus].


http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=251


Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1246
	
Common abbreviation	AGAT	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4175, http://www.uniprot.org/uniprot/P50440
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:2.1.4.1
	




http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=252

Overview
Dimethylarginine dimethylaminohydrolases (DDAH, http://www.genome.jp/kegg‐bin/search_brite?option=‐a&search_string=3.5.3.18) are cytoplasmic enzymes which hydrolyse http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5229 to form http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5177 and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=722.


Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1247
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1248
	
Common abbreviation	DDAH1	DDAH2	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2715, http://www.uniprot.org/uniprot/O94760
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2716, http://www.uniprot.org/uniprot/O95865
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.5.3.18
	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.5.3.18
	
Cofactors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=566
	–	
Inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8830 (pK
i 5.7) [http://www.ncbi.nlm.nih.gov/pubmed/19013076?dopt=AbstractPlus]	–	




http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=253

Overview
Nitric oxide synthases (NOS, http://www.genome.jp/kegg‐bin/search_brite?option=‐a&search_string=1.14.13.39) are a family of oxidoreductases that synthesize nitric oxide (NO.) via the NADPH and oxygen‐dependent consumption of http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=721 with the resultant by‐product, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=722. There are 3 NOS isoforms and they are related by their capacity to produce NO, highly conserved organization of functional domains and significant homology at the amino acid level. NOS isoforms are functionally distinguished by the cell type where they are expressed, intracellular targeting and transcriptional and post‐translation mechanisms regulating enzyme activity. The nomenclature suggested by NC‐IUPHAR of NOS I, II and III [http://www.ncbi.nlm.nih.gov/pubmed/9228663?dopt=AbstractPlus] has not gained wide acceptance, and the 3 isoforms are more commonly referred to as neuronal NOS (nNOS), inducible NOS (iNOS) and endothelial NOS (eNOS) which reflect the location of expression (nNOS and eNOS) and inducible expression (iNOS). All are dimeric enzymes that shuttle electrons from NADPH, which binds to a C‐terminal reductase domain, through the flavins FAD and FMN to the oxygenase domain of the other monomer to enable the BH4‐dependent reduction of heme bound oxygen for insertion into the substrate, L‐arginine. Electron flow from reductase to oxygenase domain is controlled by calmodulin binding to canonical calmodulin binding motif located between these domains. eNOS and nNOS isoforms are activated at concentrations of calcium greater than 100 nM, while iNOS shows higher affinity for Ca2+/http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2351 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1442, http://www.uniprot.org/uniprot/P62158) with great avidity and is essentially calcium‐independent and constitutively active. Efficient stimulus‐dependent coupling of nNOS and eNOS is achieved via subcellular targeting through respective N‐terminal PDZ and fatty acid acylation domains whereas iNOS is largely cytosolic and function is independent of intracellular location. nNOS is primarily expressed in the brain and neuronal tissue, iNOS in immune cells such as macrophages and eNOS in the endothelial layer of the vasculature although exceptions in other cells have been documented. http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5213 and related modified arginine analogues are inhibitors of all three isoforms, with IC50 values in the micromolar range.


Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1249
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1250
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1251
	
Common abbreviation	eNOS	iNOS	nNOS	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7876, http://www.uniprot.org/uniprot/P29474
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7873, http://www.uniprot.org/uniprot/P35228
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7872, http://www.uniprot.org/uniprot/P29475
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.13.39
	
http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.13.39
	
http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.13.39
	
Endogenous Substrate	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=721
	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=721
	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=721
	
Products	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2509, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=722
	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2509, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=722
	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=722, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2509
	
Cofactors	oxygen, BH4, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=566, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5185, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3041, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4349, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5184
	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4349, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5185, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5184, oxygen, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3041, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=566, BH4	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5184, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4349, oxygen, BH4, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5185, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3041, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=566
	
Selective inhibitors	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5102 (pIC50 8.2) [http://www.ncbi.nlm.nih.gov/pubmed/9030556?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5111 (pIC50 7.4) [http://www.ncbi.nlm.nih.gov/pubmed/8937711?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5246 (pIC50 7.3) [http://www.ncbi.nlm.nih.gov/pubmed/7523409?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5231 (pIC50 5.5) [http://www.ncbi.nlm.nih.gov/pubmed/7525961?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5135 [http://www.ncbi.nlm.nih.gov/pubmed/1378415?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5113 (pIC50 6.1–6.5) [http://www.ncbi.nlm.nih.gov/pubmed/7544863?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5127 (pIC50 5.3) [http://www.ncbi.nlm.nih.gov/pubmed/7693279?dopt=AbstractPlus]	



Comments
The reductase domain of NOS catalyses the reduction of cytochrome c and other redox‐active dyes [http://www.ncbi.nlm.nih.gov/pubmed/9433128?dopt=AbstractPlus]. NADPH:O2 oxidoreductase catalyses the formation of superoxide anion/http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2448 in the absence of http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=721 and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5276.

Further reading on Nitric oxide synthases
Garcia‐Ortiz A and Serrador JM (2018) Nitric Oxide Signaling in T Cell‐Mediated Immunity Trends Mol Med
24: 412–427 https://www.ncbi.nlm.nih.gov/pubmed/29519621


Lundberg JO et al. (2015) Strategies to increase nitric oxide signalling in cardiovascular disease. Nat Rev Drug Discov
14: 623–41 https://www.ncbi.nlm.nih.gov/pubmed/26265312?dopt=AbstractPlus


Oliveira‐Paula GH et al. (2016) Endothelial nitric oxide synthase: From biochemistry and gene structure to clinical implications of NOS3 polymorphisms. Gene
575: 584–99 https://www.ncbi.nlm.nih.gov/pubmed/26428312?dopt=AbstractPlus


Stuehr DJ and Haque MM (2019) Nitric oxide synthase enzymology in the 20 years after the Nobel Prize. BrJPharmacol
176: 177–188 https://www.ncbi.nlm.nih.gov/pubmed/30402946


Wallace JL (2019) Nitric oxide in the gastrointestinal tract: opportunities for drug development. Br J Pharmacol
176: 147–154 https://www.ncbi.nlm.nih.gov/pubmed/30357812


Further reading on L‐Arginine turnover
Lai L et al. (2016) Modulating DDAH/NOS Pathway to Discover Vasoprotective Insulin Sensitizers. J Diabetes Res
2016: 1982096 https://www.ncbi.nlm.nih.gov/pubmed/26770984?dopt=AbstractPlus


Moncada S et al. (1997) International Union of Pharmacology Nomenclature in Nitric Oxide Re‐search. Pharmacol. Rev. 49: 137–42 https://www.ncbi.nlm.nih.gov/pubmed/9228663?dopt=AbstractPlus


Pekarova M et al. (2015) The crucial role of l‐arginine in macrophage activation: What you need to know about it. Life Sci. 137: 44–8 https://www.ncbi.nlm.nih.gov/pubmed/26188591?dopt=AbstractPlus


Pudlo M et al. (2017) Arginase Inhibitors: A Rational Approach Over One Century. Med Res Rev
37: 475–513 https://www.ncbi.nlm.nih.gov/pubmed/27862081?dopt=AbstractPlus


Sudar‐Milovanovic E et al. (2016) Benefits of L‐Arginine on Cardiovascular System. Mini Rev Med Chem
16: 94–103 https://www.ncbi.nlm.nih.gov/pubmed/26471966?dopt=AbstractPlus



http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=842

Overview
Carbonic anhydrases facilitate the interconversion of water and carbon dioxide with bicarbonate ions and protons (EC 4.2.1.1), with over a dozen gene products identified in man. The enzymes function in acid‐base balance and the movement of carbon dioxide and water. They are targetted for therapeutic gain by particular antiglaucoma agents and diuretics.


Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2597
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2749
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2747
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2748
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2598
	
Common abbreviation	CA I	CA VII	CA XII	CA XIII	CA XIV	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1368, http://www.uniprot.org/uniprot/P00915
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1381, http://www.uniprot.org/uniprot/P43166
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1371, http://www.uniprot.org/uniprot/O43570
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:14914, http://www.uniprot.org/uniprot/Q8N1Q1
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1372, http://www.uniprot.org/uniprot/Q9ULX7
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:4.2.1.1
	
http://www.genome.jp/dbget‐bin/www_bget?ec:4.2.1.1
	
http://www.genome.jp/dbget‐bin/www_bget?ec:4.2.1.1
	
http://www.genome.jp/dbget‐bin/www_bget?ec:4.2.1.1
	
http://www.genome.jp/dbget‐bin/www_bget?ec:4.2.1.1
	
Inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7147 (pK
i 6.5)	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6828 (pK
i 8.7) [http://www.ncbi.nlm.nih.gov/pubmed/23965175?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6792 (pK
i 8.6) [http://www.ncbi.nlm.nih.gov/pubmed/20605094?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6797 (pK
i 8.6) [http://www.ncbi.nlm.nih.gov/pubmed/23965175?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7147 (pK
i 8.6) [http://www.ncbi.nlm.nih.gov/pubmed/19119014?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10149 (pK
i 8.4) [http://www.ncbi.nlm.nih.gov/pubmed/26233435?dopt=AbstractPlus]	–	–	



Further reading on Carbonic anhydrases
Imtaiyaz Hassan M, Shajee B, Waheed A, Ahmad F and Sly WS. (2013) Structure, function and applications of carbonic anhydrase isozymes. Bioorg Med Chem
21: 1570–70 https://www.ncbi.nlm.nih.gov/pubmed/22607884


Supuran CT (2017) Advances in structure‐based drug discovery of carbonic anhydrase inhibitors. Expert Opin Drug Discov
12: 61–88 https://www.ncbi.nlm.nih.gov/pubmed/27783541


Supuran CT (2018) Carbonic anhydrase activators. Future Med Chem
10: 561–573 https://www.ncbi.nlm.nih.gov/pubmed/29478330



http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=240


http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=255

Overview
The carboxylases allow the production of new carbon‐carbon bonds by introducing HCO3
‐ or CO2 into target molecules. Two groups of carboxylase activities, some of which are bidirectional, can be defined on the basis of the cofactor requirement, making use of http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4787 (EC 6.4.1.‐) or http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5286 (EC 4.1.1.‐).


Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1262
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1263
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1264
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1265
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1268
	
Common abbreviation	PC	ACC1	ACC2	PCCA,PCCB	GGCX	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8636, http://www.uniprot.org/uniprot/P11498
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:84, http://www.uniprot.org/uniprot/Q13085
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:85, http://www.uniprot.org/uniprot/O00763
	–	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4247, http://www.uniprot.org/uniprot/P38435
	
Subunits	–	–	–	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1267, http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1266
	–	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:6.4.1.1
	
http://www.genome.jp/dbget‐bin/www_bget?ec:6.4.1.2
	
http://www.genome.jp/dbget‐bin/www_bget?ec:6.4.1.2
	
http://www.genome.jp/dbget‐bin/www_bget?ec:6.4.1.3
	
http://www.genome.jp/dbget‐bin/www_bget?ec:4.1.1.90
	
Endogenous substrates	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4809
	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3038
	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3038, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713
	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5248, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713
	glutamyl peptides	
Products	Pi, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1712, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5236
	Pi, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1712, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5219
	Pi, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1712, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5219
	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1712, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5223, Pi
	carboxyglutamyl peptides	
Cofactors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4787
	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4787
	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4787
	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4787
	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5286, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3041
	
Inhibitors	–	–	–	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6960
	
Selective inhibitors	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8884 (pIC50 8) [http://www.ncbi.nlm.nih.gov/pubmed/23981033?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5280 (pIC50 4.9) [http://www.ncbi.nlm.nih.gov/pubmed/14612531?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8884 (pIC50 8.4) [http://www.ncbi.nlm.nih.gov/pubmed/23981033?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5280 (pIC50 4.9) [http://www.ncbi.nlm.nih.gov/pubmed/14612531?dopt=AbstractPlus]	–	–	
Comments	–	Citrate and other dicarboxylic acids are allosteric activators of acetyl‐CoA carboxylase.	Citrate and other dicarboxylic acids are allosteric activators of acetyl‐CoA carboxylase.	Propionyl‐CoA carboxylase is able to function in both forward and reverse activity modes, as a ligase (carboxylase) or lyase (decarboxylase), respectively.	Loss‐of‐function mutations in γ‐glutamyl carboxylase are associated with http://omim.org/entry/277450.	



Comments
Dicarboxylic acids including http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2478 are able to activate ACC1/ACC2 activity allosterically. PCC is able to function in forward and reverse modes as a ligase (carboxylase) or lyase (decarboxylase) activity, respectively. Loss‐of‐function mutations in GGCX are associated with clotting disorders.


http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=256

Overview
The decarboxylases generate CO2 and the indicated products from acidic substrates, requiring http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5249 or http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4809 as a co‐factor.


Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1272
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1273
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1274
	
Common abbreviation	GAD1	GAD2	HDC	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4092, http://www.uniprot.org/uniprot/Q99259
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4093, http://www.uniprot.org/uniprot/Q05329
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4855, http://www.uniprot.org/uniprot/P19113
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:4.1.1.15: http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1369 + H+ ‐> http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1067 + CO2
	
http://www.genome.jp/dbget‐bin/www_bget?ec:4.1.1.15: http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1369 + H+ ‐> http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1067 + CO2
	
http://www.genome.jp/dbget‐bin/www_bget?ec:4.1.1.22
	
Endogenous substrates	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1369, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3309
	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1369, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3309
	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3310
	
Products	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1067
	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1067
	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1204
	
Cofactors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5249
	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5249
	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5249
	
Selective inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5267
	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5267
	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5134, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5189 [http://www.ncbi.nlm.nih.gov/pubmed/7452304?dopt=AbstractPlus]	
Comments	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3309 is a less rapidly metabolised substrate of mouse brain glutamic acid decarboxylase generating β‐alanine [http://www.ncbi.nlm.nih.gov/pubmed/4700449?dopt=AbstractPlus]. Autoantibodies against GAD1 and GAD2 are elevated in type 1 diabetes mellitus and neurological disorders (see Further reading).	–	




Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1270
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1271
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1275
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1276
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1277
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1269
	
Common abbreviation	ADC	AADC	MLYCD	ODC	PSDC	SAMDC	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:29957, http://www.uniprot.org/uniprot/Q96A70
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2719, http://www.uniprot.org/uniprot/P20711
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7150, http://www.uniprot.org/uniprot/O95822
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8109, http://www.uniprot.org/uniprot/P11926
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8999, http://www.uniprot.org/uniprot/Q9UG56
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:457, http://www.uniprot.org/uniprot/P17707
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:4.1.1.19
	
http://www.genome.jp/dbget‐bin/www_bget?ec:4.1.1.28: http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3639 ‐> http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=940 + CO2
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4671 ‐> http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5 + CO2 This enzyme also catalyses the following reaction:: http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=717 ‐> http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=125 + CO2
	
http://www.genome.jp/dbget‐bin/www_bget?ec:4.1.1.9
	
http://www.genome.jp/dbget‐bin/www_bget?ec:4.1.1.17
	
http://www.genome.jp/dbget‐bin/www_bget?ec:4.1.1.65
	
http://www.genome.jp/dbget‐bin/www_bget?ec:4.1.1.50
	
Endogenous substrates	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=721
	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3639, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4671, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=717
	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5219
	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=725
	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3638
	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4786
	
Products	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4127 [http://www.ncbi.nlm.nih.gov/pubmed/14738999?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=940
	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3038
	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2388
	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2796
	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5121
	
Cofactors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5249
	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5249
	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5249
	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5249
	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4809
	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4809
	
Selective inhibitors	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5116, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5217, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5150 [http://www.ncbi.nlm.nih.gov/pubmed/22384042?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5159
	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5139 (pIC50 7.5) [http://www.ncbi.nlm.nih.gov/pubmed/1573631?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5176 (pK
d 4.9) [http://www.ncbi.nlm.nih.gov/pubmed/12859253?dopt=AbstractPlus]	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5268 (pIC50 8) [http://www.ncbi.nlm.nih.gov/pubmed/8340919?dopt=AbstractPlus]	
Comments	The presence of a functional ADC activity in human tissues has been questioned [http://www.ncbi.nlm.nih.gov/pubmed/14763899?dopt=AbstractPlus].	AADC is a homodimer.	Inhibited by AMP‐activated protein kinase‐evoked phosphorylation [http://www.ncbi.nlm.nih.gov/pubmed/10854420?dopt=AbstractPlus]	The activity of ODC is regulated by the presence of an antizyme (http://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000104904;r=19:2269520‐2273487;t=ENST00000322297) and an ODC antizyme inhibitor (http://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000155096;r=8:103838585‐103906092).	S‐allylglycine is also an inhibitor of SAMDC [http://www.ncbi.nlm.nih.gov/pubmed/438812?dopt=AbstractPlus].	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5267 is also an inhibitor of SAMDC [http://www.ncbi.nlm.nih.gov/pubmed/438812?dopt=AbstractPlus].	



Further reading on Carboxylases and decarboxylases
Bale S et al. (2010) Structural biology of S‐adenosylmethionine decarboxylase. Amino Acids
38: 451–60 [https://www.ncbi.nlm.nih.gov/pubmed/19997761?dopt=AbstractPlus


Di Bartolomeo F et al. (2017) Cell biology, physiology and enzymology of phosphatidylserine decarboxylase. Biochim Biophys Acta Mol Cell Biol Lipids
1862: 25–38 https://www.ncbi.nlm.nih.gov/pubmed/27650064


Jitrapakdee S et al. (2008) Structure, mechanism and regulation of pyruvate carboxylase. Biochem. J. 413: 369–87 https://www.ncbi.nlm.nih.gov/pubmed/18613815?dopt=AbstractPlus


Lietzan AD et al. (2014) Functionally diverse biotin‐dependent enzymes with oxaloacetate decarboxylase activity. Arch. Biochem. Biophys. 544: 75–86 https://www.ncbi.nlm.nih.gov/pubmed/24184447?dopt=AbstractPlus


Sanchez‐Jimenez F et al. (2016) Structural and functional analogies and differences between histi‐dine decarboxylase and aromatic l‐amino acid decarboxylase molecular networks: Biomedical implications Pharmacol Res
114: 90–102 https://www.ncbi.nlm.nih.gov/pubmed/27769832


Salie MJ and Thelen JJ (2016) Regulation and structure of the heteromeric acetyl‐CoA carboxylase. Biochim Biophys Acta
1861: 1207–1213 https://www.ncbi.nlm.nih.gov/pubmed/27091637


Tong L. (2013) Structure and function of biotin‐dependent carboxylases. Cell. Mol. Life Sci. 70: 863–91 https://www.ncbi.nlm.nih.gov/pubmed/22869039?dopt=AbstractPlus


Vance JE et al. (2013) Formation and function of phosphatidylserine and phosphatidylethanolamine in mammalian cells. Biochim. Biophys. Acta
1831: 543–54 https://www.ncbi.nlm.nih.gov/pubmed/22960354?dopt=AbstractPlus



http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=766

Overview
Catecholamines are defined by the presence of two adjacent hydroxyls on a benzene ring with a sidechain containing an amine. The predominant catacholamines in mammalian biology are the neurotransmitter/hormones http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=940, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=505 (norepinephrine) and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=479 (epinephrine). These hormone/transmitters are synthesized by sequential metabolism from http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3313 via http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4791. Hydroxylation of http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4791 generates http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3639, which is decarboxylated to form http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=940. Hydroxylation of the ethylamine sidechain generates http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=505 (norepinephrine), which can be methylated to form http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=479 (epinephrine). In particular neuronal and adrenal chromaffin cells, the catecholamines http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=940, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=505 and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=479 are accumulated into vesicles under the influence of the http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=193 (VMAT1/SLC18A1 and VMAT2/SLC18A2). After release into the synapse or the blood‐stream, catecholamines are accumulated through the action cell‐surface transporters, primarily the dopamine (http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=144#Monoamine_transporter_subfamily) and norepinephrine transporter (http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=144#Monoamine transporter subfamily). The primary routes of metabolism of these catecholamines are oxidation via monoamine oxidase activities of methylation via catechol O‐methyltransferase.


Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1240
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2527
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1243
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2486
	
Common abbreviation	–	TAT	–	DBH	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8582, http://www.uniprot.org/uniprot/P00439
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11573, http://www.uniprot.org/uniprot/P17735
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11782, http://www.uniprot.org/uniprot/P07101
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2689, http://www.uniprot.org/uniprot/P09172
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.16.1: http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3313 + O2 ‐> http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4791
	
http://www.genome.jp/dbget‐bin/www_bget?ec:2.6.1.5: http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4791 + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3636 ‐> http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6629 + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1369
	
http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.16.2: http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4791 + O2 ‐> http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3639
	
http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.17.1: http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=940 + O2 = http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=505 + H2O	
Endogenous substrates	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3313
	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4791
	–	
Products	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4791
	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3639
	–	
Cofactors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5276
	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5249
	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5276, Fe2+
	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4164, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4781
	
Endogenous activators	Protein kinase A‐mediated phosphorylation (Rat) [http://www.ncbi.nlm.nih.gov/pubmed/182695?dopt=AbstractPlus]	–	Protein kinase A‐mediated phosphorylation [http://www.ncbi.nlm.nih.gov/pubmed/33381?dopt=AbstractPlus]	–	
Selective inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5093 [http://www.ncbi.nlm.nih.gov/pubmed/944951?dopt=AbstractPlus] – Rat, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5240
	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5095, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5114, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5117, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6956
	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6630 (pIC50 8) [http://www.ncbi.nlm.nih.gov/pubmed/9283721?dopt=AbstractPlus]	
Comments	PAH is an iron bound homodimer or ‐tetramer from the same structural family as tyrosine 3‐monooxygenase and the tryptophan hydroxylases. Deficiency or loss‐of‐function of PAH is associated with http://omim.org/entry/612349
	Tyrosine may also be metabolized in the liver by tyrosine transaminase to generate http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6629, which can be further metabolized to homogentisic acid. TAT is a homodimer, where loss‐of‐function mutations are associated with http://omim.org/entry/276600.	TH is a homotetramer, which is inhibited by dopamine and other catecholamines in a physiological negative feedback pathway [http://www.ncbi.nlm.nih.gov/pubmed/21176768?dopt=AbstractPlus].	DBH is a homotetramer. A protein structurally‐related to DBH (http://www.genenames.org/data/hgnc_data.php?hgnc_id=21063, http://www.uniprot.org/uniprot/Q6UVY6) has been described and for which a function has yet to be identified [http://www.ncbi.nlm.nih.gov/pubmed/9751809?dopt=AbstractPlus].	




Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1271
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2496
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2472
	
Common abbreviation	AADC	PNMT	COMT	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2719, http://www.uniprot.org/uniprot/P20711
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9160, http://www.uniprot.org/uniprot/P11086
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2228, http://www.uniprot.org/uniprot/P21964
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:4.1.1.28: http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3639 ‐> http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=940 + CO2
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4671 ‐> http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5 + CO2 This enzyme also catalyses the following reaction:: http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=717 ‐> http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=125 + CO2
	
http://www.genome.jp/dbget‐bin/www_bget?ec:2.1.1.28: http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=505 ‐> http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=479
	
http://www.genome.jp/dbget‐bin/www_bget?ec:2.1.1.6: S‐adenosyl‐L‐methionine + a catechol = S‐adenosyl‐L‐homocysteine + a guaiacol http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=505 ‐> http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6643
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=940 ‐> http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6642
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6633 ‐> http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6645
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=479 ‐> http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6644
	
Endogenous substrates	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3639, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4671, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=717
	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4786
	
Products	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=940
	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6646 (soluble enzyme) (pK
i 9.6) [http://www.ncbi.nlm.nih.gov/pubmed/7703232?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6646 (membrane‐bound enzyme) (pK
i 9.5) [http://www.ncbi.nlm.nih.gov/pubmed/7703232?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6647 (soluble enzyme) (pK
i 9.5) [http://www.ncbi.nlm.nih.gov/pubmed/7703232?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6647 (membrane‐bound enzyme) (pK
i 8.7) [http://www.ncbi.nlm.nih.gov/pubmed/7703232?dopt=AbstractPlus]	
Cofactors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5249
	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4786
	–	
Inhibitors	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6631 (pK
i 7.6) [http://www.ncbi.nlm.nih.gov/pubmed/6268095?dopt=AbstractPlus]	COMT appears to exist in both membrane‐bound and soluble forms. COMT has also been described to methylate steroids, particularly hydroxyestradiols	
Selective inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5116, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5217, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5150 [http://www.ncbi.nlm.nih.gov/pubmed/22384042?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5159
	–	–	
Comments	AADC is a homodimer.	–	–	




Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2489
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2490
	
Common abbreviation	MAO‐A	MAO‐B	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6833, http://www.uniprot.org/uniprot/P21397
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6834, http://www.uniprot.org/uniprot/P27338
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:1.4.3.4
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=479 ‐> http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6633 + NH3
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=505 ‐> http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6633 + NH3
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2150 ‐> http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6635 + NH3
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=940 ‐> http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6632 + NH3
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5 ‐> http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6634 + NH3
	
http://www.genome.jp/dbget‐bin/www_bget?ec:1.4.3.4
	
Cofactors	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5184 +	
Inhibitors	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6641 (pIC50 7.8) [http://www.ncbi.nlm.nih.gov/pubmed/11159700?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7266 (Irreversible inhibition) (pK
i 7.8) [http://www.ncbi.nlm.nih.gov/pubmed/18426226?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6640 (pK
i 7.1) [http://www.ncbi.nlm.nih.gov/pubmed/2122653?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/16137882?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6639 (pK
i 5.7–6) [http://www.ncbi.nlm.nih.gov/pubmed/15974574?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/21377879?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5281 (pIC50 4.7) [http://www.ncbi.nlm.nih.gov/pubmed/15110846?dopt=AbstractPlus]	
Selective inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5184
	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8291 (pK
i 6.3) [http://www.ncbi.nlm.nih.gov/pubmed/15027868?dopt=AbstractPlus]	
Comments	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7428 (pK
i 8.3) [http://www.ncbi.nlm.nih.gov/pubmed/21680183?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7266 (Irreversible inhibition) (pK
i 7.3) [http://www.ncbi.nlm.nih.gov/pubmed/18426226?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5281 (pIC50 4.7) [http://www.ncbi.nlm.nih.gov/pubmed/15110846?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6639 (pK
i 4.2) [http://www.ncbi.nlm.nih.gov/pubmed/21377879?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6637 [http://www.ncbi.nlm.nih.gov/pubmed/10333983?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6636, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6638 [http://www.ncbi.nlm.nih.gov/pubmed/9564636?dopt=AbstractPlus]	–	



Further reading on Catecholamine turnover
Bastos P et al. (2017) Catechol‐O‐Methyltransferase (COMT): An Update on Its Role in Cancer, Neuro‐and Cardiovascular Diseases. Rev Biochem Pharmacol
173: 1–39 https://www.ncbi.nlm.nih.gov/pubmed/28456872


Deshwal S etal. (2017) Emerging role of monoamine oxidase as a therapeutic target for cardiovascular disease. Curr Opin Pharmacol
33: 64–69 https://www.ncbi.nlm.nih.gov/pubmed/28528298?dopt=AbstractPlus


Fisar Z. (2016) Drugs related to monoamine oxidase activity. Prog. Neuropsychopharmacol. Biol. Psychiatry
69: 112–24 https://www.ncbi.nlm.nih.gov/pubmed/26944656?dopt=AbstractPlus


Ramsay RR. (2016) Molecular aspects of monoamine oxidase B. Prog. Neuropsychopharmacol. Biol. Psychiatry
69: 81–9 https://www.ncbi.nlm.nih.gov/pubmed/26891670?dopt=AbstractPlus


Walen K et al. (2017) Tyrosine and tryptophan hydroxylases as therapeutic targets in human disease. Expert Opin. Ther. Targets
21: 167–180 https://www.ncbi.nlm.nih.gov/pubmed/27973928?dopt=AbstractPlus



http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=767

Overview
Ceramides are a family of sphingophospholipids synthesized in the endoplasmic reticulum, which mediate cell stress responses, including apoptosis, autophagy and senescence, Serine palmitoyltransferase generates http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6654, which is reduced to http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2453 (dihydrosphingosine). N‐Acylation allows the formation of dihydroceramides, which are subsequently reduced to form ceramides. Once synthesized, ceramides are trafficked from the ER to the Golgi bound to the ceramide transfer protein, CERT (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2205, http://www.uniprot.org/uniprot/Q9Y5P4). Ceramide can be metabolized via multiple routes, ensuring tight regulation of its cellular levels. Addition of phosphocholine generates sphingomyelin while carbohydrate is added to form glucosyl‐ or galactosylceramides.

Ceramidase re‐forms sphingosine or sphinganine from ceramide or dihydroceramide. Phosphorylation of ceramide generates ceramide phosphate. The determination of accurate kinetic parameters for many of the enzymes in the sphingolipid metabolic pathway is complicated by the lipophilic nature of the substrates.


http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=788

Overview
The functional enzyme is a heterodimer of SPT1 (LCB1) with either SPT2 (LCB2) or SPT3 (LCB2B); the small subunits of SPT (ssSPTa or ssSPTb) bind to the heterodimer to enhance enzymatic activity. The complexes of SPT1/SPT2/ssSPTa and SPT1/SPT2/ssSPTb were most active with palmitoylCoA as substrate, with the latter complex also showing some activity with stearoylCoA [http://www.ncbi.nlm.nih.gov/pubmed/19416851?dopt=AbstractPlus]. Complexes involving SPT3 appeared more broad in substrate selectivity, with incorporation of myristoylCoA prominent for SPT1/SPT3/ssSPTa complexes, while SP1/SPT3/ssSPTb complexes had similar activity with C16, C18 and C20 acylCoAs [http://www.ncbi.nlm.nih.gov/pubmed/19416851?dopt=AbstractPlus].


Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2509
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2510
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2511
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2512
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2513
	
Common abbreviation	SPT1	SPT2	SPT3	SPTSSA	SPTSSB	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11277, http://www.uniprot.org/uniprot/O15269
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11278, http://www.uniprot.org/uniprot/O15270
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:16253, http://www.uniprot.org/uniprot/Q9NUV7
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:20361, http://www.uniprot.org/uniprot/Q969W0
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:24045, http://www.uniprot.org/uniprot/Q8NFR3
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:2.3.1.50: http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=726 + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6765 ‐>
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6654+ http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3044 + CO2
	
http://www.genome.jp/dbget‐bin/www_bget?ec:2.3.1.50: http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=726 + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6765 ‐>
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6654 + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3044 + CO2
	
http://www.genome.jp/dbget‐bin/www_bget?ec:2.3.1.50: http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=726 + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6765 ‐>
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6654+ http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3044 + CO2
	–	–	
Cofactors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5249
	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5249
	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5249
	–	–	
Selective inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6664 (pK
i 9.6) [http://www.ncbi.nlm.nih.gov/pubmed/7794249?dopt=AbstractPlus] – Mouse	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6664 [http://www.ncbi.nlm.nih.gov/pubmed/7794249?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6664 [http://www.ncbi.nlm.nih.gov/pubmed/7794249?dopt=AbstractPlus]	–	–	




http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=789

Overview
This family of enzymes, also known as sphingosine N‐acyltransferase, is located in the ER facing the cytosol with an as‐yet undefined topology and stoichiometry. Ceramide synthase in vitro is sensitive to inhibition by the fungal derived toxin, fumonisin B1.


Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2474
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2475
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2476
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2477
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2478
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2479
	
Common abbreviation	CERS1	CERS2	CERS3	CERS4	CERS5	CERS6	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:14253, http://www.uniprot.org/uniprot/P27544
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:14076, http://www.uniprot.org/uniprot/Q96G23
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:23752, http://www.uniprot.org/uniprot/Q8IU89
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:23747, http://www.uniprot.org/uniprot/Q9HA82
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:23749, http://www.uniprot.org/uniprot/Q8N5B7
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:23826, http://www.uniprot.org/uniprot/Q6ZMG9
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:2.3.1.24: acylCoA+ http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2453 ‐> dihydroceramide + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3044
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2452 + acylCoA ‐> ceramide + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3044
	
http://www.genome.jp/dbget‐bin/www_bget?ec:2.3.1.24: acylCoA + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2453 ‐> dihydroceramide + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3044
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2452 + acylCoA ‐> ceramide + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3044
	
http://www.genome.jp/dbget‐bin/www_bget?ec:2.3.1.24: acylCoA + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2453 ‐> dihydroceramide + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3044
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2452 + acylCoA ‐> ceramide + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3044
	
http://www.genome.jp/dbget‐bin/www_bget?ec:2.3.1.24: acylCoA + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2453 ‐> dihydroceramide + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3044
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2452 + acylCoA ‐> ceramide + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3044
	
http://www.genome.jp/dbget‐bin/www_bget?ec:2.3.1.24: acylCoA + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2453 ‐> dihydroceramide + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3044
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2452 + acylCoA ‐> ceramide + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3044
	
http://www.genome.jp/dbget‐bin/www_bget?ec:2.3.1.24: acylCoA + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2453 ‐> dihydroceramide + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3044
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2452 + acylCoA ‐> ceramide + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3044
	
Substrates	C18‐CoA [http://www.ncbi.nlm.nih.gov/pubmed/12105227?dopt=AbstractPlus]	C24‐ and C26‐CoA [http://www.ncbi.nlm.nih.gov/pubmed/18165233?dopt=AbstractPlus]	C26‐CoA and longer [http://www.ncbi.nlm.nih.gov/pubmed/14511335?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/18308723?dopt=AbstractPlus]	C18‐, C20‐ and C22‐CoA [http://www.ncbi.nlm.nih.gov/pubmed/12912983?dopt=AbstractPlus]	C16‐CoA [http://www.ncbi.nlm.nih.gov/pubmed/16100120?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12912983?dopt=AbstractPlus]	C14‐ and C16‐CoA [http://www.ncbi.nlm.nih.gov/pubmed/15823095?dopt=AbstractPlus]	




http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=790

Overview
DEGS1 and DEGS2 are 4TM proteins.


Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2484
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2485
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:13709, http://www.uniprot.org/uniprot/O15121
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:20113, http://www.uniprot.org/uniprot/Q6QHC5
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.‐.‐
	
http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.‐.‐
	
Cofactors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2451
	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2451
	
Inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6041 (pK
i 6.5) [http://www.ncbi.nlm.nih.gov/pubmed/24875537?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8879 (pIC50 4.7) [http://www.ncbi.nlm.nih.gov/pubmed/22537678?dopt=AbstractPlus]	–	
Comments	Myristoylation of DEGS1 enhances its activity and targets it to the mitochondria [http://www.ncbi.nlm.nih.gov/pubmed/19647031?dopt=AbstractPlus].	–	



Comments
DEGS1 activity is inhibited by a number of natural products, including http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7000 and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2424 [http://www.ncbi.nlm.nih.gov/pubmed/22200621?dopt=AbstractPlus].


http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=774

Overview
Following translocation from the ER to the Golgi under the influence of the ceramide transfer protein, sphingomyelin synthases allow the formation of sphingomyelin by the transfer of phosphocholine from the phospholipid phosphatidylcholine. Sphingomyelin synthase‐related protein 1 is structurally related but lacks sphingomyelin synthase activity.


Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2520
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2521
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2525
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:29799, http://www.uniprot.org/uniprot/Q86VZ5
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:28395, http://www.uniprot.org/uniprot/Q8NHU3
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:26320, http://www.uniprot.org/uniprot/Q96LT4
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.8.27: ceramide + phosphatidylcholine ‐> sphingomyelin + diacylglycerol	
http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.8.27: ceramide + phosphatidylcholine ‐> sphingomyelin + diacylglycerol	
http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.8.‐: ceramide + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2796 ‐> ceramide phosphoethanolamine	
Inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8835 (pIC50 5.7) [http://www.ncbi.nlm.nih.gov/pubmed/26314925?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8834 (pIC50 4.9) [http://www.ncbi.nlm.nih.gov/pubmed/24374347?dopt=AbstractPlus]	–	
Comments	–	Palmitoylation of sphingomyelin synthase 2 may allow targeting to the plasma membrane [http://www.ncbi.nlm.nih.gov/pubmed/19233134?dopt=AbstractPlus].	–	




http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=773

Overview
Also known as sphingomyelinase.


Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2514
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2515
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2516
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2517
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2518
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2519
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11120, http://www.uniprot.org/uniprot/P17405
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11121, http://www.uniprot.org/uniprot/O60906
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:14240, http://www.uniprot.org/uniprot/Q9NY59
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:32949, http://www.uniprot.org/uniprot/Q9NXE4
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:17389, http://www.uniprot.org/uniprot/Q92484
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:21416, http://www.uniprot.org/uniprot/Q92485
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.4.12: sphingomyelin ‐> ceramide + phosphocholine	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.4.12: sphingomyelin ‐> ceramide + phosphocholine	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.4.12: sphingomyelin ‐> ceramide + phosphocholine	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.4.12: sphingomyelin ‐> ceramide + phosphocholine	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.4.‐: sphingomyelin ‐> ceramide + phosphocholine	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.4.‐: sphingomyelin ‐> ceramide + phosphocholine	
Inhibitors	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8847 (pK
i 5.8) [http://www.ncbi.nlm.nih.gov/pubmed/12482429?dopt=AbstractPlus] – Bovine	–	–	–	–	




http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=772

Overview
Protein FAN [http://www.ncbi.nlm.nih.gov/pubmed/8808629?dopt=AbstractPlus] and polycomb protein EED [http://www.ncbi.nlm.nih.gov/pubmed/20080539?dopt=AbstractPlus] allow coupling between TNF receptors and neutral sphingomyelinase phosphodiesterases.


Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2487
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2495
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3188, http://www.uniprot.org/uniprot/O75530
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8017, http://www.uniprot.org/uniprot/Q92636
	
Selective inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9525 (Binding) (pK
i 9.4) [http://www.ncbi.nlm.nih.gov/pubmed/28135237?dopt=AbstractPlus]	–	




http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=775


Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2528
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:12524, http://www.uniprot.org/uniprot/Q16739
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:2.4.1.80: http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1783 + ceramide = http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1749 + glucosylceramide	
Inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4841 (pK
i 5.1) [68]	
Comments	Glycoceramides are an extended family of sphingolipids, differing in the content and organization of the sugar moieties, as well as the acyl sidechains.	




http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=769

Overview
The six human ceramidases may be divided on the basis of pH optimae into acid, neutral and alkaline ceramidases, which also differ in their subcellular location.


Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2491
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:735, http://www.uniprot.org/uniprot/Q13510
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.5.1.23: ceramide ‐>
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2452 + a fatty acid	
Comments	This lysosomal enzyme is proteolysed to form the mature protein made up of two chains from the same gene product [http://www.ncbi.nlm.nih.gov/pubmed/8955159?dopt=AbstractPlus].	




http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=770

Overview
The six human ceramidases may be divided on the basis of pH optimae into acid, neutral and alkaline ceramidases, which also differ in their subcellular location.


Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2492
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2493
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:18860, http://www.uniprot.org/uniprot/Q9NR71
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:23456, http://www.uniprot.org/uniprot/P0C7U1
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.5.1.23: ceramide ‐> http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2452 + a fatty acid	–	
Comments	The enzyme is associated with the plasma membrane [http://www.ncbi.nlm.nih.gov/pubmed/12499379?dopt=AbstractPlus].	–	



Comments
ASAH2B appears to be an enzymatically inactive protein, which may result from gene duplication and truncation.


http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=768

Overview
The six human ceramidases may be divided on the basis of pH optimae into acid, neutral and alkaline ceramidases, which also differ in their subcellular location.


Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2468
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2469
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2470
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:18356, http://www.uniprot.org/uniprot/Q8TDN7
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:23675, http://www.uniprot.org/uniprot/Q5QJU3
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:16066, http://www.uniprot.org/uniprot/Q9NUN7
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.5.1.23: ceramide ‐> http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2452 + a fatty acid	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.5.1.23: ceramide ‐> http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2452 + a fatty acid	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.5.1.‐	
Comments	ACER1 is associated with the ER [http://www.ncbi.nlm.nih.gov/pubmed/17713573?dopt=AbstractPlus].	ACER2 is associated with the Golgi apparatus [http://www.ncbi.nlm.nih.gov/pubmed/16940153?dopt=AbstractPlus].	ACER3 is associated with the ER and Golgi apparatus [http://www.ncbi.nlm.nih.gov/pubmed/11356846?dopt=AbstractPlus].	




http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=771


Nomenclature	
http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=771
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:19256, http://www.uniprot.org/uniprot/Q8TCT0
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.138: ceramide + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713 ‐> ceramide 1‐phosphate + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1712
	
Inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6668 (pIC50 7.9) [http://www.ncbi.nlm.nih.gov/pubmed/18612076?dopt=AbstractPlus]	



Comments
A ceramide kinase‐like protein has been identified in the human genome (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:21699, http://www.uniprot.org/uniprot/Q49MI3).

Further reading on Ceramide turnover
Brachtendorf S et al. (2019) Ceramide synthases in cancer therapy and chemoresistance. Prog Lipid Res
74: 160‐185 https://www.ncbi.nlm.nih.gov/pubmed/30953657


Chen Y and Cao Y. (2017) The sphingomyelin synthase family: proteins, diseases, and inhibitors. Biol Chem
398: 1319‐1325 https://www.ncbi.nlm.nih.gov/pubmed/28742512


Fang Z et al. (2019) Ceramide and sphingosine 1‐phosphate in adipose dysfunction. Prog Lipid Res
74: 145‐159 https://www.ncbi.nlm.nih.gov/pubmed/30951736


Hernández‐Corbacho MJ et al. (2017) Sphingolipids in mitochondria. Biochim Biophys Acta
1862: 56‐68 https://www.ncbi.nlm.nih.gov/pubmed/27697478?dopt=AbstractPlus


Ilan Y. (2016) Compounds of the sphingomyelin‐ceramide‐glycosphingolipid pathways as secondary messenger molecules: new targets for novel therapies for fatty liver disease and insulin resistance. Am. J. Physiol. Gastrointest. Liver Physiol. 310: G1102‐17 https://www.ncbi.nlm.nih.gov/pubmed/27173510?dopt=AbstractPlus


Iqbal J et al. (2017) Sphingolipids and Lipoproteins in Health and Metabolic Disorders. Trends Endocrinol. Metab. 28: 506‐518 https://www.ncbi.nlm.nih.gov/pubmed/28462811?dopt=AbstractPlus


Kihara A. (2016) Synthesis and degradation pathways, functions, and pathology of ceramides and epidermal acylceramides. Prog. Lipid Res. 63: 50‐69 https://www.ncbi.nlm.nih.gov/pubmed/27107674?dopt=AbstractPlus


Ogretmen B (2018) Sphingolipid metabolism in cancer signalling and therapy. Nat Rev Cancer
18: 33‐50 https://www.ncbi.nlm.nih.gov/pubmed/29147025


Parashuraman S and D’Angelo. (2019) Visualizing sphingolipid biosynthesis in cells. Chem Phys Lipids
218: 103‐111 https://www.ncbi.nlm.nih.gov/pubmed/30476485


Rodriguez‐Cuenca S et al. (2017) Sphingolipids and glycerophospholipids ‐ The “ying and yang” of lipotoxicity in metabolic diseases. Prog. Lipid Res. 66: 14‐29 https://www.ncbi.nlm.nih.gov/pubmed/28104532?dopt=AbstractPlus


Snider et al. (2019) Approaches for probing and evaluating mammalian sphingolipid metabolism. Anal Biochem
575: 70‐86 https://www.ncbi.nlm.nih.gov/pubmed/30917945


Vogt D et al. (2017) Therapeutic Strategies and Pharmacological Tools Influencing S1P Signaling and Metabolism. Med Res Rev
37: 3‐51 https://www.ncbi.nlm.nih.gov/pubmed/27480072?dopt=AbstractPlus


Wegner MS et al. (2016) The enigma of ceramide synthase regulation in mammalian cells. Prog. Lipid Res. 63: 93‐119 https://www.ncbi.nlm.nih.gov/pubmed/27180613?dopt=AbstractPlus



http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=865

Overview
Chromatin modifying enzymes, and other chromatin‐modifying proteins, fall into three broad categories: writers, readers and erasers. The function of these proteins is to dynamically maintain cell identity and regulate processes such as differentiation, development, proliferation and genome integrity via recognition of specific ’marks’ (covalent post‐translational modifications) on histone proteins and DNA [http://www.ncbi.nlm.nih.gov/pubmed/17320507?dopt=AbstractPlus]. In normal cells, tissues and organs, precise co‐ordination of these proteins ensures expression of only those genes required to specify phenotype or which are required at specific times, for specific functions. Chromatin modifications allow DNA modifications not coded by the DNA sequence to be passed on through the genome and underlies heritable phenomena such as X chromosome inactivation, aging, heterochromatin formation, reprogramming, and gene silencing (epigenetic control).

To date at least eight distinct types of modifications are found on histones. These include small covalent modifications such as acetylation, methylation, and phosphorylation, the attachment of larger modifiers such as ubiquitination or sumoylation, and ADP ribosylation, proline isomerization and deimination. Chromatin modifications and the functions they regulate in cells are reviewed by Kouzarides (2007) [http://www.ncbi.nlm.nih.gov/pubmed/17320507?dopt=AbstractPlus].


Writer proteins include the histone methyltransferases, histone acetyltransferases, some kinases and ubiquitin ligases.


Readers include proteins which contain methyl‐lysinerecognition motifs such as bromodomains, chromodomains, tudor domains, PHD zinc fingers, PWWP domains and MBT domains.


Erasers include the histone demethylases and histone deacetylases (HDACs and sirtuins).

Dysregulated epigenetic control can be associated with human diseases such as cancer [http://www.ncbi.nlm.nih.gov/pubmed/18337604?dopt=AbstractPlus], where awide variety of cellular and protein abberations are known to perturb chromatin structure, gene transcription and ultimately cellular pathways [http://www.ncbi.nlm.nih.gov/pubmed/21941284?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/24104525?dopt=AbstractPlus]. Due to the reversible nature of epigenetic modifications, chromatin regulators are very tractable targets for drug discovery and the development of novel therapeutics. Indeed, small molecule inhibitors of writers (e.g. http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6796 and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6805 target the DNA methyltransferases DNMT1 and DNMT3 for the treatment of myelodysplastic syndromes [http://www.ncbi.nlm.nih.gov/pubmed/21220589?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/24523604?dopt=AbstractPlus]) and erasers (e.g. the HDAC inhibitors http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6852, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7006 and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7496 for the treatment of T‐cell lymphomas [http://www.ncbi.nlm.nih.gov/pubmed/21493798?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/22124371?dopt=AbstractPlus]) are already being used in the clinic. The search for the next generation of compounds with improved specificity against chromatin‐associated proteins is an area of intense basic and clinical research [http://www.ncbi.nlm.nih.gov/pubmed/25974248?dopt=AbstractPlus]. Current progress in this field is reviewed by Simó‐Riudalbas and Esteller (2015) [http://www.ncbi.nlm.nih.gov/pubmed/25039449?dopt=AbstractPlus].


http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=254

Overview
Protein arginine N‐methyltransferases (PRMT, EC 2.1.1.‐) encompass histone arginine N‐methyltransferases (PRMT4, PRMT7, http://www.genome.jp/kegg‐bin/search_brite?option=‐a&search_string=2.1.1.125) and myelin basic protein N‐methyltransferases (PRMT7, http://www.genome.jp/kegg‐bin/search_brite?option=‐a&search_string=2.1.1.126). They are dimeric or tetrameric enzymes which use http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4786 as a methyl donor, generating http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5265 as a by‐product. They generate both mono‐methylated and dimethylated products; these may be symmetric (http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5271) or asym metric (http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5229) versions, where both guanidine nitrogens are monomethylated or one of the two is dimethylated, respectively.

Information on members of this family may be found in the http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=254.


http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=848

Overview
Histone deacetylases act as erasers of epigenetic acetylation marks on lysine residues in histones. Removal of the acetyl groups facilitates tighter packing of chromatin (heterochromatin formation) leading to transcriptional repression.

The histone deacetylase family has been classified in to five subfamilies based on phylogenetic comparison with yeast homologues:

Class I contains HDACs 1, 2, 3 and 8

Class IIa contains HDACs 4, 5, 7 and 9

Class IIb contains HDACs 6 and 10

Class III contains the sirtuins (SIRT1‐7)

Class IV contains only HDAC11.

Classes I, II and IV use Zn+ as a co‐factor, whereas catalysis by Class III enzymes requires NAD+ as a co‐factor, and members of this subfamily have ADP‐ribosylase activity in addition to protein deacetylase function [http://www.ncbi.nlm.nih.gov/pubmed/20132909?dopt=AbstractPlus].

HDACs have more general protein deacetylase activity, being able to deacetylate lysine residues in non‐histone proteins [http://www.ncbi.nlm.nih.gov/pubmed/19608861?dopt=AbstractPlus] such as microtubules [http://www.ncbi.nlm.nih.gov/pubmed/12024216?dopt=AbstractPlus], the hsp90 chaperone [http://www.ncbi.nlm.nih.gov/pubmed/15916966?dopt=AbstractPlus] and the tumour suppressor p53 [http://www.ncbi.nlm.nih.gov/pubmed/11099047?dopt=AbstractPlus].

Dysregulated HDACactivity has been identified in cancer cells and tumour tissues [http://www.ncbi.nlm.nih.gov/pubmed/11704848?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/19383284?dopt=AbstractPlus], making HDACs attractive molecular targets in the search for novel mechanisms to treat cancer [http://www.ncbi.nlm.nih.gov/pubmed/24382387?dopt=AbstractPlus]. Several small molecule HDAC inhibitors are already approved for clinical use: http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7006, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7496, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6852, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7489, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7496, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7009 and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8305. HDACs and HDAC inhibitors currently in development as potential anti‐cancer therapeutics are reviewed by Simó‐Riudalbas and Esteller (2015) [http://www.ncbi.nlm.nih.gov/pubmed/25039449?dopt=AbstractPlus].


Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2618
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:14064, http://www.uniprot.org/uniprot/Q9UBN7
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.5.1.98
	
Inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7005 (pK
i 9) [http://www.ncbi.nlm.nih.gov/pubmed/20139990?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6852 (pK
i 8.8) [http://www.ncbi.nlm.nih.gov/pubmed/20139990?dopt=AbstractPlus], romidepsin (pK
i 8) [http://www.ncbi.nlm.nih.gov/pubmed/20139990?dopt=AbstractPlus]	
Selective inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7010 (pIC50 8.3) [http://www.ncbi.nlm.nih.gov/pubmed/22262760?dopt=AbstractPlus]	



Further reading on 3.5.1.‐ Histone deacetylases (HDACs)
Ellmeier W et al. (2018) Histone deacetylase function in CD4+ T cells. Nat. Rev. Immunol. 18: 617‐634 https://www.ncbi.nlm.nih.gov/pubmed/30022149?dopt=AbstractPlus


Maolanon AR et al. (2017) Natural and Synthetic Macrocyclic Inhibitors of the Histone Deacetylase Enzymes. Chembiochem
18: 5‐49 https://www.ncbi.nlm.nih.gov/pubmed/27748555?dopt=AbstractPlus


Micelli C et al. (2015) Histone deacetylases: structural determinants of inhibitor selectivity. Drug Discov Today
20: 718‐35 https://www.ncbi.nlm.nih.gov/pubmed/25687212?dopt=AbstractPlus


Millard CJ et al. (2017) Targeting Class I Histone Deacetylases in a "Complex" Environment. Trends Pharmacol Sci
38: 363‐377 https://www.ncbi.nlm.nih.gov/pubmed/28139258?dopt=AbstractPlus


Roche J et al. (2016) Inside HDACs with more selective HDAC inhibitors. Eur J Med Chem
121: 451‐483 https://www.ncbi.nlm.nih.gov/pubmed/27318122?dopt=AbstractPlus


Zagni C et al. (2017) The Search for Potent, Small‐Molecule HDACIs in Cancer Treatment: A Decade After Vorinostat. Med Res Rev
37: 1373‐1428 https://www.ncbi.nlm.nih.gov/pubmed/28181261?dopt=AbstractPlus


Further reading on Chromatin modifying enzymes
Angus SP et al. (2018) Epigenetic Mechanisms Regulating Adaptive Responses to Targeted Kinase Inhibitors in Cancer. Annu Rev Pharmacol Toxicol
58: 209‐229 https://www.ncbi.nlm.nih.gov/pubmed/28934561?dopt=AbstractPlus


Bennett RL et al. (2018) Targeting Epigenetics in Cancer. Annu Rev Pharmacol Toxicol
58: 187‐207 https://www.ncbi.nlm.nih.gov/pubmed/28992434?dopt=AbstractPlus


Lauschke VM et al. (2018) Pharmacoepigenetics and Toxicoepigenetics: Novel Mechanistic Insights and Therapeutic Opportunities. Annu Rev Pharmacol Toxicol
58: 161‐185 https://www.ncbi.nlm.nih.gov/pubmed/29029592?dopt=AbstractPlus



http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=241

Overview
Cyclic nucleotides are second messengers generated by cyclase enzymes from precursor triphosphates and hydrolysed by phosphodiesterases. The cellular actions of these cyclic nucleotides are mediated through activation of protein kinases (http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=284‐ and http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=287‐dependent protein kinases), ion channels (http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=71, and http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=71) and guanine nucleotide exchange factors (GEFs, http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=259).


http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=257

Overview
Adenylyl cyclase, http://www.genome.jp/kegg‐bin/search_brite?option=‐a&search_string=4.6.1.1, converts http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713 to http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2352 and pyrophosphate. Mammalian membranedelimited adenylyl cyclases (nomenclature as approved by the NC‐IUPHAR Subcommittee on Adenylyl cyclases [http://www.ncbi.nlm.nih.gov/pubmed/28255005?dopt=AbstractPlus]) are typically made up of two clusters of six TM domains separating two intracellular, overlapping catalytic domains that are the target for the nonselective activators Gαs (the stimulatory G protein α subunit) and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5190 (except AC9, [http://www.ncbi.nlm.nih.gov/pubmed/8662814?dopt=AbstractPlus]). http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2844 and its derivatives (e.g. http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5108), acting through the P‐site,are inhibitors of adenylyl cyclase activity [http://www.ncbi.nlm.nih.gov/pubmed/11087399?dopt=AbstractPlus]. Four families of membranous adenylyl cyclase are distinguishable: http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2351 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1442
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1445
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1449, http://www.uniprot.org/uniprot/P62158)‐stimulated (AC1, AC3 and AC8), Ca2+‐ and Gβγ‐inhibitable (AC5, AC6 and AC9), Gβγ‐stimulated and Ca2+‐insensitive (AC2, AC4 and AC7), and forskolin‐insensitive (AC9) forms. A soluble adenylyl cyclase (AC10) lacks membrane spanning regions and is insensitive to G proteins.It functions as a cytoplasmic bicarbonate (pH‐insensitive) sensor [http://www.ncbi.nlm.nih.gov/pubmed/10915626?dopt=AbstractPlus].


Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1278
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1279
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1280
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1281
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1282
	
Common abbreviation	AC1	AC2	AC3	AC4	AC5	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:232, http://www.uniprot.org/uniprot/Q08828
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:233, http://www.uniprot.org/uniprot/Q08462
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:234, http://www.uniprot.org/uniprot/O60266
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:235, http://www.uniprot.org/uniprot/Q8NFM4
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:236, http://www.uniprot.org/uniprot/O95622
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:4.6.1.1
	
http://www.genome.jp/dbget‐bin/www_bget?ec:4.6.1.1
	
http://www.genome.jp/dbget‐bin/www_bget?ec:4.6.1.1
	
http://www.genome.jp/dbget‐bin/www_bget?ec:4.6.1.1
	
http://www.genome.jp/dbget‐bin/www_bget?ec:4.6.1.1
	
Endogenous activators	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2351 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1445, http://www.uniprot.org/uniprot/P62158), PKC‐evoked phosphorylation [http://www.ncbi.nlm.nih.gov/pubmed/8440678?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/2022671?dopt=AbstractPlus]	Gβγ, PKC‐evoked phosphorylation, Raf‐evoked phosphorylation [http://www.ncbi.nlm.nih.gov/pubmed/8389756?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/15385642?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8390980?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8416978?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2351 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1445, http://www.uniprot.org/uniprot/P62158), PKC‐evoked phosphorylation [http://www.ncbi.nlm.nih.gov/pubmed/1633161?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8440678?dopt=AbstractPlus]	Gβγ [http://www.ncbi.nlm.nih.gov/pubmed/1946437?dopt=AbstractPlus]	PKC‐evoked phophorylation, Gβγ, Raf‐evoked phophorylation [http://www.ncbi.nlm.nih.gov/pubmed/15385642?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/17110384?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8206971?dopt=AbstractPlus]	
Activators	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8809 (pIC50 7.7) [http://www.ncbi.nlm.nih.gov/pubmed/8709105?dopt=AbstractPlus] – Bovine	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10214 [http://www.ncbi.nlm.nih.gov/pubmed/11602596?dopt=AbstractPlus]	–	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10215 [http://www.ncbi.nlm.nih.gov/pubmed/11602596?dopt=AbstractPlus]	
Endogenous inhibitors	Gαi, Gαo, Gbg [http://www.ncbi.nlm.nih.gov/pubmed/8416978?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8119955?dopt=AbstractPlus]	–	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2808, Gβγ, CaM kinase II‐evoked phosphorylation [http://www.ncbi.nlm.nih.gov/pubmed/16275644?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/11234015?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7665559?dopt=AbstractPlus]	PKC‐evoked phophorylation [http://www.ncbi.nlm.nih.gov/pubmed/8900209?dopt=AbstractPlus]	Gαi, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=707, PKA‐evoked phosphorylation, Gβγ, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2509 [http://www.ncbi.nlm.nih.gov/pubmed/17110384?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10781930?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/1618857?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7759492?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8119955?dopt=AbstractPlus]	
Inhibitors	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=944 [http://www.ncbi.nlm.nih.gov/pubmed/24008337?dopt=AbstractPlus]	–	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5233 (pIC50 5.2) [http://www.ncbi.nlm.nih.gov/pubmed/24006339?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/11602596?dopt=AbstractPlus]	
Selective inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10092 (pIC50 5.6) [http://www.ncbi.nlm.nih.gov/pubmed/28223412?dopt=AbstractPlus]	–	–	–	–	
Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1283
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1284
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1285
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1286
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3068
	
Common abbreviation	AC6	AC7	AC8	AC9	AC10	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:237, http://www.uniprot.org/uniprot/O43306
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:238, http://www.uniprot.org/uniprot/P51828
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:239, http://www.uniprot.org/uniprot/P40145
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:240, http://www.uniprot.org/uniprot/O60503
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:21285, http://www.uniprot.org/uniprot/Q96PN6
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:4.6.1.1
	
http://www.genome.jp/dbget‐bin/www_bget?ec:4.6.1.1
	
http://www.genome.jp/dbget‐bin/www_bget?ec:4.6.1.1
	
http://www.genome.jp/dbget‐bin/www_bget?ec:4.6.1.1
	–	
Endogenous activators	Gβγ, Raf‐evoked phosphorylation [http://www.ncbi.nlm.nih.gov/pubmed/15385642?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/17110384?dopt=AbstractPlus]	Gβγ, PKC‐evoked phosphorylation [http://www.ncbi.nlm.nih.gov/pubmed/15581358?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7961850?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2351 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1445, http://www.uniprot.org/uniprot/P62158) [http://www.ncbi.nlm.nih.gov/pubmed/8163524?dopt=AbstractPlus]	–	Bicarbonate, Ca2+ [http://www.ncbi.nlm.nih.gov/pubmed/10915626?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12609998?dopt=AbstractPlus]	
Endogenous inhibitors	Gαi, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=707, PKA‐evoked phosphorylation, PKC‐evoked phosphorylation, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2509 [http://www.ncbi.nlm.nih.gov/pubmed/9391159?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10781930?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10462552?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8119955?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/1379717?dopt=AbstractPlus]	–	PKA‐evoked phosphorylation [http://www.ncbi.nlm.nih.gov/pubmed/22976297?dopt=AbstractPlus]	Ca2+/calcineurin [http://www.ncbi.nlm.nih.gov/pubmed/10987815?dopt=AbstractPlus]	–	
Inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5233 (pIC50 4.8) [http://www.ncbi.nlm.nih.gov/pubmed/24006339?dopt=AbstractPlus]	–	–	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10216 (pIC50 5–5.5) [http://www.ncbi.nlm.nih.gov/pubmed/16054031?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10023 (pIC50 5) [http://www.ncbi.nlm.nih.gov/pubmed/27547922?dopt=AbstractPlus]	



Comments
Many of the activators and inhibitors listed are only somewhat selective or have not been tested against all AC isoforms [http://www.ncbi.nlm.nih.gov/pubmed/24006339?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/24008337?dopt=AbstractPlus]. AC3 shows only modest in vitro activation by Ca2+/CaM.

Further reading on Adenylyl cyclases (ACs)
Dessauer CW et al. (2017) International Union of Basic and Clinical Pharmacology. CI. Structures and Small Molecule Modulators of Mammalian Adenylyl Cyclases. Pharmacol. Rev. 69: 93‐139 https://www.ncbi.nlm.nih.gov/pubmed/28255005?dopt=AbstractPlus


Halls ML et al. (2017) Adenylyl cyclase signalling complexes ‐ Pharmacological challenges and opportunities. Pharmacol. Ther. 172: 171‐180 https://www.ncbi.nlm.nih.gov/pubmed/28132906?dopt=AbstractPlus


Wiggins SV et al. (2018) Pharmacological modulation of the CO2/HCO‐
3/pH‐, calcium‐, and ATP‐sensing soluble adenylyl cyclase. Pharmacol Ther
190: 173‐186 https://www.ncbi.nlm.nih.gov/pubmed/29807057


Wu L et al. (2016) Adenylate cyclase 3: a new target for anti‐obesity drug development. Obes Rev
17: 907‐14 https://www.ncbi.nlm.nih.gov/pubmed/27256589?dopt=AbstractPlus



http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=259

Overview
Epacs are members of a family of guanine nucleotide exchange factors (http://www.ensembl.org/Homo_sapiens/Gene/Family/Genes?family=ENSFM00250000000899), which also includes https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:16862 (GFR, KIAA0277, MR‐GEF, http://www.uniprot.org/uniprot/Q92565) and https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:17428 (Link‐GEFII, http://www.uniprot.org/uniprot/Q9UHV5). They are activated endogenously by http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2352 and with some pharmacological selectivity by http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5172 [http://www.ncbi.nlm.nih.gov/pubmed/12402047?dopt=AbstractPlus]. Once activated, Epacs induce an enhanced activity of the monomeric G proteins, Rap1 and Rap2 by facilitating binding of http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1742 in place of http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2410, leading to activation of http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=244 [http://www.ncbi.nlm.nih.gov/pubmed/11715024?dopt=AbstractPlus].


Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1292
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1293
	
Common abbreviation	Epac1	Epac2	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:16629, http://www.uniprot.org/uniprot/O95398
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:16626, http://www.uniprot.org/uniprot/Q8WZA2
	
Inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7917 (pIC50 5.5) [http://www.ncbi.nlm.nih.gov/pubmed/23066090?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6556 (pIC50 6.5) [http://www.ncbi.nlm.nih.gov/pubmed/23286832?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7917 (pIC50 4.4–5.2) [http://www.ncbi.nlm.nih.gov/pubmed/23066090?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/24256330?dopt=AbstractPlus]	



Further reading on Exchange protein activated by cyclic AMP (EPACs)
Fujita T et al. (2017) The role of Epac in the heart. Cell. Mol. Life Sci. 74: 591‐606 https://www.ncbi.nlm.nih.gov/pubmed/27549789?dopt=AbstractPlus


Robichaux WG and Cheng X. (2018) Intracellular cAMP Sensor EPAC: Physiology, Pathophysiology, and Therapeutics Development. Physiol Rev
98: 919‐1053 https://www.ncbi.nlm.nih.gov/pubmed/29537337


Wang P et al. (2017) Exchange proteins directly activated by cAMP (EPACs): Emerging therapeutic targets. Bioorg. Med. Chem. Lett. 27: 1633‐1639 https://www.ncbi.nlm.nih.gov/pubmed/28283242?dopt=AbstractPlus



http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=260

Overview
3’,5’‐Cyclic nucleotide phosphodiesterases (PDEs, 3’,5’‐cyclic‐nucleotide 5’‐nucleotidohydrolase), http://www.genome.jp/kegg‐bin/search_brite?option=‐a&search_string=3.1.4.17, catalyse the hydrolysis of a 3’,5’‐cyclic nucleotide (usually http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2352 or http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2347). http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=388 is a nonselective inhibitor with an IC50 value in the millimolar range for all isoforms except PDE 8A, 8B and 9A. A 2’,3’‐cyclic nucleotide 3’‐phosphodiesterase (http://www.genome.jp/kegg‐bin/search_brite?option=‐a&search_string=3.1.4.37 CNPase) activity is associated with myelin formation in the development of the CNS.


Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1294
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1295
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1296
	
Common abbreviation	PDE1A	PDE1B	PDE1C	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8774, http://www.uniprot.org/uniprot/P54750
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8775, http://www.uniprot.org/uniprot/Q01064
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8776, http://www.uniprot.org/uniprot/Q14123
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.4.17
	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.4.17
	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.4.17
	
Rank order of affinity	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2347 > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2352
	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2347 > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2352
	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2347 = http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2352
	
Endogenous activators	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2351 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1442
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1445
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1449, http://www.uniprot.org/uniprot/P62158)	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2351 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1442
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1445
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1449, http://www.uniprot.org/uniprot/P62158)	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2351 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1442
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1445
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1449, http://www.uniprot.org/uniprot/P62158)	
Endogenous inhibitors	–	–	–	
Inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9151 (pIC50 5.2) [http://www.ncbi.nlm.nih.gov/pubmed/19303290?dopt=AbstractPlus]	–	–	
Sub/family‐selective inhibitors	–	–	–	
Selective inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5270 (pIC50 7.2) [http://www.ncbi.nlm.nih.gov/pubmed/8961086?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5285 (pIC50 5.1) [http://www.ncbi.nlm.nih.gov/pubmed/8557689?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5270 (pIC50 7.2) [http://www.ncbi.nlm.nih.gov/pubmed/8961086?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5270 (pIC50 7.2) [http://www.ncbi.nlm.nih.gov/pubmed/8961086?dopt=AbstractPlus], vinpocetine (pIC50 4.3) [http://www.ncbi.nlm.nih.gov/pubmed/8557689?dopt=AbstractPlus]	
Comments	–	–	–	




Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1297
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1298
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1299
	
Common abbreviation	PDE2A	PDE3A	PDE3B	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8777, http://www.uniprot.org/uniprot/O00408
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8778, http://www.uniprot.org/uniprot/Q14432
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8779, http://www.uniprot.org/uniprot/Q13370
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.4.17
	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.4.17
	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.4.17
	
Rank order of affinity	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2352 ≫ http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2347
	–	–	
Endogenous activators	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2347
	–	–	
Endogenous inhibitors	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2347
	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2347
	
Inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5225 (pIC50 <6.5) [http://www.ncbi.nlm.nih.gov/pubmed/10644042?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7148 (pIC50 6.7) [http://www.ncbi.nlm.nih.gov/pubmed/10644042?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7202 (pIC50 4.8) [http://www.ncbi.nlm.nih.gov/pubmed/2536438?dopt=AbstractPlus]	–	
Sub/family‐selective inhibitors	–	–	–	
Selective inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5147 (pIC50 8.3–8.8) [http://www.ncbi.nlm.nih.gov/pubmed/15555642?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5179 (pIC50 5.3) [http://www.ncbi.nlm.nih.gov/pubmed/8730511?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5167 (pIC50 7.5) [http://www.ncbi.nlm.nih.gov/pubmed/10644042?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7114 (pIC50 7.1–7.3) [http://www.ncbi.nlm.nih.gov/pubmed/3027338?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/1311763?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/1321910?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5225 (pIC50 6.3–6.4) [http://www.ncbi.nlm.nih.gov/pubmed/14592490?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10644042?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5167 (pIC50 7.3) [http://www.ncbi.nlm.nih.gov/pubmed/10644042?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7148 (pIC50 6.4) [http://www.ncbi.nlm.nih.gov/pubmed/10644042?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5225 (pIC50 6) [http://www.ncbi.nlm.nih.gov/pubmed/10644042?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7202 (pIC50 4.5) [http://www.ncbi.nlm.nih.gov/pubmed/10644042?dopt=AbstractPlus]	
Comments	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5179 is also an inhibitor of http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=248#show_object_1230 (http://www.genome.jp/kegg‐bin/search_brite?option=‐a&search_string=3.5.4.4).	–	–	




Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1300
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1301
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1302
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1303
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1304
	
Common abbreviation	PDE4A	PDE4B	PDE4C	PDE4D	PDE5A	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8780, http://www.uniprot.org/uniprot/P27815
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8781, http://www.uniprot.org/uniprot/Q07343
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8782, http://www.uniprot.org/uniprot/Q08493
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8783, http://www.uniprot.org/uniprot/Q08499
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8784, http://www.uniprot.org/uniprot/O76074
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.4.17
	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.4.17
	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.4.17
	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.4.17
	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.4.17
	
Rank order of affinity	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2352 ≫ http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2347
	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2352 ≫ http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2347
	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2352 ≫ http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2347
	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2352 ≫ http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2347
	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2347 > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2352
	
Activators	–	–	–	PKA‐mediated phosphorylation [http://www.ncbi.nlm.nih.gov/pubmed/12444918?dopt=AbstractPlus]	Protein kinase A, protein kinase G [http://www.ncbi.nlm.nih.gov/pubmed/10785399?dopt=AbstractPlus]	
Inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7399 (pIC50 7.3) [http://www.ncbi.nlm.nih.gov/pubmed/18686943?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6557 (pIC50 7.2) [http://www.ncbi.nlm.nih.gov/pubmed/9720765?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6962 (pIC50 9.4) [http://www.ncbi.nlm.nih.gov/pubmed/19195882?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7399 (pIC50 7.2) [http://www.ncbi.nlm.nih.gov/pubmed/18686943?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6557 (pIC50 6.5) [http://www.ncbi.nlm.nih.gov/pubmed/9720765?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6557 (pIC50 8.1) [http://www.ncbi.nlm.nih.gov/pubmed/9720765?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7399 (pIC50 6.6) [http://www.ncbi.nlm.nih.gov/pubmed/18686943?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6557 (pIC50 8.4) [http://www.ncbi.nlm.nih.gov/pubmed/9720765?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9776 (pIC50 >7.3) [446], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9610 (pIC50 6.1) [http://www.ncbi.nlm.nih.gov/pubmed/28613871?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6558 (pIC50 8.9) [http://www.ncbi.nlm.nih.gov/pubmed/22100260?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5225 (pIC50 7.3)	
Sub/family‐selective inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5260 (pIC50 9) [http://www.ncbi.nlm.nih.gov/pubmed/9177268?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9330 (pK
i 8) [http://www.ncbi.nlm.nih.gov/pubmed/9631241?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5258 (pIC50 6.5) [http://www.ncbi.nlm.nih.gov/pubmed/9177268?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5260 (pIC50 9) [http://www.ncbi.nlm.nih.gov/pubmed/9177268?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5258 (pIC50 6.4) [http://www.ncbi.nlm.nih.gov/pubmed/9177268?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9330 (pK
i 7.7) [http://www.ncbi.nlm.nih.gov/pubmed/9631241?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5260 (pIC50 6.5) [http://www.ncbi.nlm.nih.gov/pubmed/9177268?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5258 (pIC50 5.4) [http://www.ncbi.nlm.nih.gov/pubmed/9177268?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9330 (pK
i 8.1) [http://www.ncbi.nlm.nih.gov/pubmed/9631241?dopt=AbstractPlus], rolipram (pIC50 7.2) [http://www.ncbi.nlm.nih.gov/pubmed/9177268?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5258 (pIC50 6.2) [http://www.ncbi.nlm.nih.gov/pubmed/9177268?dopt=AbstractPlus]	–	
Selective inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5292 (pIC50 8.3) [http://www.ncbi.nlm.nih.gov/pubmed/10991987?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7372 (pIC50 7.8) [http://www.ncbi.nlm.nih.gov/pubmed/24882690?dopt=AbstractPlus]	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7372 (pIC50 6.9) [http://www.ncbi.nlm.nih.gov/pubmed/24882690?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7372 (pIC50 7.5) [http://www.ncbi.nlm.nih.gov/pubmed/24882690?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7320 (pIC50 9.7) [http://www.ncbi.nlm.nih.gov/pubmed/15837326?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5275 (pIC50 9.5) [http://www.ncbi.nlm.nih.gov/pubmed/12450574?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4743 (pIC50 8.4–9) [http://www.ncbi.nlm.nih.gov/pubmed/10385692?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/23137303?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7299 (pIC50 8.5) [http://www.ncbi.nlm.nih.gov/pubmed/21189023?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5270 (pIC50 7.2) [http://www.ncbi.nlm.nih.gov/pubmed/8961086?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2919 (pIC50 6.8) [http://www.ncbi.nlm.nih.gov/pubmed/10385692?dopt=AbstractPlus]	




Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1312
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1313
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1314
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1315
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1316
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1317
	
Common abbreviation	PDE6A	PDE6B	PDE6C	PDE6D	PDE6G	PDE6H	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8785, http://www.uniprot.org/uniprot/P16499
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8786, http://www.uniprot.org/uniprot/P35913
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8787, http://www.uniprot.org/uniprot/P51160
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8788, http://www.uniprot.org/uniprot/O43924
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8789, http://www.uniprot.org/uniprot/P18545
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8790, http://www.uniprot.org/uniprot/Q13956
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.4.17
	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.4.17
	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.4.17
	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.4.17
	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.4.17
	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.4.17
	
Inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8811 (pIC50 8) [http://www.ncbi.nlm.nih.gov/pubmed/19631533?dopt=AbstractPlus]	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4743 (pIC50 7.4) [http://www.ncbi.nlm.nih.gov/pubmed/23137303?dopt=AbstractPlus]	–	–	–	




Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1305
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1306
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1307
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1308
	
Common abbreviation	PDE7A	PDE7B	PDE8A	PDE8B	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8791, http://www.uniprot.org/uniprot/Q13946
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8792, http://www.uniprot.org/uniprot/Q9NP56
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8793, http://www.uniprot.org/uniprot/O60658
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8794, http://www.uniprot.org/uniprot/O95263
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.4.17
	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.4.17
	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.4.17
	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.4.17
	
Rank order of affinity	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2352 ≫ http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2347 [http://www.ncbi.nlm.nih.gov/pubmed/8389765?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2352 ≫ http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2347 [http://www.ncbi.nlm.nih.gov/pubmed/10872825?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2352 ≫ http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2347 [http://www.ncbi.nlm.nih.gov/pubmed/9618252?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2352 ≫ http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2347 [http://www.ncbi.nlm.nih.gov/pubmed/9784418?dopt=AbstractPlus]	
Inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9151 (pIC50 6.1) [http://www.ncbi.nlm.nih.gov/pubmed/19303290?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5154 (pIC50 4.9) [http://www.ncbi.nlm.nih.gov/pubmed/20228279?dopt=AbstractPlus]	–	–	
Selective inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5154 (pIC50 6.7–6.8) [http://www.ncbi.nlm.nih.gov/pubmed/20228279?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/15371556?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4807 (pIC50 5.7–6) [http://www.ncbi.nlm.nih.gov/pubmed/10872825?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10814504?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5270 (pIC50 5.8) [http://www.ncbi.nlm.nih.gov/pubmed/10814504?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9659 (pIC50 7.4) [http://www.ncbi.nlm.nih.gov/pubmed/24687066?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4807 (pIC50 5.1) [http://www.ncbi.nlm.nih.gov/pubmed/9618252?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4807 (pIC50 4.3) [http://www.ncbi.nlm.nih.gov/pubmed/9784418?dopt=AbstractPlus]	
Comments	PDE7A appears to be membrane‐bound or soluble for PDE7A1 and 7A2 splice variants, respectively	–	–	–	




Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1309
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1310
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1311
	
Common abbreviation	PDE9A	PDE10A	PDE11A	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8795, http://www.uniprot.org/uniprot/O76083
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8772, http://www.uniprot.org/uniprot/Q9Y233
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8773, http://www.uniprot.org/uniprot/Q9HCR9
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.4.17
	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.4.17
	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.4.17
	
Rank order of affinity	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2347 ≫ http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2352 [http://www.ncbi.nlm.nih.gov/pubmed/9624146?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2352, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2347 [http://www.ncbi.nlm.nih.gov/pubmed/10373451?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2352, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2347 [http://www.ncbi.nlm.nih.gov/pubmed/10725373?dopt=AbstractPlus]	
Inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5270 (pIC50 5.8) [http://www.ncbi.nlm.nih.gov/pubmed/9624146?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2919 (pIC50 4.5) [http://www.ncbi.nlm.nih.gov/pubmed/9624146?dopt=AbstractPlus]	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7299 (pIC50 6.5) [http://www.ncbi.nlm.nih.gov/pubmed/21189023?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6559 (pIC50 6.5) [http://www.ncbi.nlm.nih.gov/pubmed/22284362?dopt=AbstractPlus]	
Selective inhibitors	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9617 (pIC50 9.4) [http://www.ncbi.nlm.nih.gov/pubmed/19630403?dopt=AbstractPlus]	–	



Comments
PDE1A, 1B and 1C appear to act as soluble homodimers, while PDE2A is a membrane‐bound homodimer. PDE3A and PDE3B are membrane‐bound.

PDE4 isoforms are essentially http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2352 specific. The potency of http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5292 at other members of the PDE4 family has not been reported. PDE4B‐D long forms are inhibited by extracellular signal‐regulated kinase (ERK)‐mediated phosphorylation [http://www.ncbi.nlm.nih.gov/pubmed/10022832?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9639573?dopt=AbstractPlus]. PDE4A‐D splice variants can be membrane‐bound or cytosolic [http://www.ncbi.nlm.nih.gov/pubmed/12444918?dopt=AbstractPlus]. PDE4 isoforms may be labelled with http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5313.

PDE6 is a membrane‐bound tetramer composed of two catalytic chains (PDE6A or PDE6C and PDE6B), an inhibitory chain (PDE6G or PDE6H) and the PDE6D chain. The enzyme is essentially http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2347 specific and is activated by the a‐subunit of transducin (Gat) and inhibited by http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4743, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2919 and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4807 with potencies lower than those observed for PDE5A. Defects in PDE6B are a cause of retinitis pigmentosa and congenital stationary night blindness.

Further reading on Phosphodiesterases, 3’,5’‐cyclic nucleotide (PDEs)
Klussmann E. (2016) Protein‐protein interactions of PDE4 family members ‐ Functions, interactions and therapeutic value. Cell. Signal. 28: 713‐8 https://www.ncbi.nlm.nih.gov/pubmed/26498857?dopt=AbstractPlus


Korkmaz‐Icöz S et al. (2018) Targeting phosphodiesterase 5 as a therapeutic option against myocardial ischaemia/reperfusion injury and for treating heart failure. Br. J. Pharmacol. 175: 223‐231 https://www.ncbi.nlm.nih.gov/pubmed/28213937?dopt=AbstractPlus


Li H et al. (2018) Phosphodiesterase‐4 Inhibitors for the Treatment of Inflammatory Diseases. Front Pharmacol
9: 1048 https://www.ncbi.nlm.nih.gov/pubmed/30386231


Mehta A and Patel BM. (2019) Therapeutic opportunities in colon cancer: Focus on phosphodiesterase inhibitors. Life Sci
230: 150‐161 https://www.ncbi.nlm.nih.gov/pubmed/31125564


Ntontsi P et al. (2019) Experimental and investigational phosphodiesterase inhibitors in development for asthma. Expert Opin Investig Drugs
28: 261‐266 https://www.ncbi.nlm.nih.gov/pubmed/30678501


Pauls MM. (2018) The effect of phosphodiesterase‐5 inhibitors on cerebral blood flow in humans: A systematic review. J Cereb Blood Flow Metab
38: 189‐203 https://www.ncbi.nlm.nih.gov/pubmed/29256324


Peng T et al. (2018) Inhibitors of phosphodiesterase as cancer therapeutics. Eur J Med Chem
150: 742‐756 https://www.ncbi.nlm.nih.gov/pubmed/29574203


Svensson F et al. (2018) Fragment‐Based Drug Discovery of Phosphodiesterase Inhibitors. J Med Chem
61: 1415–1424 https://www.ncbi.nlm.nih.gov/pubmed/28800229


Wahlang B et al. (2018) Role of cAMP and phosphodiesterase signaling in liver health and disease. Cell Signal
49: 105‐115 https://www.ncbi.nlm.nih.gov/pubmed/29902522


Zagorska A et al. (2018) Phosphodiesterase 10 Inhibitors ‐ Novel Perspectives for Psychiatric and Neurodegenerative Drug Discovery. Curr Med Chem
25: 3455‐3481 https://www.ncbi.nlm.nih.gov/pubmed/29521210



http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=242

Overview
The cytochrome P450 enzyme family (CYP450), E.C. 1.14.‐.‐, were originally defined by their strong absorbance at 450 nm due to the reduced carbon monoxide‐complexed haem component of the cytochromes. They are an extensive family of haemcontaining monooxygenases with a huge range of both endogenous and exogenous substrates. These include sterols, fat‐soluble vitamins, pesticides and carcinogens as well as drugs. The substrates of some orphan CYP are not known. Listed below are the human enzymes; their relationship with rodent CYP450 enzyme activities is obscure in that the species orthologuemay not catalyse the metabolism of the same substrates. Although the majority of CYP450 enzyme activities are concentrated in the liver, the extrahepatic enzyme activities also contribute to patho/physiological processes. Genetic variation of CYP450 isoforms is widespread and likely underlies a significant proportion of the individual variation to drug administration.


http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=261


Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1318
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1319
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1320
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2595, http://www.uniprot.org/uniprot/P04798
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2596, http://www.uniprot.org/uniprot/P05177
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2597, http://www.uniprot.org/uniprot/Q16678
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.1.1
	
http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.1.1
	
http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.1.1
	
Inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8748 (pIC50 7.4) [http://www.ncbi.nlm.nih.gov/pubmed/23600958?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8748 (pIC50 6.4) [http://www.ncbi.nlm.nih.gov/pubmed/23600958?dopt=AbstractPlus]	stilbenes [http://www.ncbi.nlm.nih.gov/pubmed/28458135?dopt=AbstractPlus]	
Comments	CYP1A1 is an extra‐hepatic enzyme. It shows a preference for linear planar aromatic molecules [http://www.ncbi.nlm.nih.gov/pubmed/28698457?dopt=AbstractPlus].	CYP1A2 is constitutively expressed in liver. It shows a preference for triangular planar aromatic molecules [http://www.ncbi.nlm.nih.gov/pubmed/28698457?dopt=AbstractPlus].	Mainly expressed in extra‐hepatic tissues. Can metabolise 17β‐estradiol [http://www.ncbi.nlm.nih.gov/pubmed/28458135?dopt=AbstractPlus], leukotrienes and eicosanoids [http://www.ncbi.nlm.nih.gov/pubmed/23956430?dopt=AbstractPlus]. Mutations have been associated with primary congenitial glaucoma [http://www.ncbi.nlm.nih.gov/pubmed/9097971?dopt=AbstractPlus]	




http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=262


Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1321
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1322
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1323
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1324
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1325
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2610, http://www.uniprot.org/uniprot/P11509
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2611, http://www.uniprot.org/uniprot/P20853
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2608, http://www.uniprot.org/uniprot/Q16696
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2615, http://www.uniprot.org/uniprot/P20813
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2622, http://www.uniprot.org/uniprot/P10632
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.1
	
http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.1
	
http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.1
	
http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.1
	
http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.1
	
Substrates	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2585
	–	–	–	–	
Inhibitors	–	–	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7307 (pIC50 6.7) [http://www.ncbi.nlm.nih.gov/pubmed/16248836?dopt=AbstractPlus], sibutramine (pIC50 5.8) [http://www.ncbi.nlm.nih.gov/pubmed/23777987?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7622 (pK
i 5.3) [http://www.ncbi.nlm.nih.gov/pubmed/17682072?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7266 (pK
i 5.1) [http://www.ncbi.nlm.nih.gov/pubmed/16248836?dopt=AbstractPlus]	
Comments	Metabolises coumarin [http://www.ncbi.nlm.nih.gov/pubmed/2322567?dopt=AbstractPlus].	CYP2A7 does not incorporate haem and is functionally inactive [http://www.ncbi.nlm.nih.gov/pubmed/16636685?dopt=AbstractPlus]	Metabolises tobacco carcinogen, 4‐methylnitrosoamino)‐1‐(3‐pyridyl)‐1‐butanone [http://www.ncbi.nlm.nih.gov/pubmed/11016631?dopt=AbstractPlus].	Substrates include: efavirenz, bupropion, cyclophosphamide, ketamine, propofol [http://www.ncbi.nlm.nih.gov/pubmed/23152403?dopt=AbstractPlus].	Converts http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2391 to 11(R)‐12(S)‐epoxyeicosatrienoic acid or 14(R)‐15(S)‐epoxyeicosatrienoic acid [http://www.ncbi.nlm.nih.gov/pubmed/7574697?dopt=AbstractPlus]. Drug substrates include http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10018 [http://www.ncbi.nlm.nih.gov/pubmed/26721703?dopt=AbstractPlus].	




Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1328
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1329
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1330
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1331
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1332
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1333
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2621, http://www.uniprot.org/uniprot/P33261
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2625, http://www.uniprot.org/uniprot/P10635
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2631, http://www.uniprot.org/uniprot/P05181
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2632, http://www.uniprot.org/uniprot/P24903
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2634, http://www.uniprot.org/uniprot/P51589
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:20580, http://www.uniprot.org/uniprot/Q6VVX0
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.51 (S)‐limonene + [reduced NADPH–hemoprotein reductase] + O(2) <=> (‐)‐trans‐carveol + [oxidized NADPH–hemoprotein reductase] + H(2)O	
http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.1
	
http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.1
	
http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.1
	
http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.1
	
http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.13.15
	
Inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8777 (pIC50 7.3) [120]	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8756 (pK
i 7.4) [http://www.ncbi.nlm.nih.gov/pubmed/17125252?dopt=AbstractPlus]	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8832 (pIC50 6.8) [http://www.ncbi.nlm.nih.gov/pubmed/16495056?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2608 (pIC50 5.1) [http://www.ncbi.nlm.nih.gov/pubmed/16495056?dopt=AbstractPlus]	–	
Selective inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8749 (pK
i 7.7) [http://www.ncbi.nlm.nih.gov/pubmed/22239545?dopt=AbstractPlus]	–	–	–	–	–	
Comments	Substrates include: omeprazole, proguanil, mephenytoin, diazepam [http://www.ncbi.nlm.nih.gov/pubmed/2495208?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12222994?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/2291871?dopt=AbstractPlus].	Substrates include: debrisoquine, metoprolol, codeine [http://www.ncbi.nlm.nih.gov/pubmed/19102711?dopt=AbstractPlus].	Substrates: Ethanol, p‐nitrophenol [http://www.ncbi.nlm.nih.gov/pubmed/30380359?dopt=AbstractPlus].	Substrate: naphthalene [http://www.ncbi.nlm.nih.gov/pubmed/20408502?dopt=AbstractPlus].	Converts http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2391 to 14(R)‐15(S)‐epoxyeicosatrienoic acid [http://www.ncbi.nlm.nih.gov/pubmed/8631948?dopt=AbstractPlus]. Hydroxylates albendazole[http://www.ncbi.nlm.nih.gov/pubmed/23959307?dopt=AbstractPlus]. Expressed in cardiomyocytes [http://www.ncbi.nlm.nih.gov/pubmed/29695613?dopt=AbstractPlus].	Converts http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2747 to http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6921 [http://www.ncbi.nlm.nih.gov/pubmed/12867411?dopt=AbstractPlus].	




http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=263


Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1337
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1338
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1339
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1340
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2637, http://www.uniprot.org/uniprot/P08684
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2638, http://www.uniprot.org/uniprot/P20815
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2640, http://www.uniprot.org/uniprot/P24462
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:17450, http://www.uniprot.org/uniprot/Q9HB55
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.56: 1,8‐cineole + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3041 + O2 = 2‐exo‐hydroxy‐1,8‐cineole + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3045 + H2O http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.13.97: Taurochenodeoxycholate + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3041 + O2 = taurohyocholate + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3045 + H2O Lithocholate + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3041 + O2 = hyodeoxycholate + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3045 + H2O http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.55: http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2510 + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3041 + O2 = 3‐hydroxyquinine + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3045 + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2448
	
http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.1
	
http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.1
	
http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.1
	
Substrates	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2514 [http://www.ncbi.nlm.nih.gov/pubmed/3514607?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3342 [http://www.ncbi.nlm.nih.gov/pubmed/12124305?dopt=AbstractPlus]	–	–	–	
Inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10209 (pK
i 7.8) [http://www.ncbi.nlm.nih.gov/pubmed/26002732?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2568 (pK
i 7) [http://www.ncbi.nlm.nih.gov/pubmed/25923589?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8804 (pK
i >7) [http://www.ncbi.nlm.nih.gov/pubmed/18285471?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8804 (pK
i 6.9) [http://www.ncbi.nlm.nih.gov/pubmed/16248836?dopt=AbstractPlus]	–	–	
Comments	Metabolises a vast range of xenobiotics, including antidepressants, benzodiazepines, calcium channel blockers, and chemotherapeutic agents [http://www.ncbi.nlm.nih.gov/pubmed/18473749?dopt=AbstractPlus]. The active site is plastic, with both homotropic and heterotropic cooperativity observed with some substrates [http://www.ncbi.nlm.nih.gov/pubmed/26002732?dopt=AbstractPlus]. CYP3A4 catalyses the 25‐hydroxylation of http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2767 in liver microsomes [http://www.ncbi.nlm.nih.gov/pubmed/9931427?dopt=AbstractPlus].	CYP3A5 is expressed extrahepatically, including in the small intestine. It has overlapping substrate specificity with CYP3A4 [http://www.ncbi.nlm.nih.gov/pubmed/16430309?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12124305?dopt=AbstractPlus].	Fetal form, rarely expressed in adults. Has overlapping substrate specificity with CYP3A4 [http://www.ncbi.nlm.nih.gov/pubmed/16430309?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12124305?dopt=AbstractPlus].	Fetal expression only and considered an orphan fCYP [http://www.ncbi.nlm.nih.gov/pubmed/21737533?dopt=AbstractPlus]. Testosterone may be a substrate [http://www.ncbi.nlm.nih.gov/pubmed/11160875?dopt=AbstractPlus].	




http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=264


Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1341
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1342
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1343
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1344
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1345
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2642, http://www.uniprot.org/uniprot/Q02928
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:20575, http://www.uniprot.org/uniprot/Q5TCH4
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2644, http://www.uniprot.org/uniprot/P13584
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2645, http://www.uniprot.org/uniprot/P78329
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2646, http://www.uniprot.org/uniprot/Q08477
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.80
	
http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.80
	
http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.1
	
http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.78
http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.79
http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.94
	
http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.78
http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.79
http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.94
	
Inhibitors	–	–	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8851 (pK
i 5.9) [http://www.ncbi.nlm.nih.gov/pubmed/2997155?dopt=AbstractPlus]	–	
Comments	Converts http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5534 to http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6922.	Reported to be enzymatically inactive [http://www.ncbi.nlm.nih.gov/pubmed/15611369?dopt=AbstractPlus].	–	Responsible for ω‐hydroxylation of http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2487, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5216 [http://www.ncbi.nlm.nih.gov/pubmed/8389204?dopt=AbstractPlus], and tocopherols, including vitamin E [http://www.ncbi.nlm.nih.gov/pubmed/11997390?dopt=AbstractPlus]	Responsible for ω‐hydroxylation of http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2487, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5216 [http://www.ncbi.nlm.nih.gov/pubmed/8389204?dopt=AbstractPlus], and polyunsaturated fatty acids [http://www.ncbi.nlm.nih.gov/pubmed/18577768?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/16820285?dopt=AbstractPlus]	




Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1346
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1347
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1348
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1349
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1350
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1351
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1352
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2648, http://www.uniprot.org/uniprot/P98187
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:13265, http://www.uniprot.org/uniprot/Q9HBI6
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:18857, http://www.uniprot.org/uniprot/Q9HCS2
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:26820, http://www.uniprot.org/uniprot/Q6NT55
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:23198, http://www.uniprot.org/uniprot/Q6ZWL3
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:20244, http://www.uniprot.org/uniprot/Q8N118
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:20583, http://www.uniprot.org/uniprot/Q86W10
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.1
	
http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.1
http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.78
	
http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.1
	
http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.‐
	
http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.79
	
http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.1
	
http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.1
	
Comments	Converts http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4483 to 19‐hydroxyPGH2 [http://www.ncbi.nlm.nih.gov/pubmed/10791960?dopt=AbstractPlus] and 8,9‐EET or 11,12‐EET to 18‐hydroxy‐8,9‐EET or 18‐hydroxy‐11,12‐EET [http://www.ncbi.nlm.nih.gov/pubmed/19919823?dopt=AbstractPlus].	–	AC004597.1 (http://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000225607;r=19:15880826‐15890774;t=ENST00000412610) is described as being highly similar to CYP4F12	Converts http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2391 to http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6923 and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6924 [http://www.ncbi.nlm.nih.gov/pubmed/19919823?dopt=AbstractPlus].	Converts http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2806 to 14‐hydroxymyristic acid [http://www.ncbi.nlm.nih.gov/pubmed/19661213?dopt=AbstractPlus].	Converts http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2364 to 14,15‐poxyeicosatrienoic ethanolamide [http://www.ncbi.nlm.nih.gov/pubmed/18549450?dopt=AbstractPlus].	Converts lauric acid to 12‐hydroxylauric acid.	




http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=265


Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1353
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1354
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1355
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1356
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1357
	
Common abbreviation	Thromboxane synthase	–	–	Prostacyclin synthase	–	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11609, http://www.uniprot.org/uniprot/P24557
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2651, http://www.uniprot.org/uniprot/P22680
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2652, http://www.uniprot.org/uniprot/O75881
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9603, http://www.uniprot.org/uniprot/Q16647
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2653, http://www.uniprot.org/uniprot/Q9UNU6
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:5.3.99.5: http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4483 = http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4482
	
http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.23
	
http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.29
	
http://www.genome.jp/dbget‐bin/www_bget?ec:5.3.99.4
	
http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.139
http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.18.8
	
Inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9866 (pIC50 8.4) [http://www.ncbi.nlm.nih.gov/pubmed/3093741?dopt=AbstractPlus]	–	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8795 (pIC50 >6) [http://www.ncbi.nlm.nih.gov/pubmed/7861416?dopt=AbstractPlus]	–	
Comments	Inhibited by http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5175 [http://www.ncbi.nlm.nih.gov/pubmed/6795753?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5157 [http://www.ncbi.nlm.nih.gov/pubmed/7778318?dopt=AbstractPlus] and furegrelate sodium (U‐63557A: PubChem https://pubchem.ncbi.nlm.nih.gov/compound/23663954) [http://www.ncbi.nlm.nih.gov/pubmed/6316421?dopt=AbstractPlus].	Converts http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2718 to http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4351 [http://www.ncbi.nlm.nih.gov/pubmed/2384150?dopt=AbstractPlus].	Converts http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2370 to 7α‐DHEA [http://www.ncbi.nlm.nih.gov/pubmed/9144166?dopt=AbstractPlus].	Converts http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4483 to http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1915 [http://www.ncbi.nlm.nih.gov/pubmed/8766713?dopt=AbstractPlus]. Inhibited by http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5281 [http://www.ncbi.nlm.nih.gov/pubmed/824685?dopt=AbstractPlus]	Converts 7α‐hydroxycholest‐4‐en‐3‐one to 7‐alpha, 12α‐dihydroxycholest‐4‐en‐3‐one (in rabbit) [http://www.ncbi.nlm.nih.gov/pubmed/1400444?dopt=AbstractPlus] in the biosynthesis of bile acids.	




http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=266


Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1358
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1359
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1360
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1361
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1362
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1363
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1364
	
Common abbreviation	–	–	Aldosterone synthase	–	Aromatase	–	–	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2590, http://www.uniprot.org/uniprot/P05108
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2591, http://www.uniprot.org/uniprot/P15538
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2592, http://www.uniprot.org/uniprot/P19099
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2593, http://www.uniprot.org/uniprot/P05093
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2594, http://www.uniprot.org/uniprot/P11511
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:20576, http://www.uniprot.org/uniprot/Q6UW02
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2600, http://www.uniprot.org/uniprot/P08686
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.15.6
	
http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.15.4
	
http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.15.4
http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.15.5
	
http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.19
http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.32
	
http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.14
	
http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.‐.‐
	
http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.16
	
Inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6957 [http://www.ncbi.nlm.nih.gov/pubmed/23254310?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/17395972?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5224 (pIC50 7.8) [http://www.ncbi.nlm.nih.gov/pubmed/21129965?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6957
	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8310 (pIC50 9.7) [http://www.ncbi.nlm.nih.gov/pubmed/24899257?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6745 (pIC50 7.1–8.4) [http://www.ncbi.nlm.nih.gov/pubmed/18672868?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7608911?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5137 (pIC50 7.8) [http://www.ncbi.nlm.nih.gov/pubmed/20413308?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7054 [http://www.ncbi.nlm.nih.gov/pubmed/19470632?dopt=AbstractPlus]	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8871 (pIC50 5.3) [http://www.ncbi.nlm.nih.gov/pubmed/1495014?dopt=AbstractPlus] – Rat	
Selective inhibitors	–	–	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8638 (pIC50 6.5) [http://www.ncbi.nlm.nih.gov/pubmed/15828836?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5209 (pK
i 10.7) [http://www.ncbi.nlm.nih.gov/pubmed/22386564?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7073 (pIC50 7.3) [http://www.ncbi.nlm.nih.gov/pubmed/2951074?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7303 (pK
i 4.5) [http://www.ncbi.nlm.nih.gov/pubmed/7083195?dopt=AbstractPlus]	–	–	
Comments	Converts http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2718 to http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2376 plus 4‐methylpentanal.	Converts http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3450 and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5100 to http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5171 and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2868, respectively. Loss‐of‐function mutations are associated with familial adrenal hyperplasia and hypertension. Inhibited by http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5224 [http://www.ncbi.nlm.nih.gov/pubmed/412519?dopt=AbstractPlus]	Converts http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2869 to http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2872
	Converts http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2376 and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2377 to http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5104 and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5103, respectively. Converts http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5103 and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5103 to http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2370 and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2860, respectively. Converts http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2869 to http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2868.	Converts http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2860 and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2858 to http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2818 and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1013, respectively. Inhibited by http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5137 [http://www.ncbi.nlm.nih.gov/pubmed/7949201?dopt=AbstractPlus], and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5209 [http://www.ncbi.nlm.nih.gov/pubmed/2149502?dopt=AbstractPlus]	–	Converts http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2377 and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5103 to http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3450 and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5100, respectively	




http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=267


Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1365
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1366
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1367
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1368
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1369
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1370
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1371
	
Common abbreviation	–	–	–	–	Sterol 27‐hydroxylase	–	–	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2602, http://www.uniprot.org/uniprot/Q07973
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2603, http://www.uniprot.org/uniprot/O43174
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:20581, http://www.uniprot.org/uniprot/Q9NR63
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:20577, http://www.uniprot.org/uniprot/Q6V0L0
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2605, http://www.uniprot.org/uniprot/Q02318
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2606, http://www.uniprot.org/uniprot/O15528
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:33480, http://www.uniprot.org/uniprot/Q4G0S4
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.15.16
	
http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.‐.‐
	
http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.‐.‐
	
http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.‐.‐
	
http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.15.15
	
http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.15.18
	
http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.19.53
	
Inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8858 (pIC50 8.1) [http://www.ncbi.nlm.nih.gov/pubmed/15615534?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8819 (pIC50 8.1) [http://www.ncbi.nlm.nih.gov/pubmed/15615534?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8852 (pIC50 4.8) [http://www.ncbi.nlm.nih.gov/pubmed/20655626?dopt=AbstractPlus]	–	–	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8852 (pIC50 7.2) [http://www.ncbi.nlm.nih.gov/pubmed/20655626?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8858 (pIC50 <6) [http://www.ncbi.nlm.nih.gov/pubmed/15615534?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8858 (pIC50 6.3) [http://www.ncbi.nlm.nih.gov/pubmed/15615534?dopt=AbstractPlus]	–	
Selective inhibitors	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8790 (pIC50 9.5) [http://www.ncbi.nlm.nih.gov/pubmed/21838328?dopt=AbstractPlus]	–	–	–	–	–	
Comments	Converts http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2779 (calcitriol) to 1α,24R,25‐trihydroxyvitamin D3.	Converts retinoic acid to 4‐hydroxyretinoic acid. Inhibited by http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5210
	Converts retinoic acid to 4‐hydroxyretinoic acid.	Converts retinoic acid to 4‐hydroxyretinoic acid [http://www.ncbi.nlm.nih.gov/pubmed/14532297?dopt=AbstractPlus].	Converts http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2718 to http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2752.	Converts 25‐hydroxyvitamin D3 to http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2779 (calcitriol)	Converts http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4053 (vitamin A1) to 3,4‐didehydroretinol (vitamin A2) [http://www.ncbi.nlm.nih.gov/pubmed/27059013?dopt=AbstractPlus].	




http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=268


Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1372
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1373
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1374
	
Common abbreviation	–	Cholesterol 24‐hydroxylase	Lanosterol 14‐α‐demethylase	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:17449, http://www.uniprot.org/uniprot/Q9NYL5
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2641, http://www.uniprot.org/uniprot/Q9Y6A2
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2649, http://www.uniprot.org/uniprot/Q16850
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.26
	
http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.25
	–	
Inhibitors	–	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8799 (pK
i 9.1) [http://www.ncbi.nlm.nih.gov/pubmed/8340925?dopt=AbstractPlus]	
Comments	Converts 24‐hydroxycholesterol to 7α,24‐dihydroxycholesterol [http://www.ncbi.nlm.nih.gov/pubmed/10748047?dopt=AbstractPlus].	Converts http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2718 to http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2750.	Converts http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2746 to 4,4‐dimethylcholesta‐8.14.24‐trienol.	



Further reading on Cytochrome P450
Backman JT et al. (2016) Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions. Pharmacol Rev
68: 168‐241 https://www.ncbi.nlm.nih.gov/pubmed/26721703?dopt=AbstractPlus


Davis CM et al. (2017) Cytochrome P450 eicosanoids in cerebrovascular function and disease. Pharmacol Ther
179: 31‐46 https://www.ncbi.nlm.nih.gov/pubmed/28527918?dopt=AbstractPlus


Ghosh D et al. (2016) Recent Progress in the Discovery of Next Generation Inhibitors of Aromatase from the Structure‐Function Perspective. J Med Chem. 59: 5131‐48 https://www.ncbi.nlm.nih.gov/pubmed/26689671?dopt=AbstractPlus


Go RE et al. (2015) Cytochrome P450 1 family and cancers. J Steroid Biochem Mol Biol. 147: 24‐30 https://www.ncbi.nlm.nih.gov/pubmed/25448748?dopt=AbstractPlus


Guengerich FP et al. (2016) Recent Structural Insights into Cytochrome P450 Function. Trends Pharmacol Sci
37: 625‐640 https://www.ncbi.nlm.nih.gov/pubmed/27267697?dopt=AbstractPlus


Imig JD. (2018) Prospective for cytochrome P450 epoxygenase cardiovascular and renal therapeutics. Pharmacol Ther
192: 1‐19 https://www.ncbi.nlm.nih.gov/pubmed/29964123?dopt=AbstractPlus


Isvoran A et al. (2017) Pharmacogenomics of the cytochrome P450 2C family: impacts of amino acid variations on drug metabolism. Drug Discov Today
22: 366‐376 https://www.ncbi.nlm.nih.gov/pubmed/27693711?dopt=AbstractPlus


Jamieson KL et al. (2017) Cytochrome P450‐derived eicosanoids and heart function. Pharmacol Ther
179: 47–83 https://www.ncbi.nlm.nih.gov/pubmed/28551025?dopt=AbstractPlus


Mak PJ et al. (2018) Spectroscopic studies of the cytochrome P450 reaction mechanisms. Biochim Biophys Acta
1866: 178‐204 https://www.ncbi.nlm.nih.gov/pubmed/28668640?dopt=AbstractPlus


Moutinho M et al. (2016) Cholesterol 24‐hydroxylase: Brain cholesterol metabolism and beyond. Biochim Biophys Acta
1861: 1911‐1920 https://www.ncbi.nlm.nih.gov/pubmed/27663182?dopt=AbstractPlus


Shalan H et al. (2018) Keeping the spotlight on cytochrome P450. Biochim Biophys Acta
1866: 80‐87 https://www.ncbi.nlm.nih.gov/pubmed/28599858?dopt=AbstractPlus



http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=851

Overview
DNA topoisomerases regulate the supercoiling of nuclear DNA to influence the capacity for replication or transcription. The enzymatic function of this series of enzymes involves cutting the DNA to allow unwinding, followed by re‐attachment to reseal the backbone. Members of the family are targetted in anti‐cancer chemotherapy.


Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2636
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2637
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11986, http://www.uniprot.org/uniprot/P11387
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11989, http://www.uniprot.org/uniprot/P11388
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:5.99.1.2
	
http://www.genome.jp/dbget‐bin/www_bget?ec:5.99.1.2
	
Inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6823 [http://www.ncbi.nlm.nih.gov/pubmed/9655905?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8182764?dopt=AbstractPlus] – Bovine	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6815 (pIC50 7.3), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6843 [http://www.ncbi.nlm.nih.gov/pubmed/2557897?dopt=AbstractPlus] – Mouse	



Further reading on DNA topoisomerases
Bansal S et al. (2017) Topoisomerases: Resistance versus Sensitivity, How Far We Can Go? Med Res Rev
37: 404‐438 https://www.ncbi.nlm.nih.gov/pubmed/27687257?dopt=AbstractPlus


Capranico G et al. (2017) Type I DNA Topoisomerases. J. Med. Chem. 60: 2169‐2192 https://www.ncbi.nlm.nih.gov/pubmed/28072526?dopt=AbstractPlus


Nagaraja V et al. (2017) DNA topoisomerase I and DNA gyrase as targets for TB therapy. Drug Discov. Today
22: 510‐518 https://www.ncbi.nlm.nih.gov/pubmed/27856347?dopt=AbstractPlus


Pommier Y et al. (2016) Roles of eukaryotic topoisomerases in transcription, replication and genomic stability. Nat. Rev. Mol. Cell Biol. 17: 703‐721 https://www.ncbi.nlm.nih.gov/pubmed/27649880?dopt=AbstractPlus


Seol Y et al. (2016) The dynamic interplay between DNA topoisomerases and DNA topology. Biophys Rev
8: 101‐111 https://www.ncbi.nlm.nih.gov/pubmed/28510219?dopt=AbstractPlus



http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=943

Overview
The principle endocannabinoids are 2‐acylglycerol esters, such as http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=729 (2‐AG), and N‐acylethanolamines, such as http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2364 (N‐arachidonoylethanolamine, AEA). The glycerol esters and ethanolamides are synthesised and hydrolysed by parallel, independent pathways. Mechanisms for release and re‐uptake of endocannabinoids are unclear, although potent and selective inhibitors of facilitated diffusion of endocannabinoids across cell membranes have been developed [http://www.ncbi.nlm.nih.gov/pubmed/29531087?dopt=AbstractPlus]. http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2535 (https://www.uniprot.org/uniprot/Q01469) has been suggested to act as a canonical intracellular endocannabinoid transporter in vivo [http://www.ncbi.nlm.nih.gov/pubmed/28584105?dopt=AbstractPlus]. For the generation of http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=729, the key enzyme involved is diacylglycerol lipase (DAGL), whilst several routes for http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2364 synthesis have been described, the best characterized of which involves N‐acylphosphatidylethanolamine‐phospholipase D (NAPE‐PLD, [http://www.ncbi.nlm.nih.gov/pubmed/20393650?dopt=AbstractPlus]). A transacylation enzyme which forms N‐acylphosphatidylethanolamines has been identified as a cytosolic enzyme, https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:24791 (http://www.uniprot.org/uniprot/Q3MJ16) [http://www.ncbi.nlm.nih.gov/pubmed/27399000?dopt=AbstractPlus]. In vitro experiments indicate that the endocannabinoids are also substrates for oxidative metabolism via cyclooxygenase, lipoxygenase and cytochrome P450 enzyme activities [http://www.ncbi.nlm.nih.gov/pubmed/17876303?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/17618306?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/20133390?dopt=AbstractPlus].


http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=273


Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1398
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1400
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1401
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1402
	
Common abbreviation	NAPE‐PLD	FAAH	FAAH2	NAAA	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:21683, http://www.uniprot.org/uniprot/Q6IQ20
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3553, http://www.uniprot.org/uniprot/O00519
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:26440, http://www.uniprot.org/uniprot/Q6GMR7
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:736, http://www.uniprot.org/uniprot/Q02083
	
EC number	–	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.5.1.99: anandamide + H2O <=> arachidonic acid + ethanolamine oleamide + H2O <=> oleic acid + NH3
	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.5.1.99: anandamide + H2O <=> arachidonic acid + ethanolamine oleamide + H2O <=> oleic acid + NH3
	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.5.1.‐
	
Rank order of affinity	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2364 > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=284 > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2661 > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3622 [http://www.ncbi.nlm.nih.gov/pubmed/17015445?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=284 > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2661 > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2364 > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3622 [http://www.ncbi.nlm.nih.gov/pubmed/17015445?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3622 > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5221 > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3621 ≥ http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2661 > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2364 [http://www.ncbi.nlm.nih.gov/pubmed/11463796?dopt=AbstractPlus]	
Selective inhibitors	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10248 (pIC50 8.4) [http://www.ncbi.nlm.nih.gov/pubmed/29017758?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5206 (pIC50 7.8) [http://www.ncbi.nlm.nih.gov/pubmed/18693015?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5244 (pIC50 6.3–7.8) [http://www.ncbi.nlm.nih.gov/pubmed/17949010?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5235 (pIC50 7.4) [http://www.ncbi.nlm.nih.gov/pubmed/17015445?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9944 (pIC50 7), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4339 (pIC50 6.3–7) [http://www.ncbi.nlm.nih.gov/pubmed/17015445?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5243 (pIC50 6.6) [http://www.ncbi.nlm.nih.gov/pubmed/19389627?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5235 (pIC50 7.9–8.4) [http://www.ncbi.nlm.nih.gov/pubmed/19095868?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/17015445?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4339 (pIC50 7.5–8.3) [http://www.ncbi.nlm.nih.gov/pubmed/19095868?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/17015445?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10248 (pIC50 7.2) [http://www.ncbi.nlm.nih.gov/pubmed/29017758?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10121 (pIC50 8.1) [http://www.ncbi.nlm.nih.gov/pubmed/28802121?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/29572189?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9178 (Irreversible inhibition) (pIC50 7.6) [http://www.ncbi.nlm.nih.gov/pubmed/25874594?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6493 (pIC50 6.4) [http://www.ncbi.nlm.nih.gov/pubmed/19926854?dopt=AbstractPlus] – Rat, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5161 (pIC50 5.3) [http://www.ncbi.nlm.nih.gov/pubmed/14686878?dopt=AbstractPlus]	
Comments	NAPE‐PLD activity appears to be enhanced by polyamines in the physiological range [http://www.ncbi.nlm.nih.gov/pubmed/12047899?dopt=AbstractPlus], but fails to transphosphatidylate with alcohols [http://www.ncbi.nlm.nih.gov/pubmed/10428468?dopt=AbstractPlus] unlike phosphatidylcholine‐specific phospholipase D.	–	The FAAH2 gene is found in many primate genomes, marsupials, and other distantly related vertebrates, but not a variety of lower placental mammals, including mouse and rat [http://www.ncbi.nlm.nih.gov/pubmed/17015445?dopt=AbstractPlus].	–	



Comments
Routes for N‐acylethanolamine biosynthesis other than through NAPE‐PLD activity have been identified [http://www.ncbi.nlm.nih.gov/pubmed/23394527?dopt=AbstractPlus].


http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=944

Overview
ABHD12 is a 398‐aa protein, with serine hydrolase activity. It has a molecular weight of 45 kDa. A single TM is predicted at 75‐95, with an extracellular catalytic domain. ABHD12 is a monoacylglycerol hydrolase [http://www.ncbi.nlm.nih.gov/pubmed/22969151?dopt=AbstractPlus], but may also regulate lysophosphatidylserine levels [http://www.ncbi.nlm.nih.gov/pubmed/25580854?dopt=AbstractPlus]. Loss‐of‐function mutations in ABHD12 are associated with a disorder known as PHARC (polyneuropathy, hearing loss, ataxia, retinitis pigmentosa, and cataracts) [http://www.ncbi.nlm.nih.gov/pubmed/20797687?dopt=AbstractPlus].


Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1396
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1397
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1399
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2919
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3070
	
Common abbreviation	DAGLα	DAGLß	MAGL	ABHD6	–	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1165, http://www.uniprot.org/uniprot/Q9Y4D2
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:28923, http://www.uniprot.org/uniprot/Q8NCG7
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:17038, http://www.uniprot.org/uniprot/Q99685
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:21398, http://www.uniprot.org/uniprot/Q9BV23
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:15868, http://www.uniprot.org/uniprot/Q8N2K0
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.1.‐
	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.1.‐
	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.1.23
	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.1.23
	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.1.23
	
Endogenous substrates	diacylglycerol	diacylglycerol	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5112 = http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=729 ≫ http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2364 [http://www.ncbi.nlm.nih.gov/pubmed/15492019?dopt=AbstractPlus]	1‐arachidonoylglycerol > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=729 > 1‐oleoylglycerol > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5112 [http://www.ncbi.nlm.nih.gov/pubmed/22969151?dopt=AbstractPlus]	–	
Inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10246 (pIC50 8.5) [http://www.ncbi.nlm.nih.gov/pubmed/26083464?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10244 (pIC50 8.2) [http://www.ncbi.nlm.nih.gov/pubmed/26668358?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10243 (pIC50 8.2) [http://www.ncbi.nlm.nih.gov/pubmed/26668358?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10245 (pIC50 5.6) [http://www.ncbi.nlm.nih.gov/pubmed/23103940?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10244 (pIC50 8.6) [http://www.ncbi.nlm.nih.gov/pubmed/26668358?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10243 (pIC50 8.1) [http://www.ncbi.nlm.nih.gov/pubmed/26668358?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10246 (pIC50 8.1) [http://www.ncbi.nlm.nih.gov/pubmed/26083464?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10245 (pIC50 7.1) [http://www.ncbi.nlm.nih.gov/pubmed/23103940?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10028 (pIC50 8) [http://www.ncbi.nlm.nih.gov/pubmed/23731016?dopt=AbstractPlus]	–	–	
Selective inhibitors	–	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9481 (pIC50 9.3) [http://www.ncbi.nlm.nih.gov/pubmed/23521796?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9482 (pIC50 8.5) [http://www.ncbi.nlm.nih.gov/pubmed/22542104?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5207 (pIC50 8.1) [http://www.ncbi.nlm.nih.gov/pubmed/19029917?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5289 (pIC50 7.2) [http://www.ncbi.nlm.nih.gov/pubmed/17629278?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9480 (pIC50 6.4) [http://www.ncbi.nlm.nih.gov/pubmed/21084632?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10250 (pIC50 8) [http://www.ncbi.nlm.nih.gov/pubmed/30720278?dopt=AbstractPlus]	
Comments	–	–	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5289 has also been suggested to have activity at oxidative metabolic pathways independent of ABHD6 [http://www.ncbi.nlm.nih.gov/pubmed/28086912?dopt=AbstractPlus].	–	



Comments on Endocannabinoid turnover
Many of the compounds described as inhibitors are irreversible and so potency estimates will vary with incubation time. FAAH2 is not found in rodents [http://www.ncbi.nlm.nih.gov/pubmed/17015445?dopt=AbstractPlus] and a limited range of inhibitors have been assessed at this enzyme activity. http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=729 has been reported to be hydrolysed by multiple enzyme activities from neural preparations [http://www.ncbi.nlm.nih.gov/pubmed/29751000?dopt=AbstractPlus], including https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:21398 (http://www.uniprot.org/uniprot/Q9BV23) [http://www.ncbi.nlm.nih.gov/pubmed/26989199?dopt=AbstractPlus] and carboxylesterase 1 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1863, http://www.uniprot.org/uniprot/P23141 [http://www.ncbi.nlm.nih.gov/pubmed/21049984?dopt=AbstractPlus]). https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:21398 (http://www.uniprot.org/uniprot/Q9BV23) has also been described as a triacylglycerol lipase and ester hydrolase [http://www.ncbi.nlm.nih.gov/pubmed/27247428?dopt=AbstractPlus], while https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:15868 (http://www.uniprot.org/uniprot/Q8N2K0) is also able to hydrolyse lysophosphatidylserine [http://www.ncbi.nlm.nih.gov/pubmed/2397193?dopt=AbstractPlus]. https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:15868 (http://www.uniprot.org/uniprot/Q8N2K0) has been described to be inhibited selectively by pentacyclic triterpenoids, such as oleanolic acid [http://www.ncbi.nlm.nih.gov/pubmed/24879289?dopt=AbstractPlus].

Further reading on Endocannabinoid turnover
Blankman JL et al. (2013) Chemical probes of endocannabinoid metabolism. Pharmacol. Rev. 65: 849–71 https://www.ncbi.nlm.nih.gov/pubmed/23512546?dopt=AbstractPlus


Cao JK et al. (2019) ABHD6: Its Place in Endocannabinoid Signaling and Beyond. Trends Pharmacol Sci
40: 267–277 https://www.ncbi.nlm.nih.gov/pubmed/30853109


Di Marzo V. (2018) New approaches and challenges to targeting the endocannabinoid system. Nat Rev Drug Discov
17: 623–639 https://www.ncbi.nlm.nih.gov/pubmed/30116049


Fowler CJ. (2017) Endocannabinoid Turnover. Adv Pharmacol
80: 31–66 https://www.ncbi.nlm.nih.gov/pubmed/28826539


Janssen FJ et al. (2016) Inhibitors of diacylglycerol lipases in neurodegenerative and metabolic disorders. Bioorg Med Chem Lett
26: 3831–7 https://www.ncbi.nlm.nih.gov/pubmed/27394666?dopt=AbstractPlus


Maccarrone M. (2017) Metabolism of the Endocannabinoid Anandamide: Open Questions after 25 Years. Front Mol Neurosci
10: 166 https://www.ncbi.nlm.nih.gov/pubmed/28611591?dopt=AbstractPlus


Nicolussi S et al. (2015) Endocannabinoid transport revisited. Vitam Horm
98: 441–85 https://www.ncbi.nlm.nih.gov/pubmed/25817877?dopt=AbstractPlus


Tsuboi K et al. (2018) Endocannabinoids and related N‐acylethanolamines: biological activities and metabolism. Inflamm Regen
38: 28 https://www.ncbi.nlm.nih.gov/pubmed/30288203



http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=243

Overview
Eicosanoids are 20‐carbon fatty acids, where the usual focus is the polyunsaturated analogue http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2391 and its metabolites. Arachidonic acid is thought primarily to derive from http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=244#Phospholipase A2 action on membrane phosphatidylcholine, andmay be re‐cycled to form phospholipid through conjugation with http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3044 and subsequently glycerol derivatives. Oxidative metabolism of arachidonic acid is conducted through three major enzymatic routes: cyclooxygenases; lipoxygenases and cytochrome P450‐like epoxygenases, particularly http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=242#show_object_1332. Isoprostanes are structural analogues of the prostanoids (hence the nomenclature D‐, E‐, F‐isoprostanes and isothromboxanes), which are produced in the presence of elevated free radicals in a nonenzymaticmanner, leading to suggestions for their use as biomarkers of oxidative stress. Molecular targets for their action have yet to be defined.


http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=269

Overview
Prostaglandin (PG) G/H synthase, most commonly referred to as cyclooxygenase (COX, (5Z,8Z,11Z,14Z)‐icosa‐5,8,11,14‐tetraenoate,hydrogen‐donor : oxygen oxidoreductase) activity, catalyses the formation of http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5245 from http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2391. Hydroperoxidase activity inherent in the enzyme catalyses the formation of http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4483 from http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5245. COX‐1 and ‐2 can be nonselectively inhibited by http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2713, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4795, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5230, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1909 and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5239 (acetaminophen). PGH2 may then be metabolised to prostaglandins and thromboxanes by various prostaglandin synthases in an apparently tissue‐dependent manner.


Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1375
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1376
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9604, http://www.uniprot.org/uniprot/P23219
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9605, http://www.uniprot.org/uniprot/P35354
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.99.1: Hydrogen donor + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2391 + 2O2 = hydrogen acceptor + H2O + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4483
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2391 => http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5245 => http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4483 This enzyme is also associated with the following reaction:: http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1051 => PGH3
	
http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.99.1: Hydrogen donor + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2391 + 2O2 = hydrogen acceptor + H2O + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4483
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2391 => http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5245 => http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4483 This enzyme is also associated with the following reaction:: http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1051 => PGH3
	
Selective activators	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10242 (Inhibition) (pIC50 8) [http://www.ncbi.nlm.nih.gov/pubmed/9135032?dopt=AbstractPlus]	
Inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7131 (pIC50 8.1) [22], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2714 (pIC50 7.9) [http://www.ncbi.nlm.nih.gov/pubmed/16252917?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7219 (pIC50 7.3) [http://www.ncbi.nlm.nih.gov/pubmed/11844663?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4194 (pIC50 7.1) [http://www.ncbi.nlm.nih.gov/pubmed/10377455?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4820 (pIC50 6.8) [22], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4795 (pIC50 6.5) [http://www.ncbi.nlm.nih.gov/pubmed/18667313?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7298 (pIC50 6.2) [http://www.ncbi.nlm.nih.gov/pubmed/18667313?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7124 (pIC50 8.3) [22], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4194 (pIC50 8) [http://www.ncbi.nlm.nih.gov/pubmed/10091674?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7219 (pIC50 7.4) [http://www.ncbi.nlm.nih.gov/pubmed/11844663?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7141 (pIC50 7) [http://www.ncbi.nlm.nih.gov/pubmed/21873070?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6661 (pIC50 6.9) [http://www.ncbi.nlm.nih.gov/pubmed/22091869?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7401 (pIC50 6.2) [http://www.ncbi.nlm.nih.gov/pubmed/15993594?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4795 (pIC50 6.2) [http://www.ncbi.nlm.nih.gov/pubmed/18667313?dopt=AbstractPlus]	
Selective inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6661 (pIC50 9.7) [http://www.ncbi.nlm.nih.gov/pubmed/10377455?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10241 (pIC50 8.3) [http://www.ncbi.nlm.nih.gov/pubmed/21745460?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10240 (pIC50 8.1) [http://www.ncbi.nlm.nih.gov/pubmed/9789085?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5191 (pIC50 7.5) [http://www.ncbi.nlm.nih.gov/pubmed/10720634?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2892 (pIC50 8.7) [http://www.ncbi.nlm.nih.gov/pubmed/12643942?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2894 (pIC50 8.3) [http://www.ncbi.nlm.nih.gov/pubmed/10715145?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2714 (pIC50 7.7) [http://www.ncbi.nlm.nih.gov/pubmed/17341061?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2893 (pIC50 6.1–6.5) [http://www.ncbi.nlm.nih.gov/pubmed/10377455?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2897 (pK
i 6.5) [http://www.ncbi.nlm.nih.gov/pubmed/17434872?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7220 (pIC50 6.3) [http://www.ncbi.nlm.nih.gov/pubmed/9083488?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2896 (pIC50 6) [http://www.ncbi.nlm.nih.gov/pubmed/11160644?dopt=AbstractPlus]	




http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=270

Overview
Subsequent to the formation of http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4483, the http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=242 thromboxane synthase (CYP5A1, https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11609, http://www.uniprot.org/uniprot/P24557, http://www.genome.jp/kegg‐bin/search_brite?option=‐a&search_string=5.3.99.5) and prostacyclin synthase (CYP8A1, https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9603, http://www.uniprot.org/uniprot/Q16647, http://www.genome.jp/kegg‐bin/search_brite?option=‐a&search_string=5.3.99.4) generate http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4482 and prostacyclin (http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1915), respectively. Additionally, multiple enzyme activities are able to generate prostaglandin E2 (http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1883), prostaglandin D2 (http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1881) and prostaglandin F2α (http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1884). PGD2 can bemetabolised to 9α,11ß‐prostacyclin F2α through the multifunctional enzyme activity of AKR1C3. PGE2 can be metabolised to http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5129 through the 9‐ketoreductase activity of CBR1. Conversion of the 15‐hydroxyecosanoids, including prostaglandins, lipoxins and leukotrienes to their keto derivatives by the NAD‐dependent enzyme HPGD leads to a reduction in their biological activity.


Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1353
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1356
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1377
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1378
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1379
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1380
	
Common abbreviation	Thromboxane synthase	Prostacyclin synthase	–	–	–	–	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11609, http://www.uniprot.org/uniprot/P24557
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9603, http://www.uniprot.org/uniprot/Q16647
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9599, http://www.uniprot.org/uniprot/O14684
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:17822, http://www.uniprot.org/uniprot/Q9H7Z7
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:16049, http://www.uniprot.org/uniprot/Q15185
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9592, http://www.uniprot.org/uniprot/P41222
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:5.3.99.5: http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4483 = http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4482
	
http://www.genome.jp/dbget‐bin/www_bget?ec:5.3.99.4
	
http://www.genome.jp/dbget‐bin/www_bget?ec:5.3.99.3: http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4483 = http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1883
	
http://www.genome.jp/dbget‐bin/www_bget?ec:5.3.99.3: http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4483 = http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1883
	
http://www.genome.jp/dbget‐bin/www_bget?ec:5.3.99.3: http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4483 = http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1883
	
http://www.genome.jp/dbget‐bin/www_bget?ec:5.3.99.2: http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4483 = http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1881
	
Cofactors	–	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6737
	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6738
	–	–	
Inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9866 (pIC50 8.4) [http://www.ncbi.nlm.nih.gov/pubmed/3093741?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8795 (pIC50 > 6) [http://www.ncbi.nlm.nih.gov/pubmed/7861416?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8761 (pIC50 9) [http://www.ncbi.nlm.nih.gov/pubmed/19748780?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8812 (pIC50 <6) [http://www.ncbi.nlm.nih.gov/pubmed/15953724?dopt=AbstractPlus]	–	–	
Selective inhibitors	–	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8875 (pIC50 8.4) [http://www.ncbi.nlm.nih.gov/pubmed/23623673?dopt=AbstractPlus]	–	–	AT‐56 (pKi 4.1) [http://www.ncbi.nlm.nih.gov/pubmed/19131342?dopt=AbstractPlus]	
Comments	Inhibited by http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5175 [http://www.ncbi.nlm.nih.gov/pubmed/6795753?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5157 [http://www.ncbi.nlm.nih.gov/pubmed/7778318?dopt=AbstractPlus] and furegrelate sodium (U‐63557A: PubChem https://pubchem.ncbi.nlm.nih.gov/compound/23663954) [http://www.ncbi.nlm.nih.gov/pubmed/6316421?dopt=AbstractPlus].	Converts http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4483 to http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1915 [http://www.ncbi.nlm.nih.gov/pubmed/8766713?dopt=AbstractPlus]. Inhibited by http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5281 [http://www.ncbi.nlm.nih.gov/pubmed/824685?dopt=AbstractPlus]	–	–	Phosphorylated and activated by casein kinase 2 (http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?familyId=565&objectId=1548&familyType=ENZYME) [http://www.ncbi.nlm.nih.gov/pubmed/15040786?dopt=AbstractPlus]. Appears to regulate steroid hormone function by interaction with dimeric hsp90 [http://www.ncbi.nlm.nih.gov/pubmed/11050175?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8603045?dopt=AbstractPlus].	–	




Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1381
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1382
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1383
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1384
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:17890, http://www.uniprot.org/uniprot/O60760
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1382, http://www.uniprot.org/uniprot/P42330
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1383, http://www.uniprot.org/uniprot/P16152
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1384, http://www.uniprot.org/uniprot/P15428
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:5.3.99.2: http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4483 = http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1881
	
http://www.genome.jp/dbget‐bin/www_bget?ec:1.3.1.20
http://www.genome.jp/dbget‐bin/www_bget?ec:1.1.1.188: http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1881 + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3045 = http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1884 + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3041 + H+
http://www.genome.jp/dbget‐bin/www_bget?ec:1.1.1.64
http://www.genome.jp/dbget‐bin/www_bget?ec:1.1.1.239
http://www.genome.jp/dbget‐bin/www_bget?ec:1.1.1.213
	
http://www.genome.jp/dbget‐bin/www_bget?ec:1.1.1.184
http://www.genome.jp/dbget‐bin/www_bget?ec:1.1.1.189: http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1883 + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3045 = http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1884 + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3041 + H+
http://www.genome.jp/dbget‐bin/www_bget?ec:1.1.1.197
	
http://www.genome.jp/dbget‐bin/www_bget?ec:1.1.1.141 15‐hydroxyprostaglandins => 15‐ketoprostaglandins http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1034 => 15‐keto‐lipoxin A4
	
Cofactors	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3045
	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3045
	–	
Inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6662 (pIC50 5.3–5.5) [http://www.ncbi.nlm.nih.gov/pubmed/16547010?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8769 (pK
i 8.1) [http://www.ncbi.nlm.nih.gov/pubmed/17166832?dopt=AbstractPlus] http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2447, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1909, flavonoids such as 2′‐Hydroxyflavanone (pIC50 6.5) [http://www.ncbi.nlm.nih.gov/pubmed/9792917?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/19007764?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5551 (pIC50 5.4) [http://www.ncbi.nlm.nih.gov/pubmed/19097799?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8745 (pIC50 8.1) [http://www.ncbi.nlm.nih.gov/pubmed/21650226?dopt=AbstractPlus]	
Comments	–	AKR1C3 also exhibits an hydroxysteroid dehydrogenase activity.	–	–	



Comments

http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5293 has been reported to inhibit mPGES1 and 5‐LOX with a pIC50 value of 5.5 [http://www.ncbi.nlm.nih.gov/pubmed/19053751?dopt=AbstractPlus].


http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=271

Overview
The lipoxygenases (LOXs) are a structurally related family of non‐heme iron dioxygenases that function in the production, and in some cases metabolism, of fatty acid hydroperoxides. For http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2391 as substrate, these products are hydroperoxyeicosatetraenoic acids (HPETEs). In humans there are five lipoxygenases, the 5S‐(arachidonate : oxygen 5‐oxidoreductase), 12R‐(arachidonate 12‐lipoxygenase, 12R‐type), 12S‐(arachidonate : oxygen 12‐oxidoreductase), and two distinct 15S‐(arachidonate : oxygen 15‐oxidoreductase) LOXs that oxygenate arachidonic acid in different positions along the carbon chain and form the corresponding 5S‐, 12S‐, 12R‐, or 15S‐hydroperoxides, respectively.


Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1385
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1386
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1387
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1388
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1389
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1390
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:435, http://www.uniprot.org/uniprot/P09917
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:430, http://www.uniprot.org/uniprot/O75342
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:429, http://www.uniprot.org/uniprot/P18054
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:433, http://www.uniprot.org/uniprot/P16050
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:434, http://www.uniprot.org/uniprot/O15296
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:13743, http://www.uniprot.org/uniprot/Q9BYJ1
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:1.13.11.34: http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2391 + O2 = http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5214 + H2O	
http://www.genome.jp/dbget‐bin/www_bget?ec:1.13.11.31
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2391 + O2 => http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5101
	
http://www.genome.jp/dbget‐bin/www_bget?ec:1.13.11.31
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2391 + O2 => http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2481
	
http://www.genome.jp/dbget‐bin/www_bget?ec:1.13.11.33: http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2391 + O2 = http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2482
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1052 + O2 => 13S‐HPODE	
http://www.genome.jp/dbget‐bin/www_bget?ec:1.13.11.33: http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2391 + O2 = http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2482
	
http://www.genome.jp/dbget‐bin/www_bget?ec:1.13.11.‐
	
Substrates	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5222
	–	–	–	–	
Endogenous substrates	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2391
	–	–	–	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5101
	
Endogenous activators	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5183 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:436, http://www.uniprot.org/uniprot/P20292)	–	–	–	–	–	
Endogenous inhibitors	Protein kinase A‐mediated phosphorylation [http://www.ncbi.nlm.nih.gov/pubmed/15280375?dopt=AbstractPlus]	–	–	–	–	–	
Inhibitors	–	–	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10263 (pIC50 6.7) [http://www.ncbi.nlm.nih.gov/pubmed/24672829?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8750 (pIC50 7.3) [http://www.ncbi.nlm.nih.gov/pubmed/17656086?dopt=AbstractPlus]	–	
Selective inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5169 (pIC50 7.2) [http://www.ncbi.nlm.nih.gov/pubmed/15197110?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9054 (pIC50 6.6) [http://www.ncbi.nlm.nih.gov/pubmed/20378715?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5297 (pIC50 6.4) [http://www.ncbi.nlm.nih.gov/pubmed/1848634?dopt=AbstractPlus]	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8752 (pIC50 6.5) [http://www.ncbi.nlm.nih.gov/pubmed/24393039?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8751 (pK
i >8) [http://www.ncbi.nlm.nih.gov/pubmed/20866075?dopt=AbstractPlus]	–	–	
Comments	FLAP activity can be inhibited by http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2655 [http://www.ncbi.nlm.nih.gov/pubmed/2300173?dopt=AbstractPlus] and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5148 [http://www.ncbi.nlm.nih.gov/pubmed/8381000?dopt=AbstractPlus] leading to a selective inhibition of 5‐LOX activity	–	–	–	Inhibited by http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10264 (pKi 5.6) [http://www.ncbi.nlm.nih.gov/pubmed/25111178?dopt=AbstractPlus].	E‐LOX metabolises the product from the 12R‐lipoxygenase (12R‐HPETE) to a specific epoxyalcohol compound [http://www.ncbi.nlm.nih.gov/pubmed/12881489?dopt=AbstractPlus].	



Comments
An 8‐LOX(http://www.genome.jp/kegg‐bin/search_brite?option=‐a&search_string=1.13.11.40, arachidonate:oxygen 8‐oxidoreductase) may be the mouse orthologue of 15‐LOX‐2 [http://www.ncbi.nlm.nih.gov/pubmed/12432921?dopt=AbstractPlus]. Some general LOX inhibitors are http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4265 and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5180. http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5297 and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5155 are used as 5‐lipoxygenase inhibitors, while http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5144 and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5162 are 12‐lipoxygenase inhibitors. The specificity of these inhibitors has not been rigorously assessed with all LOX forms: http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5144, along with other flavonoids, such as http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5182 and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5215, also inhibits 15‐LOX‐1 [http://www.ncbi.nlm.nih.gov/pubmed/12628491?dopt=AbstractPlus].


http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=272

Overview
Leukotriene A4 (http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5214), produced by 5‐LOX activity, and lipoxins may be subject to further oxidative metabolism; ω‐hydroxylation is mediated by http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=242#show_object_1344 and http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=242#show_object_1345, while ß‐oxidation in mitochondria and peroxisomes proceeds in a manner dependent on coenzyme A conjugation. Conjugation of http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5214 at the 6 position with reduced glutathione to generate http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3354 occurs under the influence of leukotriene C4 synthase, with the subsequent formation of http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3353 and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3352, all three of which are agonists at http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=35. http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3353 formation is catalysed by γ‐glutamyltransferase, and subsequently dipeptidase 2 removes the terminal http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=727 from http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3353 to generate http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3352. Leukotriene A4 hydrolase converts the 5,6‐epoxide LTA4 to the 5‐hydroxylated LTB4, an agonist for http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=35. http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5214 is also acted upon by 12S‐LOX to produce the trihydroxyeicosatetraenoic acids lipoxins http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1034 and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5216. Treatment with a LTA4 hydrolase inhibitor in a murine model of allergic airway inflammation increased LXA4 levels, in addition to reducing http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2487, in lung lavage fluid [http://www.ncbi.nlm.nih.gov/pubmed/20110560?dopt=AbstractPlus]. LTA4 hydrolase is also involved in biosynthesis of http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=134. http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4139 has been reported to increase endogenous formation of 18S‐hydroxyeicosapentaenoate (http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5105) compared with http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3400, a resolvin precursor. Both enantiomers may be metabolised by human recombinant 5‐LOX; recombinant LTA4 hydrolase converted chiral 5S(6)‐epoxide‐containing intermediates to http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3333 and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5106 [http://www.ncbi.nlm.nih.gov/pubmed/21206090?dopt=AbstractPlus].


Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1391
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1392
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1393
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1394
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1395
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6719, http://www.uniprot.org/uniprot/Q16873
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:21705, http://www.uniprot.org/uniprot/O75223
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3002, http://www.uniprot.org/uniprot/P16444
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:23028, http://www.uniprot.org/uniprot/Q9H4A9
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6710, http://www.uniprot.org/uniprot/P09960
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:4.4.1.20: http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3354 = http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6737 + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5214
	
http://www.genome.jp/dbget‐bin/www_bget?ec:2.3.2.2: (5‐L‐glutamyl)‐peptide + an amino acid = a peptide + a 5‐L‐glutamyl amino acid http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3354 + H2O => http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3353 + L‐glutamate	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.4.13.19: http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3353 + H2O = http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3352 + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=727
	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.4.13.19: http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3353 + H2O = http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3352 + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=727
	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.3.2.6
	
Inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9555 (pIC50 8.1) [508], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8875 (pIC50 <5.5) [551]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10265 (pK
i 3.8) [http://www.ncbi.nlm.nih.gov/pubmed/17260973?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5166 (pK
i 6) [http://www.ncbi.nlm.nih.gov/pubmed/3495664?dopt=AbstractPlus]	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5151 (pK
i 5.4) [http://www.ncbi.nlm.nih.gov/pubmed/1846352?dopt=AbstractPlus]	



Comments
LTA4H is a member of a family of arginyl aminopeptidases (http://www.ensembl.org/Homo_sapiens/Gene/Family/Genes?family=ENSFM00250000001675), which also includes aminopeptidase B (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10078, http://www.uniprot.org/uniprot/9H4A4) and aminopeptidase B‐like 1 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10079, http://www.uniprot.org/uniprot/Q9HAU8). Dipeptidase 1 and 2 are members of a family of membrane dipeptidases, which also includes (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:23029, http://www.uniprot.org/uniprot/Q9H4B8) for which http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3353 appears not to be a substrate.

Further reading on Eicosanoid turnover
Ackermann JA et al. (2017) The double‐edged role of 12/15‐lipoxygenase during inflammation and immunity. Biochim. Biophys. Acta
1862: 371–381 https://www.ncbi.nlm.nih.gov/pubmed/27480217?dopt=AbstractPlus


Grosser T et al. (2017) The Cardiovascular Pharmacology of Nonsteroidal Anti‐Inflammatory Drugs. Trends Pharmacol. Sci. 38: 733–748 https://www.ncbi.nlm.nih.gov/pubmed/28651847?dopt=AbstractPlus


Haeggstrom JZ. (2018) Leukotriene biosynthetic enzymes as therapeutic targets. J Clin Invest
128: 2680–2690 https://www.ncbi.nlm.nih.gov/pubmed/30108195


Hafner AK et al. (2019) Beyond leukotriene formation‐The noncanonical functions of 5‐lipoxygenase. Prostaglandins Other Lipid Mediat
142: 24–32 https://www.ncbi.nlm.nih.gov/pubmed/30930090


Mitchell JA and Kirkby NS. (2019) Eicosanoids, prostacyclin and cyclooxygenase in the cardiovascular system. Br J Pharmacol
176: 1038–1050 https://www.ncbi.nlm.nih.gov/pubmed/29468666


Koeberle A et al. (2015) Perspective of microsomal prostaglandin E2 synthase‐1 as drug target in inflammation‐related disorders. Biochem. Pharmacol. 98: 1–15 https://www.ncbi.nlm.nih.gov/pubmed/26123522?dopt=AbstractPlus


Kuhn H et al. (2015) Mammalian lipoxygenases and their biological relevance. Biochim. Biophys. Acta
1851: 308–30 https://www.ncbi.nlm.nih.gov/pubmed/25316652?dopt=AbstractPlus


Patrignani P et al. (2015) Cyclooxygenase inhibitors: From pharmacology to clinical read‐outs. Biochim. Biophys. Acta
1851: 422–32 https://www.ncbi.nlm.nih.gov/pubmed/25263946?dopt=AbstractPlus


Rådmark O et al. (2015) 5‐Lipoxygenase, a key enzyme for leukotriene biosynthesis in health and disease. Biochim. Biophys. Acta
1851: 331–9 https://www.ncbi.nlm.nih.gov/pubmed/25152163?dopt=AbstractPlus


Sasaki Y et al. (2017) Role of prostacyclin synthase in carcinogenesis. Prostaglandins Other Lipid Mediat. 133: 49–52 https://www.ncbi.nlm.nih.gov/pubmed/28506876?dopt=AbstractPlus


Seo MJ et al. (2017) Prostaglandin synthases: Molecular characterization and involvement in prostaglandin biosynthesis. Prog. Lipid Res. 66: 50–68 https://www.ncbi.nlm.nih.gov/pubmed/28392405?dopt=AbstractPlus


Vitale P et al. (2016) COX‐1 Inhibitors: Beyond Structure Toward Therapy. Med Res Rev
36: 641–71 https://www.ncbi.nlm.nih.gov/pubmed/27111555?dopt=AbstractPlus



http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=764

Overview
The inhibitory neurotransmitter γ‐aminobutyrate (GABA, 4‐aminobutyrate) is generated in neurones by glutamic acid decarboxylase. GAD1 and GAD2 are differentially expressed during development, whereGAD2 is thought to subserve a trophic role in early life and is distributed throughout the cytoplasm. GAD1 is expressed in later life and is more associated with nerve terminals [http://www.ncbi.nlm.nih.gov/pubmed/8126575?dopt=AbstractPlus] where GABA is principally accumulated in vesicles through the action of the vesicular inhibitory amino acid transporter http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=219. The role of γ‐aminobutyraldehyde dehydrogenase (ALDH9A1) in neurotransmitter GABA synthesis is less clear. Following release from neurons, GABA may interact with either GABAA or GABAB receptors and may be accumulated in neurones and glia through the action of members of the http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=144. Successive metabolism through GABA transaminase and succinate semialdehyde dehydrogenase generates succinic acid, which may be further metabolized in the mitochondria in the tricarboxylic acid cycle.


Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1272
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1273
	
Common abbreviation	GAD1	GAD2	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4092, http://www.uniprot.org/uniprot/Q99259
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4093, http://www.uniprot.org/uniprot/Q05329
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:4.1.1.15: http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1369 + H+ ‐> http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1067 + CO2
	
http://www.genome.jp/dbget‐bin/www_bget?ec:4.1.1.15: http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1369 + H+ ‐> http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1067 + CO2
	
Endogenous substrates	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1369, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3309
	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1369, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3309
	
Products	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1067
	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1067
	
Cofactors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5249
	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5249
	
Selective inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5267
	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5267
	
Comments	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3309 is a less rapidly metabolised substrate of mouse brain glutamic acid decarboxylase generating ß‐alanine [http://www.ncbi.nlm.nih.gov/pubmed/4700449?dopt=AbstractPlus]. Autoantibodies against GAD1 and GAD2 are elevated in type 1 diabetes mellitus and neurological disorders (see Further reading).	




Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2467
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2464
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2466
	
Common abbreviation	–	GABA‐T	SSADH	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:412, http://www.uniprot.org/uniprot/P49189
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:23, http://www.uniprot.org/uniprot/P80404
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:408, http://www.uniprot.org/uniprot/P51649
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:1.2.1.19: http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6606 + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2451 + H2O = http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1067 + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4487 + H+
http://www.genome.jp/dbget‐bin/www_bget?ec:1.2.1.47: http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6604 + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2451 + H2O = http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6605 + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3041 + 2H+
http://www.genome.jp/dbget‐bin/www_bget?ec:1.2.1.3: an aldehyde + H2O + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2451 = a carboxylate + 2H+ + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4487
	
http://www.genome.jp/dbget‐bin/www_bget?ec:2.6.1.19: http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1067 + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3636 = http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1369 + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6608
http://www.genome.jp/dbget‐bin/www_bget?ec:2.6.1.22: http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6610 + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3636 = http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6611 + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1369
	
http://www.genome.jp/dbget‐bin/www_bget?ec:1.2.1.24: http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6608 + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2451 + H2O = http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3637 + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4487 + 2H+ 4‐hydroxy‐trans‐2‐nonenal + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2451 + H2O = 4‐hydroxy‐trans‐2‐nonenoate + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4487 + 2H+
	
Cofactors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2451
	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5249
	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2451 [http://www.ncbi.nlm.nih.gov/pubmed/22677141?dopt=AbstractPlus]	
Inhibitors	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4821 (Irreversible inhibition) (pK
i 3.1) [http://www.ncbi.nlm.nih.gov/pubmed/856582?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/22168767?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8841 (pIC50 6.5) [http://www.ncbi.nlm.nih.gov/pubmed/16290145?dopt=AbstractPlus]	



Further reading on GABA turnover
Koenig MK et al. (2017) Phenotype of GABA‐transaminase deficiency. Neurology
88: 1919–1924 https://www.ncbi.nlm.nih.gov/pubmed/28411234?dopt=AbstractPlus


Lee H et al. (2015) Ornithine aminotransferase versus GABA aminotransferase: implications for the design of new anticancer drugs. Med Res Rev
35: 286–305 https://www.ncbi.nlm.nih.gov/pubmed/25145640?dopt=AbstractPlus



http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=244

Overview
Phospholipids are the basic barrier components of membranes in eukaryotic cells divided into glycerophospholipids (phosphatidic acid, phosphatidylethanolamine, phosphatidylcholine, phosphatidylserine, phosphatidylinositol and its phosphorylated derivatives) and sphingolipids (ceramide phosphorylcholine and ceramide phosphorylethanolamine).


http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=274

Overview
Phosphoinositide‐specific phospholipase C (PLC, EC 3.1.4.11), catalyses the hydrolysis of http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2387 to http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4222 and 1,2‐diacylglycerol, each of which have major second messenger functions. Two domains, X and Y, essential for catalytic activity, are conserved in the different forms of PLC. Isoforms of PLC‐ß are activated primarily by G protein‐coupled receptors through members of the Gq/11 family of G proteins. The receptor‐mediated activation of PLC‐γ involves their phosphorylation by http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=304 in response to activation of a variety of growth factor receptors and immune system receptors. PLC‐ ∈1 may represent a point of convergence of signalling via both G protein‐coupled and catalytic receptors. Ca2+ ions are required for catalytic activity of PLC isoforms and have been suggested to be the major physiological form of regulation of PLC‐δ activity. PLC has been suggested to be activated non‐selectively by the small molecule http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5097 [http://www.ncbi.nlm.nih.gov/pubmed/12695532?dopt=AbstractPlus], although this mechanism of action has been questioned [http://www.ncbi.nlm.nih.gov/pubmed/15302681?dopt=AbstractPlus]. The aminosteroid http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5283 has been described as an inhibitor of phosphoinositide‐specific PLC [http://www.ncbi.nlm.nih.gov/pubmed/2338654?dopt=AbstractPlus], although its selectivity among the isoforms is untested and it has been reported to occupy the H1 histamine receptor [http://www.ncbi.nlm.nih.gov/pubmed/11138848?dopt=AbstractPlus].


Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1403
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1404
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1405
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1406
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:15917, http://www.uniprot.org/uniprot/Q9NQ66
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9055, http://www.uniprot.org/uniprot/Q00722
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9056, http://www.uniprot.org/uniprot/Q01970
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9059, http://www.uniprot.org/uniprot/Q15147
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.4.11: 1‐phosphatidyl‐1D‐myo‐inositol 4,5‐bisphosphate + H2O = 1D‐myo‐inositol 1,4,5‐trisphosphate + diacylglycerol	
Endogenous activators	Gαq, Gα11, Gßγ [http://www.ncbi.nlm.nih.gov/pubmed/8314796?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8383116?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/1846707?dopt=AbstractPlus]	Gα16, Gßγ, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5251 (http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5251, http://www.uniprot.org/uniprot/P15153) [http://www.ncbi.nlm.nih.gov/pubmed/1465133?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12441352?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12509427?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/1322889?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8383116?dopt=AbstractPlus]	Gαq, Gßγ [http://www.ncbi.nlm.nih.gov/pubmed/8380773?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/1322889?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8383116?dopt=AbstractPlus]	Gαq [http://www.ncbi.nlm.nih.gov/pubmed/8454637?dopt=AbstractPlus]	




Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1407
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1408
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1409
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1410
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1411
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9065, http://www.uniprot.org/uniprot/P19174
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9066, http://www.uniprot.org/uniprot/P16885
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9060, http://www.uniprot.org/uniprot/P51178
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9061, http://www.uniprot.org/uniprot/Q8N3E9
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9062, http://www.uniprot.org/uniprot/Q9BRC7
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.4.11: 1‐phosphatidyl‐1D‐myo‐inositol 4,5‐bisphosphate + H2O = 1D‐myo‐inositol 1,4,5‐trisphosphate + diacylglycerol	
	
	
	
	
Endogenous activators	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2353 [http://www.ncbi.nlm.nih.gov/pubmed/9468499?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2353, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5250 (http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5250, http://www.uniprot.org/uniprot/P63000), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5251 (http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5251, http://www.uniprot.org/uniprot/P15153), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5252 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9803, http://www.uniprot.org/uniprot/P60763) [http://www.ncbi.nlm.nih.gov/pubmed/9468499?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/16172125?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/18728011?dopt=AbstractPlus]	Transglutaminase II, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5237 {Rat}, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=710, Gßγ [http://www.ncbi.nlm.nih.gov/pubmed/1654825?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7835339?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10518533?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8383116?dopt=AbstractPlus]	–	–	
Endogenous inhibitors	–	–	Sphingomyelin [http://www.ncbi.nlm.nih.gov/pubmed/1497353?dopt=AbstractPlus]	–	–	
Inhibitors	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8820 (pIC50 5.5) [http://www.ncbi.nlm.nih.gov/pubmed/19303309?dopt=AbstractPlus]	–	–	–	




Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1412
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1413
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1414
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1415
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:17175, http://www.uniprot.org/uniprot/Q9P212
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:19218, http://www.uniprot.org/uniprot/Q86YW0
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:29185, http://www.uniprot.org/uniprot/Q4KWH8
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:29037, http://www.uniprot.org/uniprot/O75038
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.4.11: 1‐phosphatidyl‐1D‐myo‐inositol 4,5‐bisphosphate + H2O = 1D‐myo‐inositol 1,4,5‐trisphosphate + diacylglycerol	
	
	
	
Endogenous activators	Ras, rho [http://www.ncbi.nlm.nih.gov/pubmed/11022048?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/14993441?dopt=AbstractPlus]	–	–	Gßγ [http://www.ncbi.nlm.nih.gov/pubmed/16107206?dopt=AbstractPlus]	



Comments
A series of PLC‐like proteins (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9063, http://www.uniprot.org/uniprot/Q15111; https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9064, http://www.uniprot.org/uniprot/Q9UPR0 and https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:29185, http://www.uniprot.org/uniprot/Q4KWH8) form a family with PLCδ and PLCζ1 isoforms, but appear to lack catalytic activity. PLC‐δ2 has been cloned from bovine sources [http://www.ncbi.nlm.nih.gov/pubmed/1848183?dopt=AbstractPlus].

Further reading on Phosphoinositide‐specific phospholipase C
Cocco L et al. (2015) Phosphoinositide‐specific phospholipase C in health and disease. J. Lipid Res.56: 1853–60 https://www.ncbi.nlm.nih.gov/pubmed/25821234?dopt=AbstractPlus


Cockcroft S et al. (2016) Topological organisation of the phosphatidylinositol 4,5‐bisphosphatephospholipase C resynthesis cycle: PITPs bridge the ER‐PM gap. Biochem. J. 473: 4289–4310 https://www.ncbi.nlm.nih.gov/pubmed/27888240?dopt=AbstractPlus


Litosch I. (2015) Regulating G protein activity by lipase‐independent functions of phospholipase C. Life Sci. 137: 116–24 https://www.ncbi.nlm.nih.gov/pubmed/26239437?dopt=AbstractPlus


Nakamura Y et al. (2017) Regulation and physiological functions of mammalian phospholipase C. J. Biochem. 161: 315–321 https://www.ncbi.nlm.nih.gov/pubmed/28130414?dopt=AbstractPlus


Swann K et al. (2016) The sperm phospholipase C‐ζ and Ca2+ signalling at fertilization in mammals. Biochem. Soc. Trans. 44: 267–72 https://www.ncbi.nlm.nih.gov/pubmed/26862214?dopt=AbstractPlus



http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=244#Phospholipase A2

Overview
Phospholipase A2 (PLA2, EC 3.1.1.4) cleaves the sn‐2 fatty acid of phospholipids, primarily phosphatidylcholine, to generate http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2508 and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2391. Most commonly‐used inhibitors (e.g. http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5149, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5142 or http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5218) are either non‐selective within the family of phospholipase A2 enzymes or have activity against other eicosanoid‐metabolising enzymes.

Secreted or extracellular forms
sPLA2‐1B, sPLA2‐2A, sPLA2‐2D, sPLA2‐2E, sPLA2‐2F, sPLA2‐3, sPLA2‐10 and sPLA2‐12A

Cytosolic, calcium‐dependent forms
cPLA2‐4A, cPLA2‐4B, cPLA2‐4C, cPLA2‐4D, cPLA2‐4E and cPLA2‐4F

Other forms
PLA2‐G5, iPLA2‐G6, PLA2‐G7 and PAFAH2 (platelet‐activating factor acetylhydrolase 2)


Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1416
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1417
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1418
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1419
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1420
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1421
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9030, http://www.uniprot.org/uniprot/P04054
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9031, http://www.uniprot.org/uniprot/P14555
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9033, http://www.uniprot.org/uniprot/Q9UNK4
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:13414, http://www.uniprot.org/uniprot/Q9NZK7
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:30040, http://www.uniprot.org/uniprot/Q9BZM2
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:17934, http://www.uniprot.org/uniprot/Q9NZ20
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.1.4
	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.1.4
	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.1.4
	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.1.4
	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.1.4
	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.1.4
	
Inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8764 (pIC50 8.9) [http://www.ncbi.nlm.nih.gov/pubmed/8809154?dopt=AbstractPlus]	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8787 (pIC50 8.1) [http://www.ncbi.nlm.nih.gov/pubmed/18605714?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8787 (pIC50 8.1) [http://www.ncbi.nlm.nih.gov/pubmed/18605714?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8787 (pIC50 7.3) [http://www.ncbi.nlm.nih.gov/pubmed/18605714?dopt=AbstractPlus]	–	
Comments	–	–	–	–	–	–	




Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1424
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1425
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1426
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1427
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1428
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1429
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9035, http://www.uniprot.org/uniprot/P47712
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9036, http://www.uniprot.org/uniprot/P0C869
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9037, http://www.uniprot.org/uniprot/Q9UP65
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:30038, http://www.uniprot.org/uniprot/Q86XP0
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:24791, http://www.uniprot.org/uniprot/Q3MJ16
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:27396, http://www.uniprot.org/uniprot/Q68DD2
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.1.4
	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.1.4
	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.1.4
	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.1.4
	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.1.4
	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.1.4
	
Inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8771 (pIC50 8.4) [http://www.ncbi.nlm.nih.gov/pubmed/16610804?dopt=AbstractPlus]	–	–	–	–	–	
Comments	cPLA2‐4A also expresses lysophospholipase (http://www.genome.jp/kegg‐bin/search_brite?option=‐a&search_string=3.1.1.5) activity [http://www.ncbi.nlm.nih.gov/pubmed/8083230?dopt=AbstractPlus].	–	–	–	–	–	




Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1430
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1431
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1432
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1422
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1423
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2508
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9038, http://www.uniprot.org/uniprot/P39877
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9039, http://www.uniprot.org/uniprot/O60733
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9040, http://www.uniprot.org/uniprot/Q13093
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9029, http://www.uniprot.org/uniprot/O15496
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:18554, http://www.uniprot.org/uniprot/Q9BZM1
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8579, http://www.uniprot.org/uniprot/Q99487
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.1.4
	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.1.4
	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.1.4
	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.1.4
	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.1.4
	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.1.47
	
Inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8787 (pIC50 7.5) [http://www.ncbi.nlm.nih.gov/pubmed/18605714?dopt=AbstractPlus]	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6696 (pIC50 10) [http://www.ncbi.nlm.nih.gov/pubmed/12643913?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8787 (pIC50 7.7) [http://www.ncbi.nlm.nih.gov/pubmed/18605714?dopt=AbstractPlus]	–	–	
Selective inhibitors	–	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7376 (Competitive) (pIC50 9.6) [http://www.ncbi.nlm.nih.gov/pubmed/19667981?dopt=AbstractPlus]	–	–	–	
Comments	–	–	–	–	–	PAFAH2 also expresses PAF hydrolase activity (EC 3.1.1.47)	



Comments
The sequence of PLA2‐2C suggests a lack of catalytic activity, while PLA2‐12B (GXIIB, GXIII sPLA2‐like) appears to be catalytically inactive [http://www.ncbi.nlm.nih.gov/pubmed/14516201?dopt=AbstractPlus]. A further fragment has been identified with sequence similarities to Group II PLA2 members. Otoconin 90 (OC90) shows sequence homology to PLA2‐G10.

A binding protein for secretory phospholipase A2 has been identified which shows modest selectivity for sPLA2‐1B over sPLA2‐2A, and also binds snake toxin phospholipase A2 [http://www.ncbi.nlm.nih.gov/pubmed/7548076?dopt=AbstractPlus]. The binding protein appears to have clearance function for circulating secretory phospholipase A2, as well as signalling functions, and is a candidate antigen for idiopathic membraneous nephropathy [http://www.ncbi.nlm.nih.gov/pubmed/19571279?dopt=AbstractPlus].

PLA2‐G7 and PAFAH2 also express platelet‐activating factor acetylhydrolase activity (http://www.genome.jp/kegg‐bin/search_brite?option=‐a&search_string=3.1.1.47).

Further reading on Phospholipase A2

Astudillo AM. (2019) Selectivity of phospholipid hydrolysis by phospholipase A2 enzymes in activated cells leading to polyunsaturated fatty acid mobilization. Biochim Biophys Acta Mol Cell Biol Lipids
1864: 772–783 https://www.ncbi.nlm.nih.gov/pubmed/30010011


Kita Y etal. (2019) Cytosolic phospholipase A2 and lysophospholipid acyltransferases. Biochim Biophys Acta Mol Cell Biol Lipids
1864: 838–845 https://www.ncbi.nlm.nih.gov/pubmed/30905348


Mouchlis VD and Dennis EA. (2019) Phospholipase A2 catalysis and lipid. mediator lipidomics. Biochim Biophys Acta Mol Cell Biol Lipids
1864: 766–771 https://www.ncbi.nlm.nih.gov/pubmed/30905345


Murakami M et al. (2019) Group IID, IIE, IIF and III secreted phospholipase A2s. Biochim Biophys Acta Mol Cell Biol Lipids. 1864: 803–818 https://www.ncbi.nlm.nih.gov/pubmed/30905347


Samuchiwal SK and Balestrieri B. (2019) Harmful and protective roles of group V phospholipase A2: Current perspectives and future directions. Biochim Biophys Acta Mol Cell Biol Lipids
1864: 819–826 https://www.ncbi.nlm.nih.gov/pubmed/30308324


Shayman JA and Tesmer JJG. (2019) Lysosomal phospholipase A2. Biochim Biophys Acta Mol Cell Biol Lipids. 1864: 932–940 https://www.ncbi.nlm.nih.gov/pubmed/30077006



http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=276

Overview
Phosphatidylcholine‐specific phospholipase D (PLD, EC 3.1.4.4) catalyses the formation of phosphatidic acid from phosphatidylcholine. In addition, the enzyme can make use of alcohols, such as butanol in a transphosphatidylation reaction [http://www.ncbi.nlm.nih.gov/pubmed/2186929?dopt=AbstractPlus].


Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1433
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1434
	
HGNC, UniProt	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1433, http://www.uniprot.org/uniprot/Q13393
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1434, http://www.uniprot.org/uniprot/O14939
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.4.4
	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.4.4 A phosphatidylcholine + H2O <=> choline + a phosphatidate	
Endogenous activators	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5305 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:652, http://www.uniprot.org/uniprot/P84077), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2387, RhoA, PKC evoked phosphorylation, RalA [http://www.ncbi.nlm.nih.gov/pubmed/9013646?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9207251?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5305 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:652, http://www.uniprot.org/uniprot/P84077), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2387 [http://www.ncbi.nlm.nih.gov/pubmed/9582313?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1054 [http://www.ncbi.nlm.nih.gov/pubmed/12374567?dopt=AbstractPlus]	
Endogenous inhibitors	Gßγ [http://www.ncbi.nlm.nih.gov/pubmed/16638972?dopt=AbstractPlus]	Gßγ [http://www.ncbi.nlm.nih.gov/pubmed/16638972?dopt=AbstractPlus]	
Inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8781 (pIC50 8) [http://www.ncbi.nlm.nih.gov/pubmed/19136975?dopt=AbstractPlus]	–	
Selective inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8782 (pIC50 7.3) [http://www.ncbi.nlm.nih.gov/pubmed/19136975?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5287 (pIC50 7.7) [http://www.ncbi.nlm.nih.gov/pubmed/20735042?dopt=AbstractPlus]	



Comments
A lysophospholipase D activity (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3357, http://www.uniprot.org/uniprot/Q13822, also known as ectonucleotide pyrophosphatase/ phosphodiesterase 2, phosphodiesterase I, nucleotide pyrophosphatase 2, autotaxin) has been described, which not only catalyses the production of lysophosphatidic acid (http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2906) from http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2508, but also cleaves http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713 (see Goding et al., 2003 [http://www.ncbi.nlm.nih.gov/pubmed/12757929?dopt=AbstractPlus]). Additionally, an N‐acylethanolaminespecific phospholipase D (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:21683, http://www.uniprot.org/uniprot/Q6IQ20) has been characterized, which appears to have a role in the generation of http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=273/endovanilloids, including http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2364 [http://www.ncbi.nlm.nih.gov/pubmed/14634025?dopt=AbstractPlus]. This enzyme activity appears to be enhanced by polyamines in the physiological range [http://www.ncbi.nlm.nih.gov/pubmed/12047899?dopt=AbstractPlus] and fails to transphosphatidylate with alcohols [http://www.ncbi.nlm.nih.gov/pubmed/10428468?dopt=AbstractPlus].

Three further, less well‐characterised isoforms are PLD3 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:17158, http://www.uniprot.org/uniprot/Q8IV08, other names Choline phosphatase 3, HindIII K4L homolog, Hu‐K4), PLD4 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:23792, http://www.uniprot.org/uniprot/Q96BZ4, other names Choline phosphatase 4, Phosphatidylcholine‐hydrolyzing phospholipase, D4C14orf175 UNQ2488/PRO5775) and PLD5 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:26879, http://www.uniprot.org/uniprot/Q8N7P1). PLD3 has been reported to be involved in myogenesis [http://www.ncbi.nlm.nih.gov/pubmed/22428023?dopt=AbstractPlus]. PLD4 is described not to have phospholipase D catalytic activity [http://www.ncbi.nlm.nih.gov/pubmed/21085684?dopt=AbstractPlus], but has been associated with inflammatory disorders [http://www.ncbi.nlm.nih.gov/pubmed/22446963?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/23577190?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/23124809?dopt=AbstractPlus]. Sequence analysis suggests that PLD5 is catalytically inactive.

Further reading on Phosphatidylcholine‐specific phospholipase D
Brown HA et al. (2017) Targeting phospholipase D in cancer, infection and neurodegenerative disorders. Nat Rev Drug Discov
16: 351‐367 https://www.ncbi.nlm.nih.gov/pubmed/28209987?dopt=AbstractPlus


Frohman MA. (2015) The phospholipase D superfamily as therapeutic targets. Trends Pharmacol. Sci. 36: 137‐44 https://www.ncbi.nlm.nih.gov/pubmed/25661257?dopt=AbstractPlus


Nelson RK et al. (2015) Physiological and pathophysiological roles for phospholipase D. J. Lipid Res. 56: 2229‐37 https://www.ncbi.nlm.nih.gov/pubmed/25926691?dopt=AbstractPlus



http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=277

Overview
Lipid phosphate phosphatases, divided into phosphatidic acid phosphatases or lipins catalyse the dephosphorylation of phosphatidic acid (and other phosphorylated lipid derivatives) to generate inorganic phosphate and diacylglycerol. PTEN, a phosphatase and tensin homolog (BZS, MHAM, MMAC1, PTEN1, TEP1) is a phosphatidylinositol 3,4,5‐trisphosphate 3‐phosphatase which acts as a tumour suppressor by reducing cellular levels of PI 3,4,5‐P, thereby toning down activity of PDK1 and PKB. Loss‐of‐function mutations are frequently identified as somatic mutations in cancers.


Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1435
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1436
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1437
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1438
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1439
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1440
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2497
	
Common abbreviation	–	–	–	–	–	–	PTEN	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:13345, http://www.uniprot.org/uniprot/Q14693
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:14450, http://www.uniprot.org/uniprot/Q92539
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:14451, http://www.uniprot.org/uniprot/Q9BQK8
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9228, http://www.uniprot.org/uniprot/O14494
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9229, http://www.uniprot.org/uniprot/O14495
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9230, http://www.uniprot.org/uniprot/O43688
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9588, http://www.uniprot.org/uniprot/P60484
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.3.4
	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.3.4
	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.3.4
	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.3.4
	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.3.4
	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.3.4
	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.3.67
http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.3.48
http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.3.16
	
Substrates	–	phosphatidic acid	–	–	phosphatidic acid	–	phosphatidylinositol (3,4,5)‐trisphosphate	



Further reading on Lipid phosphate phosphatases
Knafo S and Esteban JA. (2017) PTEN: Local and Global Modulation of Neuronal Function in Health and Disease. Trends Neurosci
40: 83‐91 https://www.ncbi.nlm.nih.gov/pubmed/28081942


Lee YR et al. (2018) The functions and regulation of the PTEN tumour suppressor: new modes and prospects. Nat Rev Mol Cell Biol
19: 547‐562 https://www.ncbi.nlm.nih.gov/pubmed/29858604


Yehia L et al. (2019) PTEN‐opathies: from biological insights to evidence‐based precision medicine. J Clin Invest
129: 452‐464 https://www.ncbi.nlm.nih.gov/pubmed/30614812



http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=781

Overview
Phosphatidylinositol may be phosphorylated at either 3‐ or 4‐ positions on the inositol ring by PI 3‐kinases or PI 4‐kinases, respectively.

Phosphatidylinositol 3‐kinases
Phosphatidylinositol 3‐kinases (PI3K, provisional nomenclature) catalyse the introduction of a phosphate into the 3‐position of phosphatidylinositol (PI), phosphatidylinositol 4‐phosphate (PIP) or phosphatidylinositol 4,5‐bisphosphate (PIP2). There is evidence that PI3K can also phosphorylate serine/threonine residues on proteins. In addition to the classes described below, further serine/threonine protein kinases, including https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:795 (http://www.uniprot.org/uniprot/Q13315) and https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3942 (http://www.uniprot.org/uniprot/P42345), have been described to phosphorylate phosphatidylinositol and have been termed PI3Krelated kinases. Structurally, PI3Ks have common motifs of at least one C2, calcium‐binding domain and helical domains, alongside structurally‐conserved catalytic domains. http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6060 and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6004 are widely‐used inhibitors of PI3K activities. http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6060 is irreversible and shows modest selectivity between Class I and Class II PI3K, while LY294002 is reversible and selective for Class I compared to Class II PI3K.


Class I PI3Ks (EC 2.7.1.153) phosphorylate phosphatidylinositol 4,5‐bisphosphate to generate phosphatidylinositol 3,4,5‐trisphosphate and are heterodimeric, matching catalytic and regulatory subunits. Class IA PI3Ks include p110α, p110ß and p110δ catalytic subunits, with predominantly p85 and p55 regulatory subunits. The single catalytic subunit that forms Class IB PI3K is p110γ. Class IA PI3Ks are more associated with receptor tyrosine kinase pathways, while the Class IB PI3K is linkedmore with GPCR signalling.


Class II PI3Ks (EC 2.7.1.154) phosphorylate phosphatidylinositol to generate phosphatidylinositol 3‐phosphate (and possibly phosphatidylinositol 4‐phosphate to generate phosphatidylinositol 3,4‐bisphosphate). Three monomeric members exist, PI3KC2α, ß and ß, and include Ras‐binding, Phox homology and two C2domains.

The only class III PI3K isoform (EC 2.7.1.137) is a heterodimer formed of a catalytic subunit (VPS34) and regulatory subunit (VPS15).


Phosphatidylinositol 4‐kinases


Phosphatidylinositol 4‐kinases (EC 2.7.1.67) generate phosphatidylinositol 4‐phosphate and may be divided into higher molecular weight type III and lower molecular weight type II forms.


http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=638


Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2148
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2149
	
Common abbreviation	PI4KIIIα/PIK4CA	PI4KIIIß/PIK4CB	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8983, http://www.uniprot.org/uniprot/P42356
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8984, http://www.uniprot.org/uniprot/Q9UBF8
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.67
	
http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.67
	
Endogenous activation	–	PKD‐mediated phosphorylation [http://www.ncbi.nlm.nih.gov/pubmed/16100512?dopt=AbstractPlus]	
Sub/family‐selective inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6060 (pIC50 6.7–6.8) [http://www.ncbi.nlm.nih.gov/pubmed/10101268?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9020160?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6060 (pIC50 6.7–6.8) [http://www.ncbi.nlm.nih.gov/pubmed/10101268?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9020160?dopt=AbstractPlus]	
Selective inhibitors	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6062 (pIC50 7.7) [http://www.ncbi.nlm.nih.gov/pubmed/18077555?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/16647110?dopt=AbstractPlus]	




http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=671


Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2150
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2151
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2288
	
Common abbreviation	C2α/PIK3C2A	C2ß/PIK3C2B	C2γ/PIK3C2G	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8971, http://www.uniprot.org/uniprot/O00443
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8972, http://www.uniprot.org/uniprot/O00750
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8973, http://www.uniprot.org/uniprot/O75747
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.154
	
http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.154
	
http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.154
	
Inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8839 (pIC50 7.6) [http://www.ncbi.nlm.nih.gov/pubmed/21322566?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5701 (pIC50 8) [http://www.ncbi.nlm.nih.gov/pubmed/17601739?dopt=AbstractPlus]	–	




http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=672


Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2152
	
Common abbreviation	VPS34	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8974, http://www.uniprot.org/uniprot/Q8NEB9
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.137
	




http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=673

Overview
PI3K activation is one of the most important signal transduction pathways used to transmit signals from cell‐surface receptors to regulate intracellular processes (cell growth, survival, proliferation and movement). PI3K catalytic (and regulatory) subunits play vital roles in normal cell function and in disease. Progress made in developing PI3K‐targeted agents as potential therapeutics for treating cancer and other diseases is reviewed by Fruman et al. (2017) [http://www.ncbi.nlm.nih.gov/pubmed/28802037?dopt=AbstractPlus].


Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2153
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2154
	
Common abbreviation	PI3Kα	PI3Kß	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8975, http://www.uniprot.org/uniprot/P42336
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8976, http://www.uniprot.org/uniprot/P42338
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.153
http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.11.1
	
http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.153
	
Inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8012 (pIC50 9.5) [http://www.ncbi.nlm.nih.gov/pubmed/17601739?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7940 (pIC50 9.4) [http://www.ncbi.nlm.nih.gov/pubmed/20166697?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7936 (pK
i 9.2) [http://www.ncbi.nlm.nih.gov/pubmed/24900269?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5701 (pIC50 8.7) [http://www.ncbi.nlm.nih.gov/pubmed/19584227?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7951 (pIC50 8.4) [http://www.ncbi.nlm.nih.gov/pubmed/22357447?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8011 (pIC50 8.4) [http://www.ncbi.nlm.nih.gov/pubmed/23855836?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7950 (pIC50 8.4) [http://www.ncbi.nlm.nih.gov/pubmed/18606717?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7888 (pIC50 8.3) [http://www.ncbi.nlm.nih.gov/pubmed/21981714?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8012 (pIC50 8.2) [http://www.ncbi.nlm.nih.gov/pubmed/16647110?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8011 (pIC50 9.3) [http://www.ncbi.nlm.nih.gov/pubmed/23855836?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5701 (pIC50 8.5) [http://www.ncbi.nlm.nih.gov/pubmed/19584227?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8059 (pIC50 8) [http://www.ncbi.nlm.nih.gov/pubmed/22906130?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7965 (pIC50 7.4–7.8) [665, http://www.ncbi.nlm.nih.gov/pubmed/16622124?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7888 (pIC50 7.6) [http://www.ncbi.nlm.nih.gov/pubmed/21981714?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7951 (pIC50 7.2) [http://www.ncbi.nlm.nih.gov/pubmed/22357447?dopt=AbstractPlus]	
Sub/family‐selective inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5682 (pIC50 8.5) [http://www.ncbi.nlm.nih.gov/pubmed/18754654?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5682 (pIC50 7.5) [http://www.ncbi.nlm.nih.gov/pubmed/18754654?dopt=AbstractPlus]	
Selective inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9826 (pIC50 8.7) [http://www.ncbi.nlm.nih.gov/pubmed/24900173?dopt=AbstractPlus]	–	




Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2156
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2155
	
Common abbreviation	PI3Kγ	PI3Kδ	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8978, http://www.uniprot.org/uniprot/P48736
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8977, http://www.uniprot.org/uniprot/O00329
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.153
	
http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.153
	
Inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7950 (pIC50 8.3) [http://www.ncbi.nlm.nih.gov/pubmed/18606717?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7888 (pIC50 7.8) [http://www.ncbi.nlm.nih.gov/pubmed/21981714?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5701 (pIC50 7.8) [http://www.ncbi.nlm.nih.gov/pubmed/19584227?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7951 (pIC50 7.4) [http://www.ncbi.nlm.nih.gov/pubmed/22357447?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7965 (pIC50 7.3–7.3) [665, http://www.ncbi.nlm.nih.gov/pubmed/16622124?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5715 (pIC50 7.1) [http://www.ncbi.nlm.nih.gov/pubmed/17685602?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7955 (pIC50 6.6) [http://www.ncbi.nlm.nih.gov/pubmed/23726034?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8011 (pIC50 6.2) [http://www.ncbi.nlm.nih.gov/pubmed/23855836?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8011 (pIC50 > 10) [http://www.ncbi.nlm.nih.gov/pubmed/23855836?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6741 (in vitro activity against recombinant enzyme) (pIC50 8.6) [http://www.ncbi.nlm.nih.gov/pubmed/20959606?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5701 (pIC50 8.5) [http://www.ncbi.nlm.nih.gov/pubmed/19584227?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7965 (pIC50 8.2–8.3) [665, http://www.ncbi.nlm.nih.gov/pubmed/16622124?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7888 (pIC50 8.2) [http://www.ncbi.nlm.nih.gov/pubmed/21981714?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7950 (pIC50 8.1) [http://www.ncbi.nlm.nih.gov/pubmed/18606717?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7955 (pIC50 6.5) [http://www.ncbi.nlm.nih.gov/pubmed/23726034?dopt=AbstractPlus]	
Sub/family‐selective inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5682 (pIC50 7.1) [http://www.ncbi.nlm.nih.gov/pubmed/18754654?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5682 (pIC50 8.5) [http://www.ncbi.nlm.nih.gov/pubmed/18754654?dopt=AbstractPlus]	
Selective inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6653 (pIC50 7.6) [http://www.ncbi.nlm.nih.gov/pubmed/22544264?dopt=AbstractPlus]	–	




http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=913


Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2857
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:23785, http://www.uniprot.org/uniprot/Q9Y2I7
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.150: ATP + 1‐phosphatidyl‐1D‐myo‐inositol 3‐phosphate = ADP + 1‐phosphatidyl‐1D‐myo‐inositol 3,5‐bisphosphate	




http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=675

Overview
Type I PIP kinases are required for the production of the second messenger phosphatidylinositol 4,5‐bisphosphate (PtdIns(4,5)P2) by phosphorylating PtdIns(4)P [http://www.ncbi.nlm.nih.gov/pubmed/9367159?dopt=AbstractPlus]. This enzyme family is also known as type I PIP(5)Ks.


Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2164
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2165
	
Common abbreviation	PIP5K1A	PIP5K1C	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8994, http://www.uniprot.org/uniprot/Q99755
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8996, http://www.uniprot.org/uniprot/O60331
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.68
	
http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.68
	
Inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8444 [http://www.ncbi.nlm.nih.gov/pubmed/25071204?dopt=AbstractPlus]	–	




http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=674

Overview
Type II PIP kinases are essential for the production of the second messenger phosphatidylinositol 4,5‐bisphosphate (PtdIns(4,5)P2) by phosphorylating PtdIns(5)P [http://www.ncbi.nlm.nih.gov/pubmed/9367159?dopt=AbstractPlus]. This enzyme family is also known as type II PIP(5)Ks.


Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2858
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2162
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2163
	
Common abbreviation	PIP4K2A	PIP4K2B	PIP4K2C	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8997, http://www.uniprot.org/uniprot/P48426
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8998, http://www.uniprot.org/uniprot/P78356
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:23786, http://www.uniprot.org/uniprot/Q8TBX8
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.149 ATP + 1‐phosphatidyl‐1D‐myo‐inositol 5‐phosphate <=> ADP + 1‐phosphatidyl‐1D‐myo‐inositol 4,5‐bisphosphate	
http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.149
	
http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.149
	




http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=787

Overview
SPHK1 and SPHK2 are encoded by different genes with some redundancy of function; genetic deletion of both Sphk1 and Sphk2, but not either alone, is embryonic lethal in mice. There are splice variants of each isoform (SphK1a‐c and SphK2a, b), distinguished by their N‐terminal sequences. SPHK1 and SPHK2 differ in tissue distribution, sub‐cellular localisation, biochemical properties and regulation. They regulate discrete pools of S1P. Receptor stimulation induces SPHK1 translocation from the cytoplasm to the plasma membrane. SPHK1 translocation is regulated by phosphorylation/dephosphorylation, specific protein:protein interactions and interaction with specific lipids at the plasma membrane. SPHK1 is a dimeric protein, as confirmed by its crystal structure which forms a positive cluster, between protomers, essential for interaction with anionic phospholipids in the plasma membrane. SPHK2 is localised to the ER or associated with mitochondria or shuttles in/out of the nucleus, regulated by phosphorylation. Intracellular targets of nuclear S1P include the catalytic subunit of telomerase (TERT) and regulators of gene expression including histone deacetylases (HDAC 1/2) and peroxisome proliferator‐activated receptor gamma (PPARγ). SPHK2 phosphorylates the pro‐drug FTY720 (http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2407, which is used to treat some forms of multiple sclerosis) to a mimic of S1P and that acts as a functional antagonist of S1P1 receptors. Inhibitors of SPHK1 and SPHK2 have therapeutic potential in many diseases.


Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2204
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2205
	
Common abbreviation	SPHK1	SPHK2	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11240, http://www.uniprot.org/uniprot/Q9NYA1
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:18859, http://www.uniprot.org/uniprot/Q9NRA0
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.91: http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2452 + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713 = http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=911 + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1712 dihydrosphingosine + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713 = http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=911 + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1712
	
http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.91: http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2452 + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713 = http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=911 + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1712 dihydrosphingosine + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713 = http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=911 + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1712
	
Cofactors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=708 [http://www.ncbi.nlm.nih.gov/pubmed/22677141?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=708
	
Inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6041 (pK
i 4.8) [http://www.ncbi.nlm.nih.gov/pubmed/20061445?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10219 (pIC50 4.6) [http://www.ncbi.nlm.nih.gov/pubmed/25788259?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10219 (pK
i 5.2) [http://www.ncbi.nlm.nih.gov/pubmed/25788259?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6041 (pK
i 5.1) [http://www.ncbi.nlm.nih.gov/pubmed/22970244?dopt=AbstractPlus]	
Selective inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6623 (pK
i 8.4) [http://www.ncbi.nlm.nih.gov/pubmed/22397330?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10217 (pK
i 7.1) [http://www.ncbi.nlm.nih.gov/pubmed/28406646?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10218 (pIC50 6.8) [http://www.ncbi.nlm.nih.gov/pubmed/28231433?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6624 (pK
i 5) [http://www.ncbi.nlm.nih.gov/pubmed/20061445?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6625 (pK
i 4.8) [http://www.ncbi.nlm.nih.gov/pubmed/21620961?dopt=AbstractPlus]	
Comments	SK1 inhibitors induce its proteasomal degradation [http://www.ncbi.nlm.nih.gov/pubmed/20926375?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/26934645?dopt=AbstractPlus]. SK1 crystal structures confirm that it is dimeric [http://www.ncbi.nlm.nih.gov/pubmed/27021309?dopt=AbstractPlus]; there is no crystal structure available for SK2.	There is no crystal structure available for SK2.	



Comments

http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10219 is competitive with ATP; other SPHK inhibitors are competitive with sphingosine. ABC294640 (http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6624) has known off‐target effects on dihydroceramide desaturase (DEGS1) [http://www.ncbi.nlm.nih.gov/pubmed/26934645?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/26494858?dopt=AbstractPlus]) and induces proteasomal degradation of SK1 [http://www.ncbi.nlm.nih.gov/pubmed/26934645?dopt=AbstractPlus]. ABC294640 is in clinical trials for advanced cholangiocarcinoma, advanced hepatocellular carcinoma and refractory/relapsed multiple myeloma (to view ClinicalTrials.gov list click https://clinicaltrials.gov/ct2/results?cond=&term=ABC294640).

Further reading on Sphingosine kinase
Adams DR et al. (2016) Sphingosine Kinases: Emerging Structure‐Function Insights. Trends Biochem. Sci. 41: 395‐409 https://www.ncbi.nlm.nih.gov/pubmed/27021309?dopt=AbstractPlus


Lynch KR et al. (2016) Sphingosine kinase inhibitors: a review of patent literature (2006‐2015). Expert Opin Ther Pat
26: 1409‐1416 https://www.ncbi.nlm.nih.gov/pubmed/27539678?dopt=AbstractPlus


Pitman MR et al. (2016) Recent advances in the development of sphingosine kinase inhibitors. Cell. Signal. 28: 1349‐63 https://www.ncbi.nlm.nih.gov/pubmed/27297359?dopt=AbstractPlus


Pulkoski‐Gross MJ et al. (2018) An intrinsic lipid‐binding interface controls sphingosine kinase 1 function. J. Lipid Res. 59: 462‐474 https://www.ncbi.nlm.nih.gov/pubmed/29326159?dopt=AbstractPlus


Pyne NJ et al. (2017) Sphingosine Kinase 2 in Autoimmune/Inflammatory Disease and the Development of Sphingosine Kinase 2 Inhibitors. Trends Pharmacol. Sci. 38: 581‐591 https://www.ncbi.nlm.nih.gov/pubmed/28606480?dopt=AbstractPlus


Pyne S et al. (2018) Sphingosine Kinases as Druggable Targets. Handb Exp Pharmacol
https://www.ncbi.nlm.nih.gov/pubmed/29460151?dopt=AbstractPlus



Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2156
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2499
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2155
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2150
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2151
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2288
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2152
	
Common abbreviation	PI3Kγ	PI4KIIß/PI4K2B	PI3Kδ	C2α/PIK3C2A	C2ß/PIK3C2B	C2γ/PIK3C2G	VPS34	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8978, http://www.uniprot.org/uniprot/P48736
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:18215, http://www.uniprot.org/uniprot/Q8TCG2
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8977, http://www.uniprot.org/uniprot/O00329
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8971, http://www.uniprot.org/uniprot/O00443
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8972, http://www.uniprot.org/uniprot/O00750
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8973, http://www.uniprot.org/uniprot/O75747
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8974, http://www.uniprot.org/uniprot/Q8NEB9
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.153
	
http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.67
	
http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.153
	
http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.154
	
http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.154
	
http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.154
	
http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.137
	
Inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7950 (pIC50 8.3) [http://www.ncbi.nlm.nih.gov/pubmed/18606717?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7888 (pIC50 7.8) [http://www.ncbi.nlm.nih.gov/pubmed/21981714?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5701 (pIC50 7.8) [http://www.ncbi.nlm.nih.gov/pubmed/19584227?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7951 (pIC50 7.4) [http://www.ncbi.nlm.nih.gov/pubmed/22357447?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7965 (pIC50 7.3–7.3) [651, http://www.ncbi.nlm.nih.gov/pubmed/16622124?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5715 (pIC50 7.1) [http://www.ncbi.nlm.nih.gov/pubmed/17685602?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7955 (pIC50 6.6) [http://www.ncbi.nlm.nih.gov/pubmed/23726034?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8011 (pIC50 6.2) [http://www.ncbi.nlm.nih.gov/pubmed/23855836?dopt=AbstractPlus]	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8011 (pIC50 > 10) [http://www.ncbi.nlm.nih.gov/pubmed/23855836?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6741 (in vitro activity against recombinant enzyme) (pIC50 8.6) [http://www.ncbi.nlm.nih.gov/pubmed/20959606?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5701 (pIC50 8.5) [http://www.ncbi.nlm.nih.gov/pubmed/19584227?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7965 (pIC50 8.2–8.3) [651, http://www.ncbi.nlm.nih.gov/pubmed/16622124?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7888 (pIC50 8.2) [http://www.ncbi.nlm.nih.gov/pubmed/21981714?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7950 (pIC50 8.1) [http://www.ncbi.nlm.nih.gov/pubmed/18606717?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7955 (pIC50 6.5) [http://www.ncbi.nlm.nih.gov/pubmed/23726034?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8839 (pIC50 7.6) [http://www.ncbi.nlm.nih.gov/pubmed/21322566?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5701 (pIC50 8) [http://www.ncbi.nlm.nih.gov/pubmed/17601739?dopt=AbstractPlus]	–	–	
Sub/family‐selective inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5682 (pIC50 7.1) [http://www.ncbi.nlm.nih.gov/pubmed/18754654?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2844 (pIC50 4.5–5) [http://www.ncbi.nlm.nih.gov/pubmed/21704602?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5682 (pIC50 8.5) [http://www.ncbi.nlm.nih.gov/pubmed/18754654?dopt=AbstractPlus]	–	–	–	–	
Selective inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6653 (pIC50 7.6) [http://www.ncbi.nlm.nih.gov/pubmed/22544264?dopt=AbstractPlus]	–	–	–	–	–	–	



Comments

http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6060 also inhibits type III phosphatidylinositol 4‐kinases and polo‐like kinase [http://www.ncbi.nlm.nih.gov/pubmed/15664519?dopt=AbstractPlus]. PIK93 also inhibits PI 3‐kinases [http://www.ncbi.nlm.nih.gov/pubmed/16647110?dopt=AbstractPlus]. Adenosine activates http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=3.

Further reading on Phosphatidylinositol kinases
Raphael J et al. (2018) Phosphoinositide 3‐kinase inhibitors in advanced breast cancer: A systematic review and meta‐analysis. Eur J Cancer
91: 38‐46 https://www.ncbi.nlm.nih.gov/pubmed/29331750


Wang D et al. (2019) Upstream regulators of phosphoinositide 3‐kinase and their role in diseases. J Cell Physiol. https://www.ncbi.nlm.nih.gov/pubmed/30710358


Goncalves MD et al. (2018) Phosphatidylinositol 3‐Kinase, Growth Disorders, and Cancer. N Engl J Med
379: 2052‐2062 https://www.ncbi.nlm.nih.gov/pubmed/30462943



http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=782

Overview
PIP2 is generated by phosphorylation of PI 4‐phosphate or PI 5‐phosphate by type I PI 4‐phosphate 5‐kinases or type II PI 5‐phosphate 4‐kinases.


Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2164
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2500
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2165
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2858
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2162
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2163
	
Common abbreviation	PIP5K1A	PIP5K1B	PIP5K1C	PIP4K2A	PIP4K2B	PIP4K2C	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8994, http://www.uniprot.org/uniprot/Q99755
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8995, http://www.uniprot.org/uniprot/O14986
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8996, http://www.uniprot.org/uniprot/O60331
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8997, http://www.uniprot.org/uniprot/P48426
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8998, http://www.uniprot.org/uniprot/P78356
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:23786, http://www.uniprot.org/uniprot/Q8TBX8
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.68
	
http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.68
	
http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.68
	
http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.149 ATP + 1‐phosphatidyl‐1D‐myo‐inositol 5‐phosphate <=> ADP + 1‐phosphatidyl‐1D‐myo‐inositol 4,5‐bisphosphate	
http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.149
	
http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.149
	
Inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8444 [http://www.ncbi.nlm.nih.gov/pubmed/25071204?dopt=AbstractPlus]	–	–	–	–	–	



Further reading on Glycerophospholipid turnover
Cauvin C et al. (2015) Phosphoinositides: Lipids with informative heads and mastermind functions in cell division. Biochim. Biophys. Acta
1851: 832‐43 https://www.ncbi.nlm.nih.gov/pubmed/25449648?dopt=AbstractPlus


Irvine RF. (2016) A short history of inositol lipids. J. Lipid Res. 57: 1987‐1994 https://www.ncbi.nlm.nih.gov/pubmed/27623846?dopt=AbstractPlus


Poli A et al. (2016) Nuclear Phosphatidylinositol Signaling: Focus on Phosphatidylinositol Phosphate Kinases and Phospholipases C. J. Cell. Physiol. 231: 1645‐55 https://www.ncbi.nlm.nih.gov/pubmed/26626942?dopt=AbstractPlus



http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=278

Overview
Haem oxygenase (heme,hydrogen‐donor:oxygen oxidoreductase (α‐methene‐oxidizing, hydroxylating)), http://www.genome.jp/kegg‐bin/search_brite?option=‐a&search_string=1.14.99.3, converts http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4349 into http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5153 and carbonmonoxide, utilizing http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3041 as cofactor.


Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1441
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1442
	
Common abbreviation	HO1	HO2	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:5013, http://www.uniprot.org/uniprot/P09601
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:5014, http://www.uniprot.org/uniprot/P30519
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.18 Protoheme + 3 [reduced NADPH‐hemoprotein reductase] + 3 O(2) <=> biliverdin + Fe(2+) + CO + 3 [oxidized NADPH‐hemoprotein reductase] + 3 H(2)O	
http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.18 Protoheme + 3 [reduced NADPH–hemoprotein reductase] + 3 O(2) <=> biliverdin + Fe(2+) + CO + 3 [oxidized NADPH–hemoprotein reductase] + 3 H(2)O	
Inhibitors	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8873 (pIC50 3.5) [http://www.ncbi.nlm.nih.gov/pubmed/16821802?dopt=AbstractPlus] – Rat	



Comments
The existence of a third non‐catalytic version of haem oxygenase, HO3, has been proposed, although this has been suggested to be a pseudogene [http://www.ncbi.nlm.nih.gov/pubmed/15246535?dopt=AbstractPlus]. The chemical http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5279 acts as a haem oxygenase inhibitor in rat liver with an IC50 value of 11 nM [http://www.ncbi.nlm.nih.gov/pubmed/6947237?dopt=AbstractPlus].

Further reading on Haem oxygenase
Magierowska K et al. (2018) Emerging role of carbon monoxide in regulation of cellular pathways and in the maintenance of gastric mucosal integrity. Pharmacol Res
129: 56‐64 https://www.ncbi.nlm.nih.gov/pubmed/29360501


Rochette L et al. (2018) Redox Functions of Heme Oxygenase‐1 and Biliverdin Reductase in Diabetes Trends. Endocrinol Metab. 29: 74‐85 https://www.ncbi.nlm.nih.gov/pubmed/29249571


Salerno L et al. (2017) Heme oxygenase‐1: A new druggable target in the management of chronic and acute myeloid leukemia. Eur J Med Chem. 142: 163‐178 https://www.ncbi.nlm.nih.gov/pubmed/28756878


Sebastian VP et al. (2018) Heme Oxygenase‐1 as a Modulator of Intestinal Inflammation Development and Progression. Front Immunol. 9: 1956 https://www.ncbi.nlm.nih.gov/pubmed/30258436


Tomczyk M et al. (2019) Modulation of the monocyte/macrophage system in heart failure by targeting heme oxygenase‐1. Vascul Pharmacol. 112: 79‐90 https://www.ncbi.nlm.nih.gov/pubmed/30213580


Vijayan V et al. (2018) The macrophage heme‐heme oxygenase‐1 system and its role in inflammation. Biochem Pharmacol. 153: 159‐167 https://www.ncbi.nlm.nih.gov/pubmed/29452096



http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=279

Overview
Hydrogen sulfide is a gasotransmitter, with similarities to nitric oxide and carbon monoxide. Although the enzymes indicated below have multiple enzymatic activities, the focus here is the generation of hydrogen sulphide (H2S) and the enzymatic characteristics are described accordingly. Cystathionine β‐synthase (CBS) and cystathionine γ‐lyase (CSE) are pyridoxal phosphate (PLP)‐dependent enzymes. 3‐mercaptopyruvate sulfurtransferase (3‐MPST) functions to generate H2S; only CAT is PLP‐dependent, while 3‐MPST is not. Thus, this third pathway is sometimes referred to as PLP‐independent. CBS and CSE are predominantly cytosolic enzymes, while 3‐MPST is found both in the cytosol and the mitochondria. For an authoritative review on the pharmacological modulation of H2S levels, see Szabo and Papapetropoulos, 2017 [http://www.ncbi.nlm.nih.gov/pubmed/28978633?dopt=AbstractPlus].


Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1443
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1444
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1445
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1446
	
Common abbreviation	CBS	CSE	CAT	MPST	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1550, http://www.uniprot.org/uniprot/P35520
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2501, http://www.uniprot.org/uniprot/P32929
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1564, http://www.uniprot.org/uniprot/Q16773
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7223, http://www.uniprot.org/uniprot/P25325
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:4.2.1.22
	
http://www.genome.jp/dbget‐bin/www_bget?ec:4.4.1.1
	
http://www.genome.jp/dbget‐bin/www_bget?ec:4.4.1.13
	
http://www.genome.jp/dbget‐bin/www_bget?ec:2.8.1.2
	
Endogenous substrates	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4782 (K
m 6×10‐3M) [http://www.ncbi.nlm.nih.gov/pubmed/15520012?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5198 [http://www.ncbi.nlm.nih.gov/pubmed/15520012?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4782
	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4782
	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5118 (K
m 1.2×10‐3M) [http://www.ncbi.nlm.nih.gov/pubmed/7608189?dopt=AbstractPlus]	
Products	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5173
	NH3, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4809
	NH3, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4809
	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4809
	
Cofactors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5249
	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5249
	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5249
	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=566
	
Inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5136 (pIC50 5.1) [http://www.ncbi.nlm.nih.gov/pubmed/23488457?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8860 (pIC50 6) [http://www.ncbi.nlm.nih.gov/pubmed/23488457?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5136 (pIC50 6) [http://www.ncbi.nlm.nih.gov/pubmed/23488457?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8859 (pIC50 5.8) [http://www.ncbi.nlm.nih.gov/pubmed/23488457?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5247 (pIC50 4.4) [http://www.ncbi.nlm.nih.gov/pubmed/23488457?dopt=AbstractPlus]	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10210 (pIC50 5.6) [http://www.ncbi.nlm.nih.gov/pubmed/28079151?dopt=AbstractPlus]	



Further reading on Hydrogen sulphide synthesis
Asimakopoulou A et al. (2013) Selectivity of commonly used pharmacological inhibitors for cystathionine β synthase (CBS) and cystathionine γ lyase (CSE). Br J Pharmacol. 169: 922‐32 https://www.ncbi.nlm.nih.gov/pubmed/23488457?dopt=AbstractPlus


Szabo C et al. (2017) International Union of Basic and Clinical Pharmacology. CII: Pharmacological Modulation of H2S Levels: H2S Donors and H2S Biosynthesis Inhibitors. Pharmacol. Rev. 69: 497‐564 https://www.ncbi.nlm.nih.gov/pubmed/28978633?dopt=AbstractPlus



http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=799

Overview
Listed in this section are hydrolases not accumulated in other parts of the Concise Guide, such as monoacylglycerol lipase and acetylcholinesterase. Pancreatic lipase is the predominant mechanism of fat digestion in the alimentary system; its inhibition is associated with decreased fat absorption. CES1 is present at lower levels in the gut than CES2 (http://www.uniprot.org/uniprot/P23141), but predominates in the liver, where it is responsible for the hydrolysis of many aliphatic, aromatic and steroid esters. Hormone‐sensitive lipase is also a relatively non‐selective esterase associated with steroid ester hydrolysis and triglyceride metabolism, particularly in adipose tissue. Endothelial lipase is secreted from endothelial cells and regulates circulating cholesterol in high density lipoproteins.


Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2590
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2593
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2591
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2592
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2888
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2889
	
Systematic nomenclature	–	–	–	–	CD39	CD39L1	
Common abbreviation	PNLIP	LIPE	LIPG	CES1	NTPDase‐1	NTPDase‐2	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9155, http://www.uniprot.org/uniprot/P16233
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6621, http://www.uniprot.org/uniprot/Q05469
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6623, http://www.uniprot.org/uniprot/Q9Y5X9
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1863, http://www.uniprot.org/uniprot/P23141
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3363, http://www.uniprot.org/uniprot/P49961
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3364, http://www.uniprot.org/uniprot/Q9Y5L3
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.1.3
	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.1.79
	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.1.3
	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.1.1
	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.6.1.5 Hydrolyzes NTPs to nucleotide monophosphates (NMPs): A nucleoside 5′‐triphosphate + 2 H2O <=> a nucleoside 5′‐phosphate + 2 phosphate	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.6.1.‐ Hydrolyzes extracellular nucleotide 5′‐triphosphates: NTP>NMP + 2 phosphate	
Inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5277 (pIC50 8.9) [66]	–	–	–	–	–	
Selective inhibitors	–	–	–	–	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9033 (pK
i 5.1) [http://www.ncbi.nlm.nih.gov/pubmed/18630897?dopt=AbstractPlus]	
Comments	–	–	–	–	ENTPD1 sequentially converts extracellular purine nucleotides (ATP and ADP) to the monophosphate form. Adenosine is then generated by the action of http://www.guidetopharmacology.org/GRAC/guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1232 (CD73). ENTPD1 is the rate‐limiting step. Extracellular ATP acts as a damage‐associated molecular pattern (DAMP) that activates innate immune cells through adenosine‐induced activation of P2X and P2Y purinogenic receptors.	–	



Further reading on Hydrolases
Allard B et al.. (2017) The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets. Immunol Rev. 276: 121‐144 https://www.ncbi.nlm.nih.gov/pubmed/28258700


Kishore BK et al. (2018) CD39‐adenosinergic axis in renal pathophysiology and therapeutics. Purinergic Signal
14: 109‐120 https://www.ncbi.nlm.nih.gov/pubmed/29332180


Rasmussen HB et al. (2018) Carboxylesterase 1 genes: systematic review and evaluation of existing genotyping procedures. Drug Metab Pers Ther
33: 3‐14 https://www.ncbi.nlm.nih.gov/pubmed/29427553


Zou LW et al. (2018) Carboxylesterase Inhibitors: An Update. Curr Med Chem. 25: 1627‐1649 https://www.ncbi.nlm.nih.gov/pubmed/29210644



http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=245

Overview
The sugar alcohol D‐myo‐inositol is a component of the http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=244, where the principal second messenger is inositol 1,4,5‐trisphosphate, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4222, which acts at intracellular ligand‐gated ion channels, http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=123 to elevate intracellular calcium. http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4222 is recycled to inositol by phosphatases or phosphorylated to form other active inositol polyphosphates. Inositol produced from dephosphorylation of http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4222 is recycled into membrane phospholipid under the influence of phosphatidyinositol synthase activity (CDP‐diacylglycerol‐inositol 3‐phosphatidyltransferase [http://www.genome.jp/kegg‐bin/search_brite?option=‐a&search_string=2.7.8.11]).


http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=280

Overview
Inositol 1,4,5‐trisphosphate 3‐kinases (http://www.genome.jp/kegg‐bin/search_brite?option=‐a&search_string=2.7.1.127, http://www.ensembl.org/Homo_sapiens/Gene/Family/Genes?family=ENSFM00250000001260) catalyse the generation of inositol 1,3,4,5‐tetrakisphosphate (http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5202) from http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4222. IP3 kinase activity is enhanced in the presence of calcium/http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2351 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1442
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1445
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1449, http://www.uniprot.org/uniprot/P62158) [http://www.ncbi.nlm.nih.gov/pubmed/2559811?dopt=AbstractPlus].

Information on members of this family may be found in the http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=280.


http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=281

Overview
Members of this family exhibit phosphatase activity towards IP3, as well as towards other inositol derivatives, including the phospholipids http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2387 and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2353. With http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4222 as substrate, 1‐phosphatase (http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.3.57) generates http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5119, 4‐phosphatases (http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.3.66, http://www.ensembl.org/Homo_sapiens/Gene/Family/Genes?family=ENSFM00250000001432) generate http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5099 and 5‐phosphatases (http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.3.36 or http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.3.56) generate http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5098.

Information on members of this family may be found in the http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=281.

Comments

In vitro analysis suggested http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4222 and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5202 were poor substrates for SKIP, synaptojanin 1 and synaptojanin 2, but suggested that http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2387 and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2353 were more efficiently hydrolysed [http://www.ncbi.nlm.nih.gov/pubmed/15474001?dopt=AbstractPlus].


http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=282

Overview
Inositol monophosphatase (http://www.genome.jp/kegg‐bin/search_brite?option=‐a&search_string=3.1.3.25, IMPase, myo‐inositol‐1(or 4)‐phosphate phosphohydrolase) is a magnesium‐dependent homodimer which hydrolyses myoinositol monophosphate to generate http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4495 and phosphate. http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5195 may be a physiological phosphate acceptor. http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5212 is a nonselective un‐competitive inhibitor more potent at IMPase 1 (pKi
ca. 3.5, [http://www.ncbi.nlm.nih.gov/pubmed/1377913?dopt=AbstractPlus]; pIC50 3.2, [http://www.ncbi.nlm.nih.gov/pubmed/17068342?dopt=AbstractPlus]) than IMPase 2 (pIC50 1.8‐2.1, [http://www.ncbi.nlm.nih.gov/pubmed/17068342?dopt=AbstractPlus]). IMPase activity may be inhibited competitively by http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5208 (pKi 5.5, [http://www.ncbi.nlm.nih.gov/pubmed/1377913?dopt=AbstractPlus]), although the enzyme selectivity is not yet established.


Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1463
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1464
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6050, http://www.uniprot.org/uniprot/P29218
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6051, http://www.uniprot.org/uniprot/O14732
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.3.25
	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.3.25
	
Rank order of affinity	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5205 > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5204 > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5203 [http://www.ncbi.nlm.nih.gov/pubmed/1377913?dopt=AbstractPlus]	–	
Inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5212 (pK
i 3.5) [http://www.ncbi.nlm.nih.gov/pubmed/1377913?dopt=AbstractPlus]	–	



Comments
Polymorphisms in either of the genes encoding these enzymes have been linked with bipolar disorder [http://www.ncbi.nlm.nih.gov/pubmed/10822345?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9339367?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9322233?dopt=AbstractPlus]. Disruption of the gene encoding IMPase 1, but not IMPase 2, appears to mimic the effects of http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5212 in mice [http://www.ncbi.nlm.nih.gov/pubmed/16841073?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/17460611?dopt=AbstractPlus].

Further reading on Inositol phosphate turnover
Irvine R. (2016) A tale of two inositol trisphosphates. Biochem. Soc. Trans. 44: 202‐11 https://www.ncbi.nlm.nih.gov/pubmed/26862207?dopt=AbstractPlus


Livermore TM et al. (2016) Phosphate, inositol and polyphosphates. Biochem. Soc. Trans. 44: 253‐9 https://www.ncbi.nlm.nih.gov/pubmed/26862212?dopt=AbstractPlus


Miyamoto A et al. (2017) Probes for manipulating and monitoring IP_3. Cell Calcium
64: 57‐64 https://www.ncbi.nlm.nih.gov/pubmed/27887748?dopt=AbstractPlus


Windhorst S et al. (2017) Inositol‐1,4,5‐trisphosphate 3‐kinase‐A (ITPKA) is frequently over‐expressed and functions as an oncogene in several tumor types. Biochem. Pharmacol. 137: 1‐9 https://www.ncbi.nlm.nih.gov/pubmed/28377279?dopt=AbstractPlus



http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=698

Overview
Protein kinases (http://www.genome.jp/kegg‐bin/search_brite?option=‐a&search_string=2.7.11.1) use the co‐substrate http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713 to phosphorylate serine and/or threonine residues on target proteins. Analysis of the human genome suggests the presence of 518 protein kinases in man (divided into 15 subfamilies), with over 100 protein kinase‐like pseudogenes [http://www.ncbi.nlm.nih.gov/pubmed/12471243?dopt=AbstractPlus]. It is beyond the scope of the Concise Guide to list all these protein kinase activities, but full listings are available on the ’Detailed page’ provided for each enzyme.

Most inhibitors of these enzymes have been assessed in cell‐free investigations and so may appear to ’lose’ potency and selectivity in intact cell assays. In particular, ambient http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713 concentrations may be influential in responses to inhibitors, since the majority are directed at the ATP binding site [http://www.ncbi.nlm.nih.gov/pubmed/10998351?dopt=AbstractPlus].


http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=289

Overview
Rho kinase (also known as P160ROCK, Rho‐activated kinase) is activated by members of the Rho small G protein family, which are activated by GTP exchange factors, such as https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:681 (http://www.uniprot.org/uniprot/Q92888, p115‐RhoGEF), which in turn may be activated by Gα12/13 subunits [http://www.ncbi.nlm.nih.gov/pubmed/9641915?dopt=AbstractPlus].


Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1503
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1504
	
Systematic nomenclature	ROCK1	ROCK2	
Common abbreviation	Rho kinase 1	Rho kinase 2	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10251, http://www.uniprot.org/uniprot/Q13464
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10252, http://www.uniprot.org/uniprot/O75116
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.11.1
	
http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.11.1
	
Inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8152 (pIC50 >9) [http://www.ncbi.nlm.nih.gov/pubmed/23275831?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5290 (pIC50 5.9–7.3) [http://www.ncbi.nlm.nih.gov/pubmed/19597037?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/20462760?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5181 (pK
i 7) [http://www.ncbi.nlm.nih.gov/pubmed/21145740?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5290 (pK
i 6.8) [http://www.ncbi.nlm.nih.gov/pubmed/9353125?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5181 (pIC50 5.5–5.6) [http://www.ncbi.nlm.nih.gov/pubmed/19597037?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/21145740?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8152 (pIC50 >9) [http://www.ncbi.nlm.nih.gov/pubmed/23275831?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8197 (pIC50 >9) [95], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8037 (pIC50 8.4) [http://www.ncbi.nlm.nih.gov/pubmed/17018693?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8184 (pIC50 8.4) [http://www.ncbi.nlm.nih.gov/pubmed/20471253?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8205 (pIC50 7.7) [http://www.ncbi.nlm.nih.gov/pubmed/20462760?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5290 (pIC50 6.3–7.2) [http://www.ncbi.nlm.nih.gov/pubmed/19597037?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/20462760?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5290 (pK
i 6.8–6.9) [http://www.ncbi.nlm.nih.gov/pubmed/19597037?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9353125?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5181 (pIC50 5.9–5.9) [http://www.ncbi.nlm.nih.gov/pubmed/19597037?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/21145740?dopt=AbstractPlus]	
Selective inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8037 (pIC50 8.8) [http://www.ncbi.nlm.nih.gov/pubmed/17018693?dopt=AbstractPlus]	–	



Further reading on Rho kinase
Feng Y et al. (2016) Rho Kinase (ROCK) Inhibitors and Their Therapeutic Potential. J. Med. Chem. 59: 2269‐300 https://www.ncbi.nlm.nih.gov/pubmed/26486225?dopt=AbstractPlus


Nishioka T et al. (2015) Developing novel methods to search for substrates of protein kinases such as Rho‐kinase. Biochim. Biophys. Acta
1854: 1663‐6 https://www.ncbi.nlm.nih.gov/pubmed/25770685?dopt=AbstractPlus


Shimokawa H et al. (2016) RhoA/Rho‐Kinase in the Cardiovascular System. Circ. Res. 118: 352‐66 https://www.ncbi.nlm.nih.gov/pubmed/26838319?dopt=AbstractPlus



http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=286

Overview
Protein kinase C is the target for the tumour‐promoting phorbol esters, such as tetradecanoyl‐β‐phorbol acetate (TPA, also known as http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2341).


Classical protein kinase C isoforms:
PKCα, PKCβ, and PKCγ are activated by http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=707 and diacylglycerol, and may be inhibited by http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5193, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5156, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5192, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5953 and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5259.


Novel protein kinase C isoforms:
PKC
δ, PKC
∈, PKC
η, PKC
ϑ and PKC
μ are activated by diacylglycerol and may be inhibited by http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5156, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5192 and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5953.


Atypical protein kinase C isoforms:
PKC
ι, PKC
ζ.


http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=532


Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1483
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1484
	
Common abbreviation	PKCβ	PKCγ	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9395, http://www.uniprot.org/uniprot/P05771
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9402, http://www.uniprot.org/uniprot/P05129
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.11.13
	
http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.11.13
	
Inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7946 (pIC50 8.7) [http://www.ncbi.nlm.nih.gov/pubmed/19827831?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5192 (pIC50 8.1) [http://www.ncbi.nlm.nih.gov/pubmed/8772178?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5193 (pIC50 7.8) [http://www.ncbi.nlm.nih.gov/pubmed/1874734?dopt=AbstractPlus] – Bovine, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7907 (pIC50 7.5) [http://www.ncbi.nlm.nih.gov/pubmed/8022414?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5192 (pIC50 8.2) [zhttp://www.ncbi.nlm.nih.gov/pubmed/8772178?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7907 (pIC50 7.5) [http://www.ncbi.nlm.nih.gov/pubmed/8022414?dopt=AbstractPlus]	
Selective inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5263 (pIC50 8.2) [http://www.ncbi.nlm.nih.gov/pubmed/8709095?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5693 (pIC50 7.5) [http://www.ncbi.nlm.nih.gov/pubmed/12749884?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5163 (pIC50 6.4) [http://www.ncbi.nlm.nih.gov/pubmed/9121494?dopt=AbstractPlus]	–	




http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=533


			
Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1482
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1485
	
Common abbreviation	PKCα	PKCδ
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9393, http://www.uniprot.org/uniprot/P17252
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9399, http://www.uniprot.org/uniprot/Q05655
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.11.13
	
http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.11.13
	
Activators	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7443 (pK
i 9.4) [http://www.ncbi.nlm.nih.gov/pubmed/15126366?dopt=AbstractPlus]	
Inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7946 (pIC50 8.7) [http://www.ncbi.nlm.nih.gov/pubmed/19827831?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5192 (pIC50 8.1) [http://www.ncbi.nlm.nih.gov/pubmed/8772178?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7907 (pIC50 7.5) [http://www.ncbi.nlm.nih.gov/pubmed/8022414?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7946 (pIC50 8.9) [http://www.ncbi.nlm.nih.gov/pubmed/19827831?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5192 (pIC50 8) [http://www.ncbi.nlm.nih.gov/pubmed/8772178?dopt=AbstractPlus]	




http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=534


Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1486
	
Common abbreviation	PKC∈
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9401, http://www.uniprot.org/uniprot/Q02156
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.11.13
	
Inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7946 (pIC50 8.2) [http://www.ncbi.nlm.nih.gov/pubmed/19827831?dopt=AbstractPlus]	



Further reading on Protein kinase C (PKC) family
Igumenova TI. (2015) Dynamics and Membrane Interactions of Protein Kinase C. Biochemistry
54: 4953‐68 https://www.ncbi.nlm.nih.gov/pubmed/26214365?dopt=AbstractPlus


Newton AC et al. (2017) Reversing the Paradigm: Protein Kinase C as a Tumor Suppressor. Trends Pharmacol. Sci. 38: 438‐447 https://www.ncbi.nlm.nih.gov/pubmed/28283201?dopt=AbstractPlus


Salzer E et al. (2016) Protein Kinase C δ: a Gatekeeper of Immune Homeostasis. J. Clin. Immunol. 36: 631‐40 https://www.ncbi.nlm.nih.gov/pubmed/27541826?dopt=AbstractPlus



http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=529


Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2109
	
Common abbreviation	mTOR	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3942, http://www.uniprot.org/uniprot/P42345
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.11.1
	
Inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7884 (pIC50 9.7) [http://www.ncbi.nlm.nih.gov/pubmed/21482695?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8004 (pIC50 9.5) [http://www.ncbi.nlm.nih.gov/pubmed/20860370?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7933 (pIC50 9) [http://www.ncbi.nlm.nih.gov/pubmed/22367541?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7933 (pK
i 8.9) [http://www.ncbi.nlm.nih.gov/pubmed/22367541?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7940 (pIC50 8.8) [http://www.ncbi.nlm.nih.gov/pubmed/20166697?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7950 (pIC50 8.2) [http://www.ncbi.nlm.nih.gov/pubmed/18606717?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8013 (pIC50 8) [http://www.ncbi.nlm.nih.gov/pubmed/18849971?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7973 (pIC50 8) [http://www.ncbi.nlm.nih.gov/pubmed/23394126?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7936 (pK
i 7.8) [http://www.ncbi.nlm.nih.gov/pubmed/24900269?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7888 (pK
i 7.8) [http://www.ncbi.nlm.nih.gov/pubmed/21981714?dopt=AbstractPlus]	
Selective inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5889 (pIC50 8.7) [http://www.ncbi.nlm.nih.gov/pubmed/9723437?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5704 (pIC50 8.1) [http://www.ncbi.nlm.nih.gov/pubmed/18849971?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5892 (pIC50 5.8) [http://www.ncbi.nlm.nih.gov/pubmed/21438579?dopt=AbstractPlus]	



Further reading on FRAP subfamily
Hukelmann JL et al. (2016) The cytotoxic T cell proteome and its shaping by the kinase mTOR. Nat. Immunol. 17: 104‐12 https://www.ncbi.nlm.nih.gov/pubmed/26551880?dopt=AbstractPlus


Saxton RA et al. (2017) mTOR Signaling in Growth, Metabolism, and Disease. Cell
169: 361‐371 https://www.ncbi.nlm.nih.gov/pubmed/28388417?dopt=AbstractPlus



http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=453

Overview
Five of the cyclin‐dependent kinases (CDKs: 7, 8, 9, 12, and 13) are involved in the phosphorylation of serine residues in the C‐terminal domain of RNA polymerase II, the enzyme that is responsible for the transcription of protein‐coding genes into mRNA in eukaryotes. Phosphorylation of RNA polymerase II at Ser5 is essential for transcriptional initiation, and phosphorylation of Ser 2 contributes to transcriptional elongation and termination. All five of the C‐terminal domain kinases can phosphorylate Ser5, but only CDK9, CDK12, and CDK13 can phosphorylate at Ser2 [http://www.ncbi.nlm.nih.gov/pubmed/24879308?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/22512864?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/25561469?dopt=AbstractPlus].


http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=488


Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1976
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1978
	
Common abbreviation	CDK4	CDK6	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1773, http://www.uniprot.org/uniprot/P11802
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1777, http://www.uniprot.org/uniprot/Q00534
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.11.22
	
http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.11.22
	
Inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5707 (pK
i 9) [http://www.ncbi.nlm.nih.gov/pubmed/17121911?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7380 (pIC50 8) [http://www.ncbi.nlm.nih.gov/pubmed/15542782?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8203 (pIC50 7.7) [144], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7934 (pIC50 7.2) [http://www.ncbi.nlm.nih.gov/pubmed/17363486?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5680 (pK
i 7.2) [http://www.ncbi.nlm.nih.gov/pubmed/8674031?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7380 (pIC50 7.8) [http://www.ncbi.nlm.nih.gov/pubmed/15542782?dopt=AbstractPlus]	



Comments on Cyclin‐dependent kinase (CDK) family
The development of CDK inhibitors as anticancer drugs is reviewed in [http://www.ncbi.nlm.nih.gov/pubmed/26115571?dopt=AbstractPlus], with detailed content covering CDK4 and CDK6 inhibitors that are under clinical evaluation. Data produced by Jorda et al. (2018) highlights the caution that must be used when deploying commercially available CDK inhibitors as pharmacological probes [http://www.ncbi.nlm.nih.gov/pubmed/30234987?dopt=AbstractPlus], as most of them are more promiscuous in their selectivity than indicated. To make their findings easily accessible the Jorda data is hosted on the http://rustreg.upol.cz/CDKiDB/.


http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=509


Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2030
	
Common abbreviation	GSK3B	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4617, http://www.uniprot.org/uniprot/P49841
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.11.26
	
Inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8016 (pIC50 9.2) [http://www.ncbi.nlm.nih.gov/pubmed/12606497?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7958 (pIC50 9) [http://www.ncbi.nlm.nih.gov/pubmed/15267232?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8014 (pIC50 8.2) [http://www.ncbi.nlm.nih.gov/pubmed/12606497?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8015 (pIC50 ~8.1) [http://www.ncbi.nlm.nih.gov/pubmed/11033082?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8018 (pIC50 7.7) [http://www.ncbi.nlm.nih.gov/pubmed/14698171?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8019 (pIC50 ~7.4) [http://www.ncbi.nlm.nih.gov/pubmed/11033082?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8017 (pIC50 7.3) [http://www.ncbi.nlm.nih.gov/pubmed/20708937?dopt=AbstractPlus]	
Selective inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8478 (pK
i 8.3) [http://www.ncbi.nlm.nih.gov/pubmed/22489897?dopt=AbstractPlus]	
Comments	Due to its Tau phosphorylating activity, small molecule inhibitors of GSK‐3β are being investigated as potential treatments for Alzheimer's disease (AD) [http://www.ncbi.nlm.nih.gov/pubmed/22489897?dopt=AbstractPlus]. GSK‐3β also plays a role in canonical Wnt pathway signalling, the normal activity of which is crucial for the maintenance of normal bone mass. It is hypothesised that small molecule inhibitors of GSK‐3β may provide effective therapeutics for the treatment of diseases characterised by low bone mass [http://www.ncbi.nlm.nih.gov/pubmed/22142634?dopt=AbstractPlus].	



Further reading on GSK subfamily
Beurel E et al. (2015) Glycogen synthase kinase‐3 (GSK3): regulation, actions, and diseases. Pharmacol. Ther. 148: 114‐31 https://www.ncbi.nlm.nih.gov/pubmed/25435019?dopt=AbstractPlus


Domoto T et al. (2016) Glycogen synthase kinase‐3β is a pivotal mediator of cancer invasion and resistance to therapy. Cancer Sci. 107: 1363‐1372 https://www.ncbi.nlm.nih.gov/pubmed/27486911?dopt=AbstractPlus


Khan I et al. (2017) Natural and synthetic bioactive inhibitors of glycogen synthase kinase. Eur J Med Chem
125: 464‐477 https://www.ncbi.nlm.nih.gov/pubmed/27689729?dopt=AbstractPlus


Maqbool M et al. (2016) Pivotal role of glycogen synthase kinase‐3: A therapeutic target for Alzheimer's disease. Eur J Med Chem
107: 63‐81 https://www.ncbi.nlm.nih.gov/pubmed/26562543?dopt=AbstractPlus



http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=602


Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2171
	
Common abbreviation	PLK4	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11397, http://www.uniprot.org/uniprot/O00444
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.11.21
	
Inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8063 (β 8.6) [http://www.ncbi.nlm.nih.gov/pubmed/25043604?dopt=AbstractPlus]	




http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=623


Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2062
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2063
	
Common abbreviation	MEK1	MEK2	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6840, http://www.uniprot.org/uniprot/Q02750
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6842, http://www.uniprot.org/uniprot/P36507
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.12.2
	
http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.12.2
	
Inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6495 (pIC50 9–9.1) [http://www.ncbi.nlm.nih.gov/pubmed/21245089?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/21523318?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7935 (pIC50 8.1) [http://www.ncbi.nlm.nih.gov/pubmed/23474388?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6495 (pIC50 8.7) [http://www.ncbi.nlm.nih.gov/pubmed/21523318?dopt=AbstractPlus]	
Allosteric modulators	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7921 (Negative) (pIC50 7.9) [468], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7942 (Negative) (pIC50 7.7) [http://www.ncbi.nlm.nih.gov/pubmed/19706763?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5676 (Negative) (pK
d 6.9) [http://www.ncbi.nlm.nih.gov/pubmed/22037378?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7921 (Negative) (pIC50 7.9) [468], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7942 (Negative) (pIC50 7.3) [http://www.ncbi.nlm.nih.gov/pubmed/19706763?dopt=AbstractPlus]	
Selective allosteric modulators	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7626 (Negative) (pIC50 9.1) [500]	–	




http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=553


Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1923
	
Common abbreviation	Abl	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:76, http://www.uniprot.org/uniprot/P00519
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.2
	
Inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8170 (pIC50 9.7) [http://www.ncbi.nlm.nih.gov/pubmed/21561767?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5678 (pIC50 9.6) [http://www.ncbi.nlm.nih.gov/pubmed/23279183?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8147 (pIC50 9.3) [http://www.ncbi.nlm.nih.gov/pubmed/23441572?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5699 (pK
d 9.2) [http://www.ncbi.nlm.nih.gov/pubmed/22037378?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5710 (pIC50 9) [http://www.ncbi.nlm.nih.gov/pubmed/12543790?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5699 (pIC50 ~8.3) [http://www.ncbi.nlm.nih.gov/pubmed/12154025?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7906 (pIC50 7.6–8.2) [http://www.ncbi.nlm.nih.gov/pubmed/17376680?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/16105974?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5890 (pIC50 8.1) [http://www.ncbi.nlm.nih.gov/pubmed/20513156?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5697 (pIC50 7.8) [http://www.ncbi.nlm.nih.gov/pubmed/15930265?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8013 (pIC50 7.7) [http://www.ncbi.nlm.nih.gov/pubmed/18849971?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5687 (pIC50 6.7) [http://www.ncbi.nlm.nih.gov/pubmed/17376680?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8065 (pIC50 6.7) [http://www.ncbi.nlm.nih.gov/pubmed/20072125?dopt=AbstractPlus]	




http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=554


Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2246
	
Common abbreviation	Ack	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:19297, http://www.uniprot.org/uniprot/Q07912
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.2
	
Inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8193 (pIC50 9) [http://www.ncbi.nlm.nih.gov/pubmed/17280833?dopt=AbstractPlus]	




http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=581

Overview
Janus kinases (JAKs) are a fam.ily of four enzymes; JAK1, JAK2, JAK3 and tyrosine kinase 2 (TYK2). They are essential for cytokine signalling and are strongly linked to both cancer and inflammatory diseases.


Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2047
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2048
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2049
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2269
	
Common abbreviation	JAK1	JAK2	JAK3	Tyk2	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6190, http://www.uniprot.org/uniprot/P23458
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6192, http://www.uniprot.org/uniprot/O60674
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6193, http://www.uniprot.org/uniprot/P52333
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:12440, http://www.uniprot.org/uniprot/P29597
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.2
	
http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.2
	
http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.2
	
http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.2
	
Inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5688 (pIC50 8.5–10.1) [http://www.ncbi.nlm.nih.gov/pubmed/23061660?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/20130243?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7913 (pIC50 8) [http://www.ncbi.nlm.nih.gov/pubmed/24006460?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7839 (pIC50 9.1) [http://www.ncbi.nlm.nih.gov/pubmed/22829185?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7954 (pIC50 9) [http://www.ncbi.nlm.nih.gov/pubmed/22015772?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7949 (pIC50 8.9) [http://www.ncbi.nlm.nih.gov/pubmed/19143567?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7971 (pIC50 8.7) [http://www.ncbi.nlm.nih.gov/pubmed/23127890?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5716 (pIC50 8.5) [http://www.ncbi.nlm.nih.gov/pubmed/21106455?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/18394554?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7909 (pIC50 8.4) [http://www.ncbi.nlm.nih.gov/pubmed/23584399?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7949 (pIC50 9) [http://www.ncbi.nlm.nih.gov/pubmed/19143567?dopt=AbstractPlus]	–	
Selective inhibitors	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8123 (pIC50 >9) [http://www.ncbi.nlm.nih.gov/pubmed/21493067?dopt=AbstractPlus]	–	–	
Comments	–	The JAK2V617F mutation, which causes constitutive activation, plays an oncogenic role in the pathogenesis of the myeloproliferative disorders, polycythemia vera, essential thrombocythemia, and idiopathic myelofibrosis [http://www.ncbi.nlm.nih.gov/pubmed/17151367?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/17131059?dopt=AbstractPlus]. Small molecule compounds which inhibit aberrant JAK2 activity are being developed as novel anti‐cancer pharmaceuticals.	–	–	




http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=619

Overview
Activation of Src‐family kinases leads to both stimulatory and inhibitory signaling responses, with cell‐specific and signaling pathway‐specific outcomes and redundancy of kinase function.

Immune system
In immune cells Src kinases are involved in many signalling pathways, including ITAM‐ and ITIM‐domain‐containing receptor signaling, integrin signaling, and responses to chemokines/chemoattractants, cytokines, innate immune stimuli and a large variety of non‐immune cell specific stimuli (UV irradiation, heat, osmotic shock etc.). In many cases Src kinases signal to MAP kinase or NF‐κB pathways, but they can also modulate other pathways through less well characterized mechanisms.

The primary T cell Src kinases are Lck and Fyn; the main B cell Srcs are Lyn, Fyn and Blk. Mast cells express Fyn and Lyn, with low expression of Src.


Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1940
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2025
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2026
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2060
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2206
	
Common abbreviation	Blk	FRK	Fyn	Lyn	Src	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1057, http://www.uniprot.org/uniprot/P51451
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3955, http://www.uniprot.org/uniprot/P42685
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4037, http://www.uniprot.org/uniprot/P06241
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6735, http://www.uniprot.org/uniprot/P07948
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11283, http://www.uniprot.org/uniprot/P12931
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.2
	
http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.2
	
http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.2
	
http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.2
	
http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.2
	
Inhibitors	–	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8836 (pIC50 8.2) [http://www.ncbi.nlm.nih.gov/pubmed/8557675?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7906 (pIC50 8) [http://www.ncbi.nlm.nih.gov/pubmed/17376680?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8068 (pIC50 8.2) [http://www.ncbi.nlm.nih.gov/pubmed/16884310?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8183 (pK
i 8.1) [http://www.ncbi.nlm.nih.gov/pubmed/9400019?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8013 (pIC50 7.8) [http://www.ncbi.nlm.nih.gov/pubmed/18849971?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7885 (pIC50 7.7) [http://www.ncbi.nlm.nih.gov/pubmed/19320489?dopt=AbstractPlus]	




http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=629


Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1942
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1948
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2268
	
Common abbreviation	Etk	Btk	TXK	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1079, http://www.uniprot.org/uniprot/P51813
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1133, http://www.uniprot.org/uniprot/Q06187
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:12434, http://www.uniprot.org/uniprot/P42681
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.2
	
http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.2
	
http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.2
	
Inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8145 (pIC50 9.1) [http://www.ncbi.nlm.nih.gov/pubmed/24915291?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6912 (pIC50 9.1) [http://www.ncbi.nlm.nih.gov/pubmed/22394077?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8148 (pIC50 8.7) [http://www.ncbi.nlm.nih.gov/pubmed/24915291?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6912 (pIC50 9.3) [http://www.ncbi.nlm.nih.gov/pubmed/17154430?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8148 (pIC50 8.4) [http://www.ncbi.nlm.nih.gov/pubmed/24915291?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8145 (pIC50 >8.4) [http://www.ncbi.nlm.nih.gov/pubmed/24915291?dopt=AbstractPlus]	–	
Selective inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9269 (pIC50 8.1) [http://www.ncbi.nlm.nih.gov/pubmed/23594111?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8066 (pIC50 8.7) [http://www.ncbi.nlm.nih.gov/pubmed/21113169?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9516 (Irreversible inhibition) (pIC50 7.6) [http://www.ncbi.nlm.nih.gov/pubmed/28352114?dopt=AbstractPlus]	–	




http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=610


Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1943
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2184
	
Common abbreviation	B‐Raf	c‐Raf	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1097, http://www.uniprot.org/uniprot/P15056
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9829, http://www.uniprot.org/uniprot/P04049
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.11.1
	
http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.11.1
	
Inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5681 (pIC50 9.7–9.9) [http://www.ncbi.nlm.nih.gov/pubmed/22037378?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/18676143?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6494 (pIC50 8.5) [337], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5891 (pIC50 7.6) [http://www.ncbi.nlm.nih.gov/pubmed/22222036?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5893 (pIC50 7) [http://www.ncbi.nlm.nih.gov/pubmed/22808911?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5703 (pK
d 6.5) [http://www.ncbi.nlm.nih.gov/pubmed/22037378?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8548 (pK
d 6.3) [http://www.ncbi.nlm.nih.gov/pubmed/26061392?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5674 (pK
d 5.9) [http://www.ncbi.nlm.nih.gov/pubmed/22037378?dopt=AbstractPlus]	–	
Selective inhibitors	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8072 (pIC50 8.1) [http://www.ncbi.nlm.nih.gov/pubmed/15255937?dopt=AbstractPlus]	



Further reading on Kinases (EC 2.7.x.x)
Eglen R et al. (2011) Drug discovery and the human kinome: recent trends. Pharmacol. Ther. 130: 144‐56 https://www.ncbi.nlm.nih.gov/pubmed/21256157?dopt=AbstractPlus


Graves LM et al. (2013) The dynamic nature of the kinome. Biochem. J. 450: 1‐8 https://www.ncbi.nlm.nih.gov/pubmed/23343193?dopt=AbstractPlus


Liu Q et al. (2013) Developing irreversible inhibitors of the protein kinase cysteinome. Chem. Biol. 20: 146‐59 https://www.ncbi.nlm.nih.gov/pubmed/23438744?dopt=AbstractPlus


Martin KJ et al. (2012) Selective kinase inhibitors as tools for neuroscience research. Neuropharmacology
63: 1227–37 https://www.ncbi.nlm.nih.gov/pubmed/22846224?dopt=AbstractPlus


Tarrant MK et al. (2009) The chemical biology of protein phosphorylation. Annu. Rev. Biochem. 78: 797‐825 https://www.ncbi.nlm.nih.gov/pubmed/19489734?dopt=AbstractPlus


Wu‐Zhang AX et al. (2013) Protein kinase C pharmacology: refining the toolbox. Biochem. J. 452: 195‐209 https://www.ncbi.nlm.nih.gov/pubmed/23662807?dopt=AbstractPlus



http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=104

Overview
Lanosterol is a precursor for cholesterol, which is synthesized primarily in the liver in a pathway often described as the mevalonate or HMG‐CoA reductase pathway. The first two steps (formation of http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3039 and the mitochondrial generation of http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3040) are also associated with oxidation of fatty acids.


Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2435
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2436
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=638
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2432
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:93, http://www.uniprot.org/uniprot/P24752
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:94, http://www.uniprot.org/uniprot/Q9BWD1
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:5007, http://www.uniprot.org/uniprot/Q01581
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:5008, http://www.uniprot.org/uniprot/P54868
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:2.3.1.9: 2http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3038 = http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3039 + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3044
	
http://www.genome.jp/dbget‐bin/www_bget?ec:2.3.1.9 2http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3038 = http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3039 + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3044
	
http://www.genome.jp/dbget‐bin/www_bget?ec:2.3.3.10: http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3038 + H2O+ http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3039 ‐> http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3040 + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3044
	
http://www.genome.jp/dbget‐bin/www_bget?ec:2.3.3.10: http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3038 + H2O+ http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3039 ‐> http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3040 + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3044
	
Comments	–	–	HMGCoA synthase is found in cytosolic (HMGCoA synthase 1) and mitochondrial (HMGCoA synthase 2) versions; the former associated with http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3042 synthesis and the latter with ketogenesis.	




Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=639
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:5006, http://www.uniprot.org/uniprot/P04035
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:1.1.1.34: http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3040 + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3041 ‐>http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3042 + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3044 + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3045 Reaction mechanism:: First step: (S)‐3‐hydroxy‐3‐methylglutaryl‐CoA + NADPH ‐> mevaldyl‐CoA + NADP+
Second step: mevaldyl‐CoA + H2O ‐>(R)‐mevalonate + NADP+
	
Inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2739 (Competitive) (pK
i 9.2) [http://www.ncbi.nlm.nih.gov/pubmed/6933445?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2954 (Competitive) (pIC50 8.3) [http://www.ncbi.nlm.nih.gov/pubmed/11349148?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2950 (Competitive) (pK
i 8.2) [http://www.ncbi.nlm.nih.gov/pubmed/16128575?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2949 (Competitive) (pIC50 8.1) [http://www.ncbi.nlm.nih.gov/pubmed/11349148?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2950 (Competitive) (pIC50 8) [http://www.ncbi.nlm.nih.gov/pubmed/15686906?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2955 (Competitive) (pIC50 8) [http://www.ncbi.nlm.nih.gov/pubmed/11349148?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2951 (Competitive) (pIC50 7.6) [http://www.ncbi.nlm.nih.gov/pubmed/11349148?dopt=AbstractPlus]	
Comments	HMGCoA reductase is associated with intracellular membranes; enzymatic activity is inhibited by phosphorylation by AMP‐activated kinase. The enzymatic reaction is a three‐step reaction involving the intermediate generation of mevaldehyde‐CoA and mevaldehyde.	




Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=640
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=641
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=642
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7530, http://www.uniprot.org/uniprot/Q03426
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9141, http://www.uniprot.org/uniprot/Q15126
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7529, http://www.uniprot.org/uniprot/P53602
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.36: http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713 + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3042 ‐> http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1712 + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3046
	
http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.4.2: http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713 + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3046 = http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1712 + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3047
	
http://www.genome.jp/dbget‐bin/www_bget?ec:4.1.1.33: http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713 + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3047 ‐> http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1712 + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3048 + CO2 + PO3
4‐
	
Comments	Mevalonate kinase activity is regulated by the downstream products http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2910 and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3051 as an example of feedback inhibition.	–	–	




Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=646
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=647
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=643
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:5387, http://www.uniprot.org/uniprot/Q13907
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:23487, http://www.uniprot.org/uniprot/Q9BXS1
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4249, http://www.uniprot.org/uniprot/O95749
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:5.3.3.2: http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3048 = http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3049
	
http://www.genome.jp/dbget‐bin/www_bget?ec:5.3.3.2: http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3048 = http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3049
	
http://www.genome.jp/dbget‐bin/www_bget?ec:2.5.1.29: http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3050 + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3048 ‐>http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3052 + diphosphate http://www.genome.jp/dbget‐bin/www_bget?ec:2.5.1.10: http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3051 + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3048 ‐> http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3050 + diphosphate http://www.genome.jp/dbget‐bin/www_bget?ec:2.5.1.1: http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3049 + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3048 = http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3051 +diphosphate	




Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=644
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=645
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2433
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2434
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3631, http://www.uniprot.org/uniprot/P14324
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3629, http://www.uniprot.org/uniprot/P37268
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11279, http://www.uniprot.org/uniprot/Q14534
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6708, http://www.uniprot.org/uniprot/P48449
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:2.5.1.10: http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3051 + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3048 ‐> http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3050 + diphosphate http://www.genome.jp/dbget‐bin/www_bget?ec:2.5.1.1: http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3049 + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3048 = http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3051 + diphosphate	
http://www.genome.jp/dbget‐bin/www_bget?ec:2.5.1.21: 2http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3050 ‐> http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3053 + diphosphate http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3053 + NAD(P)H + H+ ‐> http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3054 + diphosphate + NAD(P)+
	
http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.13.132: H+ + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3041 + O2 + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3054 = H2O + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3045 + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6551
	
http://www.genome.jp/dbget‐bin/www_bget?ec:5.4.99.7: http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6551 = http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2746
	
Cofactors	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3041
	–	–	
Inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3176 (pIC50 8.4) [http://www.ncbi.nlm.nih.gov/pubmed/10620343?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3177 (pK
i 7.1) [http://www.ncbi.nlm.nih.gov/pubmed/18327899?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3141 (pIC50 6.3) [http://www.ncbi.nlm.nih.gov/pubmed/10620343?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3057 (pK
i 10.1) [http://www.ncbi.nlm.nih.gov/pubmed/8419946?dopt=AbstractPlus] – Rat, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3057 (pIC50 9.2) [http://www.ncbi.nlm.nih.gov/pubmed/9473303?dopt=AbstractPlus]	–	–	
Selective inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3059 (pK
i 6.7) [http://www.ncbi.nlm.nih.gov/pubmed/18327899?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7259 (pIC50 6.7) [http://www.ncbi.nlm.nih.gov/pubmed/18327899?dopt=AbstractPlus]	–	–	–	



Further reading on Lanosterol biosynthesis pathway
Moutinho M et al. (2017) The mevalonate pathway in neurons: It's not just about cholesterol. Exp. Cell Res. 360: 55–60 https://www.ncbi.nlm.nih.gov/pubmed/28232115?dopt=AbstractPlus


Mullen PJ et al. (2016) The interplay between cell signalling and the mevalonate pathway in cancer. Nat. Rev. Cancer
16: 718–731 https://www.ncbi.nlm.nih.gov/pubmed/27562463?dopt=AbstractPlus


Ness GC. (2015) Physiological feedback regulation of cholesterol biosynthesis: Role of translational control of hepatic HMG‐CoA reductase and possible involvement of oxylanosterols. Biochim. Biophys. Acta
1851: 667–73 https://www.ncbi.nlm.nih.gov/pubmed/25701719?dopt=AbstractPlus


Porter TD. (2015) Electron Transfer Pathways in Cholesterol Synthesis. Lipids
50: 927–36 https://www.ncbi.nlm.nih.gov/pubmed/26344922?dopt=AbstractPlus


Samaras K et al. (2016) Does statin use cause memory decline in the elderly? Trends Cardiovasc. Med. 26: 550–65 https://www.ncbi.nlm.nih.gov/pubmed/27177529?dopt=AbstractPlus



http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=920

Overview
The de novo synthesis and salvage of nucleosides have been targetted for therapeutic advantage in the treatment of particular cancers and gout. Dihydrofolate reductase produces tetrahydrofolate, a cofactor required for synthesis of purines, pyrimidines and amino acids. GART allows formylation of phosphoribosylglycinamide, an early step in purine biosynthesis. Dihydroorotate dehydrogenase produces orotate, a key intermediate in pyrimidine synthesis. IMP dehydrogenase generates xanthosine monophosphate, an intermediate in GTP synthesis.


Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2603
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2612
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2604
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2624
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2625
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2642
	
Common abbreviation	DHFR	GART	DHODH	IMPDH1	IMPDH2	TYMS	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2861, http://www.uniprot.org/uniprot/P00374
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4163, http://www.uniprot.org/uniprot/P22102
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2867, http://www.uniprot.org/uniprot/Q02127
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6052, http://www.uniprot.org/uniprot/P20839
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6053, http://www.uniprot.org/uniprot/P12268
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:12441, http://www.uniprot.org/uniprot/P04818
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:1.5.1.3
	
http://www.genome.jp/dbget‐bin/www_bget?ec:2.1.2.2
http://www.genome.jp/dbget‐bin/www_bget?ec:6.3.3.1
http://www.genome.jp/dbget‐bin/www_bget?ec:6.3.4.13
	
http://www.genome.jp/dbget‐bin/www_bget?ec:1.3.5.2
	
http://www.genome.jp/dbget‐bin/www_bget?ec:1.1.1.205
	
http://www.genome.jp/dbget‐bin/www_bget?ec:1.1.1.205
	
http://www.genome.jp/dbget‐bin/www_bget?ec:2.1.1.45
	
Inhibitors	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6837 (pK
i 5) [http://www.ncbi.nlm.nih.gov/pubmed/9762351?dopt=AbstractPlus] – Mouse	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6844 (pK
i 7.5) [http://www.ncbi.nlm.nih.gov/pubmed/17228860?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6832 (pIC50 7.7) [http://www.ncbi.nlm.nih.gov/pubmed/1967654?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6832 (pIC50 7.7) [http://www.ncbi.nlm.nih.gov/pubmed/1967654?dopt=AbstractPlus]	–	
Selective inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4815 (pK
i 8.9) [http://www.ncbi.nlm.nih.gov/pubmed/7877140?dopt=AbstractPlus]	–	–	–	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7403 (pIC50 6.5) [http://www.ncbi.nlm.nih.gov/pubmed/22739090?dopt=AbstractPlus]	




Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2841
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2646
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2630
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2631
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2754
	
Common abbreviation	PNP	XDH	ribonucleotide reductase M1	ribonucleotide reductase M2	ribonucleotide reductase M2B (TP53 inducible)	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7892, http://www.uniprot.org/uniprot/P00491
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:12805, http://www.uniprot.org/uniprot/P47989
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10451, http://www.uniprot.org/uniprot/P23921
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10452, http://www.uniprot.org/uniprot/P31350
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:17296, http://www.uniprot.org/uniprot/Q7LG56
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:1.4.2.1 Purine‐nucleoside phosphorylase: Purine nucleoside + phosphate <=> purine + alpha‐D‐ribose 1‐phosphate Purine deoxynucleoside + phosphate <=> purine + 2′‐deoxy‐alpha‐D‐ribose 1‐phosphate	
http://www.genome.jp/dbget‐bin/www_bget?ec:1.17.1.4
	
http://www.genome.jp/dbget‐bin/www_bget?ec:1.17.14.1
	
http://www.genome.jp/dbget‐bin/www_bget?ec:1.17.4.1
	
http://www.genome.jp/dbget‐bin/www_bget?ec:1.17.1.4
	
Inhibitors	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6817 (pIC50 8.9) [http://www.ncbi.nlm.nih.gov/pubmed/24508129?dopt=AbstractPlus]	–	–	–	



Comments
TYMS allows the interconversion of dUMP and dTMP, thereby acting as a crucial step in DNA synthesis. PNP allows separation of a nucleoside into the nucleobase and ribose phosphate for nucleotide salvage. XDH generates urate in the purine degradation pathway. Post‐translational modifications of XDH convert the enzymatic reaction to a xanthine oxidase, allowing the interconversion of hypoxanthine and xanthine, with the production (or consumption) of reactive oxygen species.

Further reading on Nucleoside synthesis and metabolism
Day RO et al. (2016) Xanthine oxidoreductase and its inhibitors: relevance for gout. Clin Sci (Lond). 130: 2167–2180 https://www.ncbi.nlm.nih.gov/pubmed/27798228


Okafor ON et al. (2017) Allopurinol as a therapeutic option in cardiovascular disease. Pharmacol Ther. 172: 139–150 https://www.ncbi.nlm.nih.gov/pubmed/27916655



http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=1018

Overview
Paraoxonases (PON) are calcium‐dependent esterases, whichmay be involved in lipoprotein turnover and the conversion of lactone statin prodrugs, as well as being targets of organophosphates, such as the insecticide paraoxon.


Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3052
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3053
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3054
	
Common abbreviation	PON1	PON2	PON3	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9204, http://www.uniprot.org/uniprot/P27169
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9205, http://www.uniprot.org/uniprot/Q15165
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9206, http://www.uniprot.org/uniprot/Q15166
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.8.1 An aryl dialkyl phosphate + H(2)O <=> dialkyl phosphate + an aryl alcohol http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.1.2 A phenyl acetate + H(2)O <=> a phenol + acetate http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.1.81 An N‐acyl‐L‐homoserine lactone + H(2)O <=> an N‐acyl‐L‐homoserine	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.1.2 A phenyl acetate + H(2)O <=> a phenol + acetate http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.1.81 A N‐acyl‐L‐homoserine lactone + H(2)O <=> a N‐acyl‐L‐homoserine	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.8.1 An aryl dialkyl phosphate + H(2)O <=> dialkyl phosphate + an aryl alcohol http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.1.2 A phenyl acetate + H(2)O <=> a phenol + acetate http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.1.81 A N‐acyl‐L‐homoserine lactone + H(2)O <=> a N‐acyl‐L‐homoserine	
Comments	PON1 forms homodimers. Loss‐of‐function mutations in PON1 are associated with microvascular complications of diabetes [http://www.ncbi.nlm.nih.gov/pubmed/11918623?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9661650?dopt=AbstractPlus].	PON2 forms heterotrimers [http://www.ncbi.nlm.nih.gov/pubmed/15772423?dopt=AbstractPlus].	PON3 likely forms heterodimers in vivo [http://www.ncbi.nlm.nih.gov/pubmed/15772423?dopt=AbstractPlus].	



Further reading on Paraoxonase
Dardiotis E et al. (2019) Paraoxonase‐1 genetic polymorphisms in organophosphate metabolism. Toxicology. 411: 24–31 https://www.ncbi.nlm.nih.gov/pubmed/30359673


Lioudaki S et al. (2019) Paraoxonase‐1: Characteristics and Role in Atherosclerosis and Carotid Artery Disease. Curr Vasc Pharmacol. 17: 141–146 https://www.ncbi.nlm.nih.gov/pubmed/29189170



http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=759

Overview
Peptidases and proteinases hydrolyse peptide bonds, and can be simply divided on the basis of whether terminal peptide bonds are cleaved (exopeptidases and exoproteinases) at the amino terminus (aminopeptidases) or carboxy terminus (carboxypeptidases). Non‐terminal peptide bonds are cleaved by endopeptidases and endoproteinases, which are divided into serine endopeptidases (EC 3.4.21.‐), cysteine endopeptidases (EC 3.4.22.‐), aspartate endopeptidases (EC 3.4.23.‐), metalloendopeptidases (EC 3.4.24.‐) and threonine endopeptidases (EC 3.4.25.‐).

Since it is beyond the scope of the Guide to list all peptidase and proteinase activities, this summary focuses on selected enzymes of significant pharmacological interest that have ligands (mostly small‐molecules) directed against them. For those interested in detailed background we recommend the MEROPS database [493] (with whom we collaborate) as an information resource [http://www.ncbi.nlm.nih.gov/pubmed/26527717?dopt=AbstractPlus].


http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=726


Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2413
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9958, http://www.uniprot.org/uniprot/P00797
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.4.23.15
	
Inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4812 (pIC50 9.2) [http://www.ncbi.nlm.nih.gov/pubmed/18307734?dopt=AbstractPlus]	




http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=727

Overview
Presenilin (PS)‐1 or ‐2 act as the catalytic component/ essential co‐factor of the γ‐secretase complex responsible for the final carboxy‐terminal cleavage of amyloid precursor protein (APP) [http://www.ncbi.nlm.nih.gov/pubmed/2881207?dopt=AbstractPlus] in the generation of amyloid beta (Aβ) [http://www.ncbi.nlm.nih.gov/pubmed/21115843?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12660785?dopt=AbstractPlus]. Given that the accumulation and aggregation of Aβ in the brain is pivotal in the development of Alzheimer's disease (AD), inhibition of PS activity is one mechanism being investigated as a therapeutic option for AD [http://www.ncbi.nlm.nih.gov/pubmed/11378516?dopt=AbstractPlus]. Several small molecule inhibitors of PS‐1 have been investigated, with some reaching early clinical trials, but none have been formally approved. Dewji et al. (2015) have reported that small peptide fragments of human PS‐1 can significantly inhibit Aβ production (total Aβ, Aβ40 and Aβ42) both in vitro and when infused in to the brains of APP transgenic mice [http://www.ncbi.nlm.nih.gov/pubmed/25923432?dopt=AbstractPlus]. The most active small peptides in this report were http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8344 and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8345, from the amino‐terminal domain of PS‐1.

Information on members of this family may be found in the http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=727.


http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=734

Overview
Caspases, (http://www.genome.jp/kegg‐bin/search_brite?option=‐a&search_string=3.4.22.‐) which derive their name from Cysteine ASPartate‐specific proteASES, include at least two families; initiator caspases (caspases 2, 8, 9 and 10), which are able to hydrolyse and activate a second family of effector caspases (caspases 3, 6 and 7), which themselves are able to hydrolyse further cellular proteins to bring about programmed cell death. Caspases are heterotetrameric, being made up of two pairs of subunits, generated by a single gene product, which is proteolysed to form the mature protein. Members of the mammalian inhibitors of apoptosis proteins (IAP) are able to bind the procaspases, thereby preventing maturation to active proteinases.

Information on members of this family may be found in the http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=734.

Comments
CARD16 (Caspase recruitment domain‐containing protein 16, caspase‐1 inhibitor COP, CARD only domain‐containing protein 1, pseudo interleukin‐1β converting enzyme, pseudo‐ICE, http://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000204397;r=11:104912053‐104972158) shares sequence similarity with some of the caspases.


http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=737

Overview
Aminopeptidases catalyze the cleavage of amino acids from the amino (N) terminus of protein or peptide substrates, and are involved in many essential cellular functions. Members of this enzyme family may be monomeric or multi‐subunit complexes, and many are zinc metalloenzymes [http://www.ncbi.nlm.nih.gov/pubmed/8440407?dopt=AbstractPlus].


Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1395
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6710, http://www.uniprot.org/uniprot/P09960
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.3.2.6
	
Inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5151 (pK
i 5.4) [http://www.ncbi.nlm.nih.gov/pubmed/1846352?dopt=AbstractPlus]	




http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=741


Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1613
	
Common abbreviation	ACE	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2707, http://www.uniprot.org/uniprot/P12821
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.4.15.1
	
Substrates	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10060
	
Endogenous substrates	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=583 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:333, http://www.uniprot.org/uniprot/P01019) > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2504 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:333, http://www.uniprot.org/uniprot/P01019)	
Inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6463 (pK
i 9.4) [http://www.ncbi.nlm.nih.gov/pubmed/2836590?dopt=AbstractPlus] – Rabbit, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5158 (pKi 8.4) [http://www.ncbi.nlm.nih.gov/pubmed/9187274?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6462
	
Selective inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6373 (pIC50 9) [http://www.ncbi.nlm.nih.gov/pubmed/17716647?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6461 (pIC50 8.7) [http://www.ncbi.nlm.nih.gov/pubmed/2527528?dopt=AbstractPlus] – Rabbit, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6378 (pIC50 8.7) [http://www.ncbi.nlm.nih.gov/pubmed/17547476?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7893 (C‐domain assay) (pIC50 8.2) [http://www.ncbi.nlm.nih.gov/pubmed/20233165?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7894 (N‐domain selective inhibition) (pIC50 8.1) [http://www.ncbi.nlm.nih.gov/pubmed/22628311?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6457 (pIC50 8) [http://www.ncbi.nlm.nih.gov/pubmed/2481187?dopt=AbstractPlus] – Rabbit, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6332 (pIC50 7.5) [http://www.ncbi.nlm.nih.gov/pubmed/7527095?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6375 (pIC50 6.6) [http://www.ncbi.nlm.nih.gov/pubmed/17506720?dopt=AbstractPlus]	
Comments	Reports of ACE GPI hydrolase activity [http://www.ncbi.nlm.nih.gov/pubmed/15665832?dopt=AbstractPlus] have been refuted [http://www.ncbi.nlm.nih.gov/pubmed/16270062?dopt=AbstractPlus]	




http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=738

Overview
Matrix metalloproteinases (MMP) are calcium‐ and zinc‐dependent proteinases regulating the extracellular matrix and are often divided (e.g. [http://www.ncbi.nlm.nih.gov/pubmed/17275314?dopt=AbstractPlus]) on functional and structural bases into gelatinases, collagenases, stromyelinases and matrilysins, as well as membrane type‐MMP (MT‐MMP).


Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1629
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1632
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7166, http://www.uniprot.org/uniprot/P08253
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7175, http://www.uniprot.org/uniprot/P22894
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.4.24.24
	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.4.24.34
	
Selective inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5140 [http://www.ncbi.nlm.nih.gov/pubmed/16483784?dopt=AbstractPlus]	–	
Comments	MMP2 is categorised as a gelatinase with substrate specificity for gelatinase A.	MMP8 is categorised as a collagenase.	



Comments
A number of small molecule ‘broad spectrum’ inhibitors of MMP have been described, including http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5220 and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5145.


Tissue inhibitors of metalloproteinase (TIMP) proteins are endogenous inhibitors acting to chelate MMP proteins: http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5309 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11820, http://www.uniprot.org/uniprot/P01033), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5310 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11821, http://www.uniprot.org/uniprot/P16035), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5311 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11822, http://www.uniprot.org/uniprot/P35625), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5312 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11823, http://www.uniprot.org/uniprot/Q99727)


http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=739

Overview
ADAM (A Disintegrin And Metalloproteinase domain containing proteins) metalloproteinases cleave cell‐surface or transmembrane proteins to generate soluble and membrane‐limited products.

ADAMTS (with thrombospondin motifs) metalloproteinases cleave cell‐surface or transmembrane proteins to generate soluble and membrane‐limited products.

Information on members of this family may be found in the http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=739.

Comments
Additional ADAM family members include AC123767.2 (cDNA FLJ58962, moderately similar tomouse ADAM3, ENSG00000231168), AL160191.3 (ADAM21‐like protein, http://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000235812;r=14:70712470‐70714518), AC136428.3‐2 (ENSG00000185520) and ADAMDEC1 (decysin 1, http://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000134028;r=8:24241798‐24263526).

Other ADAMTS family members include AC104758.12‐5 (FLJ00317 protein Fragment ENSG00000231463), AC139425.3‐1 (ENSG00000225577), and AC126339.6‐1 (ENSG00000225734).


http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=748


Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1606
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3788, http://www.uniprot.org/uniprot/Q04609
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.4.17.21
	
Antibodies	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6878 (Binding)	
Comments	Folate hydrolase is also known as NAALADase as it is responsible for the hydrolysis of N‐acetaspartylglutamate to form N‐acetylaspartate and L‐glutamate (http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1369). In the gut, the enzyme assists in the assimilation of folate by hydrolysing dietary poly‐gamma‐glutamylfolate. The enzyme is highly expressed in the prostate, and its expression is up‐regulated in cancerous tissue. A tagged version of the antibody http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6878 has been used for imaging purposes.	



Comments
Folate hydrolase is also known as NAALADase as it is responsible for the hydrolysis of N‐acetaspartylglutamate to form N‐acetylaspartate and L‐glutamate. In the gut, the enzyme assists in the assimilation of folate by hydrolysing dietary poly‐gamma‐glutamylfolate. The enzyme is highly expressed in the prostate, and its expression is up‐regulated in cancerous tissue. A tagged version of the antibody http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6878 has been used for imaging purposes.


http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=749


Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1393
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3002, http://www.uniprot.org/uniprot/P16444
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.4.13.19: http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3353 + H2O = http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3352 + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=727
	
Inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5166 (pK
i 6) [http://www.ncbi.nlm.nih.gov/pubmed/3495664?dopt=AbstractPlus]	




http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=751


Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2334
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2362
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2359
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1246, http://www.uniprot.org/uniprot/P00736
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3535, http://www.uniprot.org/uniprot/P00734
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3528, http://www.uniprot.org/uniprot/P00742
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.4.21.41
	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.4.21.5
	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.4.21.6
	
Inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4262 (pIC50 4.9) [http://www.ncbi.nlm.nih.gov/pubmed/9544206?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6469 (pK
i 13) [http://www.ncbi.nlm.nih.gov/pubmed/16363236?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6458 (pK
i 12.7) [http://www.ncbi.nlm.nih.gov/pubmed/1894196?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7727 (pK
i 9.5) [21], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6382 (pK
i 8.7) [http://www.ncbi.nlm.nih.gov/pubmed/9459334?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6470 (pK
i 8.6) [http://www.ncbi.nlm.nih.gov/pubmed/1290488?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6380 (pK
i 8.3) [http://www.ncbi.nlm.nih.gov/pubmed/11960487?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6385 (pK
i 7.7) [http://www.ncbi.nlm.nih.gov/pubmed/9361377?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6390 (pK
i 10.1) [http://www.ncbi.nlm.nih.gov/pubmed/18315548?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6388 (pK
i 9.4) [http://www.ncbi.nlm.nih.gov/pubmed/20139357?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7575 (pK
i 9.2) [http://www.ncbi.nlm.nih.gov/pubmed/20503967?dopt=AbstractPlus]	
Selective inhibitors	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8760 (pK
i 10.4) [192], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7688 (pIC50 8.4) [http://www.ncbi.nlm.nih.gov/pubmed/19492147?dopt=AbstractPlus]	–	




Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2358
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2394
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2392
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2397
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2424
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3309, http://www.uniprot.org/uniprot/P08246
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9071, http://www.uniprot.org/uniprot/P00747
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9051, http://www.uniprot.org/uniprot/P00750
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9475, http://www.uniprot.org/uniprot/P07477
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:12019, http://www.uniprot.org/uniprot/Q15661
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.4.21.37
	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.4.21.7
	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.4.21.68
	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.4.21.4
	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.4.21.59
	
Inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6476 (pK
i 8) [http://www.ncbi.nlm.nih.gov/pubmed/21791628?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6441 (pIC50 7.4) [http://www.ncbi.nlm.nih.gov/pubmed/21741848?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6570 {Bovine} (Binding) (pIC50 6.8) [http://www.ncbi.nlm.nih.gov/pubmed/17666018?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6573 (Binding) (pIC50 3.6) [http://www.ncbi.nlm.nih.gov/pubmed/17666018?dopt=AbstractPlus]	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4262 (pIC50 7.8) [http://www.ncbi.nlm.nih.gov/pubmed/9544206?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4262 (pIC50 10) [http://www.ncbi.nlm.nih.gov/pubmed/12939527?dopt=AbstractPlus]	
Selective inhibitors	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6574 (Binding) (pIC50 4.4) [http://www.ncbi.nlm.nih.gov/pubmed/24900876?dopt=AbstractPlus]	–	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7863 (pIC50 8.5) [http://www.ncbi.nlm.nih.gov/pubmed/11172730?dopt=AbstractPlus]	




http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=752

Overview
The T1 macropain beta subunits form the catalytic proteinase core of the 20S proteasome complex [http://www.ncbi.nlm.nih.gov/pubmed/16142822?dopt=AbstractPlus]. This catalytic core enables the degradation of peptides with Arg, Phe, Tyr, Leu, and Glu adjacent to the cleavage site. The β5 subunit is the principal target of the approved drug proteasome inhibitor http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6391.


Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2406
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9542, http://www.uniprot.org/uniprot/P28074
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.4.25.1
	
Inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6391 (pIC50 7.7) [http://www.ncbi.nlm.nih.gov/pubmed/19428245?dopt=AbstractPlus]	
Selective inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8450 (pK
i 9) [http://www.ncbi.nlm.nih.gov/pubmed/20160034?dopt=AbstractPlus]	




http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=755

Overview
One member of this family has garnered intense interest as a clinical drug target. As liver PCSK9 acts to maintain cholesterol homeostasis, it has become a target of intense interest for clinical drug development. Inhibition of PCSK9 can lower low‐density cholesterol (LDL‐C) by clearing LDLR‐bound LDL particles, thereby lowering circulating cholesterol levels. It is hypothesised that this action may improve outcomes in patients with atherosclerotic cardiovascular disease [http://www.ncbi.nlm.nih.gov/pubmed/18836590?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/25083925?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/19506257?dopt=AbstractPlus]. Therapeutics which inhibit PCSK9 are viewed as potentially lucrative replacements for statins, upon statin patent expiry. Several monoclonal antibodies including http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6744, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7343, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7730, RG‐7652 and LY3015014 are under development. One RNAi therapeutic, code named ALN‐PCS02, is also in development [http://www.ncbi.nlm.nih.gov/pubmed/24145894?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/24094767?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/18695239?dopt=AbstractPlus].

Information on members of this family may be found in the http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=755.


http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=758


Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1612
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3009, http://www.uniprot.org/uniprot/P27487
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.4.14.5
	
Endogenous substrates	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5194 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4191, http://www.uniprot.org/uniprot/P01275)	
Inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6316 (pK
i 9.2) [http://www.ncbi.nlm.nih.gov/pubmed/19149538?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6318 (pK
i 9) [http://www.ncbi.nlm.nih.gov/pubmed/18052023?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6286 (pIC50 8.1) [http://www.ncbi.nlm.nih.gov/pubmed/20927248?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6310 (pK
i 7.8) [http://www.ncbi.nlm.nih.gov/pubmed/19149538?dopt=AbstractPlus]	
Selective inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9627 (Competitive) (pK
i 8.3) [http://www.ncbi.nlm.nih.gov/pubmed/28452143?dopt=AbstractPlus]	




http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=883

Overview
The Poly ADP‐ribose polymerase family is a series of enzymes, where the best characterised members are nuclear proteins which are thought to function by binding to single strand breaks in DNA, allowing the recruitment of repair enzymes by the synthesis of NAD‐derived ADP‐ribose polymers, which are subsequently degraded by a glycohydrolase (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8605, http://www.uniprot.org/uniprot/Q86W56).


Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2771
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2772
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2864
	
Common abbreviation	PARP1	PARP2	PARP3	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:270, http://www.uniprot.org/uniprot/P09874
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:272, http://www.uniprot.org/uniprot/Q9UGN5
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:273, http://www.uniprot.org/uniprot/Q9Y6F1
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:2.4.2.30
	
http://www.genome.jp/dbget‐bin/www_bget?ec:2.4.2.30
	–	



Further reading on Poly ADP‐ribose polymerases
Berger NA et al. (2018) Opportunities for the repurposing of PARP inhibitors for the therapy of non‐oncological diseases. Br J Pharmacol. 175: 192‐222 https://www.ncbi.nlm.nih.gov/pubmed/28213892


Faraoni I et al. (2019) Targeting ADP‐ribosylation by PARP inhibitors in acute myeloid leukaemia and related disorders. Biochem Pharmacol
https://www.ncbi.nlm.nih.gov/pubmed/31028744


Zeniou M et al. (2019) Therapeutic considerations of PARP in stem cell biology: Relevance in cancer and beyond. Biochem Pharmacol
https://www.ncbi.nlm.nih.gov/pubmed/31202733



http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=900

Overview
Hypoxia‐inducible factors (HIFs) are rapidly‐responding sensors of reductions in local oxygen tensions, prompting changes in gene transcription. Listed here are the 4‐prolyl hydroxylase family, members of which have been identified to hydroxylate proline residues in HIF1α (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4910; https://www.uniprot.org/uniprot/Q16665) leading to an increased degradation through proteasomal hydrolysis. This action requires molecular oxygen and 2‐oxoglutarate, and so reduced oxygen tensions prevents HIF1α hydroxylation, allowing its translocation to the nucleus and dimerisation with HIF1β (also known as https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:700; https://www.uniprot.org/uniprot/P27540), thereby allowing interaction with the genome as a transcription factor.


Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2832
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2833
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2834
	
Common abbreviation	PHD1	PHD2	PHD3	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:14660, http://www.uniprot.org/uniprot/Q96KS0
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1232, http://www.uniprot.org/uniprot/Q9GZT9
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:14661, http://www.uniprot.org/uniprot/Q9H6Z9
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.11.29
	
http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.11.29
	
http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.11.29
	



Further reading on Prolyl hydroxylases
Joharapurkar AA et al. (2018) Prolyl Hydroxylase Inhibitors: A Breakthrough in the Therapy of Anemia Associated with Chronic Diseases. J Med Chem
61: 6964‐6982 https://www.ncbi.nlm.nih.gov/pubmed/29712435


Lanigan SM and O’Connor JJ. (2019) Prolyl hydroxylase domain inhibitors: can multiple mechanisms be an opportunity for ischemic stroke? Neuropharmacology
148: 117‐130 https://www.ncbi.nlm.nih.gov/pubmed/30578795


Singh L et al. (2018) Prolyl hydroxylase 2: a promising target to inhibit hypoxia‐induced cellular metabolism in cancer cells. Drug Discov Today
23: 1873‐1882 https://www.ncbi.nlm.nih.gov/pubmed/29772209


Vasta JD and Raines RT et al. (2018) Collagen Prolyl 4‐Hydroxylase as a Therapeutic Target. J Med Chem
61: 10403‐10411 https://www.ncbi.nlm.nih.gov/pubmed/29986141


Watts ER and Walmsley SR. (2019) Inflammation and Hypoxia: HIF and PHD Isoform Selectivity. Trends Mol Med
25: 33‐46 https://www.ncbi.nlm.nih.gov/pubmed/30442494



http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=776

Overview
S1P (http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=911) is a bioactive lipid which, after release from cells via certain transporters, acts as a ligand for a family of five S1P‐specific G protein‐coupled receptors (S1P1‐5). However, it also has a number of intracellular targets. S1P is formed by the ATP‐dependent phosphorylation of sphingosine, catalysed by two isoforms of sphingosine kinase (EC 2.7.1.91). It can be dephosphorylated back to sphingosine by sphingosine 1‐phosphate phosphatase (EC 3.1.3) or cleaved into phosphoethanolamine and hexadecenal by sphingosine 1‐phosphate lyase (EC 4.1.2.27). Recessive mutations in the S1P lyase (SPL) gene underlie a recently identified sphingolipidosis: SPL Insufficiency Syndrome (SPLIS). In general, S1P promotes cell survival, proliferation, migration, adhesion and inhibition of apoptosis. Intracellular S1P affects epigenetic regulation, endosomal processing, mitochondrial function and cell proliferation/senescence. S1P has myriad physiological functions, including vascular development, lymphocyte trafficking and neurogenesis. However, S1P is also involved in a number of diseases such as cancer, inflammation and fibrosis. Therefore, its GPCRs and enzymes of synthesis and degradation are a major focus for drug discovery.


http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=777

Overview
SPHK1 and SPHK2 are encoded by different genes with some redundancy of function; genetic deletion of both Sphk1 and Sphk2, but not either alone, is embryonic lethal in mice. There are splice variants of each isoform (SphK1a‐c and SphK2a, b), distinguished by their N‐terminal sequences. SPHK1 and SPHK2 differ in tissue distribution, sub‐cellular localisation, biochemical properties and regulation. They regulate discrete pools of S1P. Receptor stimulation induces SPHK1 translocation from the cytoplasm to the plasma membrane. SPHK1 translocation is regulated by phosphorylation/dephosphorylation, specific protein:protein interactions and interaction with specific lipids at the plasma membrane. SPHK1 is a dimeric protein, as confirmed by its crystal structure which forms a positive cluster, between protomers, essential for interaction with anionic phospholipids in the plasma membrane. SPHK2 is localised to the ER or associated with mitochondria or shuttles in/out of the nucleus, regulated by phosphorylation. Intracellular targets of nuclear S1P include the catalytic subunit of telomerase (TERT) and regulators of gene expression including histone deacetylases (HDAC 1/2) and peroxisome proliferator‐activated receptor gamma (PPARγ). SPHK2 phosphorylates the pro‐drug FTY720 (http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2407, which is used to treat some forms of multiple sclerosis) to a mimic of S1P and that acts as a functional antagonist of S1P1 receptors. Inhibitors of SPHK1 and SPHK2 have therapeutic potential in many diseases.


Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2204
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2205
	
Common abbreviation	SPHK1	SPHK2	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11240, http://www.uniprot.org/uniprot/Q9NYA1
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:18859, http://www.uniprot.org/uniprot/Q9NRA0
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.91 + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713 = http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=911 + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1712 dihydrosphingosine + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713 = http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=911 + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1712
	
http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.91: http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2452 + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713 = http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=911 + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1712 dihydrosphingosine + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713 = http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=911 + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1712
	
Cofactors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=708 [http://www.ncbi.nlm.nih.gov/pubmed/22677141?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=708
	
Inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6041 (pK
i 4.8) [http://www.ncbi.nlm.nih.gov/pubmed/20061445?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10219 (pIC50 4.6) [http://www.ncbi.nlm.nih.gov/pubmed/25788259?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10219 (pK
i 5.2) [http://www.ncbi.nlm.nih.gov/pubmed/25788259?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6041 (pK
i 5.1) [http://www.ncbi.nlm.nih.gov/pubmed/22970244?dopt=AbstractPlus]	
Selective inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6623 (pK
i 8.4) [http://www.ncbi.nlm.nih.gov/pubmed/22397330?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10217 (pK
i 7.1) [http://www.ncbi.nlm.nih.gov/pubmed/28406646?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10218 (pIC50 6.8) [http://www.ncbi.nlm.nih.gov/pubmed/28231433?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6624 (pK
i 5) [http://www.ncbi.nlm.nih.gov/pubmed/20061445?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6625 (pK
i 4.8) [http://www.ncbi.nlm.nih.gov/pubmed/21620961?dopt=AbstractPlus]	
Comments	SK1 inhibitors induce its proteasomal degradation [http://www.ncbi.nlm.nih.gov/pubmed/20926375?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/26934645?dopt=AbstractPlus]. SK1 crystal structures confirm that it is dimeric [http://www.ncbi.nlm.nih.gov/pubmed/27021309?dopt=AbstractPlus]; there is no crystal structure available for SK2.	There is no crystal structure available for SK2.	



Comments

http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10219 is competitive with ATP; other SPHK inhibitors are competitive with sphingosine. ABC294640 (http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6624) has known off‐target effects on dihydroceramide desaturase (DEGS1) [http://www.ncbi.nlm.nih.gov/pubmed/26934645?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/26494858?dopt=AbstractPlus]) and induces proteasomal degradation of SK1 [http://www.ncbi.nlm.nih.gov/pubmed/26934645?dopt=AbstractPlus]. ABC294640 is in clinical trials for advanced cholangiocarcinoma, advanced hepatocellular carcinoma and refractory/relapsed multiple myeloma (to view ClinicalTrials.gov list click https://clinicaltrials.gov/ct2/results?cond=&term=ABC294640).

Further reading on Sphingosine kinase
Adams DR et al. (2016) Sphingosine Kinases: Emerging Structure‐Function Insights. Trends Biochem. Sci. 41: 395‐409 https://www.ncbi.nlm.nih.gov/pubmed/27021309?dopt=AbstractPlus


Lynch KR et al. (2016) Sphingosine kinase inhibitors: a review of patent literature (2006‐2015). Expert Opin Ther Pat
26: 1409‐1416 https://www.ncbi.nlm.nih.gov/pubmed/27539678?dopt=AbstractPlus


Pitman MR et al. (2016) Recent advances in the development of sphingosine kinase inhibitors. Cell. Signal. 28: 1349‐63 https://www.ncbi.nlm.nih.gov/pubmed/27297359?dopt=AbstractPlus


Pulkoski‐Gross MJ et al. (2018) An intrinsic lipid‐binding interface controls sphingosine kinase 1 function. J. Lipid Res. 59: 462‐474 https://www.ncbi.nlm.nih.gov/pubmed/29326159?dopt=AbstractPlus


Pyne NJ et al. (2017) Sphingosine Kinase 2 in Autoimmune/Inflammatory Disease and the Development of Sphingosine Kinase 2 Inhibitors. Trends Pharmacol. Sci. 38: 581‐591 https://www.ncbi.nlm.nih.gov/pubmed/28606480?dopt=AbstractPlus


Pyne S et al. (2018) Sphingosine Kinases as Druggable Targets. Handb Exp Pharmacol
https://www.ncbi.nlm.nih.gov/pubmed/29460151?dopt=AbstractPlus



http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=778


Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2523
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2524
	
Common abbreviation	SGPP1	SGPP2	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:17720, http://www.uniprot.org/uniprot/Q9BX95
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:19953, http://www.uniprot.org/uniprot/Q8IWX5
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.3.‐: http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=911 ‐> http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2452 + inorganic phosphate	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.3.‐: http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=911 ‐> http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2452 + inorganic phosphate	
Comments	Depletion of S1P phosphohydrolase‐1 (SPP1), which degrades intracellular S1P, induces the unfolded protein response and endoplasmic reticulum stress‐induced autophagy [http://www.ncbi.nlm.nih.gov/pubmed/22052905?dopt=AbstractPlus].	–	



Comments
SGPP1 and SGPP2 are non‐redundant endoplasmic reticulum enzymes that dephosphorylate intracellular http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=911. The phenotype of Sgpp1(‐/‐) mice differ with genetic background. Sgpp2(‐/‐) mice are also available. No specific SGPP inhibitors available [http://www.ncbi.nlm.nih.gov/pubmed/22052905?dopt=AbstractPlus].

Further reading on Sphingosine 1‐phosphate phosphatase
Allende ML et al. (2013) Sphingosine‐1‐phosphate phosphatase 1 regulates keratinocyte differentiation and epidermal homeostasis. J. Biol. Chem. 288: 18381‐91 https://www.ncbi.nlm.nih.gov/pubmed/23637227?dopt=AbstractPlus


Huang WC et al. (2016) Sphingosine‐1‐phosphate phosphatase 2 promotes disruption of mucosal integrity, and contributes to ulcerative colitis in mice and humans. FASEB J. 30: 2945‐58 https://www.ncbi.nlm.nih.gov/pubmed/27130484?dopt=AbstractPlus


Lépine S et al. (2011) Sphingosine‐1‐phosphate phosphohydrolase‐1 regulates ER stress‐induced autophagy. Cell Death Differ. 18: 350‐61 https://www.ncbi.nlm.nih.gov/pubmed/20798685?dopt=AbstractPlus


Mandala SM et al. (2000) Molecular cloning and characterization of a lipid phosphohydrolase that degrades sphingosine‐1‐ phosphate and induces cell death. Proc. Natl. Acad. Sci. U.S.A. 97: 7859‐64 https://www.ncbi.nlm.nih.gov/pubmed/10859351?dopt=AbstractPlus


Taguchi Y et al. (2016) Sphingosine‐1‐phosphate Phosphatase 2 Regulates Pancreatic Islet β‐Cell Endoplasmic Reticulum Stress and Proliferation. J. Biol. Chem. 291: 12029‐38 https://www.ncbi.nlm.nih.gov/pubmed/27059959?dopt=AbstractPlus



http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=777


Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2522
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10817, http://www.uniprot.org/uniprot/O95470
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:4.1.2.27: http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=911 ‐> http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6628 + hexadecenal http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2921 ‐> http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6628 + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6627
	
Cofactors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5249
	
Inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8465 (pIC50 6.7) [http://www.ncbi.nlm.nih.gov/pubmed/27519818?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/23499842?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/25630683?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/24809814?dopt=AbstractPlus]	



Comments

http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6626 (2‐Acetyl‐5‐tetrahydroxybutyl imidazole) inhibits the enzyme activity in intact cell preparations [http://www.ncbi.nlm.nih.gov/pubmed/16151014?dopt=AbstractPlus]. Recessive mutations in the S1P lyase (SGPL1) gene underlie a recently identified sphingolipidosis: SPL Insufficiency Syndrome (SPLIS) [http://www.ncbi.nlm.nih.gov/pubmed/30274713?dopt=AbstractPlus]. A Phase 2 clinical trial of LX3305 (http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9851) for rheumatoid arthritis has been completed (see https://clinicaltrials.gov/ct2/show/NCT00903383).

Further reading on Sphingosine 1‐phosphate lyase
Bamborschke D et al. (2018) A novel mutation in sphingosine‐1‐phosphate lyase causing congenital brain malformation. Brain Dev. 40: 480‐483 https://www.ncbi.nlm.nih.gov/pubmed/29501407?dopt=AbstractPlus


Choi YJ et al. (2019) Sphingosine phosphate lyase insufficiency syndrome (SPLIS): A novel inborn error of sphingolipid metabolism. Adv Biol Regul
71: 128‐140 https://www.ncbi.nlm.nih.gov/pubmed/30274713


Lovric S et al. (2017) Mutations in sphingosine‐1‐phosphate lyase cause nephrosis with ichthyosis and adrenal insufficiency. J. Clin. Invest. 127: 912‐928 https://www.ncbi.nlm.nih.gov/pubmed/28165339?dopt=AbstractPlus


Prasad R et al. (2017) Sphingosine‐1‐phosphate lyase mutations cause primary adrenal insufficiency and steroid‐resistant nephrotic syndrome. J. Clin. Invest. 127: 942‐953 https://www.ncbi.nlm.nih.gov/pubmed/28165343?dopt=AbstractPlus



http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=779

Overview
The thyroid hormones triiodothyronine and thyroxine, usually abbreviated as http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2634 and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2635, respectively, are synthesized in the thyroid gland by sequential metabolism of tyrosine residues in the glycosylated homodimeric protein thyroglobulin (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11764, http://www.uniprot.org/uniprot/P01266) under the influence of the haem‐containing protein iodide peroxidase. Iodide peroxidase/TPO is a haem‐containing enzyme, from the same structural family as eosinophil peroxidase (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3423, http://www.uniprot.org/uniprot/P11678), lactoperoxidase (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6678, http://www.uniprot.org/uniprot/P22079) and myeloperoxidase (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7218, http://www.uniprot.org/uniprot/P05164). Circulating thyroid hormone is bound to thyroxine‐binding globulin (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11583, http://www.uniprot.org/uniprot/P05543).

Tissue deiodinases
These are 1 TM selenoproteins that remove an iodine from http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2635 (3,3′,5,5′‐tetraiodothyronine) to generate http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2634 (3,3′,5‐triiodothyronine, a more potent agonist at thyroid hormone receptors) or http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2636 (rT3, 3,3′,5′‐triiodothyronine, a relatively inactive analogue). DIO1 is also able to deiodinate RT3 to form 3,3′‐diidothyronine (http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6648). Iodotyrosine deiodinase is a 1TM homodimeric enzyme.


Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2526
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2481
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2482
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2483
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2488
	
Common abbreviation	TPO	DIO1	DIO2	DIO3	IYD	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:12015, http://www.uniprot.org/uniprot/P07202
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2883, http://www.uniprot.org/uniprot/P49895
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2884, http://www.uniprot.org/uniprot/Q92813
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2885, http://www.uniprot.org/uniprot/P55073
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:21071, http://www.uniprot.org/uniprot/Q6PHW0
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:1.11.1.8: [Thyroglobulin]‐L‐tyrosine + http://www.genome.jp/dbget‐bin/www_bget?ec:1.97.1.10 + H+ + I‐ ‐> [Thyroglobulin]‐3,5,3′‐triiodo‐L‐thyronine + [thyroglobulin]‐aminoacrylate + H2O	
http://www.genome.jp/dbget‐bin/www_bget?ec:1.97.1.10: http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2635 ‐> http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2634
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2636 ‐> http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6648
	
http://www.genome.jp/dbget‐bin/www_bget?ec:1.97.1.10: http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2635 ‐> http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2634
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2636 ‐> http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6648
	
http://www.genome.jp/dbget‐bin/www_bget?ec:1.97.1.11: http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2635 ‐> http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2634
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2636 ‐> http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6648
	
http://www.genome.jp/dbget‐bin/www_bget?ec:1.22.1.1: http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5117 ‐> http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4791 + I‐
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6651 ‐> http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5117 + I‐
	
Cofactors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=707
	–	–	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5184, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3041
	
Inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6649 [http://www.ncbi.nlm.nih.gov/pubmed/748042?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6650 [http://www.ncbi.nlm.nih.gov/pubmed/748042?dopt=AbstractPlus]	–	–	–	–	
Comments	Carbimazole is a pro‐drug for http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6649
	–	–	–	–	



Further reading on Thyroid hormone turnover
Darras VM et al. (2015) Intracellular thyroid hormone metabolism as a local regulator of nuclear thyroid hormone receptor‐mediated impact on vertebrate development. Biochim. Biophys. Acta
1849: 130‐41 https://www.ncbi.nlm.nih.gov/pubmed/24844179?dopt=AbstractPlus


Gereben B et al. (2015) Scope and limitations of iodothyronine deiodinases in hypothyroidism. Nat Rev Endocrinol
11: 642‐652 https://www.ncbi.nlm.nih.gov/pubmed/26416219?dopt=AbstractPlus


Mondal S et al. (2017) Novel thyroid hormone analogues, enzyme inhibitors andmimetics, and their action. Mol. Cell. Endocrinol. 458: 91‐104 https://www.ncbi.nlm.nih.gov/pubmed/28408161?dopt=AbstractPlus


Schweizer U et al. (2015) New insights into the structure and mechanism of iodothyronine deiodinases. J. Mol. Endocrinol. 55: R37‐52 https://www.ncbi.nlm.nih.gov/pubmed/26390881?dopt=AbstractPlus


van der Spek AH et al. (2017) Thyroid hormone metabolism in innate immune cells. J. Endocrinol. 232: R67‐R81 https://www.ncbi.nlm.nih.gov/pubmed/27852725?dopt=AbstractPlus



http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=923


Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2886
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6381, http://www.uniprot.org/uniprot/O15229
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.13.9 L‐kynurenine + NADPH + O2 <=> 3‐hydroxy‐L‐kynurenine + NADP(+) + H2O	
Comments	Kynurenine 3‐monooxygenase participates in metabolism of the essential amino acid tryptophan.	



Further reading on 1.14.13.9 Kynurenine 3‐monooxygenase
Dounay AB et al. (2015) Challenges and Opportunities in the Discovery of New Therapeutics Targeting the Kynurenine Pathway. J. Med. Chem. 58: 8762‐82 https://www.ncbi.nlm.nih.gov/pubmed/26207924?dopt=AbstractPlus


Erhardt S et al. (2017) The kynurenine pathway in schizophrenia and bipolar disorder. Neuropharmacology
112: 297‐306 https://www.ncbi.nlm.nih.gov/pubmed/27245499?dopt=AbstractPlus


Fujigaki H et al. (2017) L‐Tryptophan‐kynurenine pathway enzymes are therapeutic target for neuropsychiatric diseases: Focus on cell type differences. Neuropharmacology
112: 264‐274 https://www.ncbi.nlm.nih.gov/pubmed/26767951?dopt=AbstractPlus


Smith JR et al. (2016) Kynurenine‐3‐monooxygenase: a review of structure, mechanism, and inhibitors. Drug Discov. Today
21: 315‐24 https://www.ncbi.nlm.nih.gov/pubmed/26589832?dopt=AbstractPlus


Song P et al. (2017) Abnormal kynurenine pathway of tryptophan catabolism in cardiovascular diseases. Cell. Mol. Life Sci. 74: 2899‐2916 https://www.ncbi.nlm.nih.gov/pubmed/28314892?dopt=AbstractPlus



http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=898

Overview
Farnesyltransferase is a member of the prenyltransferases family which also includes geranylgeranyltransferase types I (EC 2.5.1.59) and II (EC 2.5.1.60) [http://www.ncbi.nlm.nih.gov/pubmed/8621375?dopt=AbstractPlus]. Protein farnesyltransferase catalyses the post‐translational formation of a thioether linkage between the C‐1 of an isoprenyl group and a cysteine residue fourth from the C‐terminus of a protein (ie to the CaaX motif, where ’a’ is an aliphatic amino acid and ’X’ is usually serine, methionine, alanine or glutamine; leucine for EC 2.5.1.59) [http://www.ncbi.nlm.nih.gov/pubmed/7756316?dopt=AbstractPlus]. Farnesyltransferase is a dimer, composed of an alpha and beta subunit and requires Mg2+ and Zn2+ ions as cofactors. The active site is located between the subunits. Prenylation creates a hydrophobic domain on protein tails which acts as a membrane anchor.

Substrates of the prenyltransferases include Ras, Rho, Rab, other Ras‐related small GTP‐binding proteins, G‐protein γ‐subunits, nuclear lamins, centromeric proteins and many proteins involved in visual signal transduction.

In relation to the causative association between oncogenic Ras proteins and cancer, farnesyltransferase has become an important mechanistic drug discovery target.

Information on members of this family may be found in the http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=898.

Further reading on 2.5.1.58 Protein farnesyltransferase
Gao S et al. (2016) The Role of Geranylgeranyltransferase I‐Mediated Protein Prenylation in the Brain. Mol. Neurobiol. 53: 6925‐6937 https://www.ncbi.nlm.nih.gov/pubmed/26666664?dopt=AbstractPlus


Shen M et al. (2015) Farnesyltransferase and geranylgeranyltransferase I: structures, mechanism, inhibitors and molecular modeling. Drug Discov. Today
20: 267‐76 https://www.ncbi.nlm.nih.gov/pubmed/25450772?dopt=AbstractPlus


Shen Y et al. (2015) The Recent Development of Farnesyltransferase Inhibitors as Anticancer and Antimalarial Agents. Mini Rev Med Chem
15: 837‐57 https://www.ncbi.nlm.nih.gov/pubmed/25963569?dopt=AbstractPlus


Wang M et al. (2016) Protein prenylation: unique fats make their mark on biology. Nat. Rev. Mol. Cell Biol. 17: 110‐22 https://www.ncbi.nlm.nih.gov/pubmed/26790532?dopt=AbstractPlus



http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=848

Overview
Histone deacetylases act as erasers of epigenetic acetylation marks on lysine residues in histones. Removal of the acetyl groups facilitates tighter packing of chromatin (heterochromatin formation) leading to transcriptional repression.

The histone deacetylase family has been classified in to five subfamilies based on phylogenetic comparison with yeast homologues:

Class I contains HDACs 1, 2, 3 and 8

Class IIa contains HDACs 4, 5, 7 and 9

Class IIb contains HDACs 6 and 10

Class III contains the sirtuins (SIRT1‐7)

Class IV contains only HDAC11.

Classes I, II and IV use Zn+ as a co‐factor, whereas catalysis by Class III enzymes requires NAD+ as a co‐factor, and members of this subfamily have ADP‐ribosylase activity in addition to protein deacetylase function [http://www.ncbi.nlm.nih.gov/pubmed/20132909?dopt=AbstractPlus].

HDACs have more general protein deacetylase activity, being able to deacetylate lysine residues in non‐histone proteins [http://www.ncbi.nlm.nih.gov/pubmed/19608861?dopt=AbstractPlus] such as microtubules [http://www.ncbi.nlm.nih.gov/pubmed/12024216?dopt=AbstractPlus], the hsp90 chaperone [http://www.ncbi.nlm.nih.gov/pubmed/15916966?dopt=AbstractPlus] and the tumour suppressor p53 [http://www.ncbi.nlm.nih.gov/pubmed/11099047?dopt=AbstractPlus].

Dysregulated HDACactivity has been identified in cancer cells and tumour tissues [http://www.ncbi.nlm.nih.gov/pubmed/11704848?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/19383284?dopt=AbstractPlus], making HDACs attractive molecular targets in the search for novel mechanisms to treat cancer [http://www.ncbi.nlm.nih.gov/pubmed/24382387?dopt=AbstractPlus]. Several small molecule HDAC inhibitors are already approved for clinical use: http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7006, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7496, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6852, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7489, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7496, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7009 and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8305. HDACs and HDAC inhibitors currently in development as potential anti‐cancer therapeutics are reviewed by Simó‐Riudalbas and Esteller (2015) [http://www.ncbi.nlm.nih.gov/pubmed/25039449?dopt=AbstractPlus].


Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2618
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:14064, http://www.uniprot.org/uniprot/Q9UBN7
	
EC number	
http://www.genome.jp/dbget‐bin/www_bget?ec:3.5.1.98
	
Inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7005 (pK
i 9) [http://www.ncbi.nlm.nih.gov/pubmed/20139990?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6852 (pK
i 8.8) [http://www.ncbi.nlm.nih.gov/pubmed/20139990?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7006 (pK
i 8) [http://www.ncbi.nlm.nih.gov/pubmed/20139990?dopt=AbstractPlus]	
Selective inhibitors	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7010 (pIC50 8.3) [http://www.ncbi.nlm.nih.gov/pubmed/22262760?dopt=AbstractPlus]	



Further reading on 3.5.1.‐ Histone deacetylases (HDACs)
Ellmeier W et al. (2018) Histone deacetylase function in CD4+ T cells. Nat. Rev. Immunol. 18: 617‐634 https://www.ncbi.nlm.nih.gov/pubmed/30022149?dopt=AbstractPlus


Maolanon AR et al. (2017) Natural and Synthetic Macrocyclic Inhibitors of the Histone Deacetylase Enzymes. Chembiochem
18: 5‐49 https://www.ncbi.nlm.nih.gov/pubmed/27748555?dopt=AbstractPlus


Micelli C et al. (2015) Histone deacetylases: structural determinants of inhibitor selectivity. Drug Discov. Today
20: 718‐35 https://www.ncbi.nlm.nih.gov/pubmed/25687212?dopt=AbstractPlus


Millard CJ et al. (2017) Targeting Class I Histone Deacetylases in a "Complex" Environment. Trends Pharmacol. Sci. 38: 363‐377 https://www.ncbi.nlm.nih.gov/pubmed/28139258?dopt=AbstractPlus


Roche J et al. (2016) Inside HDACs with more selective HDAC inhibitors. Eur J Med Chem
121: 451‐483 https://www.ncbi.nlm.nih.gov/pubmed/27318122?dopt=AbstractPlus


Zagni C et al. (2017) The Search for Potent, Small‐Molecule HDACIs in Cancer Treatment: A Decade After Vorinostat. Med Res Rev
37: 1373‐1428 https://www.ncbi.nlm.nih.gov/pubmed/28181261?dopt=AbstractPlus



http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=918

Overview
In humans, the peptidyl arginine deiminases (PADIs; http://www.genenames.org/cgi‐bin/genefamilies/set/677) are a family of five enzymes, PADI1‐4 and PADI6. PADIs catalyze the deimination of protein L‐arginine residues to L‐citrulline and ammonia, generating peptidyl‐citrulline on histones, fibrinogen, and other biologically relevant proteins. The human isozymes exhibit tissue‐specific expression patterns [http://www.ncbi.nlm.nih.gov/pubmed/12606753?dopt=AbstractPlus]. Overexpression and/or increased PADI activity is observed in several diseases, including rheumatoid arthritis, Alzheimer's disease, multiple sclerosis, lupus, Parkinson's disease, and cancer [http://www.ncbi.nlm.nih.gov/pubmed/23175390?dopt=AbstractPlus]. Pharmacological PADI inhibition reverses protein‐hypercitrullination and disease in mouse models of multiple sclerosis [http://www.ncbi.nlm.nih.gov/pubmed/23118341?dopt=AbstractPlus].

Information on members of this family may be found in the http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=918.

Further reading on 3.5.3.15 Peptidyl arginine deiminases (PADI)
Koushik S et al. (2017) PAD4: pathophysiology, current therapeutics and future perspective in rheumatoid arthritis. Expert Opin. Ther. Targets
21: 433‐447 https://www.ncbi.nlm.nih.gov/pubmed/28281906?dopt=AbstractPlus


Tu R et al. (2016) Peptidyl Arginine Deiminases and Neurodegenerative Diseases. Curr. Med. Chem. 23: 104‐14 https://www.ncbi.nlm.nih.gov/pubmed/26577926?dopt=AbstractPlus


Whiteley CG. (2014) Arginine metabolising enzymes as targets against Alzheimers’ disease. Neurochem. Int. 67: 23‐31 https://www.ncbi.nlm.nih.gov/pubmed/24508404?dopt=AbstractPlus



http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=896

Overview
small G‐proteins, are a family of hydrolase enzymes that can bind and hydrolyze guanosine triphosphate (GTP). They are a type of G‐protein found in the cytosol that are homologous to the alpha subunit of heterotrimeric G‐proteins, but unlike the alpha subunit of G proteins, a small GTPase can function independently as a hydrolase enzyme to bind to and hydrolyze a guanosine triphosphate (GTP) to form guanosine diphosphate (GDP). The best‐known members are the Ras GTPases and hence they are sometimes called Ras subfamily GTPases.


http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=897

Overview
The RAS proteins (HRAS, NRAS and KRAS) are small membrane‐localised G protein‐likemolecules of 21 kd. They act as an on/off switch linking receptor and non‐receptor tyrosine kinase activation to downstream cytoplasmic or nuclear events. Binding of GTP activates the switch, and hydrolysis of the GTP to GDP inactivates the switch.

The RAS proto‐oncogenes are the most frequently mutated class of proteins in human cancers. Common mutations compromise the GTP‐hydrolysing ability of the proteins causing constitutive activation [http://www.ncbi.nlm.nih.gov/pubmed/7900159?dopt=AbstractPlus], which leads to increased cell proliferation and decreased apoptosis [http://www.ncbi.nlm.nih.gov/pubmed/17721087?dopt=AbstractPlus]. Because of their importance in oncogenic transformation these proteins have become the targets of intense drug discovery effort [http://www.ncbi.nlm.nih.gov/pubmed/22004085?dopt=AbstractPlus].

Information on members of this family may be found in the http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=897.

Further reading on RAS subfamily
Dorard C et al. (2017) Deciphering the RAS/ERK pathway in vivo. Biochem. Soc. Trans. 45: 27‐36 https://www.ncbi.nlm.nih.gov/pubmed/28202657?dopt=AbstractPlus


Keeton AB et al. (2017) The RAS‐Effector Interaction as a Drug Target. Cancer Res. 77: 221‐226 https://www.ncbi.nlm.nih.gov/pubmed/28062402?dopt=AbstractPlus


Lu S et al. (2016) Ras Conformational Ensembles, Allostery, and Signaling. Chem. Rev. 116: 6607‐65 https://www.ncbi.nlm.nih.gov/pubmed/26815308?dopt=AbstractPlus


Ostrem JM et al. (2016) Direct small‐molecule inhibitors of KRAS: from structural insights to mechanism‐based design. Nat Rev Drug Discov
15: 771‐785 https://www.ncbi.nlm.nih.gov/pubmed/27469033?dopt=AbstractPlus


Papke B et al. (2017) Drugging RAS: Know the enemy. Science
355: 1158‐1163 https://www.ncbi.nlm.nih.gov/pubmed/28302824?dopt=AbstractPlus


Quah SY et al. (2016) Pharmacological modulation of oncogenic Ras by natural products and their derivatives: Renewed hope in the discovery of novel anti‐Ras drugs. Pharmacol. Ther. 162: 35‐57 https://www.ncbi.nlm.nih.gov/pubmed/27016467?dopt=AbstractPlus


Simanshu DK et al. (2017) RAS Proteins and Their Regulators in Human Disease. Cell
170: 17‐33 https://www.ncbi.nlm.nih.gov/pubmed/28666118?dopt=AbstractPlus



http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=938

Overview
The Rab family of proteins is a member of the Ras superfamily of monomeric G proteins. Rab GTPases regulate many steps of membrane traffic, including vesicle formation, vesicle movement along actin and tubulin networks, and membrane fusion. These processes make up the route through which cell surface proteins are trafficked from the Golgi to the plasma membrane and are recycled. Surface protein recycling returns proteins to the surface whose function involves carrying another protein or substance inside the cell, such as the transferrin receptor, or serves as a means of regulating the number of a certain type of protein molecules on the surface ( see http://www.genenames.org/cgi‐bin/genefamilies/set/388, http://www.genenames.org/cgi‐bin/genefamilies/set/388 ).

Information on members of this family may be found in the http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=938.
==== Refs
References
1 

Aaltonen 
N 

et al (2013 ) http://www.ncbi.nlm.nih.gov/pubmed/23521796?dopt=AbstractPlus

2 

Abita 
JP 

et al (1976 ) http://www.ncbi.nlm.nih.gov/pubmed/182695?dopt=AbstractPlus

3 

Aboraia 
AS 

et al (2010 ) http://www.ncbi.nlm.nih.gov/pubmed/20655626?dopt=AbstractPlus

4 

Adam-Klages 
S 

et al (1996 ) http://www.ncbi.nlm.nih.gov/pubmed/8808629?dopt=AbstractPlus

5 

Adams 
DR 

et al (2016 ) http://www.ncbi.nlm.nih.gov/pubmed/27021309?dopt=AbstractPlus

6 

Agarwal 
RP 

et al (1977 ) http://www.ncbi.nlm.nih.gov/pubmed/849330?dopt=AbstractPlus

7 

Ahn 
K 

et al (2007 ) http://www.ncbi.nlm.nih.gov/pubmed/17949010?dopt=AbstractPlus

8 

Ahn 
K 

et al (2009 ) http://www.ncbi.nlm.nih.gov/pubmed/19389627?dopt=AbstractPlus

9 

Ahn 
K 

et al (2010 ) http://www.ncbi.nlm.nih.gov/pubmed/21115843?dopt=AbstractPlus

10 

Akama 
T 

et al (2009 ) http://www.ncbi.nlm.nih.gov/pubmed/19303290?dopt=AbstractPlus

11 

Alaamery 
MA 

et al (2010 ) http://www.ncbi.nlm.nih.gov/pubmed/20228279?dopt=AbstractPlus

12 

Alberts 
AW 

et al (1980 ) http://www.ncbi.nlm.nih.gov/pubmed/6933445?dopt=AbstractPlus

13 

Albrecht 
W 

et al (2017 ) http://www.ncbi.nlm.nih.gov/pubmed/28613871?dopt=AbstractPlus

14 

Alexander 
SP 

et al (2007 ) http://www.ncbi.nlm.nih.gov/pubmed/17876303?dopt=AbstractPlus

15 

Almahariq 
M 

et al (2013 ) http://www.ncbi.nlm.nih.gov/pubmed/23066090?dopt=AbstractPlus

16 

Ancian 
P 

et al (1995 ) http://www.ncbi.nlm.nih.gov/pubmed/7548076?dopt=AbstractPlus

17 

Aoki 
M 

et al (2000 ) http://www.ncbi.nlm.nih.gov/pubmed/10991987?dopt=AbstractPlus

18 

Apsel 
B 

et al (2008 ) http://www.ncbi.nlm.nih.gov/pubmed/18849971?dopt=AbstractPlus

19 

Aritake 
K 

et al (2006 ) http://www.ncbi.nlm.nih.gov/pubmed/16547010?dopt=AbstractPlus

20 

Asimakopoulou 
A 

et al (2013 ) http://www.ncbi.nlm.nih.gov/pubmed/23488457?dopt=AbstractPlus

21 AstraZeneca. AZ12971554.
22 

Auerbach 
SS 

et al. National Toxicology Program: Dept of Health and Human Services.
23 

Avvaru 
BS 

et al (2010 ) http://www.ncbi.nlm.nih.gov/pubmed/20605094?dopt=AbstractPlus

24 

Babbedge 
RC 

et al (1993 ) http://www.ncbi.nlm.nih.gov/pubmed/7693279?dopt=AbstractPlus

25 

Bachovchin 
DA 

et al (2010 ) http://www.ncbi.nlm.nih.gov/pubmed/21084632?dopt=AbstractPlus

26 

Backman 
JT 

et al (2016 ) http://www.ncbi.nlm.nih.gov/pubmed/26721703?dopt=AbstractPlus

27 

Bae 
SH 

et al (2013 ) http://www.ncbi.nlm.nih.gov/pubmed/23777987?dopt=AbstractPlus

28 

Bae 
YS 

et al (1998 ) http://www.ncbi.nlm.nih.gov/pubmed/9468499?dopt=AbstractPlus

29 

Bae 
YS 

et al (2003 ) http://www.ncbi.nlm.nih.gov/pubmed/12695532?dopt=AbstractPlus

30 

Baggelaar 
MP 

et al (2015 ) http://www.ncbi.nlm.nih.gov/pubmed/26083464?dopt=AbstractPlus

31 

Baggelaar 
MP 

et al (2018 ) http://www.ncbi.nlm.nih.gov/pubmed/29751000?dopt=AbstractPlus

32 

Baggio 
R 

et al (1999 ) http://www.ncbi.nlm.nih.gov/pubmed/10454520?dopt=AbstractPlus

33 

Baines 
AT 

et al (2011 ) http://www.ncbi.nlm.nih.gov/pubmed/22004085?dopt=AbstractPlus

34 

Balla 
A 

et al (2008 ) http://www.ncbi.nlm.nih.gov/pubmed/18077555?dopt=AbstractPlus

35 

Baylin 
SB 

et al (2011 ) http://www.ncbi.nlm.nih.gov/pubmed/21941284?dopt=AbstractPlus

36 

Bayly 
CI 

et al (1999 ) http://www.ncbi.nlm.nih.gov/pubmed/10091674?dopt=AbstractPlus

37 

Beauchamp 
E 

et al (2009 ) http://www.ncbi.nlm.nih.gov/pubmed/19647031?dopt=AbstractPlus

38 

Beck 
LH 

et al (2009 ) http://www.ncbi.nlm.nih.gov/pubmed/19571279?dopt=AbstractPlus

39 

Beeler 
JA 

et al (2004 ) http://www.ncbi.nlm.nih.gov/pubmed/15581358?dopt=AbstractPlus

40 

Bellier 
JP 

et al (2011 ) http://www.ncbi.nlm.nih.gov/pubmed/21382474?dopt=AbstractPlus

41 

Berg 
S 

et al (2012 ) http://www.ncbi.nlm.nih.gov/pubmed/22489897?dopt=AbstractPlus

42 

Bergamini 
G 

et al (2012 ) http://www.ncbi.nlm.nih.gov/pubmed/22544264?dopt=AbstractPlus

43 

Bergstrom 
JD 

et al (2000 ) http://www.ncbi.nlm.nih.gov/pubmed/10620343?dopt=AbstractPlus

44 

Bergstrom 
JD 

et al (1993 ) http://www.ncbi.nlm.nih.gov/pubmed/8419946?dopt=AbstractPlus

45 

Bertilsson 
L 

et al (1989 ) http://www.ncbi.nlm.nih.gov/pubmed/2495208?dopt=AbstractPlus

46 

Bhatnagar 
AS 

et al (1990 ) http://www.ncbi.nlm.nih.gov/pubmed/2149502?dopt=AbstractPlus

47 

Bicker 
KL 

et al (2013 ) http://www.ncbi.nlm.nih.gov/pubmed/23175390?dopt=AbstractPlus

48 

Binda 
C 

et al (2004 ) http://www.ncbi.nlm.nih.gov/pubmed/15027868?dopt=AbstractPlus

49 

Binda 
C 

et al (2008 ) http://www.ncbi.nlm.nih.gov/pubmed/18426226?dopt=AbstractPlus

50 

Black 
WC 

et al (2003 ) http://www.ncbi.nlm.nih.gov/pubmed/12643942?dopt=AbstractPlus

51 

Blackie 
JA 

et al (2003 ) http://www.ncbi.nlm.nih.gov/pubmed/12643913?dopt=AbstractPlus

52 

Bland-Ward 
PA 

et al (1995 ) http://www.ncbi.nlm.nih.gov/pubmed/7544863?dopt=AbstractPlus

53 

Blankman 
JL 

et al (2007 ) http://www.ncbi.nlm.nih.gov/pubmed/18096503?dopt=AbstractPlus

54 

Blobaum 
AL 

et al (2007 ) http://www.ncbi.nlm.nih.gov/pubmed/17341061?dopt=AbstractPlus

55 

Blobaum 
AL 

et al (2007 ) http://www.ncbi.nlm.nih.gov/pubmed/17434872?dopt=AbstractPlus

56 

Boess 
FG 

et al (2004 ) http://www.ncbi.nlm.nih.gov/pubmed/15555642?dopt=AbstractPlus

57 

Boison 
D. 
 (2013 ) http://www.ncbi.nlm.nih.gov/pubmed/23592612?dopt=AbstractPlus

58 

Bosanac 
T 

et al (2010 ) http://www.ncbi.nlm.nih.gov/pubmed/20471253?dopt=AbstractPlus

59 

Bowman 
EA 

et al (2014 ) http://www.ncbi.nlm.nih.gov/pubmed/24879308?dopt=AbstractPlus

60 

Boyle 
CD 

et al (2005 ) http://www.ncbi.nlm.nih.gov/pubmed/15837326?dopt=AbstractPlus

61 

Bradner 
JE 

et al (2010 ) http://www.ncbi.nlm.nih.gov/pubmed/20139990?dopt=AbstractPlus

62 

Brand 
CS 

et al (2013 ) http://www.ncbi.nlm.nih.gov/pubmed/24006339?dopt=AbstractPlus

63 

Brunschweiger 
A 

et al (2008 ) http://www.ncbi.nlm.nih.gov/pubmed/18630897?dopt=AbstractPlus

64 

Brust 
TF 

et al (2017 ) http://www.ncbi.nlm.nih.gov/pubmed/28223412?dopt=AbstractPlus

65 

Burger 
RM 

et al (1975 ) http://www.ncbi.nlm.nih.gov/pubmed/1169962?dopt=AbstractPlus

66 

Bustanji 
Y 

et al (2010 ) J Med Plant Res 
4 : 2235 -2242 

67 

Butini 
S 

et al (2008 ) http://www.ncbi.nlm.nih.gov/pubmed/18479118?dopt=AbstractPlus

68 

Butters 
TD 

et al (2000 ) Tetrahedron: Assymetry 
11 : 113 -124 

69 

Bylund 
J 

et al (2000 ) http://www.ncbi.nlm.nih.gov/pubmed/10791960?dopt=AbstractPlus

70 

Bézière 
N 

et al (2008 ) http://www.ncbi.nlm.nih.gov/pubmed/18667313?dopt=AbstractPlus

71 

Cabaye 
A 

et al (2015 ) http://www.ncbi.nlm.nih.gov/pubmed/25974248?dopt=AbstractPlus

72 

Cali 
JJ 

et al (1994 ) http://www.ncbi.nlm.nih.gov/pubmed/8163524?dopt=AbstractPlus

73 

Camacho 
L 

et al (2012 ) http://www.ncbi.nlm.nih.gov/pubmed/22537678?dopt=AbstractPlus

74 

Campbell 
PJ 

et al (2006 ) http://www.ncbi.nlm.nih.gov/pubmed/17151367?dopt=AbstractPlus

75 

Camps 
M 

et al (1992 ) http://www.ncbi.nlm.nih.gov/pubmed/1465133?dopt=AbstractPlus

76 

Cano 
C 

et al (2013 ) http://www.ncbi.nlm.nih.gov/pubmed/23855836?dopt=AbstractPlus

77 

Carbonell 
T 

et al (2005 ) http://www.ncbi.nlm.nih.gov/pubmed/16128575?dopt=AbstractPlus

78 

Cardozo 
MG 

et al (1992 ) http://www.ncbi.nlm.nih.gov/pubmed/1738151?dopt=AbstractPlus

79 

Carlson 
BA 

et al (1996 ) http://www.ncbi.nlm.nih.gov/pubmed/8674031?dopt=AbstractPlus

80 

Carozzi 
A 

et al (1993 ) http://www.ncbi.nlm.nih.gov/pubmed/8380773?dopt=AbstractPlus

81 

Carter 
GW 

et al (1991 ) http://www.ncbi.nlm.nih.gov/pubmed/1848634?dopt=AbstractPlus

82 

Casey 
PJ 

et al (1996 ) http://www.ncbi.nlm.nih.gov/pubmed/8621375?dopt=AbstractPlus

83 

Ceconi 
C 

et al (2007 ) http://www.ncbi.nlm.nih.gov/pubmed/17716647?dopt=AbstractPlus

84 

Ceyhan 
O 

et al (2012 ) http://www.ncbi.nlm.nih.gov/pubmed/22284362?dopt=AbstractPlus

85 

Chadli 
A 

et al (2000 ) http://www.ncbi.nlm.nih.gov/pubmed/11050175?dopt=AbstractPlus

86 

Chalfant 
CE 

et al (1996 ) http://www.ncbi.nlm.nih.gov/pubmed/9121494?dopt=AbstractPlus

87 

Chambers 
KJ 

et al (1998 ) http://www.ncbi.nlm.nih.gov/pubmed/9751809?dopt=AbstractPlus

88 

Chang 
JW 

et al (2012 ) http://www.ncbi.nlm.nih.gov/pubmed/22542104?dopt=AbstractPlus

89 

Chen 
H 

et al (2013 ) http://www.ncbi.nlm.nih.gov/pubmed/23286832?dopt=AbstractPlus

90 

Chen 
H 

et al (2014 ) http://www.ncbi.nlm.nih.gov/pubmed/24256330?dopt=AbstractPlus

91 

Chen 
J 

et al (1993 ) http://www.ncbi.nlm.nih.gov/pubmed/8389756?dopt=AbstractPlus

92 

Chen 
X 

et al (2004 ) http://www.ncbi.nlm.nih.gov/pubmed/15520012?dopt=AbstractPlus

93 

Chen 
Y 

et al (2000 ) http://www.ncbi.nlm.nih.gov/pubmed/10915626?dopt=AbstractPlus

94 

Chen 
Y 

et al (1997 ) http://www.ncbi.nlm.nih.gov/pubmed/9391159?dopt=AbstractPlus

95 

Chen 
YT 

et al (2011 ) Med Chem Commun 
2 : 73 -75 

96 

Cheng 
JB 

et al (2003 ) http://www.ncbi.nlm.nih.gov/pubmed/12867411?dopt=AbstractPlus

97 

Cheng 
L 

et al (2014 ) http://www.ncbi.nlm.nih.gov/pubmed/24900876?dopt=AbstractPlus

98 

Chevillard 
C 

et al (1994 ) http://www.ncbi.nlm.nih.gov/pubmed/7527095?dopt=AbstractPlus

99 

Chicca 
A 

et al (2017 ) http://www.ncbi.nlm.nih.gov/pubmed/28584105?dopt=AbstractPlus

100 

Childress 
ES 

et al (2017 ) http://www.ncbi.nlm.nih.gov/pubmed/28406646?dopt=AbstractPlus

101 

Chin 
PC 

et al (2004 ) http://www.ncbi.nlm.nih.gov/pubmed/15255937?dopt=AbstractPlus

102 

Choi 
EJ 

et al (1992 ) http://www.ncbi.nlm.nih.gov/pubmed/1633161?dopt=AbstractPlus

103 

Choi 
YJ 

et al (2019 ) http://www.ncbi.nlm.nih.gov/pubmed/30274713?dopt=AbstractPlus

104 

Choudhary 
C 

et al (2009 ) http://www.ncbi.nlm.nih.gov/pubmed/19608861?dopt=AbstractPlus

105 

Christiansen 
JS. 
 (1985 ) http://www.ncbi.nlm.nih.gov/pubmed/2951074?dopt=AbstractPlus

106 

Ciechanover 
A. 
 (2005 ) http://www.ncbi.nlm.nih.gov/pubmed/16142822?dopt=AbstractPlus

107 

Cingolani 
F 

et al (2014 ) http://www.ncbi.nlm.nih.gov/pubmed/24875537?dopt=AbstractPlus

108 

Clark 
JK 

et al (2002 ) http://www.ncbi.nlm.nih.gov/pubmed/12182861?dopt=AbstractPlus

109 

Coghlan 
MP 

et al (2000 ) http://www.ncbi.nlm.nih.gov/pubmed/11033082?dopt=AbstractPlus

110 

Coleman 
CS 

et al (2004 ) http://www.ncbi.nlm.nih.gov/pubmed/14763899?dopt=AbstractPlus

111 

Colleluori 
DM 

et al (2001 ) http://www.ncbi.nlm.nih.gov/pubmed/11478904?dopt=AbstractPlus

112 

Congiu 
C 

et al (2015 ) http://www.ncbi.nlm.nih.gov/pubmed/26233435?dopt=AbstractPlus

113 

Conigrave 
AD 

et al (1989 ) http://www.ncbi.nlm.nih.gov/pubmed/2559811?dopt=AbstractPlus

114 

Conley 
JM 

et al (2013 ) http://www.ncbi.nlm.nih.gov/pubmed/24008337?dopt=AbstractPlus

115 

Corbett 
JA 

et al (1992 ) http://www.ncbi.nlm.nih.gov/pubmed/1378415?dopt=AbstractPlus

116 

Corbin 
JD 

et al (2000 ) http://www.ncbi.nlm.nih.gov/pubmed/10785399?dopt=AbstractPlus

117 

Cortés 
A 

et al (2015 ) http://www.ncbi.nlm.nih.gov/pubmed/24933472?dopt=AbstractPlus

118 

Covey 
DF 

et al (1982 ) http://www.ncbi.nlm.nih.gov/pubmed/7083195?dopt=AbstractPlus

119 

Crocetti 
L 

et al (2011 ) http://www.ncbi.nlm.nih.gov/pubmed/21741848?dopt=AbstractPlus

120 

Crosignani 
S 

et al (2011 ) ACS Med Chem Lett 
2 : 938 -942 
24900284 
121 

Cryns 
K 

et al (2007 ) http://www.ncbi.nlm.nih.gov/pubmed/16841073?dopt=AbstractPlus

122 

Cryns 
K 

et al (2008 ) http://www.ncbi.nlm.nih.gov/pubmed/17460611?dopt=AbstractPlus

123 

Cully 
M. 
 (2013 ) http://www.ncbi.nlm.nih.gov/pubmed/24145894?dopt=AbstractPlus

124 

Curet 
O 

et al (1998 ) http://www.ncbi.nlm.nih.gov/pubmed/10333983?dopt=AbstractPlus

125 

Daidone 
F 

et al (2012 ) http://www.ncbi.nlm.nih.gov/pubmed/22384042?dopt=AbstractPlus

126 

Daly 
AK. 
 (2006 ) http://www.ncbi.nlm.nih.gov/pubmed/16430309?dopt=AbstractPlus

127 

Daubner 
SC 

et al (2011 ) http://www.ncbi.nlm.nih.gov/pubmed/21176768?dopt=AbstractPlus

128 

Davies 
SP 

et al (2000 ) http://www.ncbi.nlm.nih.gov/pubmed/10998351?dopt=AbstractPlus

129 

Davis 
JA 

et al (2010 ) http://www.ncbi.nlm.nih.gov/pubmed/20927248?dopt=AbstractPlus

130 

Davis 
MI 

et al (2011 ) http://www.ncbi.nlm.nih.gov/pubmed/22037378?dopt=AbstractPlus

131 

DeForrest 
JM 

et al (1989 ) http://www.ncbi.nlm.nih.gov/pubmed/2481187?dopt=AbstractPlus

132 

Deinum 
J 

et al (2009 ) http://www.ncbi.nlm.nih.gov/pubmed/19492147?dopt=AbstractPlus

133 

Delhommeau 
F 

et al (2006 ) http://www.ncbi.nlm.nih.gov/pubmed/17131059?dopt=AbstractPlus

134 

Deng 
X 

et al (2014 ) http://www.ncbi.nlm.nih.gov/pubmed/24374347?dopt=AbstractPlus

135 

DePinto 
W 

et al (2006 ) http://www.ncbi.nlm.nih.gov/pubmed/17121911?dopt=AbstractPlus

136 

Desai 
B 

et al (2013 ) http://www.ncbi.nlm.nih.gov/pubmed/23441572?dopt=AbstractPlus

137 

Dessauer 
CW 

et al (2017 ) http://www.ncbi.nlm.nih.gov/pubmed/28255005?dopt=AbstractPlus

138 

Desta 
Z 

et al (2002 ) http://www.ncbi.nlm.nih.gov/pubmed/12222994?dopt=AbstractPlus

139 

Dewji 
NN 

et al (2015 ) http://www.ncbi.nlm.nih.gov/pubmed/25923432?dopt=AbstractPlus

140 

Di Paolo 
JA 

et al (2011 ) http://www.ncbi.nlm.nih.gov/pubmed/21113169?dopt=AbstractPlus

141 

Di Santo 
R 

et al (2005 ) http://www.ncbi.nlm.nih.gov/pubmed/15974574?dopt=AbstractPlus

142 

Diel 
S 

et al (2006 ) http://www.ncbi.nlm.nih.gov/pubmed/16275644?dopt=AbstractPlus

143 

DiMauro 
EF 

et al (2007 ) http://www.ncbi.nlm.nih.gov/pubmed/17280833?dopt=AbstractPlus

144 

Ding 
Q 

et al (2006 ) Patent number: US7094896.
145 

Ding 
Q 

et al (2004 ) http://www.ncbi.nlm.nih.gov/pubmed/15385642?dopt=AbstractPlus

146 

Divanovic 
S 

et al (2013 ) http://www.ncbi.nlm.nih.gov/pubmed/23956430?dopt=AbstractPlus

147 

Dixon 
RA 

et al (1990 ) http://www.ncbi.nlm.nih.gov/pubmed/2300173?dopt=AbstractPlus

148 

Dodds 
HM 

et al (1998 ) http://www.ncbi.nlm.nih.gov/pubmed/9655905?dopt=AbstractPlus

149 

Doe 
C 

et al (2007 ) http://www.ncbi.nlm.nih.gov/pubmed/17018693?dopt=AbstractPlus

150 

Draganov 
DI 

et al (2005 ) http://www.ncbi.nlm.nih.gov/pubmed/15772423?dopt=AbstractPlus

151 

Drake 
FH 

et al (1989 ) http://www.ncbi.nlm.nih.gov/pubmed/2557897?dopt=AbstractPlus

152 

Drummond 
GS 

et al (1981 ) http://www.ncbi.nlm.nih.gov/pubmed/6947237?dopt=AbstractPlus

153 

Dunford 
JE 

et al (2008 ) http://www.ncbi.nlm.nih.gov/pubmed/18327899?dopt=AbstractPlus

154 

Dutour 
R 

et al (2017 ) http://www.ncbi.nlm.nih.gov/pubmed/28458135?dopt=AbstractPlus

155 

Eckhardt 
M 

et al (2007 ) http://www.ncbi.nlm.nih.gov/pubmed/18052023?dopt=AbstractPlus

156 

Edmondson 
SD 

et al (2003 ) http://www.ncbi.nlm.nih.gov/pubmed/14592490?dopt=AbstractPlus

157 

Engler 
TA 

et al (2004 ) http://www.ncbi.nlm.nih.gov/pubmed/15267232?dopt=AbstractPlus

158 

Enserink 
JM 

et al (2002 ) http://www.ncbi.nlm.nih.gov/pubmed/12402047?dopt=AbstractPlus

159 

Erba 
F 

et al (2001 ) http://www.ncbi.nlm.nih.gov/pubmed/11172730?dopt=AbstractPlus

160 

Esclapez 
M 

et al (1994 ) http://www.ncbi.nlm.nih.gov/pubmed/8126575?dopt=AbstractPlus

161 

Esteller 
M. 
 (2008 ) http://www.ncbi.nlm.nih.gov/pubmed/18337604?dopt=AbstractPlus

162 

Evenäs 
J 

et al (2014 ) http://www.ncbi.nlm.nih.gov/pubmed/24508129?dopt=AbstractPlus

163 

Fabrias 
G 

et al (2012 ) http://www.ncbi.nlm.nih.gov/pubmed/22200621?dopt=AbstractPlus

164 

Faraci 
WS 

et al (1996 ) http://www.ncbi.nlm.nih.gov/pubmed/8937711?dopt=AbstractPlus

165 

Faul 
MM 

et al (2003 ) http://www.ncbi.nlm.nih.gov/pubmed/12749884?dopt=AbstractPlus

166 

Faull 
AW 

et al (1995 ) http://www.ncbi.nlm.nih.gov/pubmed/7861416?dopt=AbstractPlus

167 

Fawcett 
L 

et al (2000 ) http://www.ncbi.nlm.nih.gov/pubmed/10725373?dopt=AbstractPlus

168 

Fer 
M 

et al (2008 ) http://www.ncbi.nlm.nih.gov/pubmed/18577768?dopt=AbstractPlus

169 

Fischer 
L 

et al (2004 ) http://www.ncbi.nlm.nih.gov/pubmed/15197110?dopt=AbstractPlus

170 

Fisher 
DA 

et al (1998 ) http://www.ncbi.nlm.nih.gov/pubmed/9624146?dopt=AbstractPlus

171 

Fisher 
DA 

et al (1998 ) http://www.ncbi.nlm.nih.gov/pubmed/9618252?dopt=AbstractPlus

172 

Fiskerstrand 
T 

et al (2010 ) http://www.ncbi.nlm.nih.gov/pubmed/20797687?dopt=AbstractPlus

173 

Fitzgerald 
K 

et al (2014 ) http://www.ncbi.nlm.nih.gov/pubmed/24094767?dopt=AbstractPlus

174 

Folkes 
AJ 

et al (2008 ) http://www.ncbi.nlm.nih.gov/pubmed/18754654?dopt=AbstractPlus

175 

Fontana 
E 

et al (2005 ) http://www.ncbi.nlm.nih.gov/pubmed/16248836?dopt=AbstractPlus

176 

Forsyth 
T 

et al (2012 ) http://www.ncbi.nlm.nih.gov/pubmed/23127890?dopt=AbstractPlus

177 

Foss 
FM 

et al (2011 ) http://www.ncbi.nlm.nih.gov/pubmed/21493798?dopt=AbstractPlus

178 

Foti 
RS 

et al (2012 ) http://www.ncbi.nlm.nih.gov/pubmed/22239545?dopt=AbstractPlus

179 

Fowler 
CJ. 
 (2007 ) http://www.ncbi.nlm.nih.gov/pubmed/17618306?dopt=AbstractPlus

180 

Frank-Kamenetsky 
M 

et al (2008 ) http://www.ncbi.nlm.nih.gov/pubmed/18695239?dopt=AbstractPlus

181 

French 
KJ 

et al (2010 ) http://www.ncbi.nlm.nih.gov/pubmed/20061445?dopt=AbstractPlus

182 

Fruman 
DA 

et al (2017 ) http://www.ncbi.nlm.nih.gov/pubmed/28802037?dopt=AbstractPlus

183 

Fry 
DW 

et al (2004 ) http://www.ncbi.nlm.nih.gov/pubmed/15542782?dopt=AbstractPlus

184 

Fujishige 
K 

et al (1999 ) http://www.ncbi.nlm.nih.gov/pubmed/10373451?dopt=AbstractPlus

185 

Fukami 
T 

et al (2006 ) http://www.ncbi.nlm.nih.gov/pubmed/16636685?dopt=AbstractPlus

186 

Fuller 
RW 

et al (1981 ) http://www.ncbi.nlm.nih.gov/pubmed/6268095?dopt=AbstractPlus

187 

Furet 
P 

et al (2013 ) http://www.ncbi.nlm.nih.gov/pubmed/23726034?dopt=AbstractPlus

188 

Furfine 
ES 

et al (1995 ) http://www.ncbi.nlm.nih.gov/pubmed/7756316?dopt=AbstractPlus

189 

Furster 
C 

et al (1999 ) http://www.ncbi.nlm.nih.gov/pubmed/9931427?dopt=AbstractPlus

190 

Fürstenberger 
G 

et al (2002 ) http://www.ncbi.nlm.nih.gov/pubmed/12432921?dopt=AbstractPlus

191 

Gainer 
JV 

et al (2005 ) http://www.ncbi.nlm.nih.gov/pubmed/15611369?dopt=AbstractPlus

192 

Galemmo 
RA 
Jr.
et al (1996 ) Bioorg Med Chem Lett 
6 : 2913 -2918 

193 

Galli 
A 

et al (1994 ) http://www.ncbi.nlm.nih.gov/pubmed/8039548?dopt=AbstractPlus

194 

Gangjee 
A 

et al (2012 ) http://www.ncbi.nlm.nih.gov/pubmed/22739090?dopt=AbstractPlus

195 

Gao 
BN 

et al (1991 ) http://www.ncbi.nlm.nih.gov/pubmed/1946437?dopt=AbstractPlus

196 

Gao 
P 

et al (2012 ) http://www.ncbi.nlm.nih.gov/pubmed/22970244?dopt=AbstractPlus

197 

Gao 
X 

et al (2007 ) http://www.ncbi.nlm.nih.gov/pubmed/17110384?dopt=AbstractPlus

198 

Garbarg 
M 

et al (1980 ) http://www.ncbi.nlm.nih.gov/pubmed/7452304?dopt=AbstractPlus

199 

Garcia-Manero 
G 

et al (2011 ) http://www.ncbi.nlm.nih.gov/pubmed/21220589?dopt=AbstractPlus

200 

Gardner 
C 

et al (2000 ) http://www.ncbi.nlm.nih.gov/pubmed/10872825?dopt=AbstractPlus

201 

Garvey 
EP 

et al (1997 ) http://www.ncbi.nlm.nih.gov/pubmed/9030556?dopt=AbstractPlus

202 

Garvey 
EP 

et al (1994 ) http://www.ncbi.nlm.nih.gov/pubmed/7523409?dopt=AbstractPlus

203 

Gehrmann 
T 

et al (1999 ) http://www.ncbi.nlm.nih.gov/pubmed/10101268?dopt=AbstractPlus

204 

Ghafouri 
N 

et al (2004 ) http://www.ncbi.nlm.nih.gov/pubmed/15492019?dopt=AbstractPlus

205 

Giacobini 
E. 
 (2003 ) http://www.ncbi.nlm.nih.gov/pubmed/12675140?dopt=AbstractPlus

206 

Gilmartin 
AG 

et al (2011 ) http://www.ncbi.nlm.nih.gov/pubmed/21245089?dopt=AbstractPlus

207 

Giroux 
A 

et al (2009 ) http://www.ncbi.nlm.nih.gov/pubmed/19748780?dopt=AbstractPlus

208 

Glazer 
RI 

et al (1986 ) http://www.ncbi.nlm.nih.gov/pubmed/3457563?dopt=AbstractPlus

209 

Goding 
JW 

et al (2003 ) http://www.ncbi.nlm.nih.gov/pubmed/12757929?dopt=AbstractPlus

210 

Golas 
JM 

et al (2003 ) http://www.ncbi.nlm.nih.gov/pubmed/12543790?dopt=AbstractPlus

211 

Golde 
TE 

et al (2001 ) http://www.ncbi.nlm.nih.gov/pubmed/11378516?dopt=AbstractPlus

212 

Gomaa 
MS 

et al (2011 ) http://www.ncbi.nlm.nih.gov/pubmed/21838328?dopt=AbstractPlus

213 

Gorman 
RR 

et al (1983 ) http://www.ncbi.nlm.nih.gov/pubmed/6316421?dopt=AbstractPlus

214 

Graf 
C 

et al (2008 ) http://www.ncbi.nlm.nih.gov/pubmed/18612076?dopt=AbstractPlus

215 

Graham 
DW 

et al (1987 ) http://www.ncbi.nlm.nih.gov/pubmed/3495664?dopt=AbstractPlus

216 

Gray 
AP 

et al (1988 ) http://www.ncbi.nlm.nih.gov/pubmed/3351860?dopt=AbstractPlus

217 

Greenblatt 
DJ 

et al (2015 ) http://www.ncbi.nlm.nih.gov/pubmed/25923589?dopt=AbstractPlus

218 

Greengard 
O 

et al (1976 ) http://www.ncbi.nlm.nih.gov/pubmed/944951?dopt=AbstractPlus

219 

Griffith 
DA 

et al (2013 ) http://www.ncbi.nlm.nih.gov/pubmed/23981033?dopt=AbstractPlus

220 

Groarke 
DA 

et al (2001 ) http://www.ncbi.nlm.nih.gov/pubmed/11160875?dopt=AbstractPlus

221 

Gryglewski 
RJ 

et al (1976 ) http://www.ncbi.nlm.nih.gov/pubmed/824685?dopt=AbstractPlus

222 

Gryglewski 
RJ 

et al (1995 ) http://www.ncbi.nlm.nih.gov/pubmed/7778318?dopt=AbstractPlus

223 

Gschwendt 
M 

et al (1996 ) http://www.ncbi.nlm.nih.gov/pubmed/8772178?dopt=AbstractPlus

224 

Guengerich 
FP 

et al (2011 ) http://www.ncbi.nlm.nih.gov/pubmed/21737533?dopt=AbstractPlus

225 

Guengerich 
FP 

et al (1986 ) http://www.ncbi.nlm.nih.gov/pubmed/3514607?dopt=AbstractPlus

226 

Gupta 
R 

et al (2009 ) http://www.ncbi.nlm.nih.gov/pubmed/19149538?dopt=AbstractPlus

227 

Guranowski 
A 

et al (1981 ) http://www.ncbi.nlm.nih.gov/pubmed/7470463?dopt=AbstractPlus

228 

Gustafsson 
D 

et al (1998 ) http://www.ncbi.nlm.nih.gov/pubmed/9459334?dopt=AbstractPlus

229 

Haber 
MT 

et al (1991 ) http://www.ncbi.nlm.nih.gov/pubmed/1654825?dopt=AbstractPlus

230 

Haefely 
WE 

et al (1990 ) http://www.ncbi.nlm.nih.gov/pubmed/2122653?dopt=AbstractPlus

231 

Hagishita 
S 

et al (1996 ) http://www.ncbi.nlm.nih.gov/pubmed/8809154?dopt=AbstractPlus

232 

Haj-Dahmane 
S 

et al (2018 ) http://www.ncbi.nlm.nih.gov/pubmed/29531087?dopt=AbstractPlus

233 

Hammond 
SM 

et al (1997 ) http://www.ncbi.nlm.nih.gov/pubmed/9013646?dopt=AbstractPlus

234 

Han 
G 

et al (2009 ) http://www.ncbi.nlm.nih.gov/pubmed/19416851?dopt=AbstractPlus

235 

Han 
L 

et al (2007 ) http://www.ncbi.nlm.nih.gov/pubmed/17260973?dopt=AbstractPlus

236 

Hanan 
EJ 

et al (2012 ) http://www.ncbi.nlm.nih.gov/pubmed/23061660?dopt=AbstractPlus

237 

Hanaoka 
K 

et al (2017 ) http://www.ncbi.nlm.nih.gov/pubmed/28079151?dopt=AbstractPlus

238 

Handratta 
VD 

et al (2005 ) http://www.ncbi.nlm.nih.gov/pubmed/15828836?dopt=AbstractPlus

239 

Hanke 
JH 

et al (1996 ) http://www.ncbi.nlm.nih.gov/pubmed/8557675?dopt=AbstractPlus

240 

Hansen 
JD 

et al (2008 ) http://www.ncbi.nlm.nih.gov/pubmed/18676143?dopt=AbstractPlus

241 

Harmon 
SD 

et al (2006 ) http://www.ncbi.nlm.nih.gov/pubmed/16820285?dopt=AbstractPlus

242 

Harris 
CM 

et al (2016 ) http://www.ncbi.nlm.nih.gov/pubmed/27519818?dopt=AbstractPlus

243 

Hartung 
IV 

et al (2013 ) http://www.ncbi.nlm.nih.gov/pubmed/23474388?dopt=AbstractPlus

244 

Hatae 
T 

et al (1996 ) http://www.ncbi.nlm.nih.gov/pubmed/8766713?dopt=AbstractPlus

245 

Hatzelmann 
A 

et al (1993 ) http://www.ncbi.nlm.nih.gov/pubmed/8381000?dopt=AbstractPlus

246 

Hauel 
NH 

et al (2002 ) http://www.ncbi.nlm.nih.gov/pubmed/11960487?dopt=AbstractPlus

247 

Hausser 
A 

et al (2005 ) http://www.ncbi.nlm.nih.gov/pubmed/16100512?dopt=AbstractPlus

248 

Hayakawa 
M 

et al (2007 ) http://www.ncbi.nlm.nih.gov/pubmed/17601739?dopt=AbstractPlus

249 

Hayashi 
M 

et al (1998 ) http://www.ncbi.nlm.nih.gov/pubmed/9784418?dopt=AbstractPlus

250 

Hayashi 
S 

et al (2004 ) http://www.ncbi.nlm.nih.gov/pubmed/15246535?dopt=AbstractPlus

251 

Hays 
SJ 

et al (1998 ) http://www.ncbi.nlm.nih.gov/pubmed/9544206?dopt=AbstractPlus

252 

He 
Y 

et al (2017 ) http://www.ncbi.nlm.nih.gov/pubmed/28135237?dopt=AbstractPlus

253 

Heikkilä 
T 

et al (2007 ) http://www.ncbi.nlm.nih.gov/pubmed/17228860?dopt=AbstractPlus

254 

Helsby 
NA 

et al (1990 ) http://www.ncbi.nlm.nih.gov/pubmed/2291871?dopt=AbstractPlus

255 

Hepler 
JR 

et al (1993 ) http://www.ncbi.nlm.nih.gov/pubmed/8314796?dopt=AbstractPlus

256 

Hess 
KC 

et al (2005 ) http://www.ncbi.nlm.nih.gov/pubmed/16054031?dopt=AbstractPlus

257 

Hieke 
M 

et al (2011 ) http://www.ncbi.nlm.nih.gov/pubmed/21873070?dopt=AbstractPlus

258 

Hill 
J 

et al (2000 ) http://www.ncbi.nlm.nih.gov/pubmed/10781930?dopt=AbstractPlus

259 

Hiraku 
S 

et al (1986 ) http://www.ncbi.nlm.nih.gov/pubmed/3093741?dopt=AbstractPlus

260 

Hoffmann 
R 

et al (1999 ) http://www.ncbi.nlm.nih.gov/pubmed/10022832?dopt=AbstractPlus

261 

Hoffmann 
R 

et al (1998 ) http://www.ncbi.nlm.nih.gov/pubmed/9639573?dopt=AbstractPlus

262 

Homma 
Y 

et al (1995 ) http://www.ncbi.nlm.nih.gov/pubmed/7835339?dopt=AbstractPlus

263 

Horbert 
R 

et al (2015 ) http://www.ncbi.nlm.nih.gov/pubmed/26061392?dopt=AbstractPlus

264 

Horio 
T 

et al (2007 ) http://www.ncbi.nlm.nih.gov/pubmed/17376680?dopt=AbstractPlus

265 

Houslay 
MD 

et al (2003 ) http://www.ncbi.nlm.nih.gov/pubmed/12444918?dopt=AbstractPlus

266 

Howard 
S 

et al (2009 ) http://www.ncbi.nlm.nih.gov/pubmed/19143567?dopt=AbstractPlus

267 

Hsieh 
AC 

et al (2012 ) http://www.ncbi.nlm.nih.gov/pubmed/22367541?dopt=AbstractPlus

268 

Hsu 
KL 

et al (2012 ) http://www.ncbi.nlm.nih.gov/pubmed/23103940?dopt=AbstractPlus

269 

Huang 
WS 

et al (2010 ) http://www.ncbi.nlm.nih.gov/pubmed/20513156?dopt=AbstractPlus

270 

Hubbert 
C 

et al (2002 ) http://www.ncbi.nlm.nih.gov/pubmed/12024216?dopt=AbstractPlus

271 

Hughes 
RO 

et al (2009 ) http://www.ncbi.nlm.nih.gov/pubmed/19631533?dopt=AbstractPlus

272 

Hughes 
SA 

et al (2000 ) http://www.ncbi.nlm.nih.gov/pubmed/11138848?dopt=AbstractPlus

273 

Illenberger 
D 

et al (2003 ) http://www.ncbi.nlm.nih.gov/pubmed/12441352?dopt=AbstractPlus

274 

Illenberger 
D 

et al (2003 ) http://www.ncbi.nlm.nih.gov/pubmed/12509427?dopt=AbstractPlus

275 

Imanishi 
J 

et al (2011 ) http://www.ncbi.nlm.nih.gov/pubmed/21745460?dopt=AbstractPlus

276 

Imiya 
M 

et al (1997 ) http://www.ncbi.nlm.nih.gov/pubmed/9361377?dopt=AbstractPlus

277 

Irikura 
D 

et al (2009 ) http://www.ncbi.nlm.nih.gov/pubmed/19131342?dopt=AbstractPlus

278 

Ishida 
H 

et al (1992 ) http://www.ncbi.nlm.nih.gov/pubmed/1400444?dopt=AbstractPlus

279 

Ishikawa 
Y 

et al (1992 ) http://www.ncbi.nlm.nih.gov/pubmed/1618857?dopt=AbstractPlus

280 

Istvan 
ES 

et al (2001 ) http://www.ncbi.nlm.nih.gov/pubmed/11349148?dopt=AbstractPlus

281 

Iverson 
C 

et al (2009 ) http://www.ncbi.nlm.nih.gov/pubmed/19706763?dopt=AbstractPlus

282 

Iwami 
G 

et al (1995 ) http://www.ncbi.nlm.nih.gov/pubmed/7759492?dopt=AbstractPlus

283 

Jacobowitz 
O 

et al (1993 ) http://www.ncbi.nlm.nih.gov/pubmed/8440678?dopt=AbstractPlus

284 

Jagrat 
M 

et al (2011 ) http://www.ncbi.nlm.nih.gov/pubmed/21680183?dopt=AbstractPlus

285 

Jain 
MR 

et al (2017 ) http://www.ncbi.nlm.nih.gov/pubmed/28452143?dopt=AbstractPlus

286 

Jameson 
2nd
JB 

et al (2014 ) http://www.ncbi.nlm.nih.gov/pubmed/25111178?dopt=AbstractPlus

287 

Jarvis 
MF 

et al (2000 ) http://www.ncbi.nlm.nih.gov/pubmed/11082453?dopt=AbstractPlus

288 

Jhon 
DY 

et al (1993 ) http://www.ncbi.nlm.nih.gov/pubmed/8454637?dopt=AbstractPlus

289 

Jirousek 
MR 

et al (1996 ) http://www.ncbi.nlm.nih.gov/pubmed/8709095?dopt=AbstractPlus

290 

Joh 
TH 

et al (1978 ) http://www.ncbi.nlm.nih.gov/pubmed/33381?dopt=AbstractPlus

291 

Johansen 
PA 

et al (1996 ) http://www.ncbi.nlm.nih.gov/pubmed/8592157?dopt=AbstractPlus

292 

Johnson 
J 

et al (1996 ) http://www.ncbi.nlm.nih.gov/pubmed/8603045?dopt=AbstractPlus

293 

Johnson 
PH 

et al (1991 ) http://www.ncbi.nlm.nih.gov/pubmed/1894196?dopt=AbstractPlus

294 

Jones 
CE 

et al (2003 ) http://www.ncbi.nlm.nih.gov/pubmed/12606753?dopt=AbstractPlus

295 

Jones 
GH 

et al (1987 ) http://www.ncbi.nlm.nih.gov/pubmed/3027338?dopt=AbstractPlus

296 

Jorda 
R 

et al (2018 ) http://www.ncbi.nlm.nih.gov/pubmed/30234987?dopt=AbstractPlus

297 

Joshi 
KS 

et al (2007 ) http://www.ncbi.nlm.nih.gov/pubmed/17363486?dopt=AbstractPlus

298 

Kahraman 
M 

et al (2004 ) http://www.ncbi.nlm.nih.gov/pubmed/15615534?dopt=AbstractPlus

299 

Kalgutkar 
AS 

et al (2002 ) http://www.ncbi.nlm.nih.gov/pubmed/11844663?dopt=AbstractPlus

300 

Kamat 
SS 

et al (2015 ) http://www.ncbi.nlm.nih.gov/pubmed/25580854?dopt=AbstractPlus

301 

Kameoka 
J 

et al (1993 ) http://www.ncbi.nlm.nih.gov/pubmed/8101391?dopt=AbstractPlus

302 

Kang 
J 

et al (1987 ) http://www.ncbi.nlm.nih.gov/pubmed/2881207?dopt=AbstractPlus

303 

Kao 
Y 

et al (2002 ) http://www.ncbi.nlm.nih.gov/pubmed/11918623?dopt=AbstractPlus

304 

Kao 
YL 

et al (1998 ) http://www.ncbi.nlm.nih.gov/pubmed/9661650?dopt=AbstractPlus

305 

Karbarz 
MJ 

et al (2009 ) http://www.ncbi.nlm.nih.gov/pubmed/19095868?dopt=AbstractPlus

306 

Kawabe 
J 

et al (1994 ) http://www.ncbi.nlm.nih.gov/pubmed/8206971?dopt=AbstractPlus

307 

Kedei 
N 

et al (2004 ) http://www.ncbi.nlm.nih.gov/pubmed/15126366?dopt=AbstractPlus

308 

Keith 
JM 

et al (2008 ) http://www.ncbi.nlm.nih.gov/pubmed/18693015?dopt=AbstractPlus

309 

Khan 
O 

et al (2012 ) http://www.ncbi.nlm.nih.gov/pubmed/22124371?dopt=AbstractPlus

310 

Kharasch 
ED 

et al (2008 ) http://www.ncbi.nlm.nih.gov/pubmed/18285471?dopt=AbstractPlus

311 

Kim 
JJ 

et al (2015 ) http://www.ncbi.nlm.nih.gov/pubmed/26206858?dopt=AbstractPlus

312 

Kim 
NN 

et al (2001 ) http://www.ncbi.nlm.nih.gov/pubmed/11258879?dopt=AbstractPlus

313 

Kimura 
S 

et al (2005 ) http://www.ncbi.nlm.nih.gov/pubmed/16105974?dopt=AbstractPlus

314 

Kitagawa 
D 

et al (2013 ) http://www.ncbi.nlm.nih.gov/pubmed/23279183?dopt=AbstractPlus

315 

Knight 
SD 

et al (2010 ) http://www.ncbi.nlm.nih.gov/pubmed/24900173?dopt=AbstractPlus

316 

Knight 
ZA 

et al (2006 ) http://www.ncbi.nlm.nih.gov/pubmed/16647110?dopt=AbstractPlus

317 

Kobayashi 
T 

et al (2004 ) http://www.ncbi.nlm.nih.gov/pubmed/15040786?dopt=AbstractPlus

318 

Koch 
J 

et al (1996 ) http://www.ncbi.nlm.nih.gov/pubmed/8955159?dopt=AbstractPlus

319 

Kodimuthali 
A 

et al (2008 ) http://www.ncbi.nlm.nih.gov/pubmed/18686943?dopt=AbstractPlus

320 

Koeberle 
A 

et al (2008 ) http://www.ncbi.nlm.nih.gov/pubmed/19053751?dopt=AbstractPlus

321 

Kohoutek 
J 

et al (2012 ) http://www.ncbi.nlm.nih.gov/pubmed/22512864?dopt=AbstractPlus

322 

Kondoh 
G 

et al (2005 ) http://www.ncbi.nlm.nih.gov/pubmed/15665832?dopt=AbstractPlus

323 

Kong 
F 

et al (2011 ) http://www.ncbi.nlm.nih.gov/pubmed/21438579?dopt=AbstractPlus

324 

Kotthaus 
J 

et al (2008 ) http://www.ncbi.nlm.nih.gov/pubmed/19013076?dopt=AbstractPlus

325 

Kouzarides 
T. 
 (2007 ) http://www.ncbi.nlm.nih.gov/pubmed/17320507?dopt=AbstractPlus

326 

Kovacs 
JJ 

et al (2005 ) http://www.ncbi.nlm.nih.gov/pubmed/15916966?dopt=AbstractPlus

327 

Kozasa 
T 

et al (1998 ) http://www.ncbi.nlm.nih.gov/pubmed/9641915?dopt=AbstractPlus

328 

Kramlinger 
VM 

et al (2016 ) http://www.ncbi.nlm.nih.gov/pubmed/27059013?dopt=AbstractPlus

329 

Krapcho 
J 

et al (1988 ) http://www.ncbi.nlm.nih.gov/pubmed/2836590?dopt=AbstractPlus

330 

Krjukova 
J 

et al (2004 ) http://www.ncbi.nlm.nih.gov/pubmed/15302681?dopt=AbstractPlus

331 

Kunick 
C 

et al (2004 ) http://www.ncbi.nlm.nih.gov/pubmed/14698171?dopt=AbstractPlus

332 

Kupperman 
E 

et al (2010 ) http://www.ncbi.nlm.nih.gov/pubmed/20160034?dopt=AbstractPlus

333 

Lafite 
P 

et al (2006 ) http://www.ncbi.nlm.nih.gov/pubmed/16495056?dopt=AbstractPlus

334 

Lahiri 
S 

et al (2005 ) http://www.ncbi.nlm.nih.gov/pubmed/16100120?dopt=AbstractPlus

335 

Lai 
HL 

et al (1999 ) http://www.ncbi.nlm.nih.gov/pubmed/10462552?dopt=AbstractPlus

336 

Lannutti 
BJ 

et al (2011 ) http://www.ncbi.nlm.nih.gov/pubmed/20959606?dopt=AbstractPlus

337 

Laquerre 
S 

et al (2009 ) Mol Cancer Ther 
8 : B88 

338 

Laviad 
EL 

et al (2008 ) http://www.ncbi.nlm.nih.gov/pubmed/18165233?dopt=AbstractPlus

339 

Lavieri 
RR 

et al (2010 ) http://www.ncbi.nlm.nih.gov/pubmed/20735042?dopt=AbstractPlus

340 

Lazer 
ES 

et al (1997 ) http://www.ncbi.nlm.nih.gov/pubmed/9083488?dopt=AbstractPlus

341 

Lee 
CH 

et al (1992 ) http://www.ncbi.nlm.nih.gov/pubmed/1322889?dopt=AbstractPlus

342 

Lefebvre 
HP 

et al (2007 ) http://www.ncbi.nlm.nih.gov/pubmed/17506720?dopt=AbstractPlus

343 

Lehmann 
TP 

et al (2013 ) http://www.ncbi.nlm.nih.gov/pubmed/23254310?dopt=AbstractPlus

344 

Leisle 
L 

et al (2005 ) http://www.ncbi.nlm.nih.gov/pubmed/16270062?dopt=AbstractPlus

345 

Lewis 
DF 

et al (2009 ) http://www.ncbi.nlm.nih.gov/pubmed/20408502?dopt=AbstractPlus

346 

Li 
W 

et al (2007 ) http://www.ncbi.nlm.nih.gov/pubmed/17629278?dopt=AbstractPlus

347 

Li 
X 

et al (2014 ) http://www.ncbi.nlm.nih.gov/pubmed/24915291?dopt=AbstractPlus

348 

Li 
Y 

et al (2017 ) http://www.ncbi.nlm.nih.gov/pubmed/28802121?dopt=AbstractPlus

349 

Li 
Y 

et al (2018 ) http://www.ncbi.nlm.nih.gov/pubmed/29572189?dopt=AbstractPlus

350 

Li 
YL 

et al (2015 ) http://www.ncbi.nlm.nih.gov/pubmed/26314925?dopt=AbstractPlus

351 

Li-Hawkins 
J 

et al (2000 ) http://www.ncbi.nlm.nih.gov/pubmed/10748047?dopt=AbstractPlus

352 

Liang 
K 

et al (2015 ) http://www.ncbi.nlm.nih.gov/pubmed/25561469?dopt=AbstractPlus

353 

Libè 
R 

et al (2007 ) http://www.ncbi.nlm.nih.gov/pubmed/17395972?dopt=AbstractPlus

354 

Lim 
KG 

et al (2011 ) http://www.ncbi.nlm.nih.gov/pubmed/21620961?dopt=AbstractPlus

355 

Lin 
RJ 

et al (2001 ) http://www.ncbi.nlm.nih.gov/pubmed/11704848?dopt=AbstractPlus

356 

Lippert 
B 

et al (1977 ) http://www.ncbi.nlm.nih.gov/pubmed/856582?dopt=AbstractPlus

357 

Litvin 
TN 

et al (2003 ) http://www.ncbi.nlm.nih.gov/pubmed/12609998?dopt=AbstractPlus

358 

Liu 
F 

et al (2013 ) http://www.ncbi.nlm.nih.gov/pubmed/23594111?dopt=AbstractPlus

359 

Liu 
J 

et al (2013 ) http://www.ncbi.nlm.nih.gov/pubmed/23600958?dopt=AbstractPlus

360 

Liu 
KK 

et al (2011 ) http://www.ncbi.nlm.nih.gov/pubmed/24900269?dopt=AbstractPlus

361 

Liu 
Q 

et al (2010 ) http://www.ncbi.nlm.nih.gov/pubmed/20860370?dopt=AbstractPlus

362 

Liu 
Q 

et al (2002 ) http://www.ncbi.nlm.nih.gov/pubmed/12047899?dopt=AbstractPlus

363 

Liu 
Q 

et al (2011 ) http://www.ncbi.nlm.nih.gov/pubmed/21322566?dopt=AbstractPlus

364 

Liu 
Y 

et al (2005 ) http://www.ncbi.nlm.nih.gov/pubmed/15664519?dopt=AbstractPlus

365 

Llerena 
A 

et al (2009 ) http://www.ncbi.nlm.nih.gov/pubmed/19102711?dopt=AbstractPlus

366 

Loetscher 
E 

et al (2013 ) http://www.ncbi.nlm.nih.gov/pubmed/23499842?dopt=AbstractPlus

367 

Long 
JZ 

et al (2009 ) http://www.ncbi.nlm.nih.gov/pubmed/19029917?dopt=AbstractPlus

368 

Lopez 
D. 
 (2008 ) http://www.ncbi.nlm.nih.gov/pubmed/18836590?dopt=AbstractPlus

369 

Lopez 
I 

et al (1998 ) http://www.ncbi.nlm.nih.gov/pubmed/9582313?dopt=AbstractPlus

370 

Lotta 
T 

et al (1995 ) http://www.ncbi.nlm.nih.gov/pubmed/7703232?dopt=AbstractPlus

371 

Lou 
Y 

et al (2012 ) http://www.ncbi.nlm.nih.gov/pubmed/22394077?dopt=AbstractPlus

372 

Loughney 
K 

et al (1996 ) http://www.ncbi.nlm.nih.gov/pubmed/8557689?dopt=AbstractPlus

373 

Loveridge 
C 

et al (2010 ) http://www.ncbi.nlm.nih.gov/pubmed/20926375?dopt=AbstractPlus

374 

Luci 
DK 

et al (2014 ) http://www.ncbi.nlm.nih.gov/pubmed/24393039?dopt=AbstractPlus

375 

Ludwig 
J 

et al (2006 ) http://www.ncbi.nlm.nih.gov/pubmed/16610804?dopt=AbstractPlus

376 

Lunniss 
CJ 

et al (2009 ) http://www.ncbi.nlm.nih.gov/pubmed/19195882?dopt=AbstractPlus

377 

Luo 
J 

et al (2000 ) http://www.ncbi.nlm.nih.gov/pubmed/11099047?dopt=AbstractPlus

378 

Luo 
JQ 

et al (1997 ) http://www.ncbi.nlm.nih.gov/pubmed/9207251?dopt=AbstractPlus

379 

Luo 
M 

et al (2004 ) http://www.ncbi.nlm.nih.gov/pubmed/15280375?dopt=AbstractPlus

380 

Luo 
W 

et al (2006 ) http://www.ncbi.nlm.nih.gov/pubmed/16570913?dopt=AbstractPlus

381 

Lustig 
KD 

et al (1993 ) http://www.ncbi.nlm.nih.gov/pubmed/8390980?dopt=AbstractPlus

382 

Lépine 
S 

et al (2011 ) http://www.ncbi.nlm.nih.gov/pubmed/22052905?dopt=AbstractPlus

383 

Löhn 
M 

et al (2009 ) http://www.ncbi.nlm.nih.gov/pubmed/19597037?dopt=AbstractPlus

384 

M 
NK 

et al (2016 ) http://www.ncbi.nlm.nih.gov/pubmed/27247428?dopt=AbstractPlus

385 

Ma 
L 

et al (2013 ) http://www.ncbi.nlm.nih.gov/pubmed/23584399?dopt=AbstractPlus

386 

Mahli 
A 

et al (2019 ) http://www.ncbi.nlm.nih.gov/pubmed/30380359?dopt=AbstractPlus

387 

Maier 
SA 

et al (2005 ) http://www.ncbi.nlm.nih.gov/pubmed/16245011?dopt=AbstractPlus

388 

Maira 
SM 

et al (2008 ) http://www.ncbi.nlm.nih.gov/pubmed/18606717?dopt=AbstractPlus

389 

Malerich 
JP 

et al (2010 ) http://www.ncbi.nlm.nih.gov/pubmed/21106455?dopt=AbstractPlus

390 

Manning 
G 

et al (2002 ) http://www.ncbi.nlm.nih.gov/pubmed/12471243?dopt=AbstractPlus

391 

Mao 
C 

et al (2001 ) http://www.ncbi.nlm.nih.gov/pubmed/11356846?dopt=AbstractPlus

392 

Markman 
B 

et al (2012 ) http://www.ncbi.nlm.nih.gov/pubmed/22357447?dopt=AbstractPlus

393 

Marsell 
R 

et al (2012 ) http://www.ncbi.nlm.nih.gov/pubmed/22142634?dopt=AbstractPlus

394 

Martin 
MW 

et al (2006 ) http://www.ncbi.nlm.nih.gov/pubmed/16884310?dopt=AbstractPlus

395 

Martinez 
GR 

et al (1992 ) http://www.ncbi.nlm.nih.gov/pubmed/1311763?dopt=AbstractPlus

396 

Masferrer 
JL 

et al (2010 ) http://www.ncbi.nlm.nih.gov/pubmed/20378715?dopt=AbstractPlus

397 

Mason 
JM 

et al (2014 ) http://www.ncbi.nlm.nih.gov/pubmed/25043604?dopt=AbstractPlus

398 

Matsuura 
K 

et al (1998 ) http://www.ncbi.nlm.nih.gov/pubmed/9792917?dopt=AbstractPlus

399 

Maurice 
DH 

et al (2014 ) http://www.ncbi.nlm.nih.gov/pubmed/24687066?dopt=AbstractPlus

400 

Mayer 
B 

et al (1997 ) http://www.ncbi.nlm.nih.gov/pubmed/9433128?dopt=AbstractPlus

401 

Mayhoub 
AS 

et al (2012 ) http://www.ncbi.nlm.nih.gov/pubmed/22386564?dopt=AbstractPlus

402 

McAllister 
G 

et al (1992 ) http://www.ncbi.nlm.nih.gov/pubmed/1377913?dopt=AbstractPlus

403 

McGaraughty 
S 

et al (2001 ) http://www.ncbi.nlm.nih.gov/pubmed/11160637?dopt=AbstractPlus

404 

McNaughton 
M 

et al (2016 ) http://www.ncbi.nlm.nih.gov/pubmed/26934645?dopt=AbstractPlus

405 

Meanwell 
NA 

et al (1992 ) http://www.ncbi.nlm.nih.gov/pubmed/1321910?dopt=AbstractPlus

406 

Medvedev 
AE 

et al (1998 ) http://www.ncbi.nlm.nih.gov/pubmed/9564636?dopt=AbstractPlus

407 

Meldrum 
E 

et al (1991 ) http://www.ncbi.nlm.nih.gov/pubmed/1848183?dopt=AbstractPlus

408 

Meyers 
R 

et al (1997 ) http://www.ncbi.nlm.nih.gov/pubmed/9020160?dopt=AbstractPlus

409 

Michaeli 
T 

et al (1993 ) http://www.ncbi.nlm.nih.gov/pubmed/8389765?dopt=AbstractPlus

410 

Michaud 
A 

et al (1997 ) http://www.ncbi.nlm.nih.gov/pubmed/9187274?dopt=AbstractPlus

411 

Michie 
AM 

et al (1996 ) http://www.ncbi.nlm.nih.gov/pubmed/8730511?dopt=AbstractPlus

412 

Miller 
MR 

et al (2016 ) http://www.ncbi.nlm.nih.gov/pubmed/26989199?dopt=AbstractPlus

413 

Mishra 
N 

et al (2011 ) http://www.ncbi.nlm.nih.gov/pubmed/21377879?dopt=AbstractPlus

414 

Miyake 
Y 

et al (1995 ) http://www.ncbi.nlm.nih.gov/pubmed/7794249?dopt=AbstractPlus

415 

Mizukami 
Y 

et al (1993 ) http://www.ncbi.nlm.nih.gov/pubmed/8389204?dopt=AbstractPlus

416 

Mizutani 
Y 

et al (2005 ) http://www.ncbi.nlm.nih.gov/pubmed/15823095?dopt=AbstractPlus

417 

Mlinar 
B 

et al (2003 ) http://www.ncbi.nlm.nih.gov/pubmed/14511335?dopt=AbstractPlus

418 

Mochida 
H 

et al (2002 ) http://www.ncbi.nlm.nih.gov/pubmed/12450574?dopt=AbstractPlus

419 

Mohamed 
HA 

et al (2011 ) http://www.ncbi.nlm.nih.gov/pubmed/21189023?dopt=AbstractPlus

420 

Moncada 
S 

et al (1997 ) http://www.ncbi.nlm.nih.gov/pubmed/9228663?dopt=AbstractPlus

421 

Moore 
WM 

et al (1994 ) http://www.ncbi.nlm.nih.gov/pubmed/7525961?dopt=AbstractPlus

422 

Mori 
S 

et al (2003 ) http://www.ncbi.nlm.nih.gov/pubmed/12939527?dopt=AbstractPlus

423 

Moscarello 
MA 

et al (2013 ) http://www.ncbi.nlm.nih.gov/pubmed/23118341?dopt=AbstractPlus

424 

Muftuoglu 
Y 

et al (2010 ) http://www.ncbi.nlm.nih.gov/pubmed/20413308?dopt=AbstractPlus

425 

Murthy 
SN 

et al (1999 ) http://www.ncbi.nlm.nih.gov/pubmed/10518533?dopt=AbstractPlus

426 

Nagahara 
N 

et al (1995 ) http://www.ncbi.nlm.nih.gov/pubmed/7608189?dopt=AbstractPlus

427 

Nagar 
B 

et al (2002 ) http://www.ncbi.nlm.nih.gov/pubmed/12154025?dopt=AbstractPlus

428 

Nakamura 
H 

et al (2009 ) http://www.ncbi.nlm.nih.gov/pubmed/19428245?dopt=AbstractPlus

429 

Nakano 
M 

et al (2009 ) http://www.ncbi.nlm.nih.gov/pubmed/19661213?dopt=AbstractPlus

430 

Nakashima 
T 

et al (1978 ) http://www.ncbi.nlm.nih.gov/pubmed/748042?dopt=AbstractPlus

431 

Nakaya 
Y 

et al (2011 ) http://www.ncbi.nlm.nih.gov/pubmed/22829185?dopt=AbstractPlus

432 

Navia-Paldanius 
D 

et al (2012 ) http://www.ncbi.nlm.nih.gov/pubmed/22969151?dopt=AbstractPlus

433 

Nelson 
PH 

et al (1990 ) http://www.ncbi.nlm.nih.gov/pubmed/1967654?dopt=AbstractPlus

434 

Nicholson 
AN 

et al (1981 ) http://www.ncbi.nlm.nih.gov/pubmed/6457252?dopt=AbstractPlus

435 

Nilsson 
T 

et al (2010 ) http://www.ncbi.nlm.nih.gov/pubmed/19919823?dopt=AbstractPlus

436 

Niphakis 
MJ 

et al (2013 ) http://www.ncbi.nlm.nih.gov/pubmed/23731016?dopt=AbstractPlus

437 

Noshiro 
M 

et al (1990 ) http://www.ncbi.nlm.nih.gov/pubmed/2384150?dopt=AbstractPlus

438 

Nylander 
S 

et al (2012 ) http://www.ncbi.nlm.nih.gov/pubmed/22906130?dopt=AbstractPlus

439 

O'Hare 
T 

et al (2005 ) http://www.ncbi.nlm.nih.gov/pubmed/15930265?dopt=AbstractPlus

440 

Ochi 
T 

et al (2000 ) http://www.ncbi.nlm.nih.gov/pubmed/10720634?dopt=AbstractPlus

441 

Ogasawara 
D 

et al (2016 ) http://www.ncbi.nlm.nih.gov/pubmed/26668358?dopt=AbstractPlus

442 

Ogasawara 
D 

et al (2019 ) http://www.ncbi.nlm.nih.gov/pubmed/30720278?dopt=AbstractPlus

443 

Ogura 
Y 

et al (2016 ) http://www.ncbi.nlm.nih.gov/pubmed/27399000?dopt=AbstractPlus

444 

Oh 
SF 

et al (2011 ) http://www.ncbi.nlm.nih.gov/pubmed/21206090?dopt=AbstractPlus

445 

Ohnishi 
T 

et al (2007 ) http://www.ncbi.nlm.nih.gov/pubmed/17068342?dopt=AbstractPlus

446 

Okada 
M 

et al (2007 ) Oxazole compound and pharmaceutical composition Patent number: WO2007058338.
447 

Okada 
Y 

et al (2012 ) http://www.ncbi.nlm.nih.gov/pubmed/22446963?dopt=AbstractPlus

448 

Okamoto 
Y 

et al (2004 ) http://www.ncbi.nlm.nih.gov/pubmed/14634025?dopt=AbstractPlus

449 

Onda 
T 

et al (2001 ) http://www.ncbi.nlm.nih.gov/pubmed/11602596?dopt=AbstractPlus

450 

Orning 
L 

et al (1991 ) http://www.ncbi.nlm.nih.gov/pubmed/1846352?dopt=AbstractPlus

451 

Osisami 
M 

et al (2012 ) http://www.ncbi.nlm.nih.gov/pubmed/22428023?dopt=AbstractPlus

452 

Oslund 
RC 

et al (2008 ) http://www.ncbi.nlm.nih.gov/pubmed/18605714?dopt=AbstractPlus

453 

Ottanà 
R 

et al (2005 ) http://www.ncbi.nlm.nih.gov/pubmed/15993594?dopt=AbstractPlus

454 

Overington 
JP 

et al (2006 ) http://www.ncbi.nlm.nih.gov/pubmed/17139284?dopt=AbstractPlus

455 

Pajunen 
AE 

et al (1979 ) http://www.ncbi.nlm.nih.gov/pubmed/438812?dopt=AbstractPlus

456 

Palanki 
MS 

et al (2007 ) http://www.ncbi.nlm.nih.gov/pubmed/17685602?dopt=AbstractPlus

457 

Pan 
Z 

et al (2007 ) http://www.ncbi.nlm.nih.gov/pubmed/17154430?dopt=AbstractPlus

458 

Panek 
RL 

et al (1997 ) http://www.ncbi.nlm.nih.gov/pubmed/9400019?dopt=AbstractPlus

459 

Park 
D 

et al (1993 ) http://www.ncbi.nlm.nih.gov/pubmed/8383116?dopt=AbstractPlus

460 

Parkkari 
T 

et al (2014 ) http://www.ncbi.nlm.nih.gov/pubmed/24879289?dopt=AbstractPlus

461 

Paterson 
JM 

et al (2000 ) http://www.ncbi.nlm.nih.gov/pubmed/10987815?dopt=AbstractPlus

462 

Pawelczyk 
T 

et al (1992 ) http://www.ncbi.nlm.nih.gov/pubmed/1497353?dopt=AbstractPlus

463 

Payne 
EJ 

et al (2009 ) http://www.ncbi.nlm.nih.gov/pubmed/19470632?dopt=AbstractPlus

464 

Penning 
TD 

et al (1997 ) http://www.ncbi.nlm.nih.gov/pubmed/9135032?dopt=AbstractPlus

465 

Perry 
MJ 

et al (1998 ) http://www.ncbi.nlm.nih.gov/pubmed/9631241?dopt=AbstractPlus

466 

Perzborn 
E 

et al (2010 ) http://www.ncbi.nlm.nih.gov/pubmed/20139357?dopt=AbstractPlus

467 

Petersen 
G 

et al (1999 ) http://www.ncbi.nlm.nih.gov/pubmed/10428468?dopt=AbstractPlus

468 

Pheneger 
J 

et al (2006 ) American College of Rheumatology. 2006 Annual Scientific Meeting. Abstract 794
469 

Philipp 
S 

et al (2010 ) http://www.ncbi.nlm.nih.gov/pubmed/20080539?dopt=AbstractPlus

470 

Piechulek 
T 

et al (2005 ) http://www.ncbi.nlm.nih.gov/pubmed/16172125?dopt=AbstractPlus

471 

Pinto 
DJ 

et al (2010 ) http://www.ncbi.nlm.nih.gov/pubmed/20503967?dopt=AbstractPlus

472 

Pinto-Bazurco Mendieta 
MA 

et al (2008 ) http://www.ncbi.nlm.nih.gov/pubmed/18672868?dopt=AbstractPlus

473 

Pireddu 
R 

et al (2012 ) http://www.ncbi.nlm.nih.gov/pubmed/23275831?dopt=AbstractPlus

474 

Pitman 
MR 

et al (2015 ) http://www.ncbi.nlm.nih.gov/pubmed/25788259?dopt=AbstractPlus

475 

Plourde 
PV 

et al (1994 ) http://www.ncbi.nlm.nih.gov/pubmed/7949201?dopt=AbstractPlus

476 

Pollard 
JR 

et al (2009 ) http://www.ncbi.nlm.nih.gov/pubmed/19320489?dopt=AbstractPlus

477 

Potter 
GA 

et al (1995 ) http://www.ncbi.nlm.nih.gov/pubmed/7608911?dopt=AbstractPlus

478 

Preininger 
AM 

et al (2006 ) http://www.ncbi.nlm.nih.gov/pubmed/16638972?dopt=AbstractPlus

479 

Premont 
RT 

et al (1996 ) http://www.ncbi.nlm.nih.gov/pubmed/8662814?dopt=AbstractPlus

480 

Purandare 
AV 

et al (2012 ) http://www.ncbi.nlm.nih.gov/pubmed/22015772?dopt=AbstractPlus

481 

Qiu 
W 

et al (2007 ) http://www.ncbi.nlm.nih.gov/pubmed/17166832?dopt=AbstractPlus

482 

Qu 
N 

et al (2003 ) http://www.ncbi.nlm.nih.gov/pubmed/12859253?dopt=AbstractPlus

483 

Quintás-Cardama 
A 

et al (2010 ) http://www.ncbi.nlm.nih.gov/pubmed/20130243?dopt=AbstractPlus

484 

Rabionet 
M 

et al (2008 ) http://www.ncbi.nlm.nih.gov/pubmed/18308723?dopt=AbstractPlus

485 

Rai 
G 

et al (2010 ) http://www.ncbi.nlm.nih.gov/pubmed/24672829?dopt=AbstractPlus

486 

Rai 
G 

et al (2010 ) http://www.ncbi.nlm.nih.gov/pubmed/20866075?dopt=AbstractPlus

487 

Rameh 
LE 

et al (1997 ) http://www.ncbi.nlm.nih.gov/pubmed/9367159?dopt=AbstractPlus

488 

Ramos-Espiritu 
L 

et al (2016 ) http://www.ncbi.nlm.nih.gov/pubmed/27547922?dopt=AbstractPlus

489 

Randall 
MJ 

et al (1981 ) http://www.ncbi.nlm.nih.gov/pubmed/6795753?dopt=AbstractPlus

490 

Randall 
RW 

et al (1990 ) http://www.ncbi.nlm.nih.gov/pubmed/2186929?dopt=AbstractPlus

491 

Rao 
NL 

et al (2010 ) http://www.ncbi.nlm.nih.gov/pubmed/20110560?dopt=AbstractPlus

492 

Rask-Andersen 
M 

et al (2014 ) http://www.ncbi.nlm.nih.gov/pubmed/24016212?dopt=AbstractPlus

493 Rawlings et al.. MEROPS
494 

Rawlings 
ND 

et al (2016 ) http://www.ncbi.nlm.nih.gov/pubmed/26527717?dopt=AbstractPlus

495 

Rawson 
DJ 

et al (2012 ) http://www.ncbi.nlm.nih.gov/pubmed/22100260?dopt=AbstractPlus

496 

Ray 
P 

et al (2011 ) http://www.ncbi.nlm.nih.gov/pubmed/21145740?dopt=AbstractPlus

497 

Raynaud 
FI 

et al (2009 ) http://www.ncbi.nlm.nih.gov/pubmed/19584227?dopt=AbstractPlus

498 

Reynisson 
J 

et al (2009 ) http://www.ncbi.nlm.nih.gov/pubmed/19303309?dopt=AbstractPlus

499 

Ribeiro 
A 

et al (2015 ) http://www.ncbi.nlm.nih.gov/pubmed/25874594?dopt=AbstractPlus

500 

Rice 
KD 

et al (2012 ) ACS Med Chem Lett 
3 : 416 -421 
24900486 
501 

Riebeling 
C 

et al (2003 ) http://www.ncbi.nlm.nih.gov/pubmed/12912983?dopt=AbstractPlus

502 

Riendeau 
D 

et al (2005 ) http://www.ncbi.nlm.nih.gov/pubmed/15953724?dopt=AbstractPlus

503 

Riendeau 
D 

et al (2001 ) http://www.ncbi.nlm.nih.gov/pubmed/11160644?dopt=AbstractPlus

504 

Ring 
DB 

et al (2003 ) http://www.ncbi.nlm.nih.gov/pubmed/12606497?dopt=AbstractPlus

505 

Rivera 
VM 

et al (2011 ) http://www.ncbi.nlm.nih.gov/pubmed/21482695?dopt=AbstractPlus

506 

Robbins 
JD 

et al (1996 ) http://www.ncbi.nlm.nih.gov/pubmed/8709105?dopt=AbstractPlus

507 

Robinson 
DM 

et al (2007 ) http://www.ncbi.nlm.nih.gov/pubmed/17547476?dopt=AbstractPlus

508 

Ronn 
R 

et al (2016 ) Cyclopropane carboxylic acid derivatives and pharmaceutical uses thereof Patent number: WO20161778-45 .
509 

Ropero 
S 

et al (2007 ) http://www.ncbi.nlm.nih.gov/pubmed/19383284?dopt=AbstractPlus

510 

Rose 
KA 

et al (1997 ) http://www.ncbi.nlm.nih.gov/pubmed/9144166?dopt=AbstractPlus

511 

Rosowsky 
A 

et al (1995 ) http://www.ncbi.nlm.nih.gov/pubmed/7877140?dopt=AbstractPlus

512 

Rotstein 
DM 

et al (1992 ) http://www.ncbi.nlm.nih.gov/pubmed/1495014?dopt=AbstractPlus

513 

Rouault 
M 

et al (2003 ) http://www.ncbi.nlm.nih.gov/pubmed/14516201?dopt=AbstractPlus

514 

Sadik 
CD 

et al (2003 ) http://www.ncbi.nlm.nih.gov/pubmed/12628491?dopt=AbstractPlus

515 

Saha 
AK 

et al (2000 ) http://www.ncbi.nlm.nih.gov/pubmed/10854420?dopt=AbstractPlus

516 

Sahebkar 
A 

et al (2014 ) http://www.ncbi.nlm.nih.gov/pubmed/25083925?dopt=AbstractPlus

517 

Saldou 
N 

et al (1998 ) http://www.ncbi.nlm.nih.gov/pubmed/9720765?dopt=AbstractPlus

518 

Santo 
L 

et al (2012 ) http://www.ncbi.nlm.nih.gov/pubmed/22262760?dopt=AbstractPlus

519 

Sarri 
E 

et al (2003 ) http://www.ncbi.nlm.nih.gov/pubmed/12374567?dopt=AbstractPlus

520 

Sasaki 
T 

et al (2000 ) http://www.ncbi.nlm.nih.gov/pubmed/10814504?dopt=AbstractPlus

521 

Sauve 
AA. 
 (2010 ) http://www.ncbi.nlm.nih.gov/pubmed/20132909?dopt=AbstractPlus

522 

Schafer 
PH 

et al (2014 ) http://www.ncbi.nlm.nih.gov/pubmed/24882690?dopt=AbstractPlus

523 

Schmid 
AC 

et al (2004 ) http://www.ncbi.nlm.nih.gov/pubmed/15474001?dopt=AbstractPlus

524 

Schmidt 
M 

et al (2001 ) http://www.ncbi.nlm.nih.gov/pubmed/11715024?dopt=AbstractPlus

525 

Schmöle 
AC 

et al (2010 ) http://www.ncbi.nlm.nih.gov/pubmed/20708937?dopt=AbstractPlus

526 

Schnute 
ME 

et al (2017 ) http://www.ncbi.nlm.nih.gov/pubmed/28231433?dopt=AbstractPlus

527 

Schnute 
ME 

et al (2012 ) http://www.ncbi.nlm.nih.gov/pubmed/22397330?dopt=AbstractPlus

528 

Schwab 
SR 

et al (2005 ) http://www.ncbi.nlm.nih.gov/pubmed/16151014?dopt=AbstractPlus

529 

Schümann 
J 

et al (2015 ) http://www.ncbi.nlm.nih.gov/pubmed/25630683?dopt=AbstractPlus

530 

Scott 
SA 

et al (2009 ) http://www.ncbi.nlm.nih.gov/pubmed/19136975?dopt=AbstractPlus

531 

Sedrani 
R 

et al (1998 ) http://www.ncbi.nlm.nih.gov/pubmed/9723437?dopt=AbstractPlus

532 

Semenas 
J 

et al (2014 ) http://www.ncbi.nlm.nih.gov/pubmed/25071204?dopt=AbstractPlus

533 

Sethi 
KK 

et al (2013 ) http://www.ncbi.nlm.nih.gov/pubmed/23965175?dopt=AbstractPlus

534 

Sevrioukova 
IF 

et al (2015 ) http://www.ncbi.nlm.nih.gov/pubmed/26002732?dopt=AbstractPlus

535 

Seynaeve 
CM 

et al (1994 ) http://www.ncbi.nlm.nih.gov/pubmed/8022414?dopt=AbstractPlus

536 

Shahrokh 
K 

et al (2012 ) http://www.ncbi.nlm.nih.gov/pubmed/22677141?dopt=AbstractPlus

537 

Shak 
S 

et al (1985 ) http://www.ncbi.nlm.nih.gov/pubmed/2997155?dopt=AbstractPlus

538 

Sharma 
RK 

et al (2012 ) http://www.ncbi.nlm.nih.gov/pubmed/22628311?dopt=AbstractPlus

539 

Sharp 
JD 

et al (1994 ) http://www.ncbi.nlm.nih.gov/pubmed/8083230?dopt=AbstractPlus

540 

Shih 
C 

et al (1998 ) http://www.ncbi.nlm.nih.gov/pubmed/9762351?dopt=AbstractPlus

541 

Shiro 
T 

et al (2013 ) http://www.ncbi.nlm.nih.gov/pubmed/23623673?dopt=AbstractPlus

542 

Silverman 
RB. 
 (2012 ) http://www.ncbi.nlm.nih.gov/pubmed/22168767?dopt=AbstractPlus

543 

Simon 
GM 

et al (2010 ) http://www.ncbi.nlm.nih.gov/pubmed/20393650?dopt=AbstractPlus

544 

Simó-Riudalbas 
L 

et al (2014 ) http://www.ncbi.nlm.nih.gov/pubmed/24104525?dopt=AbstractPlus

545 

Simó-Riudalbas 
L 

et al (2015 ) http://www.ncbi.nlm.nih.gov/pubmed/25039449?dopt=AbstractPlus

546 

Sinnarajah 
S 

et al (2001 ) http://www.ncbi.nlm.nih.gov/pubmed/11234015?dopt=AbstractPlus

547 

Sircar 
I 

et al (1989 ) http://www.ncbi.nlm.nih.gov/pubmed/2536438?dopt=AbstractPlus

548 

Sjholt 
G 

et al (2000 ) http://www.ncbi.nlm.nih.gov/pubmed/10822345?dopt=AbstractPlus

549 

Sjholt 
G 

et al (1997 ) http://www.ncbi.nlm.nih.gov/pubmed/9339367?dopt=AbstractPlus

550 

Skarydová 
L 

et al (2009 ) http://www.ncbi.nlm.nih.gov/pubmed/19007764?dopt=AbstractPlus

551 

Smith 
CJ 

et al (1998 ) http://www.ncbi.nlm.nih.gov/pubmed/9789085?dopt=AbstractPlus

552 

Smith 
RJ 

et al (1990 ) http://www.ncbi.nlm.nih.gov/pubmed/2338654?dopt=AbstractPlus

553 

Smith 
SJ 

et al (2004 ) http://www.ncbi.nlm.nih.gov/pubmed/15371556?dopt=AbstractPlus

554 

Smrcka 
AV 

et al (1991 ) http://www.ncbi.nlm.nih.gov/pubmed/1846707?dopt=AbstractPlus

555 

Snider 
NT 

et al (2010 ) http://www.ncbi.nlm.nih.gov/pubmed/20133390?dopt=AbstractPlus

556 

Solanki 
M 

et al (2018 ) http://www.ncbi.nlm.nih.gov/pubmed/29695613?dopt=AbstractPlus

557 

Solorzano 
C 

et al (2009 ) http://www.ncbi.nlm.nih.gov/pubmed/19926854?dopt=AbstractPlus

558 

Song 
C 

et al (2001 ) http://www.ncbi.nlm.nih.gov/pubmed/11022048?dopt=AbstractPlus

559 

Sontag 
TJ 

et al (2002 ) http://www.ncbi.nlm.nih.gov/pubmed/11997390?dopt=AbstractPlus

560 

Sperzel 
M 

et al (2007 ) http://www.ncbi.nlm.nih.gov/pubmed/17666018?dopt=AbstractPlus

561 

Sridhar 
J 

et al (2017 ) http://www.ncbi.nlm.nih.gov/pubmed/28698457?dopt=AbstractPlus

562 

Stanek 
J 

et al (1993 ) http://www.ncbi.nlm.nih.gov/pubmed/8340919?dopt=AbstractPlus

563 

Stanek 
J 

et al (1992 ) http://www.ncbi.nlm.nih.gov/pubmed/1573631?dopt=AbstractPlus

564 

Stanley 
LA. 
 (1995 ) http://www.ncbi.nlm.nih.gov/pubmed/7900159?dopt=AbstractPlus

565 

Stanley 
WC 

et al (1997 ) http://www.ncbi.nlm.nih.gov/pubmed/9283721?dopt=AbstractPlus

566 

Stark 
K 

et al (2008 ) http://www.ncbi.nlm.nih.gov/pubmed/18549450?dopt=AbstractPlus

567 

Steinberg 
D 

et al (2009 ) http://www.ncbi.nlm.nih.gov/pubmed/19506257?dopt=AbstractPlus

568 

Stevens 
T 

et al (2011 ) http://www.ncbi.nlm.nih.gov/pubmed/21791628?dopt=AbstractPlus

569 

Stoilov 
I 

et al (1997 ) http://www.ncbi.nlm.nih.gov/pubmed/9097971?dopt=AbstractPlus

570 

Su 
T 

et al (2000 ) http://www.ncbi.nlm.nih.gov/pubmed/11016631?dopt=AbstractPlus

571 

Sudo 
T 

et al (2000 ) http://www.ncbi.nlm.nih.gov/pubmed/10644042?dopt=AbstractPlus

572 

Sun 
W 

et al (2008 ) http://www.ncbi.nlm.nih.gov/pubmed/17713573?dopt=AbstractPlus

573 

Sutherlin 
DP 

et al (2011 ) http://www.ncbi.nlm.nih.gov/pubmed/21981714?dopt=AbstractPlus

574 

Suzuki 
T 

et al (2013 ) http://www.ncbi.nlm.nih.gov/pubmed/23577190?dopt=AbstractPlus

575 

Szabo 
C 

et al (2017 ) http://www.ncbi.nlm.nih.gov/pubmed/28978633?dopt=AbstractPlus

576 

Sánchez-Martínez 
C 

et al (2015 ) http://www.ncbi.nlm.nih.gov/pubmed/26115571?dopt=AbstractPlus

577 

Tai 
AW 

et al (2011 ) http://www.ncbi.nlm.nih.gov/pubmed/21704602?dopt=AbstractPlus

578 

Taimi 
M 

et al (2004 ) http://www.ncbi.nlm.nih.gov/pubmed/14532297?dopt=AbstractPlus

579 

Takasugi 
N 

et al (2003 ) http://www.ncbi.nlm.nih.gov/pubmed/12660785?dopt=AbstractPlus

580 

Takeuchi 
CS 

et al (2013 ) http://www.ncbi.nlm.nih.gov/pubmed/23394126?dopt=AbstractPlus

581 

Talley 
JJ 

et al (2000 ) http://www.ncbi.nlm.nih.gov/pubmed/10715145?dopt=AbstractPlus

582 

Tanaka 
M 

et al (2017 ) http://www.ncbi.nlm.nih.gov/pubmed/28086912?dopt=AbstractPlus

583 

Tang 
WJ 

et al (1991 ) http://www.ncbi.nlm.nih.gov/pubmed/2022671?dopt=AbstractPlus

584 

Tani 
M 

et al (2003 ) http://www.ncbi.nlm.nih.gov/pubmed/12499379?dopt=AbstractPlus

585 

Tani 
M 

et al (2009 ) http://www.ncbi.nlm.nih.gov/pubmed/19233134?dopt=AbstractPlus

586 

Tanizawa 
A 

et al (1994 ) http://www.ncbi.nlm.nih.gov/pubmed/8182764?dopt=AbstractPlus

587 

Tao 
YH 

et al (2006 ) http://www.ncbi.nlm.nih.gov/pubmed/16290145?dopt=AbstractPlus

588 

Taussig 
R 

et al (1993 ) http://www.ncbi.nlm.nih.gov/pubmed/8416978?dopt=AbstractPlus

589 

Taussig 
R 

et al (1994 ) http://www.ncbi.nlm.nih.gov/pubmed/8119955?dopt=AbstractPlus

590 

Taylor 
A. 
 (1993 ) http://www.ncbi.nlm.nih.gov/pubmed/8440407?dopt=AbstractPlus

591 

Temperini 
C 

et al (2009 ) http://www.ncbi.nlm.nih.gov/pubmed/19119014?dopt=AbstractPlus

592 

Tenu 
JP 

et al (1999 ) http://www.ncbi.nlm.nih.gov/pubmed/10637120?dopt=AbstractPlus

593 

Terao 
C 

et al (2013 ) http://www.ncbi.nlm.nih.gov/pubmed/23124809?dopt=AbstractPlus

594 

Tesmer 
JJ 

et al (2000 ) http://www.ncbi.nlm.nih.gov/pubmed/11087399?dopt=AbstractPlus

595 

Thilagavathi 
R 

et al (2005 ) http://www.ncbi.nlm.nih.gov/pubmed/15686906?dopt=AbstractPlus

596 

Thomas 
M 

et al (2011 ) http://www.ncbi.nlm.nih.gov/pubmed/21561767?dopt=AbstractPlus

597 

Thompson 
JF 

et al (1998 ) http://www.ncbi.nlm.nih.gov/pubmed/9473303?dopt=AbstractPlus

598 

Thorel 
MF 

et al (1990 ) http://www.ncbi.nlm.nih.gov/pubmed/2397193?dopt=AbstractPlus

599 

Toprakçí 
M 

et al (2005 ) http://www.ncbi.nlm.nih.gov/pubmed/16137882?dopt=AbstractPlus

600 

Toullec 
D 

et al (1991 ) http://www.ncbi.nlm.nih.gov/pubmed/1874734?dopt=AbstractPlus

601 

Tsuboi 
K 

et al (2004 ) http://www.ncbi.nlm.nih.gov/pubmed/14686878?dopt=AbstractPlus

602 

Tsuboi 
K 

et al (2013 ) http://www.ncbi.nlm.nih.gov/pubmed/23394527?dopt=AbstractPlus

603 

Tuccinardi 
T 

et al (2006 ) http://www.ncbi.nlm.nih.gov/pubmed/16483784?dopt=AbstractPlus

604 

Turko 
IV 

et al (1999 ) http://www.ncbi.nlm.nih.gov/pubmed/10385692?dopt=AbstractPlus

605 

Turpeinen 
M 

et al (2012 ) http://www.ncbi.nlm.nih.gov/pubmed/23152403?dopt=AbstractPlus

606 

Ueda 
N 

et al (2001 ) http://www.ncbi.nlm.nih.gov/pubmed/11463796?dopt=AbstractPlus

607 

Uehata 
M 

et al (1997 ) http://www.ncbi.nlm.nih.gov/pubmed/9353125?dopt=AbstractPlus

608 

Van Rompaey 
L 

et al (2013 ) http://www.ncbi.nlm.nih.gov/pubmed/24006460?dopt=AbstractPlus

609 

Vemulapalli 
S 

et al (1996 ) http://www.ncbi.nlm.nih.gov/pubmed/8961086?dopt=AbstractPlus

610 

Venant 
H 

et al (2015 ) http://www.ncbi.nlm.nih.gov/pubmed/26494858?dopt=AbstractPlus

611 

Venkataraman 
K 

et al (2002 ) http://www.ncbi.nlm.nih.gov/pubmed/12105227?dopt=AbstractPlus

612 

Venkatesan 
AM 

et al (2010 ) http://www.ncbi.nlm.nih.gov/pubmed/20166697?dopt=AbstractPlus

613 

Verhoest 
PR 

et al (2009 ) http://www.ncbi.nlm.nih.gov/pubmed/19630403?dopt=AbstractPlus

614 

Verma 
RP 

et al (2007 ) http://www.ncbi.nlm.nih.gov/pubmed/17275314?dopt=AbstractPlus

615 

Viegas 
A 

et al (2011 ) http://www.ncbi.nlm.nih.gov/pubmed/22091869?dopt=AbstractPlus

616 

Vlahakis 
JZ 

et al (2006 ) http://www.ncbi.nlm.nih.gov/pubmed/16821802?dopt=AbstractPlus

617 

Wagner 
J 

et al (2009 ) http://www.ncbi.nlm.nih.gov/pubmed/19827831?dopt=AbstractPlus

618 

Walker 
KA 

et al (1993 ) http://www.ncbi.nlm.nih.gov/pubmed/8340925?dopt=AbstractPlus

619 

Walliser 
C 

et al (2008 ) http://www.ncbi.nlm.nih.gov/pubmed/18728011?dopt=AbstractPlus

620 

Walsky 
RL 

et al (2007 ) http://www.ncbi.nlm.nih.gov/pubmed/17682072?dopt=AbstractPlus

621 

Wang 
G 

et al (2012 ) http://www.ncbi.nlm.nih.gov/pubmed/23137303?dopt=AbstractPlus

622 

Wang 
L 

et al (2011 ) http://www.ncbi.nlm.nih.gov/pubmed/21537079?dopt=AbstractPlus

623 

Wang 
P 

et al (1997 ) http://www.ncbi.nlm.nih.gov/pubmed/9177268?dopt=AbstractPlus

624 

Wang 
T 

et al (2011 ) http://www.ncbi.nlm.nih.gov/pubmed/21493067?dopt=AbstractPlus

625 

Wang 
X 

et al (2012 ) http://www.ncbi.nlm.nih.gov/pubmed/22808911?dopt=AbstractPlus

626 

Warkentin 
TE 

et al (2005 ) http://www.ncbi.nlm.nih.gov/pubmed/16363236?dopt=AbstractPlus

627 

Warner 
TD 

et al (1999 ) http://www.ncbi.nlm.nih.gov/pubmed/10377455?dopt=AbstractPlus

628 

Watabiki 
T 

et al (2017 ) http://www.ncbi.nlm.nih.gov/pubmed/29017758?dopt=AbstractPlus

629 

Watanuki 
M 

et al (1978 ) http://www.ncbi.nlm.nih.gov/pubmed/412519?dopt=AbstractPlus

630 

Waterfall 
JF. 
 (1989 ) http://www.ncbi.nlm.nih.gov/pubmed/2527528?dopt=AbstractPlus

631 

Watermeyer 
JM 

et al (2010 ) http://www.ncbi.nlm.nih.gov/pubmed/20233165?dopt=AbstractPlus

632 

Watson 
PA 

et al (1994 ) http://www.ncbi.nlm.nih.gov/pubmed/7961850?dopt=AbstractPlus

633 

Wayman 
GA 

et al (1995 ) http://www.ncbi.nlm.nih.gov/pubmed/7665559?dopt=AbstractPlus

634 

Wei 
BQ 

et al (2006 ) http://www.ncbi.nlm.nih.gov/pubmed/17015445?dopt=AbstractPlus

635 

Weiler 
S 

et al (2014 ) http://www.ncbi.nlm.nih.gov/pubmed/24809814?dopt=AbstractPlus

636 

Weinstein 
DS 

et al (2007 ) http://www.ncbi.nlm.nih.gov/pubmed/17656086?dopt=AbstractPlus

637 

Wells 
RA 

et al (2014 ) http://www.ncbi.nlm.nih.gov/pubmed/24523604?dopt=AbstractPlus

638 

Wernig 
G 

et al (2008 ) http://www.ncbi.nlm.nih.gov/pubmed/18394554?dopt=AbstractPlus

639 

West 
AC 

et al (2014 ) http://www.ncbi.nlm.nih.gov/pubmed/24382387?dopt=AbstractPlus

640 

Wilensky 
RL 

et al (2009 ) http://www.ncbi.nlm.nih.gov/pubmed/19667981?dopt=AbstractPlus

641 

Williams 
JA 

et al (2002 ) http://www.ncbi.nlm.nih.gov/pubmed/12124305?dopt=AbstractPlus

642 

Williams-Karnesky 
RL 

et al (2013 ) http://www.ncbi.nlm.nih.gov/pubmed/23863710?dopt=AbstractPlus

643 

Willoughby 
D 

et al (2012 ) http://www.ncbi.nlm.nih.gov/pubmed/22976297?dopt=AbstractPlus

644 

WILSON 
IB 

et al (1961 ) http://www.ncbi.nlm.nih.gov/pubmed/13785664?dopt=AbstractPlus

645 

Wing 
MR 

et al (2003 ) http://www.ncbi.nlm.nih.gov/pubmed/14993441?dopt=AbstractPlus

646 

Witting 
JI 

et al (1992 ) http://www.ncbi.nlm.nih.gov/pubmed/1290488?dopt=AbstractPlus

647 

Wong 
PC 

et al (2008 ) http://www.ncbi.nlm.nih.gov/pubmed/18315548?dopt=AbstractPlus

648 

Wu 
F 

et al (2010 ) http://www.ncbi.nlm.nih.gov/pubmed/20462760?dopt=AbstractPlus

649 

Wu 
H 

et al (2017 ) http://www.ncbi.nlm.nih.gov/pubmed/28352114?dopt=AbstractPlus

650 

Wu 
JY 

et al (1973 ) http://www.ncbi.nlm.nih.gov/pubmed/4700449?dopt=AbstractPlus

651 

Wu 
P 

et al (2012 ) Med Chem Commun 
3 : 1337 -1355 

652 

Wu 
S 

et al (1996 ) http://www.ncbi.nlm.nih.gov/pubmed/8631948?dopt=AbstractPlus

653 

Wu 
Y 

et al (2011 ) http://www.ncbi.nlm.nih.gov/pubmed/21650226?dopt=AbstractPlus

654 

Wu 
Z 

et al (2013 ) http://www.ncbi.nlm.nih.gov/pubmed/23959307?dopt=AbstractPlus

655 

Wuerzner 
G 

et al (2008 ) http://www.ncbi.nlm.nih.gov/pubmed/18307734?dopt=AbstractPlus

656 

Xie 
S 

et al (2010 ) http://www.ncbi.nlm.nih.gov/pubmed/21049984?dopt=AbstractPlus

657 

Xu 
R 

et al (2006 ) http://www.ncbi.nlm.nih.gov/pubmed/16940153?dopt=AbstractPlus

658 

Yaguchi 
S 

et al (2006 ) http://www.ncbi.nlm.nih.gov/pubmed/16622124?dopt=AbstractPlus

659 

Yamaguchi 
T 

et al (2011 ) http://www.ncbi.nlm.nih.gov/pubmed/21523318?dopt=AbstractPlus

660 

Yamano 
S 

et al (1990 ) http://www.ncbi.nlm.nih.gov/pubmed/2322567?dopt=AbstractPlus

661 

Yano 
JK 

et al (2006 ) http://www.ncbi.nlm.nih.gov/pubmed/17125252?dopt=AbstractPlus

662 

Yin 
L 

et al (2014 ) http://www.ncbi.nlm.nih.gov/pubmed/24899257?dopt=AbstractPlus

663 

Yokomatsu 
T 

et al (2003 ) http://www.ncbi.nlm.nih.gov/pubmed/12482429?dopt=AbstractPlus

664 

Yoshida 
S 

et al (2004 ) http://www.ncbi.nlm.nih.gov/pubmed/15110846?dopt=AbstractPlus

665 

Yoshikawa 
F 

et al (2010 ) http://www.ncbi.nlm.nih.gov/pubmed/21085684?dopt=AbstractPlus

666 

Yoshikawa 
T 

et al (1997 ) http://www.ncbi.nlm.nih.gov/pubmed/9322233?dopt=AbstractPlus

667 

Yoshimura 
M 

et al (1992 ) http://www.ncbi.nlm.nih.gov/pubmed/1379717?dopt=AbstractPlus

668 

Youdim 
MB 

et al (2001 ) http://www.ncbi.nlm.nih.gov/pubmed/11159700?dopt=AbstractPlus

669 

Yu 
Z 

et al (2003 ) http://www.ncbi.nlm.nih.gov/pubmed/12881489?dopt=AbstractPlus

670 

Zambon 
A 

et al (2012 ) http://www.ncbi.nlm.nih.gov/pubmed/22222036?dopt=AbstractPlus

671 

Zavialov 
AV 

et al (2010 ) http://www.ncbi.nlm.nih.gov/pubmed/20147294?dopt=AbstractPlus

672 

Zeldin 
DC 

et al (1995 ) http://www.ncbi.nlm.nih.gov/pubmed/7574697?dopt=AbstractPlus

673 

Zhang 
J 

et al (2010 ) http://www.ncbi.nlm.nih.gov/pubmed/20072125?dopt=AbstractPlus

674 

Zhang 
J 

et al (2007 ) http://www.ncbi.nlm.nih.gov/pubmed/17721087?dopt=AbstractPlus

675 

Zhou 
SF. 
 (2008 ) http://www.ncbi.nlm.nih.gov/pubmed/18473749?dopt=AbstractPlus

676 

Zhou 
W 

et al (2003 ) http://www.ncbi.nlm.nih.gov/pubmed/14612531?dopt=AbstractPlus

677 

Zhou 
Y 

et al (2005 ) http://www.ncbi.nlm.nih.gov/pubmed/16107206?dopt=AbstractPlus

678 

Zhu 
MY 

et al (2004 ) http://www.ncbi.nlm.nih.gov/pubmed/14738999?dopt=AbstractPlus

679 

Zimmer 
C 

et al (2011 ) http://www.ncbi.nlm.nih.gov/pubmed/21129965?dopt=AbstractPlus

680 

Zimmermann 
G 

et al (1996 ) http://www.ncbi.nlm.nih.gov/pubmed/8900209?dopt=AbstractPlus

681 

Zimmermann 
TJ 

et al (2009 ) http://www.ncbi.nlm.nih.gov/pubmed/19097799?dopt=AbstractPlus

